[{"to": "449", "prefix": " might clear the HIV protease inhibitor ", "from": "440", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83395", "setId": "PMC2883751", "exact": "saquinavir", "suffix": ", administered by mouth, more rapidly than subjects lacking functional CYP3A5 al"}, {"to": "9625", "prefix": " might have a higher clearance of the HIV protease inhibitor ", "from": "9616", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83395", "setId": "PMC2883751", "exact": "saquinavir", "suffix": ", administered by mouth, compared with subjects lacking functional CYP3A5 allele"}, {"to": "554", "prefix": " mouth, more rapidly than subjects lacking functional CYP3A5 alleles. Enhanced ", "from": "546", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC2883751", "exact": "midazolam", "suffix": " hydroxylation and cyclosporin metabolism occur in an in vitro P450 3A5 system a"}, {"to": "3981", "prefix": " of itraconazole, fluconazole, and voriconazole were determined against ", "from": "3973", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC2883751", "exact": "midazolam", "suffix": " hydroxylation catalyzed by liver microsomal P450 3A enzymes [14]. Inhibitory ef"}, {"to": "4947", "prefix": "-hydroxylation of ", "from": "4939", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC2883751", "exact": "midazolam", "suffix": " varied by a factor of 10 between the Ki values of fluconazole toward P450 3A4 a"}, {"to": "5507", "prefix": "bition constants of fluconazole and itraconazole toward human liver microsomal ", "from": "5499", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC2883751", "exact": "midazolam", "suffix": " 1"}, {"to": "5674", "prefix": "luconazole and itraconazole toward recombinant P450 3A4- and P450 3A5-mediated ", "from": "5666", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC2883751", "exact": "midazolam", "suffix": " 1"}, {"to": "5995", "prefix": "P450 isoforms expressed in bacterial membranes. Recombinant P450 3A5 catalyzed ", "from": "5987", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC2883751", "exact": "midazolam", "suffix": " 1"}, {"to": "6101", "prefix": ". Ki values of these triazoles for ", "from": "6093", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC2883751", "exact": "midazolam", "suffix": " hydroxylation catalyzed by recombinant P450 3A4 were lower than those catalyzed"}, {"to": "6733", "prefix": " of itraconazole, fluconazole, and voriconazole on ", "from": "6725", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC2883751", "exact": "midazolam", "suffix": " 1"}, {"to": "7973", "prefix": " metabolic rate by P450 3A5 than P450 3A4 in a Michaels-Menten kinetic manner. ", "from": "7965", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC2883751", "exact": "Midazolam", "suffix": " can adopt an orientation suitable for 1"}, {"to": "8198", "prefix": " and enhances ", "from": "8190", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC2883751", "exact": "midazolam", "suffix": " 1"}, {"to": "9166", "prefix": " in comparison with the cases of ", "from": "9158", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC2883751", "exact": "midazolam", "suffix": " (C) and thalidomide (D). Voriconazole adopted an orientation suitable for P450 "}, {"to": "584", "prefix": "bjects lacking functional CYP3A5 alleles. Enhanced midazolam hydroxylation and ", "from": "574", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "PMC2883751", "exact": "cyclosporin", "suffix": " metabolism occur in an in vitro P450 3A5 system and in liver microsomes express"}, {"to": "4097", "prefix": "y liver microsomal P450 3A enzymes [14]. Inhibitory effects of voriconazole on ", "from": "4087", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "PMC2883751", "exact": "cyclosporin", "suffix": " oxidation were also determined [14]. To predict the potential for drug interact"}, {"to": "7127", "prefix": "e efficiently by P450 3A4 than by P450 3A5 [16]. Using voriconazole to inhibit ", "from": "7117", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "PMC2883751", "exact": "cyclosporin", "suffix": " oxidation, it was found that voriconazole was a weak inhibitor of P450 3A5. Liv"}, {"to": "8232", "prefix": "-hydroxylation or ", "from": "8220", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "PMC2883751", "exact": "cyclosporin A", "suffix": " clearance of P450 3A5 [14] via an unexpected phenomenon, which is called activa"}, {"to": "8877", "prefix": "ffinity towards a P450 3A5 pocket.\n\nTable 4\nTable 4\nEffects of voriconazole on ", "from": "8865", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "PMC2883751", "exact": "cyclosporin A", "suffix": " oxidation activities of recombinant P450 3A4 and P450 3A5 and human liver micro"}, {"to": "707", "prefix": "P450 3A5 system and in liver microsomes expressing P450 3A5 in the presence of ", "from": "697", "name": "Thalidomide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10432", "setId": "PMC2883751", "exact": "thalidomide", "suffix": ". However, inhibition constants (Ki) of three triazole anti-fungal drugs (itraco"}, {"to": "1618", "prefix": " functions.\n\nKeywords: CYP3A5, CYP3A4, drug interaction, genetic polymorphism, ", "from": "1608", "name": "Thalidomide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10432", "setId": "PMC2883751", "exact": "thalidomide", "suffix": ", voriconazole\nGo to:\nIntroduction\nCytochrome P450 enzymes (P450s) are heme-thio"}, {"to": "8127", "prefix": " as well as the P450 3A4 heme. It is noteworthy that ", "from": "8117", "name": "Thalidomide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10432", "setId": "PMC2883751", "exact": "thalidomide", "suffix": " adapts closely to the P450 3A5 heme (Figure 1D) and enhances midazolam 1"}, {"to": "8448", "prefix": " mechanism distinct from that of voriconazole. In our preliminary experiments, ", "from": "8438", "name": "Thalidomide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10432", "setId": "PMC2883751", "exact": "thalidomide", "suffix": " was hydroxylated in a sigmoidal velocity curve vs. substrate, presumably becaus"}, {"to": "8709", "prefix": "c co-operativity [13]. Why the mechanism is different between voriconazole and ", "from": "8699", "name": "Thalidomide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10432", "setId": "PMC2883751", "exact": "thalidomide", "suffix": " is not known but it might be due to substrate molecular size, polarity or affin"}, {"to": "9186", "prefix": " and ", "from": "9176", "name": "Thalidomide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10432", "setId": "PMC2883751", "exact": "thalidomide", "suffix": " (D). Voriconazole adopted an orientation suitable for P450 3A4 (corresponding ."}, {"to": "793", "prefix": "", "from": "782", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC2883751", "exact": "itraconazole", "suffix": ", fluconazole, and voriconazole) for liver microsomal P450 3A5 are higher than f"}, {"to": "2504", "prefix": "al drugs are clinically important for serious, invasive fungal infections [9]. ", "from": "2493", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC2883751", "exact": "Itraconazole", "suffix": " is a fat-soluble synthetic triazole antifungal drug and is a broad spectrum ant"}, {"to": "3916", "prefix": " of ", "from": "3905", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC2883751", "exact": "itraconazole", "suffix": ", fluconazole, and voriconazole were determined against midazolam hydroxylation "}, {"to": "5151", "prefix": ", reported IC50 or Ki values of ", "from": "5140", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC2883751", "exact": "itraconazole", "suffix": " indicated 17-fold differences [19"}, {"to": "5467", "prefix": "50 3A5 [18].\n\nTable 2\nTable 2\nReported inhibition constants of fluconazole and ", "from": "5456", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC2883751", "exact": "itraconazole", "suffix": " toward human liver microsomal midazolam 1"}, {"to": "5613", "prefix": "on activities\nTable 1\nTable 1\nReported inhibition constants of fluconazole and ", "from": "5602", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC2883751", "exact": "itraconazole", "suffix": " toward recombinant P450 3A4- and P450 3A5-mediated midazolam 1"}, {"to": "6689", "prefix": " of ", "from": "6678", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC2883751", "exact": "itraconazole", "suffix": ", fluconazole, and voriconazole on midazolam 1"}, {"to": "11061", "prefix": "A5.\n\nTable 5\nTable 5\nIn vivo estimated fold increase in AUC in the presence of ", "from": "11050", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC2883751", "exact": "itraconazole", "suffix": ", fluconazole, and voriconazole from 1 "}, {"to": "806", "prefix": "itraconazole, ", "from": "796", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC2883751", "exact": "fluconazole", "suffix": ", and voriconazole) for liver microsomal P450 3A5 are higher than for liver micr"}, {"to": "2791", "prefix": "s and has an extremely broad spectrum. Voriconazole is structurally related to ", "from": "2781", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC2883751", "exact": "fluconazole", "suffix": ", but its activity and handling by the body are completely different. These tria"}, {"to": "3929", "prefix": " of itraconazole, ", "from": "3919", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC2883751", "exact": "fluconazole", "suffix": ", and voriconazole were determined against midazolam hydroxylation catalyzed by "}, {"to": "5009", "prefix": "-hydroxylation of midazolam varied by a factor of 10 between the Ki values of ", "from": "4999", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC2883751", "exact": "fluconazole", "suffix": " toward P450 3A4 and P450 3A5 [17, 18]. With human liver microsomes as the enzym"}, {"to": "5242", "prefix": "22]. Similar results have been obtained with ", "from": "5232", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC2883751", "exact": "fluconazole", "suffix": " [18"}, {"to": "5301", "prefix": "20, 23, 24]. Apparent differences in Ki of ", "from": "5291", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC2883751", "exact": "fluconazole", "suffix": " were reported between liver microsomes that either do or do not express P450 3A"}, {"to": "5450", "prefix": "o not express P450 3A5 [18].\n\nTable 2\nTable 2\nReported inhibition constants of ", "from": "5440", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC2883751", "exact": "fluconazole", "suffix": " and itraconazole toward human liver microsomal midazolam 1"}, {"to": "5596", "prefix": "-hydroxylation activities\nTable 1\nTable 1\nReported inhibition constants of ", "from": "5586", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC2883751", "exact": "fluconazole", "suffix": " and itraconazole toward recombinant P450 3A4- and P450 3A5-mediated midazolam 1"}, {"to": "6702", "prefix": " of itraconazole, ", "from": "6692", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC2883751", "exact": "fluconazole", "suffix": ", and voriconazole on midazolam 1"}, {"to": "11074", "prefix": "able 5\nIn vivo estimated fold increase in AUC in the presence of itraconazole, ", "from": "11064", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC2883751", "exact": "fluconazole", "suffix": ", and voriconazole from 1 "}, {"to": "824", "prefix": "itraconazole, fluconazole, and ", "from": "813", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC2883751", "exact": "voriconazole", "suffix": ") for liver microsomal P450 3A5 are higher than for liver microsomal P450 3A4. T"}, {"to": "1192", "prefix": ". ", "from": "1181", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC2883751", "exact": "Voriconazole", "suffix": " would be expected to cause approximately a three-fold higher increase in AUC in"}, {"to": "1632", "prefix": "Keywords: CYP3A5, CYP3A4, drug interaction, genetic polymorphism, thalidomide, ", "from": "1621", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC2883751", "exact": "voriconazole", "suffix": "\nGo to:\nIntroduction\nCytochrome P450 enzymes (P450s) are heme-thiolate mono-oxyg"}, {"to": "2605", "prefix": "soluble synthetic triazole antifungal drug and is a broad spectrum antifungal. ", "from": "2594", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC2883751", "exact": "Voriconazole", "suffix": " was approved in Europe and the United States in 2002 for the treatment of invas"}, {"to": "2752", "prefix": "r the treatment of invasive Aspergillosis and has an extremely broad spectrum. ", "from": "2741", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC2883751", "exact": "Voriconazole", "suffix": " is structurally related to fluconazole, but its activity and handling by the bo"}, {"to": "3402", "prefix": " in metabolic clearance and inhibition of triazole antifungal drugs, including ", "from": "3391", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC2883751", "exact": "voriconazole", "suffix": ", emphasising polymorphic P450 3A5 expression in genotyped livers and the potent"}, {"to": "3947", "prefix": " of itraconazole, fluconazole, and ", "from": "3936", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC2883751", "exact": "voriconazole", "suffix": " were determined against midazolam hydroxylation catalyzed by liver microsomal P"}, {"to": "4082", "prefix": "tion catalyzed by liver microsomal P450 3A enzymes [14]. Inhibitory effects of ", "from": "4071", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC2883751", "exact": "voriconazole", "suffix": " on cyclosporin oxidation were also determined [14]. To predict the potential fo"}, {"to": "4591", "prefix": "spectively, and Ki is the inhibition constant [11, 15]. Docking simulations of ", "from": "4580", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC2883751", "exact": "voriconazole", "suffix": " and other substrates in a reported structure of P450 3A4 (PDB 1WOG) and a model"}, {"to": "6720", "prefix": " of itraconazole, fluconazole, and ", "from": "6709", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC2883751", "exact": "voriconazole", "suffix": " on midazolam 1"}, {"to": "6866", "prefix": "P450 3A4 and P450 3A5 and human liver microsomes genotyped for the CYP3A5 gene\n", "from": "6855", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC2883751", "exact": "Voriconazole", "suffix": " is of particular interest because of different metabolic pathways catalyzed by "}, {"to": "6987", "prefix": "ause of different metabolic pathways catalyzed by P450 2C19 and P450 3A4 [16]. ", "from": "6976", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC2883751", "exact": "Voriconazole", "suffix": " N-oxidation and 4-hydroxylation are catalyzed more efficiently by P450 3A4 than"}, {"to": "7104", "prefix": "lation are catalyzed more efficiently by P450 3A4 than by P450 3A5 [16]. Using ", "from": "7093", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC2883751", "exact": "voriconazole", "suffix": " to inhibit cyclosporin oxidation, it was found that voriconazole was a weak inh"}, {"to": "7169", "prefix": "5 [16]. Using voriconazole to inhibit cyclosporin oxidation, it was found that ", "from": "7158", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC2883751", "exact": "voriconazole", "suffix": " was a weak inhibitor of P450 3A5. Liver microsomes expressing P450 3A5 were les"}, {"to": "7520", "prefix": "1 in the presence of ", "from": "7509", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC2883751", "exact": "voriconazole", "suffix": " (200 "}, {"to": "7592", "prefix": ", respectively, suggesting that ", "from": "7581", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC2883751", "exact": "voriconazole", "suffix": " inhibits both by competitive and noncompetitive mechanisms [25]. Docking simula"}, {"to": "7703", "prefix": "mpetitive and noncompetitive mechanisms [25]. Docking simulation revealed that ", "from": "7692", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC2883751", "exact": "voriconazole", "suffix": " can adopt an orientation suitable for N-oxidation over the P450 3A4 heme (Figur"}, {"to": "7811", "prefix": ". However, ", "from": "7800", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC2883751", "exact": "voriconazole", "suffix": " could adopt far from the P450 3A5 heme (Figure 1B), resulting in a slower metab"}, {"to": "8403", "prefix": "tion or heterotropic co-operativity [13], in a mechanism distinct from that of ", "from": "8392", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC2883751", "exact": "voriconazole", "suffix": ". In our preliminary experiments, thalidomide was hydroxylated in a sigmoidal ve"}, {"to": "8693", "prefix": "lled as homotropic co-operativity [13]. Why the mechanism is different between ", "from": "8682", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC2883751", "exact": "voriconazole", "suffix": " and thalidomide is not known but it might be due to substrate molecular size, p"}, {"to": "8860", "prefix": "e, polarity or affinity towards a P450 3A5 pocket.\n\nTable 4\nTable 4\nEffects of ", "from": "8849", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC2883751", "exact": "voriconazole", "suffix": " on cyclosporin A oxidation activities of recombinant P450 3A4 and P450 3A5 and "}, {"to": "9045", "prefix": "crosomes genotyped for the CYP3A5 gene\nFigure 1\nFigure 1\nDocking simulation of ", "from": "9034", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC2883751", "exact": "voriconazole", "suffix": " into a reported structure of P450 3A4 (A) and a homology model of P450 3A5 (B) "}, {"to": "9204", "prefix": ". ", "from": "9193", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC2883751", "exact": "Voriconazole", "suffix": " adopted an orientation suitable for P450 3A4 (corresponding ...\nIt is generally"}, {"to": "9905", "prefix": " drug clearances and drug-interactions of triazole antifungal drugs, including ", "from": "9894", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC2883751", "exact": "voriconazole", "suffix": ", are appreciably affected by the CYP3A5 genotypes (Tables 2, 3). Polymorphic P4"}, {"to": "10565", "prefix": "he findings indicated that the highest increased AUC caused by co-administered ", "from": "10554", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC2883751", "exact": "voriconazole", "suffix": " would be expected to be low in expressers of P450 3A5 (Table 5). There are not "}, {"to": "11092", "prefix": "timated fold increase in AUC in the presence of itraconazole, fluconazole, and ", "from": "11081", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC2883751", "exact": "voriconazole", "suffix": " from 1 "}, {"to": "11309", "prefix": "triazole antifungal drug clearance and the intensity of drug interactions with ", "from": "11298", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC2883751", "exact": "voriconazole", "suffix": ". P450 3A5 also shows the heterotropic co-operativity phenomenon in some cases. "}, {"to": "11441", "prefix": "-operativity phenomenon in some cases. Increased AUC caused by co-administered ", "from": "11430", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC2883751", "exact": "voriconazole", "suffix": " should be anticipated as a potential cause of toxicity, especially in subjects "}, {"to": "7339", "prefix": ". Vmax and Km for ", "from": "7330", "name": "Tacrolimus", "fullId": "http://purl.bioontology.org/ontology/MESH/D016559", "setId": "PMC2883751", "exact": "tacrolimus", "suffix": " metabolism have been reported to be 1.47 nmol min"}, {"to": "97", "prefix": "ased on in vitro rat and human hepatocyte uptake studies showing inhibition of ", "from": "90", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " uptake in the presence of the non-specific organic anion transporting polypepti"}, {"to": "367", "prefix": " single-dose, two-period, crossover design, subjects received a 7.5 mg dose of ", "from": "360", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " alone or immediately following a 600 mg intravenous dose of rifampin. Rifampin "}, {"to": "492", "prefix": "mg intravenous dose of rifampin. Rifampin did not significantly alter R- or S- ", "from": "485", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " area under the concentration-time curve (AUC) from 0"}, {"to": "734", "prefix": " and S-", "from": "727", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " (15% reduction; p "}, {"to": "936", "prefix": "ic uptake via OATPs may not be clinically important in the pharmacokinetics of ", "from": "929", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": ".\n\nKeywords: warfarin, pharmacokinetics, drug transporters, drug interaction, he"}, {"to": "957", "prefix": "ay not be clinically important in the pharmacokinetics of warfarin.\n\nKeywords: ", "from": "950", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": ", pharmacokinetics, drug transporters, drug interaction, healthy volunteers\nGo t"}, {"to": "1061", "prefix": "s, drug transporters, drug interaction, healthy volunteers\nGo to:\nINTRODUCTION\n", "from": "1054", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "Warfarin", "suffix": " is a commonly prescribed anticoagulant for the prevention of venous thromboembo"}, {"to": "1230", "prefix": "sm, systemic embolism, and other thromboembolic events. But, successful use of ", "from": "1223", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " has been challenged by its large inter-individual variation in required warfari"}, {"to": "1311", "prefix": "rfarin has been challenged by its large inter-individual variation in required ", "from": "1304", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " dose and narrow therapeutic index.(1) Doses can differ "}, {"to": "1487", "prefix": "e similar levels of anticoagulation. In attempts to explain the variability in ", "from": "1480", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " dose, formal pharmacogenetic techniques have been applied to try and identify p"}, {"to": "1718", "prefix": " in ", "from": "1711", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": "'s major metabolizing enzyme (cytochrome P-450 (CYP) 2C9) and its pharmacodynami"}, {"to": "1882", "prefix": " have a significant impact on ", "from": "1875", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " dose requirement.(2"}, {"to": "2238", "prefix": "60% of the variability in ", "from": "2231", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " dose.\n\nThe Biopharmaceutics Drug Disposition Classification System (BDDCS), whi"}, {"to": "3579", "prefix": "\n\n", "from": "3572", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "Warfarin", "suffix": " is a racemic mixture of S- and R- enatiomers with S-warfarin being 2"}, {"to": "3640", "prefix": "\n\nWarfarin is a racemic mixture of S- and R- enatiomers with S-", "from": "3633", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " being 2"}, {"to": "3830", "prefix": " and R-enatiomers are eliminated almost exclusively by CYP metabolism, i.e., S-", "from": "3823", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " principally by CYP2C9 metabolism to form the primary metabolite 7-hydroxywarfar"}, {"to": "3933", "prefix": "; R-", "from": "3926", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " principally by CYP3A4 metabolism to form 10-hydroxywarfarin.(15)\n\nSince warfari"}, {"to": "4014", "prefix": "\n\nSince ", "from": "4007", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " is classified as a BDDCS Class 2 drug(10), the potential for hepatic uptake tra"}, {"to": "4239", "prefix": " considered, a proposition not previously studied. By inhibiting the uptake of ", "from": "4232", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " into the liver, warfarin would have decreased access to its major metabolizing "}, {"to": "4264", "prefix": "n not previously studied. By inhibiting the uptake of warfarin into the liver, ", "from": "4257", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " would have decreased access to its major metabolizing CYP enzymes resulting in "}, {"to": "4454", "prefix": " on initial in vitro rat and human hepatocyte data showing decreased uptake of ", "from": "4447", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " in the presence of rifampin, a clinical trial in healthy volunteers was conduct"}, {"to": "4599", "prefix": "volunteers was conducted to examine the impact of hepatic uptake inhibition on ", "from": "4592", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " pharmacokinetics.\n\nGo to:\nRESULTS\nIn Vitro Study "}, {"to": "4755", "prefix": "M racemic ", "from": "4748", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " was decreased by 23% in rat hepatocytes (p "}, {"to": "4945", "prefix": " compared to control.\n\nFigure 1\nFigure 1\nInhibition of the uptake of ", "from": "4938", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " (1"}, {"to": "5183", "prefix": " 0.001 compared to control. ...\nClinical Study\n\nPharmacokinetics of S- and R-", "from": "5176", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": "\nFigure 2 displays the concentration-time profiles of S- and R-warfarin after a "}, {"to": "5254", "prefix": "- and R-warfarin\nFigure 2 displays the concentration-time profiles of S- and R-", "from": "5247", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " after a single oral dose of 7.5 mg warfarin alone or with a single intravenous "}, {"to": "5298", "prefix": "ntration-time profiles of S- and R-warfarin after a single oral dose of 7.5 mg ", "from": "5291", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " alone or with a single intravenous dose of rifampin. Data from a previous study"}, {"to": "5619", "prefix": ". Therefore, in the current study we focused on S- and R-", "from": "5612", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " concentration-time data from 0"}, {"to": "5792", "prefix": "e period of hepatic OATP inhibition by rifampin and when any uptake effects on ", "from": "5785", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " pharmacokinetics, if any, would be seen. Rifampin had no effect on the AUC0"}, {"to": "5886", "prefix": "12h of S-", "from": "5879", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " or R-warfarin compared to control days when warfarin was given alone (Table 1),"}, {"to": "5900", "prefix": "12h of S-warfarin or R-", "from": "5893", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " compared to control days when warfarin was given alone (Table 1), as well as Cm"}, {"to": "5939", "prefix": "12h of S-warfarin or R-warfarin compared to control days when ", "from": "5932", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " was given alone (Table 1), as well as Cmax (maximum plasma concentration) and T"}, {"to": "6178", "prefix": " S-", "from": "6171", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " and (b) R-warfarin in 10 healthy volunteers after a single oral dose of 7.5 mg "}, {"to": "6197", "prefix": " R-", "from": "6190", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " in 10 healthy volunteers after a single oral dose of 7.5 mg racemic warfarin. I"}, {"to": "6274", "prefix": "R-warfarin in 10 healthy volunteers after a single oral dose of 7.5 mg racemic ", "from": "6267", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": ". Inset: depicts 0 to 12 h data only. Error bars show ...\nTable 1\nTable 1\nPharma"}, {"to": "6396", "prefix": "y. Error bars show ...\nTable 1\nTable 1\nPharmacokinetic parametersa of R- and S-", "from": "6389", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " in 10 healthy volunteers following a single oral dose of 7.5 mg warfarin alone "}, {"to": "6469", "prefix": "and S-warfarin in 10 healthy volunteers following a single oral dose of 7.5 mg ", "from": "6462", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " alone or in combination with a single dose of intravenous rifampin.\nAnalysis of"}, {"to": "6642", "prefix": " of S-", "from": "6635", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " by 15% (p "}, {"to": "6675", "prefix": " and R-", "from": "6668", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " by 25% (p "}, {"to": "6768", "prefix": " of S-", "from": "6761", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " was not significantly different on rifampin days (p "}, {"to": "6844", "prefix": ". For R-", "from": "6837", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": ", a 25% shortening of the terminal t1"}, {"to": "7040", "prefix": " was unaffected by the presence of rifampin for both S- and R-", "from": "7033", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": ".\n\nPharmacokinetics of warfarin metabolites\nThe concentration-time profiles of 7"}, {"to": "7071", "prefix": "d by the presence of rifampin for both S- and R-warfarin.\n\nPharmacokinetics of ", "from": "7064", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " metabolites\nThe concentration-time profiles of 7-hydroxywarfarin (S-warfarin me"}, {"to": "7148", "prefix": "S-", "from": "7141", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " metabolite) and 10-hydroxywarfarin (R-warfarin metabolite) after a single oral "}, {"to": "7195", "prefix": "R-", "from": "7188", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " metabolite) after a single oral dose of 7.5 mg warfarin alone or with a single "}, {"to": "7251", "prefix": " after a single oral dose of 7.5 mg ", "from": "7244", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " alone or with a single intravenous dose of rifampin are shown in Figure 3. Rifa"}, {"to": "8257", "prefix": "", "from": "8250", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " alone, 64 "}, {"to": "8285", "prefix": " 11%; ", "from": "8278", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " plus rifampin, 44% "}, {"to": "8670", "prefix": "xywarfarin in 10 healthy volunteers after a single oral dose of 7.5 mg racemic ", "from": "8663", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": ". Inset: depicts the same data on a semilogarithmic ...\nTable 2\nTable 2\nPharmaco"}, {"to": "8781", "prefix": "e data on a semilogarithmic ...\nTable 2\nTable 2\nPharmacokinetic parametersa of ", "from": "8774", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " metabolites in 10 healthy volunteers following a single oral dose of 7.5 mg war"}, {"to": "8866", "prefix": "in metabolites in 10 healthy volunteers following a single oral dose of 7.5 mg ", "from": "8859", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " alone or in combination with a single dose of intravenous rifampin.\nAUC ratios "}, {"to": "9021", "prefix": " ratio of 7-hydroxywarfarin to S-", "from": "9014", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " and 10-hydroxywarfarin to R-warfarin increased 20% and 58% respectively with ri"}, {"to": "9058", "prefix": " ratio of 7-hydroxywarfarin to S-warfarin and 10-hydroxywarfarin to R-", "from": "9051", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " increased 20% and 58% respectively with rifampin treatment (p "}, {"to": "9295", "prefix": "nt during each treatment period.\nPharmacodynamics\nA single 7.5 mg dose of oral ", "from": "9288", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " caused a small, transient increase in INR from baseline during each treatment p"}, {"to": "9544", "prefix": ", but rifampin caused no differences in INR measures compared to ", "from": "9537", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " alone (Table 4).\n\nTable 4\nTable 4\nMean pharmacodynamic parameters in 10 healthy"}, {"to": "9683", "prefix": "mic parameters in 10 healthy volunteers following a single oral dose of 7.5 mg ", "from": "9676", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " alone or in combination with a single dose of intravenous rifampin.\nSafety\nAll "}, {"to": "10092", "prefix": "or the disposition of the widely-used, narrow therapeutic index, anticoagulant ", "from": "10085", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": ". The results of our clinical study demonstrated that co-administration of the p"}, {"to": "10306", "prefix": "12h and Cmax values of S- and R- ", "from": "10299", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " or S-warfarin's hydroxyl metabolite. Accordingly, OATP uptake transport is like"}, {"to": "10320", "prefix": "12h and Cmax values of S- and R- warfarin or S-", "from": "10313", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": "'s hydroxyl metabolite. Accordingly, OATP uptake transport is likely not clinica"}, {"to": "10447", "prefix": "P uptake transport is likely not clinically significant for the disposition of ", "from": "10440", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " and will provide no further insight into mechanisms of warfarin drug-drug inter"}, {"to": "10511", "prefix": "disposition of warfarin and will provide no further insight into mechanisms of ", "from": "10504", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " drug-drug interactions or genetic variation important in warfarin dose selectio"}, {"to": "10577", "prefix": "echanisms of warfarin drug-drug interactions or genetic variation important in ", "from": "10570", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " dose selection.\n\nRifampin was chosen as a model OATP inhibitor to block the in "}, {"to": "10702", "prefix": "as a model OATP inhibitor to block the in vivo OATP-mediated hepatic uptake of ", "from": "10695", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": "(11, 17, 18). Because of rifampin's shorter t1"}, {"to": "10798", "prefix": " relative to S- and R- ", "from": "10791", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " (39h and 49h respectively, as determined in our clinical study) and because we "}, {"to": "11028", "prefix": " enzyme induction effect, rifampin was only present in plasma for a portion of ", "from": "11021", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": "'s concentration-time curve.OATP inhibition and any potential effect on warfarin"}, {"to": "11108", "prefix": "arfarin's concentration-time curve.OATP inhibition and any potential effect on ", "from": "11101", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " pharmacokinetics occurred at most during the time of rifampin presence, and the"}, {"to": "11626", "prefix": "dy, the best parameters to capture the potential effects of OATP inhibition on ", "from": "11619", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " pharmacokinetics were the AUC0"}, {"to": "11748", "prefix": " and Cmax. No effect on either of these pharmacokinetic parameters for S- or R-", "from": "11741", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " were seen in the presence of rifampin suggesting OATP transport of warfarin is "}, {"to": "11824", "prefix": " R-warfarin were seen in the presence of rifampin suggesting OATP transport of ", "from": "11817", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " is not clinically important.\n\nTwo previous clinical studies by our laboratory u"}, {"to": "12545", "prefix": "F for S- or R-", "from": "12538", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " on rifampin days (Table 1), which we would have predicted if OATP transport pro"}, {"to": "12659", "prefix": ", which we would have predicted if OATP transport processes were important for ", "from": "12652", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " distribution.\n\nIn contrast to our clinical study, our in vitro data showed that"}, {"to": "12748", "prefix": "istribution.\n\nIn contrast to our clinical study, our in vitro data showed that ", "from": "12741", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " uptake into hepatocytes was inhibited by rifampin in both rats and humans (Figu"}, {"to": "12910", "prefix": " presumably via OATP uptake transporter inhibition. The magnitude of ", "from": "12903", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " uptake inhibition (23% in rat hepatocytes and 34% in human hepatocytes) was mod"}, {"to": "13632", "prefix": "ons of rifampin would result in additional OATP inhibition and therefore alter ", "from": "13625", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " pharmcokinetics, although the clinical relevance would be questionable. The dis"}, {"to": "14156", "prefix": "ertaken to identify polymorphisms in the human genome that may be important in ", "from": "14149", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " dose selection. In these GWAS studies, no common variants in hepatic uptake tra"}, {"to": "14333", "prefix": "or any other drug transporters were found to be significant in determining the ", "from": "14326", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " dose requirements of patients.(2"}, {"to": "14700", "prefix": "uirements. This negative predictive value has now been demonstrated nicely for ", "from": "14693", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " and OATP uptake transporters through the results of our clinical study and the "}, {"to": "15551", "prefix": ", the major metabolizing enzymes for S- and R-", "from": "15544", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " respectively, has been described after multiple dose rifampin. The effect of mu"}, {"to": "15663", "prefix": "escribed after multiple dose rifampin. The effect of multiple dose rifampin on ", "from": "15656", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " pharmacokinetics was highlighted in a clinical trial of four healthy men.(24) A"}, {"to": "15847", "prefix": "etreatment with 300 mg oral rifampin twice per day, a three-fold increase in R-", "from": "15840", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " clearance and a two-fold increase in S-warfarin clearance were seen. Interestin"}, {"to": "15895", "prefix": "ay, a three-fold increase in R-warfarin clearance and a two-fold increase in S-", "from": "15888", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " clearance were seen. Interestingly, our clinical study using only single dose r"}, {"to": "16012", "prefix": "ingly, our clinical study using only single dose rifampin immediately prior to ", "from": "16005", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " likely demonstrates a mild enzyme inductive effect indicated by the small but s"}, {"to": "16143", "prefix": " for S- and R-", "from": "16136", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " (15% decrease and 25% decrease respectively) and terminal t1"}, {"to": "16221", "prefix": "2 for R-", "from": "16214", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " (25% decrease) with rifampin treatment. The increase in Cmax and AUC for the R-"}, {"to": "16309", "prefix": " with rifampin treatment. The increase in Cmax and AUC for the R-", "from": "16302", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " metabolite 10-hydroxywarfarin and the increase in the AUC ratio of 10-hydroxywa"}, {"to": "16409", "prefix": "0-hydroxywarfarin and the increase in the AUC ratio of 10-hydroxywarfarin to R-", "from": "16402", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " further supports induction of R-warfarin metabolism via CYP3A4. The pharmacokin"}, {"to": "16450", "prefix": " AUC ratio of 10-hydroxywarfarin to R-warfarin further supports induction of R-", "from": "16443", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " metabolism via CYP3A4. The pharmacokinetics of the specific S-warfarin metaboli"}, {"to": "16521", "prefix": "on of R-warfarin metabolism via CYP3A4. The pharmacokinetics of the specific S-", "from": "16514", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " metabolite 7-hydroxywarfarin did not change with rifampin treatment and therefo"}, {"to": "16649", "prefix": "nge with rifampin treatment and therefore is not congruent with induction of S-", "from": "16642", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " metabolism via CYP2C9.\n\nThe pharmacokinetic effect of enzyme induction appeared"}, {"to": "16792", "prefix": "nzyme induction appeared to be delayed since early in the time course S- and R-", "from": "16785", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " concentration-time curves, AUC0"}, {"to": "17517", "prefix": " Nonetheless, the potential induction of ", "from": "17510", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " metabolism by single-dose rifampin in our study does not alter the interpretati"}, {"to": "17721", "prefix": "especially for the more biologically active S-", "from": "17714", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": ") and it occurred late in the time-course after the primary endpoints (0"}, {"to": "17838", "prefix": ".\n\nWe purposely selected a ", "from": "17831", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " dose for this study (7.5mg) that would provide adequate drug levels for pharmac"}, {"to": "18142", "prefix": " a previous healthy volunteer study that also used a single 7.5mg dose of oral ", "from": "18135", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": ".(31) The addition of rifampin had no effect on the warfarin pharmacodynamic res"}, {"to": "18202", "prefix": " The addition of rifampin had no effect on the ", "from": "18195", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " pharmacodynamic response as measured by INRmax and AUC0"}, {"to": "18517", "prefix": "s.\n\nIn conclusion, our single dose clinical study of the effect of rifampin on ", "from": "18510", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " pharmacokinetics in healthy volunteers suggeststhat hepatic uptake via OATP may"}, {"to": "19788", "prefix": "entration of rifampin was chosen to maximize OATP inhibition and any effect on ", "from": "19781", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " uptake Rifampin is a known inhibitor of the 3 major human OATPs, being a more p"}, {"to": "19995", "prefix": "M racemic ", "from": "19988", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " (Sigma-Aldrich; St. Louis, MO). After 2 minutes of uptake, a 0.5 mL aliquot was"}, {"to": "21850", "prefix": " 7.5 mg ", "from": "21843", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " (one 7.5 mg warfarin tab; Bristol-Myers Squibb, Princeton, NJ) or (B) 7.5 mg wa"}, {"to": "21871", "prefix": "one 7.5 mg ", "from": "21864", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " tab; Bristol-Myers Squibb, Princeton, NJ) or (B) 7.5 mg warfarin immediately fo"}, {"to": "21936", "prefix": " 7.5 mg ", "from": "21929", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " immediately following a 30-minute intravenous infusion of 600 mg rifampin (600 "}, {"to": "22325", "prefix": "randomization. Subjects fasted starting the night before until 3 hours after a ", "from": "22318", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " dose, abstained from caffeinated beverages, alcoholic beverages and orange juic"}, {"to": "22464", "prefix": "ic beverages and orange juice starting the night before until 24 hours after a ", "from": "22457", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " dose. Grapefruit and grapefruit juice were not allowed to be consumed from 7 da"}, {"to": "22726", "prefix": " for drug level measurements were collected at the following times relative to ", "from": "22719", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " dosing: predose, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours. The blood sam"}, {"to": "23033", "prefix": " were collected for INR determination at 0, 12, 24, 48, 72 and 96 hours after ", "from": "23026", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " dosing.\n\nPharmacokinetic analysis\nPharmacokinetic parameters for R- and S-warfa"}, {"to": "23116", "prefix": "arin dosing.\n\nPharmacokinetic analysis\nPharmacokinetic parameters for R- and S-", "from": "23109", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " and their major metabolites were estimated from plasma concentration data via n"}, {"to": "23664", "prefix": "n's inhibitory effect on hepatic OATPs and the anticipated changes in R- and S-", "from": "23657", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " pharmacokinetics (i.e. AUC). Given S-warfarin's much longer half-life(31, 34"}, {"to": "23710", "prefix": ". Given S-", "from": "23703", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": "'s much longer half-life(31, 34"}, {"to": "23846", "prefix": ", rifampin was expected to be present in plasma for only portion of ", "from": "23839", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": "'s concentration time profile. Data from a previous study by our laboratory and "}, {"to": "24158", "prefix": "12h of S- and R-", "from": "24151", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": ", which represents the time a potential inhibitory effect on hepatic OATPs by ri"}, {"to": "24852", "prefix": " constant estimated when fitting ", "from": "24845", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " data to a two-compartmental model with first-order absorption. Vss"}, {"to": "25451", "prefix": "ogarithmic trapezoidal method.\n\nStatistical analysis\nUsing previously reported ", "from": "25444", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " pharmacokinetic data in healthy volunteers(31), a sample size of 10 subjects wo"}, {"to": "25595", "prefix": " 80% power to detect a 30% difference in S-", "from": "25588", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " AUC0"}, {"to": "26089", "prefix": "", "from": "26082", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " alone) and their 95% confidence intervals were calculated for all parameters. T"}, {"to": "26367", "prefix": " 0.05.\n\nAnalytic Methods\nThe concentrations of S- and R-", "from": "26360", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " and their main metabolites were measured using high pressure liquid chromatogra"}, {"to": "26698", "prefix": "z for R- and S-", "from": "26691", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": ", 323"}, {"to": "26734", "prefix": "z for 7-hydroxy-", "from": "26727", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": ", 323"}, {"to": "26771", "prefix": "z for 10-hydroxy-", "from": "26764", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": ", 312"}, {"to": "26800", "prefix": "z for d5-", "from": "26793", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " (internal standard for S- and R-warfarin) and 312"}, {"to": "26841", "prefix": "internal standard for S- and R-", "from": "26834", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": ") and 312"}, {"to": "26874", "prefix": "z for d5-", "from": "26867", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " (internal standard for metabolites).\n\nThe samples and standards for S- and R-wa"}, {"to": "26960", "prefix": ".\n\nThe samples and standards for S- and R-", "from": "26953", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " (Sigma-Aldrich, St. Louis, MO) were prepared by liquid-liquid extraction of 0.5"}, {"to": "27110", "prefix": "M d5-", "from": "27103", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " as internal standard. After being vortexed for one minute, the sample was centr"}, {"to": "27438", "prefix": "hen reconstituted in acetonitrile for analysis.\n\nThe samples and standards for ", "from": "27431", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " metabolites were prepared by liquid-liquid extraction of 100"}, {"to": "27558", "prefix": "M d5-", "from": "27551", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " as internal standard. Samples were vortexed for one minute followed by centrifu"}, {"to": "27914", "prefix": "pernatant was collected for analysis.\n\nChromatographic conditions for S- and R-", "from": "27907", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " were as described by Naidong and colleagues(43). In brief, R-warfarin and S-war"}, {"to": "27984", "prefix": ". In brief, R-", "from": "27977", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " and S-warfarin were separated isocratically on a Cyclobond"}, {"to": "27999", "prefix": ". In brief, R-warfarin and S-", "from": "27992", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " were separated isocratically on a Cyclobond"}, {"to": "28188", "prefix": ". R-d5-", "from": "28181", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " and S-d5-warfarin (racemic d5-warfarin from Toronto Research Chemicals, Inc., O"}, {"to": "28206", "prefix": ". R-d5-warfarin and S-d5-", "from": "28199", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " (racemic d5-warfarin from Toronto Research Chemicals, Inc., Ontario, Canada) en"}, {"to": "28227", "prefix": "racemic d5-", "from": "28220", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " from Toronto Research Chemicals, Inc., Ontario, Canada) enantiomers were also s"}, {"to": "28374", "prefix": "-cyclodextrin column and co-eluted with R-", "from": "28367", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " and S-warfarin, respectively. The mobile phase consisted of acetonitrile:acetic"}, {"to": "28389", "prefix": "-cyclodextrin column and co-eluted with R-warfarin and S-", "from": "28382", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": ", respectively. The mobile phase consisted of acetonitrile:acetic acid:triethyla"}, {"to": "28599", "prefix": "L. Retention times were 7.5 min for S-", "from": "28592", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " and 8.3 min for R-warfarin.\n\nChromatography for warfarin metabolites was perfor"}, {"to": "28626", "prefix": "L. Retention times were 7.5 min for S-warfarin and 8.3 min for R-", "from": "28619", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": ".\n\nChromatography for warfarin metabolites was performed on an Agilent Eclipse X"}, {"to": "28656", "prefix": "es were 7.5 min for S-warfarin and 8.3 min for R-warfarin.\n\nChromatography for ", "from": "28649", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " metabolites was performed on an Agilent Eclipse XDB C18 column (150 "}, {"to": "29093", "prefix": "min. The run time was 10 min.\n\nThe methods for S- and R-", "from": "29086", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " were validated from 1.5 to 300 ng"}, {"to": "205", "prefix": " inhibitor ", "from": "198", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": ", a clinical study was conducted in 10 healthy volunteers. In a randomized, sing"}, {"to": "436", "prefix": "g dose of warfarin alone or immediately following a 600 mg intravenous dose of ", "from": "429", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": ". Rifampin did not significantly alter R- or S- warfarin area under the concentr"}, {"to": "446", "prefix": "warfarin alone or immediately following a 600 mg intravenous dose of rifampin. ", "from": "439", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "Rifampin", "suffix": " did not significantly alter R- or S- warfarin area under the concentration-time"}, {"to": "601", "prefix": "period of hepatic OATP inhibition by ", "from": "594", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": ") or Cmax (maximum plasma concentration). AUC0"}, {"to": "675", "prefix": " was decreased on ", "from": "668", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " days for both R- (25% reduction; p "}, {"to": "3243", "prefix": " Using concomitant administration of single dose intravenous ", "from": "3236", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " as a non-specific OATP inhibitor, hepatic uptake inhibition resulted in a 1.3 a"}, {"to": "4482", "prefix": " human hepatocyte data showing decreased uptake of warfarin in the presence of ", "from": "4475", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": ", a clinical trial in healthy volunteers was conducted to examine the impact of "}, {"to": "4718", "prefix": "M ", "from": "4711", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": ", the uptake of 1 "}, {"to": "4963", "prefix": " by ", "from": "4956", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " (100 "}, {"to": "5350", "prefix": "single oral dose of 7.5 mg warfarin alone or with a single intravenous dose of ", "from": "5343", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": ". Data from a previous study by our laboratory and information provided in the p"}, {"to": "5488", "prefix": "information provided in the package insert, predict relevant concentrations of ", "from": "5481", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " for up to 12 hours after a single 600 mg intravenous dose(11, 16). Therefore, i"}, {"to": "5752", "prefix": " that would represent the time period of hepatic OATP inhibition by ", "from": "5745", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " and when any uptake effects on warfarin pharmacokinetics, if any, would be seen"}, {"to": "5842", "prefix": "d when any uptake effects on warfarin pharmacokinetics, if any, would be seen. ", "from": "5835", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "Rifampin", "suffix": " had no effect on the AUC0"}, {"to": "6126", "prefix": ".\n\nFigure 2\nFigure 2\nThe effect of a single dose of intravenous ", "from": "6119", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " on the mean plasma concentrations of (a) S-warfarin and (b) R-warfarin in 10 he"}, {"to": "6536", "prefix": "e of 7.5 mg warfarin alone or in combination with a single dose of intravenous ", "from": "6529", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": ".\nAnalysis of all concentration-time data showed rifampin significantly decrease"}, {"to": "6593", "prefix": "e dose of intravenous rifampin.\nAnalysis of all concentration-time data showed ", "from": "6586", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " significantly decreased the AUC0"}, {"to": "6812", "prefix": " of S-warfarin was not significantly different on ", "from": "6805", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " days (p "}, {"to": "6904", "prefix": "2 was seen on ", "from": "6897", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " days (p "}, {"to": "7013", "prefix": " was unaffected by the presence of ", "from": "7006", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " for both S- and R-warfarin.\n\nPharmacokinetics of warfarin metabolites\nThe conce"}, {"to": "7303", "prefix": "single oral dose of 7.5 mg warfarin alone or with a single intravenous dose of ", "from": "7296", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " are shown in Figure 3. Rifampin had no significant effect on 7-hydroxywarfarin "}, {"to": "7335", "prefix": "rin alone or with a single intravenous dose of rifampin are shown in Figure 3. ", "from": "7328", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "Rifampin", "suffix": " had no significant effect on 7-hydroxywarfarin AUC0"}, {"to": "7479", "prefix": ". For 10-hydroxywarfarin, ", "from": "7472", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " also had no effect on the AUC0"}, {"to": "7672", "prefix": "roxywarfarin between treatments began to diverge with higher concentrations on ", "from": "7665", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " days (Figure 3b). The Cmax of 10-hydroxywarfarin was increased 111% on rifampin"}, {"to": "7752", "prefix": ". The Cmax of 10-hydroxywarfarin was increased 111% on ", "from": "7745", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " days (p "}, {"to": "7810", "prefix": " but no change in Tmax was seen. ", "from": "7803", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "Rifampin", "suffix": " treatment also resulted in an 84% increase in the AUC0"}, {"to": "7987", "prefix": "2 decreased 50% on ", "from": "7980", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " days (p "}, {"to": "8299", "prefix": " 11%; warfarin plus ", "from": "8292", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": ", 44% "}, {"to": "8507", "prefix": " terminal phase.\n\nFigure 3\nFigure 3\nThe effect of a single dose of intravenous ", "from": "8500", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " on the mean plasma concentrations of (a) 7-hydroxywarfarin and (b) 10-hydroxywa"}, {"to": "8933", "prefix": "e of 7.5 mg warfarin alone or in combination with a single dose of intravenous ", "from": "8926", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": ".\nAUC ratios of metabolite to parent\nThe AUC0"}, {"to": "9107", "prefix": "n and 10-hydroxywarfarin to R-warfarin increased 20% and 58% respectively with ", "from": "9100", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " treatment (p "}, {"to": "9485", "prefix": ", but ", "from": "9478", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " caused no differences in INR measures compared to warfarin alone (Table 4).\n\nTa"}, {"to": "9750", "prefix": "e of 7.5 mg warfarin alone or in combination with a single dose of intravenous ", "from": "9743", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": ".\nSafety\nAll 10 subjects who were enrolled completed the study. No significant a"}, {"to": "10201", "prefix": "linical study demonstrated that co-administration of the potent OATP inhibitor ", "from": "10194", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": ", given as a single intravenous dose, had no effect on the AUC0"}, {"to": "10603", "prefix": "-drug interactions or genetic variation important in warfarin dose selection.\n\n", "from": "10596", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "Rifampin", "suffix": " was chosen as a model OATP inhibitor to block the in vivo OATP-mediated hepatic"}, {"to": "10735", "prefix": ". Because of ", "from": "10728", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": "'s shorter t1"}, {"to": "10901", "prefix": " and because we could not give ", "from": "10894", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " as multiple doses dues to its metabolic enzyme induction effect, rifampin was o"}, {"to": "10975", "prefix": "give rifampin as multiple doses dues to its metabolic enzyme induction effect, ", "from": "10968", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " was only present in plasma for a portion of warfarin's concentration-time curve"}, {"to": "11170", "prefix": "ential effect on warfarin pharmacokinetics occurred at most during the time of ", "from": "11163", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " presence, and therefore, outcome measures for our study needed to be suitably s"}, {"to": "11384", "prefix": "on. Previous reports have shown that after a single 600 mg intravenous dose of ", "from": "11377", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " to healthy volunteers, rifampin was present for up to 12"}, {"to": "11416", "prefix": "that after a single 600 mg intravenous dose of rifampin to healthy volunteers, ", "from": "11409", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " was present for up to 12"}, {"to": "11519", "prefix": " Assuming a similar time of exposure for ", "from": "11512", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " in our clinical study, the best parameters to capture the potential effects of "}, {"to": "11786", "prefix": "e pharmacokinetic parameters for S- or R-warfarin were seen in the presence of ", "from": "11779", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " suggesting OATP transport of warfarin is not clinically important.\n\nTwo previou"}, {"to": "12072", "prefix": "pharmacokinetics of atorvastatin and glyburide with hepatic OATP inhibition by ", "from": "12065", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": "(11, 12). The AUC of atorvastatin was 680% higher and the AUC of glyburide 130% "}, {"to": "12170", "prefix": "he AUC of atorvastatin was 680% higher and the AUC of glyburide 130% higher in ", "from": "12163", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " vs. control phases. In those clinical studies rifampin also produced a large de"}, {"to": "12225", "prefix": "lyburide 130% higher in rifampin vs. control phases. In those clinical studies ", "from": "12218", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " also produced a large decrease in the Vss"}, {"to": "12557", "prefix": "F for S- or R-warfarin on ", "from": "12550", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " days (Table 1), which we would have predicted if OATP transport processes were "}, {"to": "12798", "prefix": "ur in vitro data showed that warfarin uptake into hepatocytes was inhibited by ", "from": "12791", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " in both rats and humans (Figure 1) presumably via OATP uptake transporter inhib"}, {"to": "13026", "prefix": " was modest at the concentration of ", "from": "13019", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " (100 "}, {"to": "13112", "prefix": "M concentration of ", "from": "13105", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " used in our hepatocyte uptake studies is significantly higher than peak plasma "}, {"to": "13300", "prefix": "ere likely achieved in our healthy volunteers after a single IV dose of 600 mg ", "from": "13293", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " (17"}, {"to": "13560", "prefix": "uride. We cannot rule-out the possibility that higher plasma concentrations of ", "from": "13553", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " would result in additional OATP inhibition and therefore alter warfarin pharmco"}, {"to": "15100", "prefix": "\n\nIntravenous administration of ", "from": "15093", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " conceivably minimized any potential confounding interactions in the intestine a"}, {"to": "15302", "prefix": "level although the lack of an interaction cannot be fully confirmed. By giving ", "from": "15295", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " as a single dose, we attempted to avoid the well-described and clinically relev"}, {"to": "15613", "prefix": "mes for S- and R-warfarin respectively, has been described after multiple dose ", "from": "15606", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": ". The effect of multiple dose rifampin on warfarin pharmacokinetics was highligh"}, {"to": "15651", "prefix": ", has been described after multiple dose rifampin. The effect of multiple dose ", "from": "15644", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " on warfarin pharmacokinetics was highlighted in a clinical trial of four health"}, {"to": "15796", "prefix": " After 3 days of pretreatment with 300 mg oral ", "from": "15789", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " twice per day, a three-fold increase in R-warfarin clearance and a two-fold inc"}, {"to": "15982", "prefix": " clearance were seen. Interestingly, our clinical study using only single dose ", "from": "15975", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " immediately prior to warfarin likely demonstrates a mild enzyme inductive effec"}, {"to": "16250", "prefix": " with ", "from": "16243", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " treatment. The increase in Cmax and AUC for the R-warfarin metabolite 10-hydrox"}, {"to": "16579", "prefix": "cs of the specific S-warfarin metabolite 7-hydroxywarfarin did not change with ", "from": "16572", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " treatment and therefore is not congruent with induction of S-warfarin metabolis"}, {"to": "16877", "prefix": "12h, and Cmax were similar with and without ", "from": "16870", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": ". Such a delay is expected based on the mechanism of rifampin enzyme induction t"}, {"to": "16938", "prefix": " with and without rifampin. Such a delay is expected based on the mechanism of ", "from": "16931", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " enzyme induction through activation of the nuclear transcription factor pregnan"}, {"to": "17145", "prefix": "cal study examining the time-course of CYP enzyme induction with multiple-dose ", "from": "17138", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " using verapamil as a probe substrate reported a half-life of 1 day for the incr"}, {"to": "17298", "prefix": " CYP induction after single dose ", "from": "17291", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " has previously been shown with a single dose of 1200 mg oral rifampin given 12 "}, {"to": "17368", "prefix": "gle dose rifampin has previously been shown with a single dose of 1200 mg oral ", "from": "17361", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " given 12 hours before oral nifedipine, resulting in a 64% decrease in the AUC0"}, {"to": "17552", "prefix": " Nonetheless, the potential induction of warfarin metabolism by single-dose ", "from": "17545", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " in our study does not alter the interpretation of the primary objective of this"}, {"to": "18172", "prefix": " The addition of ", "from": "18165", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " had no effect on the warfarin pharmacodynamic response as measured by INRmax an"}, {"to": "18505", "prefix": "rmacodynamics.\n\nIn conclusion, our single dose clinical study of the effect of ", "from": "18498", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " on warfarin pharmacokinetics in healthy volunteers suggeststhat hepatic uptake "}, {"to": "18734", "prefix": " this highly metabolized, narrow therapeutic index, anticoagulant. Single-dose ", "from": "18727", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " may induce metabolizing enzymes such as CYP2C9 and CYP3A4.\n\nGo to:\nMETHODS\nIn V"}, {"to": "19684", "prefix": "M ", "from": "19677", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": ". The 100 "}, {"to": "19722", "prefix": "M concentration of ", "from": "19715", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " was chosen to maximize OATP inhibition and any effect on warfarin uptake Rifamp"}, {"to": "19804", "prefix": "ampin was chosen to maximize OATP inhibition and any effect on warfarin uptake ", "from": "19797", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "Rifampin", "suffix": " is a known inhibitor of the 3 major human OATPs, being a more potent inhibitor "}, {"to": "22010", "prefix": "5 mg warfarin immediately following a 30-minute intravenous infusion of 600 mg ", "from": "22003", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " (600 mg rifampin powder for injection reconstituted in 10 ml sterile water; Bed"}, {"to": "22027", "prefix": "600 mg ", "from": "22020", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " powder for injection reconstituted in 10 ml sterile water; Bedford Laboratories"}, {"to": "23578", "prefix": "time curve. We were most interested in ", "from": "23571", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": "'s inhibitory effect on hepatic OATPs and the anticipated changes in R- and S-wa"}, {"to": "23766", "prefix": " compared to ", "from": "23759", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": "(41), rifampin was expected to be present in plasma for only portion of warfarin"}, {"to": "23780", "prefix": ", ", "from": "23773", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " was expected to be present in plasma for only portion of warfarin's concentrati"}, {"to": "24020", "prefix": "tion provided in the package insert, predict relevant plasma concentrations of ", "from": "24013", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " for up to 12 hours after a single 600 mg intravenous dose.(11, 16) Accordingly,"}, {"to": "24244", "prefix": "n, which represents the time a potential inhibitory effect on hepatic OATPs by ", "from": "24237", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " would occur.\n\nAUC0"}, {"to": "26035", "prefix": " standard deviation. In addition, the geometric mean ratios of the ", "from": "26028", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " treatment values relative to control values (warfarin alone) and their 95% conf"}, {"to": "3151", "prefix": " in the disposition of two BDDCS Class 2 drugs: ", "from": "3140", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3091944", "exact": "atorvastatin", "suffix": "(11) and glyburide.(12) Using concomitant administration of single dose intraven"}, {"to": "12017", "prefix": "esign as used here demonstrated significant changes in the pharmacokinetics of ", "from": "12006", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3091944", "exact": "atorvastatin", "suffix": " and glyburide with hepatic OATP inhibition by rifampin(11, 12). The AUC of ator"}, {"to": "12105", "prefix": ". The AUC of ", "from": "12094", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3091944", "exact": "atorvastatin", "suffix": " was 680% higher and the AUC of glyburide 130% higher in rifampin vs. control ph"}, {"to": "12298", "prefix": "", "from": "12287", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3091944", "exact": "atorvastatin", "suffix": ", 93% decrease; glyburide, 60% decrease). This decrease in Vss"}, {"to": "21752", "prefix": "y to document the importance of OATP hepatic uptake in healthy voluneteers for ", "from": "21741", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3091944", "exact": "atorvastatin", "suffix": "(11) and glyburide(12). Subjects received on Day 1 of each study period either ("}, {"to": "3169", "prefix": " and ", "from": "3161", "name": "Glyburide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4815", "setId": "PMC3091944", "exact": "glyburide", "suffix": ".(12) Using concomitant administration of single dose intravenous rifampin as a "}, {"to": "3356", "prefix": "nhibitor, hepatic uptake inhibition resulted in a 1.3 and 6.8 fold increase in ", "from": "3348", "name": "Glyburide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4815", "setId": "PMC3091944", "exact": "glyburide", "suffix": " and atorvastin exposure, respectively, as measured by the total area under the "}, {"to": "12031", "prefix": "e demonstrated significant changes in the pharmacokinetics of atorvastatin and ", "from": "12023", "name": "Glyburide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4815", "setId": "PMC3091944", "exact": "glyburide", "suffix": " with hepatic OATP inhibition by rifampin(11, 12). The AUC of atorvastatin was 6"}, {"to": "12146", "prefix": ". The AUC of atorvastatin was 680% higher and the AUC of ", "from": "12138", "name": "Glyburide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4815", "setId": "PMC3091944", "exact": "glyburide", "suffix": " 130% higher in rifampin vs. control phases. In those clinical studies rifampin "}, {"to": "12323", "prefix": "atorvastatin, 93% decrease; ", "from": "12315", "name": "Glyburide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4815", "setId": "PMC3091944", "exact": "glyburide", "suffix": ", 60% decrease). This decrease in Vss"}, {"to": "13478", "prefix": "sults, but the in vitro effects were similar to what we observed in vitro with ", "from": "13470", "name": "Glyburide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4815", "setId": "PMC3091944", "exact": "glyburide", "suffix": ". We cannot rule-out the possibility that higher plasma concentrations of rifamp"}, {"to": "21770", "prefix": " and ", "from": "21762", "name": "Glyburide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4815", "setId": "PMC3091944", "exact": "glyburide", "suffix": "(12). Subjects received on Day 1 of each study period either (A) 7.5 mg warfarin"}, {"to": "17161", "prefix": "ning the time-course of CYP enzyme induction with multiple-dose rifampin using ", "from": "17153", "name": "Verapamil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11170", "setId": "PMC3091944", "exact": "verapamil", "suffix": " as a probe substrate reported a half-life of 1 day for the increase in CYP enzy"}, {"to": "17406", "prefix": "n shown with a single dose of 1200 mg oral rifampin given 12 hours before oral ", "from": "17397", "name": "Nifedipine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7417", "setId": "PMC3091944", "exact": "nifedipine", "suffix": ", resulting in a 64% decrease in the AUC0"}, {"to": "17463", "prefix": " of ", "from": "17454", "name": "Nifedipine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7417", "setId": "PMC3091944", "exact": "nifedipine", "suffix": ".(30) Nonetheless, the potential induction of warfarin metabolism by single-dose"}, {"to": "19664", "prefix": "0.1% ", "from": "19661", "name": "Dimethyl Sulfoxide", "fullId": "http://purl.bioontology.org/ontology/MESH/D004121", "setId": "PMC3091944", "exact": "DMSO", "suffix": ") or 100 "}, {"to": "20139", "prefix": "L of silicone:", "from": "20129", "name": "Mineral Oil", "fullId": "http://purl.bioontology.org/ontology/MESH/D008899", "setId": "PMC3091944", "exact": "mineral oil", "suffix": " mixture (83.3:16.7 v"}, {"to": "27384", "prefix": "p organic layer was collected, dried under nitrogen, and then reconstituted in ", "from": "27373", "name": "acetonitrile", "fullId": "http://purl.bioontology.org/ontology/MESH/C032159", "setId": "PMC3091944", "exact": "acetonitrile", "suffix": " for analysis.\n\nThe samples and standards for warfarin metabolites were prepared"}, {"to": "28447", "prefix": "ed with R-warfarin and S-warfarin, respectively. The mobile phase consisted of ", "from": "28436", "name": "acetonitrile", "fullId": "http://purl.bioontology.org/ontology/MESH/C032159", "setId": "PMC3091944", "exact": "acetonitrile", "suffix": ":acetic acid:triethylamine (1000:3:2.5 v:v:v) and the flow rate was 1mL"}, {"to": "28473", "prefix": "warfarin, respectively. The mobile phase consisted of acetonitrile:acetic acid:", "from": "28461", "name": "triethylamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1307097", "setId": "PMC3091944", "exact": "triethylamine", "suffix": " (1000:3:2.5 v:v:v) and the flow rate was 1mL"}, {"to": "18", "prefix": "ABSTRACT\n", "from": "10", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "Tamoxifen", "suffix": " remains an important adjuvant therapy to reduce the rate of breast cancer recur"}, {"to": "203", "prefix": "nts with oestrogen-receptor-positive tumours. Cytochrome P-450 2D6 metabolises ", "from": "195", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " to metabolites that more readily bind the oestrogen receptor. This enzyme also "}, {"to": "418", "prefix": " may reduce ", "from": "410", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": "'s prevention of breast cancer recurrence. We studied citalopram use in 184 case"}, {"to": "779", "prefix": "2001 and who took ", "from": "771", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " for 1, 2, or most often for 5 years. We ascertained prescription histories by l"}, {"to": "1098", "prefix": " received at least one prescription for the SSRI citalopram while taking ", "from": "1090", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " (adjusted conditional odds ratio"}, {"to": "1216", "prefix": ". We also observed no reduction of ", "from": "1208", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " effectiveness among regular citalopram users ("}, {"to": "1290", "prefix": "30% overlap with ", "from": "1282", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " use). These results suggest that concurrent use of citalopram does not reduce t"}, {"to": "1378", "prefix": ". These results suggest that concurrent use of citalopram does not reduce ", "from": "1370", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": "'s prevention of breast cancer recurrence.\n\nKeywords: breast neoplasms, pharmaco"}, {"to": "1493", "prefix": "cer recurrence.\n\nKeywords: breast neoplasms, pharmacology and therapeutic use, ", "from": "1485", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": ", antagonists and inhibitors, serotonin reuptake inhibitors, cytochrome P-450 2D"}, {"to": "1584", "prefix": "ntagonists and inhibitors, serotonin reuptake inhibitors, cytochrome P-450 2D6\n", "from": "1576", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "Tamoxifen", "suffix": " is a selective oestrogen receptor modulator (Jordan and Dowse, 1976) that reduc"}, {"to": "1887", "prefix": ". To be pharmacologically active, ", "from": "1879", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " must be metabolised to secondary metabolites that bind the oestrogen receptor 1"}, {"to": "2002", "prefix": "ondary metabolites that bind the oestrogen receptor 100-fold more readily than ", "from": "1994", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " itself (Malet et al, 1988). Four cytochrome P-450 enzymes (CYPs) catalyse this "}, {"to": "2214", "prefix": ". CYP2D6 catalyses formation of 4-hydroxytamoxifen from ", "from": "2206", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " (Coller et al, 2002) and formation of 4-hydroxy-N-desmethyltamoxifen from N-des"}, {"to": "2625", "prefix": "are, therefore, the most important modulators of the oestrogen receptor in the ", "from": "2617", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " pathway (Lim et al, 2005).\n\nBreast cancer patients treated with tamoxifen may a"}, {"to": "2699", "prefix": ".\n\nBreast cancer patients treated with ", "from": "2691", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " may also take other prescription medications that are metabolised by some of th"}, {"to": "2817", "prefix": "ion medications that are metabolised by some of the same enzymes that activate ", "from": "2809", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": ". For example, depression is a common comorbidity in breast cancer patients (Mas"}, {"to": "3141", "prefix": ". SSRI competition with ", "from": "3133", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " and N-desmethyltamoxifen for CYP2D6, or direct inhibition of CYP2D6 by SSRI, co"}, {"to": "3263", "prefix": "D6, or direct inhibition of CYP2D6 by SSRI, could reduce the production of the ", "from": "3255", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " metabolites with high receptor-binding affinity, and thereby reduce tamoxifen's"}, {"to": "3341", "prefix": " tamoxifen metabolites with high receptor-binding affinity, and thereby reduce ", "from": "3333", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": "'s prevention of breast cancer recurrence. Competition between tamoxifen and the"}, {"to": "3413", "prefix": "reduce tamoxifen's prevention of breast cancer recurrence. Competition between ", "from": "3405", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " and the SSRI paroxetine reduced the plasma concentration of endoxifen in a cros"}, {"to": "3897", "prefix": " biological basis for the hypothesis that concomitant use of SSRI would reduce ", "from": "3889", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": "'s prevention of breast cancer recurrence.\n\nIn the largest study to date of the "}, {"to": "4032", "prefix": "drug interaction to reduce ", "from": "4024", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": "'s protection against breast cancer recurrence, we examined whether Danish breas"}, {"to": "4202", "prefix": "cancer patients with oestrogen-receptor-positive tumours who were treated with ", "from": "4194", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " for 1, 2, or most often for 5 years had a higher rate of recurrence if they wer"}, {"to": "5864", "prefix": "hose tumour expressed the oestrogen receptor protein and who were treated with ", "from": "5856", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " for at least 1 year; (b) group II women whose tumour did not express the oestro"}, {"to": "5997", "prefix": "e tumour did not express the oestrogen receptor protein, were not treated with ", "from": "5989", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": ", and who survived for at least one year; and (c) group III women, comprising al"}, {"to": "6165", "prefix": "l others, who were excluded from this analysis. Group I women were assigned to ", "from": "6157", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " therapy protocols of 1, 2, or 5 years, depending on the guideline extant in Den"}, {"to": "8199", "prefix": "agement, receipt of radiation therapy, receipt of chemotherapy, and receipt of ", "from": "8191", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " therapy) from the DBCG database.\n\nWe collected data on receipt of citalopram pr"}, {"to": "10258", "prefix": "ho ever had a citalopram prescription, we calculated the percentage of time on ", "from": "10250", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " when they were simultaneously taking citalopram. We created categories of (a) i"}, {"to": "10413", "prefix": " intermittent citalopram use, defined as citalopram use overlapping ", "from": "10405", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " use for more than 0% but less than 30% of the time on tamoxifen and (b) regular"}, {"to": "10477", "prefix": "se overlapping tamoxifen use for more than 0% but less than 30% of the time on ", "from": "10469", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " and (b) regular citalopram use, defined as citalopram use overlapping tamoxifen"}, {"to": "10557", "prefix": " regular citalopram use, defined as citalopram use overlapping ", "from": "10549", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " use for 30% or more of the time on tamoxifen. We chose 30% as the overlap bound"}, {"to": "10602", "prefix": "ned as citalopram use overlapping tamoxifen use for 30% or more of the time on ", "from": "10594", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": ". We chose 30% as the overlap boundary to allow sufficient sample size in the re"}, {"to": "10776", "prefix": "citalopram subgroup, while also investigating a substantial period of SSRI and ", "from": "10768", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " comedication.\n\nCovariates\nWe defined the following set of covariates: (a) time "}, {"to": "11529", "prefix": "on that is a CYP2D6 inhibitor or substrate, including other SSRI, while taking ", "from": "11521", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": ".\n\nAnalytic strategy\nAll analyses were conducted within strata of the two groups"}, {"to": "11665", "prefix": "oestrogen-receptor positive and treated with ", "from": "11657", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " or oestrogen-receptor negative and not treated with tamoxifen). We computed the"}, {"to": "11727", "prefix": "and treated with tamoxifen or oestrogen-receptor negative and not treated with ", "from": "11719", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": "). We computed the frequency and proportion of cases and controls within categor"}, {"to": "11844", "prefix": "and proportion of cases and controls within categories of assigned protocol of ", "from": "11836", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " duration, of citalopram use, of use of other CYP2D6 inhibitors or substrates, a"}, {"to": "12633", "prefix": ". We examined whether the effect of citalopram use was modified by duration of ", "from": "12625", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " therapy in a stratified analysis. Finally, we adjusted for residual confounding"}, {"to": "13920", "prefix": "positive oestrogen-receptor expression and treated with ", "from": "13912", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": ") were more likely to be post-menopausal (87%) than were group II women (66%; ne"}, {"to": "14067", "prefix": "66%; negative oestrogen-receptor expression and not treated with ", "from": "14059", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": "). Group I women were also less likely to receive systemic adjuvant chemotherapy"}, {"to": "14495", "prefix": "tor. Between 3 and 11% of cases and controls ever used citalopram while taking ", "from": "14487", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " (group I) or during their follow-up period (group II).\n\nTable 1\nTable 1\nFrequen"}, {"to": "14751", "prefix": " expressing the oestrogen receptor and receiving at least 1 year of ", "from": "14743", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " therapy (ERP"}, {"to": "15687", "prefix": " expressing the oestrogen receptor and receiving at least 1 year of ", "from": "15679", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " therapy (ERP"}, {"to": "15774", "prefix": ", ...\nGroup I women who ever used citalopram while taking ", "from": "15766", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " did not have a higher rate of breast cancer recurrence than women who never use"}, {"to": "15889", "prefix": " of breast cancer recurrence than women who never used citalopram while taking ", "from": "15881", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " (Table 3; OR"}, {"to": "15991", "prefix": ". This OR was not substantially modified by duration of ", "from": "15983", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " therapy (P"}, {"to": "16811", "prefix": "ours that expressed the oestrogen receptor and who received at least 1 year of ", "from": "16803", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " therapy (ERP"}, {"to": "16977", "prefix": "s study do not support the hypothesis that citalopram, taken concurrently with ", "from": "16969", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": ", reduces tamoxifen's protective effect against breast cancer recurrence in earl"}, {"to": "16996", "prefix": "ort the hypothesis that citalopram, taken concurrently with tamoxifen, reduces ", "from": "16988", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": "'s protective effect against breast cancer recurrence in early-stage patients wh"}, {"to": "17372", "prefix": "ted States oncology centre, which also reported no substantial modification of ", "from": "17364", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " effectiveness by concomitant use of SSRI inhibitors of CYP2D6 (Lehmann et al, 2"}, {"to": "17620", "prefix": " vivo evidence that support the hypothesis that CYP2D6 inhibition would reduce ", "from": "17612", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": "'s prevention of breast cancer recurrence. It is possible, however, that SSRI me"}, {"to": "17760", "prefix": "sible, however, that SSRI medications could reduce the plasma concentration of ", "from": "17752", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": "'s secondary metabolites without reducing its anti-tumorigenicity (Ponzone et al"}, {"to": "17900", "prefix": ". ", "from": "17892", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "Tamoxifen", "suffix": " doses as much as 20-fold lower than the typical US dose of 20"}, {"to": "18148", "prefix": ", so the approximately three-fold reduction in the plasma concentration of ", "from": "18140", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": "'s secondary metabolites associated with concomitant receipt of the SSRI paroxet"}, {"to": "18366", "prefix": "\n\nThe key mechanistic question may be whether reduced concentrations of active ", "from": "18358", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " metabolites result in substantially reduced occupancy of the oestrogen receptor"}, {"to": "18548", "prefix": "mg ", "from": "18540", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": ", tamoxifen and its metabolites occupy 9994 of 10"}, {"to": "18559", "prefix": "mg tamoxifen, ", "from": "18551", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " and its metabolites occupy 9994 of 10"}, {"to": "18697", "prefix": "en receptors. Replicating their calculation using the plasma concentrations of ", "from": "18689", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " and its metabolites in women with no CYP2D6 variant allele (Jin et al, 2005), t"}, {"to": "18785", "prefix": ", ", "from": "18777", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " and its metabolites would occupy 9999 of 10"}, {"to": "19004", "prefix": "g the strong CYP2D6-inhibiting SSRI paroxetine. Steady-state concentrations of ", "from": "18996", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " and its metabolites may be sufficient to manifest fully tamoxifen's antitumorig"}, {"to": "19070", "prefix": "ntrations of tamoxifen and its metabolites may be sufficient to manifest fully ", "from": "19062", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": "'s antitumorigenic effect in postmenopausal women regardless of whether CYP2D6 i"}, {"to": "19203", "prefix": "omen regardless of whether CYP2D6 inhibition reduces the concentration of some ", "from": "19195", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " metabolites.\n\nNonetheless, our results should be considered with the following "}, {"to": "19638", "prefix": ". These more potent inhibitors may reduce ", "from": "19630", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": "'s protection against breast cancer recurrence, but their interaction with tamox"}, {"to": "19722", "prefix": "ifen's protection against breast cancer recurrence, but their interaction with ", "from": "19714", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " would not have been well measured by this study.\n\nSecond, we have not collected"}, {"to": "19922", "prefix": " that affect the metabolism of ", "from": "19914", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " (Jin et al, 2005). The combination of genotype and receipt of CYP2D6-inhibiting"}, {"to": "20044", "prefix": "n of genotype and receipt of CYP2D6-inhibiting medications has been related to ", "from": "20036", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " effectiveness in a previous study (Goetz et al, 2007). We do not, however, expe"}, {"to": "20176", "prefix": ". We do not, however, expect ever-receipt of citalopram while taking ", "from": "20168", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " to be related to CYP2D6 genotype, as this genotype would be unknown to the pati"}, {"to": "20992", "prefix": " breast cancer recurrence and duration of citalopram prescription while taking ", "from": "20984", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": ". Some non-randomized studies suggest such a relation between genotype and SSRI "}, {"to": "21523", "prefix": ". Paroxetine is the most potent CYP2D6 inhibitor of ", "from": "21515", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " metabolism among the SSRI class (Jin et al, 2005). If CYP2D6 genotype does not "}, {"to": "24014", "prefix": " advantages, the study yielded only 17 cases of breast cancer recurrence among ", "from": "24006", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": "-treated women who had used citalopram while taking tamoxifen. The study was des"}, {"to": "24075", "prefix": " recurrence among tamoxifen-treated women who had used citalopram while taking ", "from": "24067", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": ". The study was designed with 80% power to detect an OR of 1.6, and ultimately h"}, {"to": "24368", "prefix": "od and Drug Administration advisory committee recently recommended relabelling ", "from": "24360", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " with information on gene"}, {"to": "24642", "prefix": "omprehensive Cancer Network note that some SSRI reduce the formation of active ", "from": "24634", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " metabolites, that citalopram and venlaflaxine appear to have minimal impact on "}, {"to": "24731", "prefix": "metabolites, that citalopram and venlaflaxine appear to have minimal impact on ", "from": "24723", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " metabolism, and that "}, {"to": "24896", "prefix": ". Breast cancer patients taking ", "from": "24888", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": " and their physicians may therefore be concerned about SSRI comedication, even w"}, {"to": "25094", "prefix": "ly indicated. Our results suggest that citalopram prescription does not reduce ", "from": "25086", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "PMC2527838", "exact": "tamoxifen", "suffix": "'s prevention of breast cancer recurrence.\n\nGo to:\nEXTERNAL DATA OBJECTS\nSupplem"}, {"to": "482", "prefix": " may reduce tamoxifen's prevention of breast cancer recurrence. We studied ", "from": "473", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " use in 184 cases of breast cancer recurrence and 184 matched controls without r"}, {"to": "1075", "prefix": " received at least one prescription for the SSRI ", "from": "1066", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " while taking tamoxifen (adjusted conditional odds ratio"}, {"to": "1255", "prefix": ". We also observed no reduction of tamoxifen effectiveness among regular ", "from": "1246", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " users ("}, {"to": "1352", "prefix": ". These results suggest that concurrent use of ", "from": "1343", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " does not reduce tamoxifen's prevention of breast cancer recurrence.\n\nKeywords: "}, {"to": "4324", "prefix": "ars had a higher rate of recurrence if they were concomitantly taking the SSRI ", "from": "4315", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " or its S-stereoisomer ("}, {"to": "4448", "prefix": " than if they were not. As described in more detail below, ", "from": "4439", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " was the most frequently prescribed SSRI in the study population.\n\nGo to:\nMATERI"}, {"to": "6357", "prefix": "ir diagnoses. We included group II women to estimate the direct association of ", "from": "6348", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " prescription with recurrence rate, if any. We further restricted the source pop"}, {"to": "6730", "prefix": ", which were used to ascertain use of prescription medications, including ", "from": "6721", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": ". Follow-up time began 1 year after the date of breast cancer diagnosis and cont"}, {"to": "8276", "prefix": " from the DBCG database.\n\nWe collected data on receipt of ", "from": "8267", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " prescription and other potential CYP2D6 inhibitors (including other SSRI) by li"}, {"to": "9248", "prefix": ", ", "from": "9239", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " (N06AB04), paroxetine (N06AB05), sertraline (N06AB06), alaproclate (N06AB07), f"}, {"to": "9389", "prefix": ", and ", "from": "9378", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "escitalopram", "suffix": " (N06AB10). We defined citalopram exposure as any prescription for citalopram (N"}, {"to": "9422", "prefix": ". We defined ", "from": "9413", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " exposure as any prescription for citalopram (N06AB04) or its S-stereoisomer esc"}, {"to": "9466", "prefix": ". We defined citalopram exposure as any prescription for ", "from": "9457", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " (N06AB04) or its S-stereoisomer escitalopram (N06AB10).\n\nWe classified cases an"}, {"to": "9511", "prefix": " or its S-stereoisomer ", "from": "9500", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "escitalopram", "suffix": " (N06AB10).\n\nWe classified cases and controls as those with no record of a cital"}, {"to": "9596", "prefix": ".\n\nWe classified cases and controls as those with no record of a ", "from": "9587", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " prescription during their follow-up time (never citalopram) and those with any "}, {"to": "9655", "prefix": "never ", "from": "9646", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": ") and those with any record of prescription for citalopram during their follow-u"}, {"to": "9713", "prefix": " and those with any record of prescription for ", "from": "9704", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " during their follow-up time (ever citalopram). We used a similar procedure to c"}, {"to": "9758", "prefix": "ever ", "from": "9749", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": "). We used a similar procedure to classify cases and controls as ever or never u"}, {"to": "10194", "prefix": "quency of their use in the study population.\n\nFor group I women who ever had a ", "from": "10185", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " prescription, we calculated the percentage of time on tamoxifen when they were "}, {"to": "10306", "prefix": "lated the percentage of time on tamoxifen when they were simultaneously taking ", "from": "10297", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": ". We created categories of (a) intermittent citalopram use, defined as citalopra"}, {"to": "10360", "prefix": " intermittent ", "from": "10351", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " use, defined as citalopram use overlapping tamoxifen use for more than 0% but l"}, {"to": "10387", "prefix": " intermittent citalopram use, defined as ", "from": "10378", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " use overlapping tamoxifen use for more than 0% but less than 30% of the time on"}, {"to": "10504", "prefix": " regular ", "from": "10495", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " use, defined as citalopram use overlapping tamoxifen use for 30% or more of the"}, {"to": "10531", "prefix": " regular citalopram use, defined as ", "from": "10522", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " use overlapping tamoxifen use for 30% or more of the time on tamoxifen. We chos"}, {"to": "10698", "prefix": "ose 30% as the overlap boundary to allow sufficient sample size in the regular ", "from": "10689", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " subgroup, while also investigating a substantial period of SSRI and tamoxifen c"}, {"to": "11868", "prefix": " and controls within categories of assigned protocol of tamoxifen duration, of ", "from": "11859", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " use, of use of other CYP2D6 inhibitors or substrates, and of the covariates. We"}, {"to": "12018", "prefix": " the covariates. We calculated the number of cases and controls ever receiving ", "from": "12009", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": ", the number of total prescriptions for citalopram summed over all cases or cont"}, {"to": "12068", "prefix": " and controls ever receiving citalopram, the number of total prescriptions for ", "from": "12059", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " summed over all cases or controls, and the range of the number of prescriptions"}, {"to": "12163", "prefix": "d over all cases or controls, and the range of the number of prescriptions for ", "from": "12154", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " received by each individual case or control.\n\nWe estimated the rate ratio assoc"}, {"to": "12260", "prefix": "d by each individual case or control.\n\nWe estimated the rate ratio associating ", "from": "12251", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " prescription with breast cancer recurrence as the odds ratio (OR) in a conditio"}, {"to": "12389", "prefix": " in a conditional logistic regression including only ", "from": "12380", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " use as the exposure variable and conditioned on the matched factors. By design,"}, {"to": "12591", "prefix": ". We examined whether the effect of ", "from": "12582", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " use was modified by duration of tamoxifen therapy in a stratified analysis. Fin"}, {"to": "12993", "prefix": "affected the log OR from the conditional logistic regression model associating ", "from": "12984", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " use with breast cancer recurrence rate by more than 10% (Greenland, 1989). All "}, {"to": "14472", "prefix": "ssed the oestrogen receptor. Between 3 and 11% of cases and controls ever used ", "from": "14463", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " while taking tamoxifen (group I) or during their follow-up period (group II).\n\n"}, {"to": "14968", "prefix": "es and controls. In both groups, SSRI prescriptions were primarily written for ", "from": "14959", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " or its S-stereoisomer, escitalopram. For example, 17 of 23 group I cases (74%) "}, {"to": "15004", "prefix": "SRI prescriptions were primarily written for citalopram or its S-stereoisomer, ", "from": "14993", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "escitalopram", "suffix": ". For example, 17 of 23 group I cases (74%) ever prescribed an SSRI had at least"}, {"to": "15116", "prefix": " ever prescribed an SSRI had at least one prescription for ", "from": "15107", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": ", accounting for 86% of the total number of prescriptions. Similarly, 22 of 30 g"}, {"to": "15286", "prefix": " ever prescribed an SSRI had at least one prescription for ", "from": "15277", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": ", accounting for 64% of their prescriptions. Sertraline accounted for the majori"}, {"to": "15751", "prefix": ", ...\nGroup I women who ever used ", "from": "15742", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " while taking tamoxifen did not have a higher rate of breast cancer recurrence t"}, {"to": "15866", "prefix": "d not have a higher rate of breast cancer recurrence than women who never used ", "from": "15857", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " while taking tamoxifen (Table 3; OR"}, {"to": "16280", "prefix": ". The effects were likewise approximately null within cumulative ", "from": "16271", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " prescription categories (intermittent use OR"}, {"to": "16399", "prefix": ". ", "from": "16390", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "Citalopram", "suffix": " use also had no substantial effect on recurrence in group II women (adjusted OR"}, {"to": "16531", "prefix": ", suggesting that ", "from": "16522", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " does not directly affect the risk of breast cancer recurrence.\n\nTable 3\nTable 3"}, {"to": "16942", "prefix": "Go to:\nDISCUSSION\nThe results of this study do not support the hypothesis that ", "from": "16933", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": ", taken concurrently with tamoxifen, reduces tamoxifen's protective effect again"}, {"to": "19378", "prefix": "tions in mind. First, the majority of SSRI prescriptions in our study were for ", "from": "19369", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " or its S-stereoisomer, both originally manufactured by Lundbeck, a company head"}, {"to": "19490", "prefix": " both originally manufactured by Lundbeck, a company headquartered in Denmark. ", "from": "19481", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "Citalopram", "suffix": " is a modest inhibitor of CYP2D6 compared with some other SSRI medications (Jepp"}, {"to": "20153", "prefix": ". We do not, however, expect ever-receipt of ", "from": "20144", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " while taking tamoxifen to be related to CYP2D6 genotype, as this genotype would"}, {"to": "20296", "prefix": "pe, as this genotype would be unknown to the patient and provider at the first ", "from": "20287", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " prescription. This study's results therefore pertain to the usual clinical sett"}, {"to": "20441", "prefix": " the usual clinical setting. In addition, CYP2D6 genotype is unlikely to cause ", "from": "20432", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " prescription, or to share a common causal ancestor, so CYP2D6 genotype does not"}, {"to": "20679", "prefix": ". It may be possible that CYP2D6 genotype is related to adherence to ", "from": "20670", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " prescription or to long-term maintenance of the prescription, resulting from di"}, {"to": "20956", "prefix": "ould confound the association between breast cancer recurrence and duration of ", "from": "20947", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " prescription while taking tamoxifen. Some non-randomized studies suggest such a"}, {"to": "21769", "prefix": " association we have reported.\n\nLast, we do not know the indications for which ", "from": "21760", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " was prescribed to the study participants, although ordinarily it would be presc"}, {"to": "23666", "prefix": "ses are expected to have high sensitivity and specificity for ascertainment of ", "from": "23657", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " prescriptions in the source population. Furthermore, because the prescription r"}, {"to": "24052", "prefix": "7 cases of breast cancer recurrence among tamoxifen-treated women who had used ", "from": "24043", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " while taking tamoxifen. The study was designed with 80% power to detect an OR o"}, {"to": "24671", "prefix": "note that some SSRI reduce the formation of active tamoxifen metabolites, that ", "from": "24662", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " and venlaflaxine appear to have minimal impact on tamoxifen metabolism, and tha"}, {"to": "25055", "prefix": "on, even when antidepressants are strongly indicated. Our results suggest that ", "from": "25046", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "PMC2527838", "exact": "citalopram", "suffix": " prescription does not reduce tamoxifen's prevention of breast cancer recurrence"}, {"to": "2199", "prefix": ". CYP2D6 catalyses formation of ", "from": "2182", "name": "afimoxifene", "fullId": "http://purl.bioontology.org/ontology/MESH/C016601", "setId": "PMC2527838", "exact": "4-hydroxytamoxifen", "suffix": " from tamoxifen (Coller et al, 2002) and formation of 4-hydroxy-N-desmethyltamox"}, {"to": "3437", "prefix": "ention of breast cancer recurrence. Competition between tamoxifen and the SSRI ", "from": "3428", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "PMC2527838", "exact": "paroxetine", "suffix": " reduced the plasma concentration of endoxifen in a cross-over clinical trial (S"}, {"to": "9270", "prefix": ", ", "from": "9261", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "PMC2527838", "exact": "paroxetine", "suffix": " (N06AB05), sertraline (N06AB06), alaproclate (N06AB07), fluvoxamine (N06AB08), "}, {"to": "18231", "prefix": "oxifen's secondary metabolites associated with concomitant receipt of the SSRI ", "from": "18222", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "PMC2527838", "exact": "paroxetine", "suffix": " (Jin et al, 2005) may have little consequence.\n\nThe key mechanistic question ma"}, {"to": "18962", "prefix": "000 receptors in women taking the strong CYP2D6-inhibiting SSRI ", "from": "18953", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "PMC2527838", "exact": "paroxetine", "suffix": ". Steady-state concentrations of tamoxifen and its metabolites may be sufficient"}, {"to": "21428", "prefix": " was not related to either the occurrence of adverse events or to adherence to ", "from": "21419", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "PMC2527838", "exact": "paroxetine", "suffix": " prescription (Murphy et al, 2003). Paroxetine is the most potent CYP2D6 inhibit"}, {"to": "21474", "prefix": ". ", "from": "21465", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "PMC2527838", "exact": "Paroxetine", "suffix": " is the most potent CYP2D6 inhibitor of tamoxifen metabolism among the SSRI clas"}, {"to": "5608", "prefix": "ss of whether they enrol in a trial, so the registry provides the data quality ", "from": "5600", "name": "imidacloprid", "fullId": "http://purl.bioontology.org/ontology/MESH/C082359", "setId": "PMC2527838", "exact": "advantage", "suffix": " of a clinical trial setting with the generalisability advantage of a population"}, {"to": "5672", "prefix": "e data quality advantage of a clinical trial setting with the generalisability ", "from": "5664", "name": "imidacloprid", "fullId": "http://purl.bioontology.org/ontology/MESH/C082359", "setId": "PMC2527838", "exact": "advantage", "suffix": " of a population-based setting.\n\nWe divided the source population into three gro"}, {"to": "9204", "prefix": "s as all those classified in group N06AB by the ATC. These are the SSRI drugs: ", "from": "9196", "name": "Zimeldine", "fullId": "http://purl.bioontology.org/ontology/MESH/D015031", "setId": "PMC2527838", "exact": "zimeldine", "suffix": " (N06AB02), fluoxetine (N06AB03), citalopram (N06AB04), paroxetine (N06AB05), se"}, {"to": "9226", "prefix": ", ", "from": "9217", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "PMC2527838", "exact": "fluoxetine", "suffix": " (N06AB03), citalopram (N06AB04), paroxetine (N06AB05), sertraline (N06AB06), al"}, {"to": "9292", "prefix": ", ", "from": "9283", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "PMC2527838", "exact": "sertraline", "suffix": " (N06AB06), alaproclate (N06AB07), fluvoxamine (N06AB08), etoperidone (N06AB09),"}, {"to": "15341", "prefix": "st one prescription for citalopram, accounting for 64% of their prescriptions. ", "from": "15332", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "PMC2527838", "exact": "Sertraline", "suffix": " accounted for the majority of the remaining prescriptions (11% of the total for"}, {"to": "9315", "prefix": ", ", "from": "9305", "name": "alaproclate", "fullId": "http://purl.bioontology.org/ontology/MESH/C025293", "setId": "PMC2527838", "exact": "alaproclate", "suffix": " (N06AB07), fluvoxamine (N06AB08), etoperidone (N06AB09), and escitalopram (N06A"}, {"to": "9338", "prefix": ", ", "from": "9328", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "PMC2527838", "exact": "fluvoxamine", "suffix": " (N06AB08), etoperidone (N06AB09), and escitalopram (N06AB10). We defined citalo"}, {"to": "9361", "prefix": ", ", "from": "9351", "name": "etoperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C013528", "setId": "PMC2527838", "exact": "etoperidone", "suffix": " (N06AB09), and escitalopram (N06AB10). We defined citalopram exposure as any pr"}, {"to": "83", "prefix": " drug-drug interactions between ", "from": "74", "name": "tipranavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C107201", "setId": "PMC2764168", "exact": "tipranavir", "suffix": "-ritonavir (TPV"}, {"to": "697", "prefix": "r at steady state versus alone. ", "from": "688", "name": "tipranavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C107201", "setId": "PMC2764168", "exact": "Tipranavir", "suffix": " PK parameters were not affected by single-dose rosuvastatin or atorvastatin. Mi"}, {"to": "1171", "prefix": "r.\n\n", "from": "1162", "name": "tipranavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C107201", "setId": "PMC2764168", "exact": "Tipranavir", "suffix": " coadministered with low-dose ritonavir (TPV"}, {"to": "5985", "prefix": "y. Subjects received a single 10-mg dose of rosuvastatin on day 1, followed by ", "from": "5976", "name": "tipranavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C107201", "setId": "PMC2764168", "exact": "tipranavir", "suffix": " 500 mg-ritonavir 200 mg twice daily for 11 days (days 3 to 13), with a single 1"}, {"to": "6480", "prefix": " for rosuvastatin and days 12 and 13 for ", "from": "6471", "name": "tipranavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C107201", "setId": "PMC2764168", "exact": "tipranavir", "suffix": " and ritonavir. A standard 670-kcal (33% fat) breakfast was served to subjects w"}, {"to": "6862", "prefix": "ints: 0 h predose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 h postdose for ", "from": "6853", "name": "tipranavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C107201", "setId": "PMC2764168", "exact": "tipranavir", "suffix": " and ritonavir and 0 h predose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, an"}, {"to": "7203", "prefix": " at steady state was undertaken. The short-term safety and steady-state PKs of ", "from": "7194", "name": "tipranavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C107201", "setId": "PMC2764168", "exact": "tipranavir", "suffix": " and ritonavir coadministered with single-dose rosuvastatin (10 mg) were also ev"}, {"to": "7875", "prefix": "All subjects had 100% adherence with study medication. The steady-state PKs of ", "from": "7866", "name": "tipranavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C107201", "setId": "PMC2764168", "exact": "tipranavir", "suffix": " were assessed on day 19 after ingestion of TPV"}, {"to": "8517", "prefix": ".\n\nBlood samples for analysis of ", "from": "8508", "name": "tipranavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C107201", "setId": "PMC2764168", "exact": "tipranavir", "suffix": " concentrations were collected in heparinized tubes on days 19 and 20 by an indw"}, {"to": "11416", "prefix": " ", "from": "11407", "name": "tipranavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C107201", "setId": "PMC2764168", "exact": "Tipranavir", "suffix": " assay.\nA validated HPLC-MS-MS method was used to measure plasma drug concentrat"}, {"to": "11514", "prefix": " validated HPLC-MS-MS method was used to measure plasma drug concentrations of ", "from": "11505", "name": "tipranavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C107201", "setId": "PMC2764168", "exact": "tipranavir", "suffix": " and ritonavir (16). In general terms, ritonavir, tipranavir, and an IS are extr"}, {"to": "11574", "prefix": ". In general terms, ritonavir, ", "from": "11565", "name": "tipranavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C107201", "setId": "PMC2764168", "exact": "tipranavir", "suffix": ", and an IS are extracted from EDTA human plasma by a two-step liquid-liquid ext"}, {"to": "11948", "prefix": "formic acid-acetic acid-acetonitrile mobile phase. For the atorvastatin study, ", "from": "11939", "name": "tipranavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C107201", "setId": "PMC2764168", "exact": "tipranavir", "suffix": " and an IS (PNU-109011) were extracted from 50 "}, {"to": "15234", "prefix": "ficant for all comparisons. The within-subject variability in the steady-state ", "from": "15225", "name": "tipranavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C107201", "setId": "PMC2764168", "exact": "tipranavir", "suffix": " AUC0-12 was calculated as the percent difference between the individual tiprana"}, {"to": "15317", "prefix": "anavir AUC0-12 was calculated as the percent difference between the individual ", "from": "15308", "name": "tipranavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C107201", "setId": "PMC2764168", "exact": "tipranavir", "suffix": " AUC0-12 values on day 19 and day 20.\n\nFor sample size calculations in both stud"}, {"to": "16598", "prefix": ". ", "from": "16589", "name": "tipranavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C107201", "setId": "PMC2764168", "exact": "Tipranavir", "suffix": " and ritonavir PK parameters were not affected by single-dose rosuvastatin (see "}, {"to": "19027", "prefix": " cm. The atorvastatin PK results from one subject and the steady-state ", "from": "19018", "name": "tipranavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C107201", "setId": "PMC2764168", "exact": "tipranavir", "suffix": " PK results from another subject were excluded from all statistical analyses bec"}, {"to": "20844", "prefix": " ...\nSingle-dose atorvastatin did not affect the steady-state PKs of ", "from": "20835", "name": "tipranavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C107201", "setId": "PMC2764168", "exact": "tipranavir", "suffix": " (Table "}, {"to": "22856", "prefix": ". Although in vitro studies indicate that ", "from": "22847", "name": "tipranavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C107201", "setId": "PMC2764168", "exact": "tipranavir", "suffix": " is an inhibitor of CYP2C9, an in vivo cocktail study determined that the steady"}, {"to": "22963", "prefix": "f CYP2C9, an in vivo cocktail study determined that the steady-state levels of ", "from": "22954", "name": "tipranavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C107201", "setId": "PMC2764168", "exact": "tipranavir", "suffix": " (500 mg) plus ritonavir 200 mg twice daily did not affect concentrations of pla"}, {"to": "25490", "prefix": ". ", "from": "25481", "name": "tipranavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C107201", "setId": "PMC2764168", "exact": "Tipranavir", "suffix": ", ritonavir, and lopinavir are also BCRP inhibitors in vitro (19, 27). Concentra"}, {"to": "25886", "prefix": "he result of dual inhibition of OATP1B1 and BCRP transporters by ritonavir and ", "from": "25877", "name": "tipranavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C107201", "setId": "PMC2764168", "exact": "tipranavir", "suffix": ". Inhibition of OATP1B1 may lead to a decrease in hepatocyte uptake of rosuvasta"}, {"to": "93", "prefix": " drug-drug interactions between tipranavir-", "from": "85", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC2764168", "exact": "ritonavir", "suffix": " (TPV"}, {"to": "1210", "prefix": "r.\n\nTipranavir coadministered with low-dose ", "from": "1202", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC2764168", "exact": "ritonavir", "suffix": " (TPV"}, {"to": "6002", "prefix": "ed a single 10-mg dose of rosuvastatin on day 1, followed by tipranavir 500 mg-", "from": "5994", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC2764168", "exact": "ritonavir", "suffix": " 200 mg twice daily for 11 days (days 3 to 13), with a single 10-mg dose of rosu"}, {"to": "6494", "prefix": " for rosuvastatin and days 12 and 13 for tipranavir and ", "from": "6486", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC2764168", "exact": "ritonavir", "suffix": ". A standard 670-kcal (33% fat) breakfast was served to subjects within 30 min b"}, {"to": "6876", "prefix": "se and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 h postdose for tipranavir and ", "from": "6868", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC2764168", "exact": "ritonavir", "suffix": " and 0 h predose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 h postdos"}, {"to": "7217", "prefix": "e was undertaken. The short-term safety and steady-state PKs of tipranavir and ", "from": "7209", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC2764168", "exact": "ritonavir", "suffix": " coadministered with single-dose rosuvastatin (10 mg) were also evaluated.\n\n(ii)"}, {"to": "8762", "prefix": ". ", "from": "8754", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC2764168", "exact": "Ritonavir", "suffix": " plasma concentrations were not measured in this study.\n\nOn PK sampling days, at"}, {"to": "11528", "prefix": "-MS-MS method was used to measure plasma drug concentrations of tipranavir and ", "from": "11520", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC2764168", "exact": "ritonavir", "suffix": " (16). In general terms, ritonavir, tipranavir, and an IS are extracted from EDT"}, {"to": "11562", "prefix": ". In general terms, ", "from": "11554", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC2764168", "exact": "ritonavir", "suffix": ", tipranavir, and an IS are extracted from EDTA human plasma by a two-step liqui"}, {"to": "16612", "prefix": ". Tipranavir and ", "from": "16604", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC2764168", "exact": "ritonavir", "suffix": " PK parameters were not affected by single-dose rosuvastatin (see Table "}, {"to": "22987", "prefix": " plus ", "from": "22979", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC2764168", "exact": "ritonavir", "suffix": " 200 mg twice daily did not affect concentrations of plasma S-warfarin, a CYP2C9"}, {"to": "25501", "prefix": ". Tipranavir, ", "from": "25493", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC2764168", "exact": "ritonavir", "suffix": ", and lopinavir are also BCRP inhibitors in vitro (19, 27). Concentration-depend"}, {"to": "25650", "prefix": "-d-glucuronide uptake by ", "from": "25642", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC2764168", "exact": "ritonavir", "suffix": " is also observed in OATP1B1-transfected HeLa cells and OATP-mediated CGamF (25,"}, {"to": "25871", "prefix": "study may be the result of dual inhibition of OATP1B1 and BCRP transporters by ", "from": "25863", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC2764168", "exact": "ritonavir", "suffix": " and tipranavir. Inhibition of OATP1B1 may lead to a decrease in hepatocyte upta"}, {"to": "27164", "prefix": "or Pgp substrates in the presence of ", "from": "27156", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC2764168", "exact": "ritonavir", "suffix": " (e.g., digoxin and saquinavir) (22, 26). Similarly near-complete absorption of "}, {"to": "27763", "prefix": "ose of drug interaction studies evaluating the effect of another PI, lopinavir-", "from": "27755", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC2764168", "exact": "ritonavir", "suffix": " (LPV"}, {"to": "28346", "prefix": ". Coadministration of atazanavir-", "from": "28338", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC2764168", "exact": "ritonavir", "suffix": " with rosuvastatin was found to result in a 210% increase in the rosuvastatin AU"}, {"to": "28506", "prefix": "tatin AUC; however, no significant interaction was observed with fosamprenavir-", "from": "28498", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC2764168", "exact": "ritonavir", "suffix": " (2). The lack of interaction observed with fosamprenavir-ritonavir may be due t"}, {"to": "28573", "prefix": ". The lack of interaction observed with fosamprenavir-", "from": "28565", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC2764168", "exact": "ritonavir", "suffix": " may be due to its low BCRP and OATP1B1 inhibitory potential (V. E. Theil-Demby,"}, {"to": "29497", "prefix": ". The combination of saquinavir-", "from": "29489", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC2764168", "exact": "ritonavir", "suffix": " 400 mg"}, {"to": "29951", "prefix": ". The combination of darunavir-", "from": "29943", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC2764168", "exact": "ritonavir", "suffix": " 300 mg"}, {"to": "118", "prefix": " and ", "from": "107", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " and atorvastatin, we conducted two prospective, open-label, single-arm, two-per"}, {"to": "365", "prefix": " for ", "from": "354", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " and 2.23 (90% CI, 1.83 to 2.72) for the maximum concentration of drug in serum "}, {"to": "468", "prefix": " for ", "from": "457", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " with TPV"}, {"to": "757", "prefix": " state versus alone. Tipranavir PK parameters were not affected by single-dose ", "from": "746", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " or atorvastatin. Mild gastrointestinal intolerance, headache, and mild reversib"}, {"to": "1011", "prefix": "drug reactions. Based on these interactions, we recommend low initial doses of ", "from": "1000", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " (5 mg) and atorvastatin (10 mg), with careful clinical monitoring of rosuvastat"}, {"to": "1093", "prefix": ", with careful clinical monitoring of ", "from": "1082", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": "- or atorvastatin-related adverse events when combined with TPV"}, {"to": "2789", "prefix": "e.g., atorvastatin [Lipitor; Pfizer, Inc., New York, NY] and ", "from": "2778", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " [Crestor; AstraZeneca Pharmaceuticals, Wilmington, DE]) are recommended for the"}, {"to": "2798", "prefix": "e.g., atorvastatin [Lipitor; Pfizer, Inc., New York, NY] and rosuvastatin [", "from": "2792", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "Crestor", "suffix": "; AstraZeneca Pharmaceuticals, Wilmington, DE]) are recommended for the treatmen"}, {"to": "3744", "prefix": "l to significantly increase circulating atorvastatin concentrations.\n\nHowever, ", "from": "3733", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " is unlikely to interact with TPV"}, {"to": "3861", "prefix": "", "from": "3855", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "Crestor", "suffix": " package insert; AstraZeneca Pharmaceuticals, Wilmington, DE). In order to provi"}, {"to": "4114", "prefix": "r and single-dose ", "from": "4103", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " ("}, {"to": "4404", "prefix": " consent was obtained from all volunteers before enrollment in these studies.\n\n", "from": "4393", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "Rosuvastatin", "suffix": " study.\nHIV-negative healthy men and nonpregnant women volunteers 18 to 65 years"}, {"to": "5809", "prefix": " ", "from": "5798", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "Rosuvastatin", "suffix": " study.\nThis was a prospective, open-label, single-arm, inpatient, steady-state "}, {"to": "5952", "prefix": "rm, inpatient, steady-state PK study. Subjects received a single 10-mg dose of ", "from": "5941", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " on day 1, followed by tipranavir 500 mg-ritonavir 200 mg twice daily for 11 day"}, {"to": "6090", "prefix": ", with a single 10-mg dose of ", "from": "6079", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " given on day 12. All study drug doses were given under direct observation by th"}, {"to": "6446", "prefix": " for ", "from": "6435", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " and days 12 and 13 for tipranavir and ritonavir. A standard 670-kcal (33% fat) "}, {"to": "6974", "prefix": "h predose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 h postdose for ", "from": "6963", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": ". A pharmacokinetic comparison of single-dose rosuvastatin with single-dose rosu"}, {"to": "7032", "prefix": "nd 48 h postdose for rosuvastatin. A pharmacokinetic comparison of single-dose ", "from": "7021", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " with single-dose rosuvastatin coadministered with TPV"}, {"to": "7062", "prefix": "tin. A pharmacokinetic comparison of single-dose rosuvastatin with single-dose ", "from": "7051", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " coadministered with TPV"}, {"to": "7262", "prefix": "d steady-state PKs of tipranavir and ritonavir coadministered with single-dose ", "from": "7251", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " (10 mg) were also evaluated.\n\n(ii) Atorvastatin study.\nThe single-dose PKs of a"}, {"to": "9573", "prefix": " ", "from": "9562", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "Rosuvastatin", "suffix": " assay.\nA bioanalytic method has been developed and validated by PPD (Richmond, "}, {"to": "9689", "prefix": " for the analysis of ", "from": "9678", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " in human plasma containing dipotassium EDTA. A 200-"}, {"to": "10571", "prefix": "ml for ", "from": "10560", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": ".\n\n(ii) Atorvastatin assay.\nPlasma concentrations of atorvastatin and its hydrox"}, {"to": "15512", "prefix": " would range from 20% to 40% for the AUCs of ", "from": "15501", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " and atorvastatin. Therefore, a sample size of 20 would provide "}, {"to": "15638", "prefix": "25% change in the AUCs of ", "from": "15627", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " and atorvastatin.\n\nGo to:\nRESULTS\nRosuvastatin study. (i) Subjects.\nOf the 29 s"}, {"to": "15685", "prefix": "25% change in the AUCs of rosuvastatin and atorvastatin.\n\nGo to:\nRESULTS\n", "from": "15674", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "Rosuvastatin", "suffix": " study. (i) Subjects.\nOf the 29 subjects (5 women, 24 men), 16 evaluable subject"}, {"to": "16076", "prefix": "r and ", "from": "16065", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": ".\nWith TPV"}, {"to": "16134", "prefix": "r coadministration, the GM AUC for ", "from": "16123", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " was 38.6 ng"}, {"to": "16202", "prefix": "ml, a 37% increase compared with that of ", "from": "16191", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " alone (P "}, {"to": "16280", "prefix": ". The GM Cmax for ", "from": "16269", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " was 5.78 ng"}, {"to": "16375", "prefix": "r coadministration, a 123% increase compared with that of ", "from": "16364", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " alone (P "}, {"to": "16427", "prefix": ". ", "from": "16416", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "Rosuvastatin", "suffix": " clearance (CL) also was decreased by 27% with TPV"}, {"to": "16672", "prefix": ". Tipranavir and ritonavir PK parameters were not affected by single-dose ", "from": "16661", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " (see Table "}, {"to": "16731", "prefix": ".\n\nFIG. 1.\nFIG. 1.\nPlasma ", "from": "16720", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " concentration-time profile in the absence (open circles) and presence (filled c"}, {"to": "16914", "prefix": "r on single-dose ", "from": "16903", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " (ROS) Cmax, plasma drug concentration at 24 h (Cp24h), and AUC0-24.\nTABLE 1.\nTA"}, {"to": "17030", "prefix": ", and AUC0-24.\nTABLE 1.\nTABLE 1.\nPK parameters of ", "from": "17019", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " alone or rosuvastatin plus TPV"}, {"to": "17052", "prefix": ", and AUC0-24.\nTABLE 1.\nTABLE 1.\nPK parameters of rosuvastatin alone or ", "from": "17041", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " plus TPV"}, {"to": "17105", "prefix": "ra\nTABLE 3.\nTABLE 3.\nEffect of ", "from": "17094", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " (n "}, {"to": "18503", "prefix": "r plus ", "from": "18492", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " could not be assessed since all liver enzyme elevations occurred before coadmin"}, {"to": "22449", "prefix": "DISCUSSION\nA PK drug interaction was predicted to be unlikely to occur between ", "from": "22438", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " and TPV"}, {"to": "22478", "prefix": "r since ", "from": "22467", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " is not a known substrate, inhibitor, or inducer of CYP3A4. Furthermore, rosuvas"}, {"to": "22563", "prefix": "statin is not a known substrate, inhibitor, or inducer of CYP3A4. Furthermore, ", "from": "22552", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " is not extensively metabolized, with approximately 10% of a radiolabeled dose r"}, {"to": "22679", "prefix": "olized, with approximately 10% of a radiolabeled dose recovered as N-desmethyl ", "from": "22668", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": ". This major metabolite is formed principally by CYP2C9 (Crestor package insert;"}, {"to": "22743", "prefix": "", "from": "22737", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "Crestor", "suffix": " package insert; AstraZeneca Pharmaceuticals, Wilmington, DE). Although in vitro"}, {"to": "23269", "prefix": "r was coadministered with ", "from": "23258", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " at steady state, the AUC0-"}, {"to": "23322", "prefix": " and Cmax of ", "from": "23311", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " were increased by 37% and 123%, respectively, after single-dose rosuvastatin. S"}, {"to": "23399", "prefix": "f rosuvastatin were increased by 37% and 123%, respectively, after single-dose ", "from": "23388", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": ". Similarly, concomitant administration of steady-state TPV"}, {"to": "23637", "prefix": "r on the PKs of ", "from": "23626", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " and atorvastatin may be due to the difference in the mechanisms of interaction."}, {"to": "23731", "prefix": "d atorvastatin may be due to the difference in the mechanisms of interaction.\n\n", "from": "23720", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "Rosuvastatin", "suffix": " is not a P-glycoprotein (Pgp) substrate, but it is a substrate of organic anion"}, {"to": "24218", "prefix": "i.e., pravastatin, cerivastatin, atorvastatin, and ", "from": "24207", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": ") (7, 10). BCRP is expressed in many tissue barriers throughout the body, includ"}, {"to": "25266", "prefix": " healthy volunteers was associated with significant increased atorvastatin and ", "from": "25255", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " AUC values of 72% and 100%, respectively (13). Cyclosporine, an OATP1B1 and BCR"}, {"to": "25395", "prefix": ". Cyclosporine, an OATP1B1 and BCRP inhibitor, significantly increases ", "from": "25384", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " and atorvastatin serum concentrations, by 11-fold and 8-fold, respectively (8, "}, {"to": "25969", "prefix": "pranavir. Inhibition of OATP1B1 may lead to a decrease in hepatocyte uptake of ", "from": "25958", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " and atorvastatin, whereas inhibition of BCRP decreases hepatobiliary excretion "}, {"to": "26075", "prefix": "in, whereas inhibition of BCRP decreases hepatobiliary excretion and increases ", "from": "26064", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " and atorvastatin absorption.\n\nIn addition to OATP1B1 and BCRP transporter-media"}, {"to": "27500", "prefix": "2. On the other hand, the ", "from": "27489", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " t1"}, {"to": "27620", "prefix": "imately twofold. This finding suggests that alternative metabolic pathways for ", "from": "27609", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " may be present.\n\nThese findings are consistent with those of drug interaction s"}, {"to": "27810", "prefix": ", when coadministered with ", "from": "27799", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " at steady state. A prospective study conducted with healthy volunteers found th"}, {"to": "27905", "prefix": "steady state. A prospective study conducted with healthy volunteers found that ", "from": "27894", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " AUC0-"}, {"to": "28168", "prefix": " not affected; however, the magnitude of the drug interaction observed between ", "from": "28157", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " and LPV"}, {"to": "28364", "prefix": ". Coadministration of atazanavir-ritonavir with ", "from": "28353", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " was found to result in a 210% increase in the rosuvastatin AUC; however, no sig"}, {"to": "28423", "prefix": "avir-ritonavir with rosuvastatin was found to result in a 210% increase in the ", "from": "28412", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " AUC; however, no significant interaction was observed with fosamprenavir-ritona"}, {"to": "31041", "prefix": ". Although the safety and efficacy of ", "from": "31030", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " and atorvastatin could not be assessed by these single-dose studies, to minimiz"}, {"to": "31382", "prefix": "d be considered.\n\nIn conclusion, we observed a clinically relevant increase in ", "from": "31371", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " and atorvastatin concentrations during coadministration of TPV"}, {"to": "31533", "prefix": "200 mg twice daily. Based on these results, a low initial dose of ", "from": "31522", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " (5 mg) and atorvastatin (10 mg) is recommended when combined with TPV"}, {"to": "31655", "prefix": "r, with careful clinical monitoring of ", "from": "31644", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": "- or atorvastatin-related AEs, such as myopathy.\n\nGo to:\nACKNOWLEDGMENTS\nThe stu"}, {"to": "32385", "prefix": "of Ottawa at The Ottawa Hospital and the Ottawa Health Research Institute. The ", "from": "32374", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2764168", "exact": "rosuvastatin", "suffix": " study is supported by a GCRC grant (RR-00052) and an investigator-initiated gra"}, {"to": "135", "prefix": " and rosuvastatin and ", "from": "124", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": ", we conducted two prospective, open-label, single-arm, two-period studies. The "}, {"to": "583", "prefix": " for the AUC of ", "from": "572", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " and 8.61 (90% CI, 7.25 to 10.21) for the Cmax of atorvastatin with TPV"}, {"to": "645", "prefix": " for the Cmax of ", "from": "634", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " with TPV"}, {"to": "773", "prefix": "one. Tipranavir PK parameters were not affected by single-dose rosuvastatin or ", "from": "762", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": ". Mild gastrointestinal intolerance, headache, and mild reversible liver enzyme "}, {"to": "1035", "prefix": " and ", "from": "1024", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " (10 mg), with careful clinical monitoring of rosuvastatin- or atorvastatin-rela"}, {"to": "1110", "prefix": ", with careful clinical monitoring of rosuvastatin- or ", "from": "1099", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": "-related adverse events when combined with TPV"}, {"to": "2734", "prefix": "e.g., ", "from": "2723", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " [Lipitor; Pfizer, Inc., New York, NY] and rosuvastatin [Crestor; AstraZeneca Ph"}, {"to": "3043", "prefix": ". ", "from": "3032", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "Atorvastatin", "suffix": " is metabolized extensively by cytochrome P450 3A4 (CYP3A4) to metabolites that "}, {"to": "3210", "prefix": "hat have in vitro inhibitory activity for HMG-CoA reductase similar to that of ", "from": "3199", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": ". Approximately 70% of the circulating inhibitory activity for HMG-CoA reductase"}, {"to": "3705", "prefix": ", it has the potential to significantly increase circulating ", "from": "3694", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " concentrations.\n\nHowever, rosuvastatin is unlikely to interact with TPV"}, {"to": "4154", "prefix": " and ", "from": "4143", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " ("}, {"to": "4995", "prefix": "ere instructed to use a barrier contraceptive method during the study period.\n\n", "from": "4984", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "Atorvastatin", "suffix": " study.\nHealthy men and women volunteers 18 to 60 years old, with body mass inde"}, {"to": "7310", "prefix": " ", "from": "7299", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "Atorvastatin", "suffix": " study.\nThe single-dose PKs of atorvastatin, orthohydroxy atorvastatin, and para"}, {"to": "7353", "prefix": " Atorvastatin study.\nThe single-dose PKs of ", "from": "7342", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": ", orthohydroxy atorvastatin, and parahydroxy atorvastatin were assessed on day 1"}, {"to": "7380", "prefix": " Atorvastatin study.\nThe single-dose PKs of atorvastatin, orthohydroxy ", "from": "7369", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": ", and parahydroxy atorvastatin were assessed on day 1 after ingestion of 40 mg o"}, {"to": "7410", "prefix": "he single-dose PKs of atorvastatin, orthohydroxy atorvastatin, and parahydroxy ", "from": "7399", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " were assessed on day 1 after ingestion of 40 mg of atorvastatin alone. From day"}, {"to": "7474", "prefix": "nd parahydroxy atorvastatin were assessed on day 1 after ingestion of 40 mg of ", "from": "7463", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " alone. From days 14 to 21, subjects received TPV"}, {"to": "8035", "prefix": "200 mg twice daily plus a single dose of ", "from": "8024", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " 10 mg, as an increase in atorvastatin concentrations was expected in combinatio"}, {"to": "8073", "prefix": "200 mg twice daily plus a single dose of atorvastatin 10 mg, as an increase in ", "from": "8062", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " concentrations was expected in combination with steady-state TPV"}, {"to": "8213", "prefix": "200 mg twice daily. Blood samples for analysis of ", "from": "8202", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " and hydroxy metabolites were collected on days 1 and 20 in EDTA-containing tube"}, {"to": "8461", "prefix": " and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 h after ingestion of ", "from": "8450", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " (14 samples).\n\nBlood samples for analysis of tipranavir concentrations were col"}, {"to": "8852", "prefix": "r plasma concentrations were not measured in this study.\n\nOn PK sampling days, ", "from": "8841", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " and TPV"}, {"to": "10591", "prefix": " ", "from": "10580", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "Atorvastatin", "suffix": " assay.\nPlasma concentrations of atorvastatin and its hydroxy metabolites were m"}, {"to": "10636", "prefix": " Atorvastatin assay.\nPlasma concentrations of ", "from": "10625", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " and its hydroxy metabolites were measured by validated liquid chromatography (L"}, {"to": "11286", "prefix": "ml for ", "from": "11275", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": ", 0.250 ng"}, {"to": "11328", "prefix": "ml for parahydroxy ", "from": "11317", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": ", and 0.175 ng"}, {"to": "11375", "prefix": "ml for orthohydroxy ", "from": "11364", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " using a 200-"}, {"to": "11930", "prefix": " with a formic acid-acetic acid-acetonitrile mobile phase. For the ", "from": "11919", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " study, tipranavir and an IS (PNU-109011) were extracted from 50 "}, {"to": "14231", "prefix": "r on ", "from": "14220", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " (day 1 versus day 20), the atorvastatin AUC0-"}, {"to": "14271", "prefix": ", the ", "from": "14260", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " AUC0-"}, {"to": "14353", "prefix": " and Cmax were multiplied by 4 to adjust for the difference in ", "from": "14342", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " dose between day 1 (40 mg) and day 20 (10 mg). No dose adjustments were made fo"}, {"to": "14534", "prefix": "ysis of the hydroxy metabolite concentrations.\n\nIn addition to the analysis of ", "from": "14523", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " and its hydroxy metabolites individually, the effect on total HMG-CoA reductase"}, {"to": "14780", "prefix": "ctivity was calculated as the sum of the time-specific molar concentrations of ", "from": "14769", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " (normalized for a 40-mg dose), orthohydroxy atorvastatin, and parahydroxy atorv"}, {"to": "14837", "prefix": ", orthohydroxy ", "from": "14826", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": ", and parahydroxy atorvastatin.\n\nNonparametric tests were used for comparisons b"}, {"to": "14867", "prefix": ", orthohydroxy atorvastatin, and parahydroxy ", "from": "14856", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": ".\n\nNonparametric tests were used for comparisons between PK parameters (Mann-Whi"}, {"to": "15529", "prefix": " would range from 20% to 40% for the AUCs of rosuvastatin and ", "from": "15518", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": ". Therefore, a sample size of 20 would provide "}, {"to": "15655", "prefix": "25% change in the AUCs of rosuvastatin and ", "from": "15644", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": ".\n\nGo to:\nRESULTS\nRosuvastatin study. (i) Subjects.\nOf the 29 subjects (5 women,"}, {"to": "17131", "prefix": " and ", "from": "17120", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " (n "}, {"to": "18671", "prefix": ". All AEs resolved with study drug discontinuation.\n\n", "from": "18660", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "Atorvastatin", "suffix": " study. (i) Subjects.\nTwenty-three subjects (11 men, 12 women) were recruited in"}, {"to": "18967", "prefix": " cm. The ", "from": "18956", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " PK results from one subject and the steady-state tipranavir PK results from ano"}, {"to": "19388", "prefix": "r and ", "from": "19377", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": ".\nTPV"}, {"to": "19436", "prefix": "r increased the dose-adjusted ", "from": "19425", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " AUC0-"}, {"to": "19650", "prefix": "2 of ", "from": "19639", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": ". TPV"}, {"to": "19726", "prefix": "r inhibited the formation of orthohydroxy and parahydroxy ", "from": "19715", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " and reduced the AUC0-"}, {"to": "20179", "prefix": "-time profiles for ", "from": "20168", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " (A), orthohydroxy atorvastatin (B), and parahydroxy atorvastatin (C). Shown are"}, {"to": "20210", "prefix": ", orthohydroxy ", "from": "20199", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " (B), and parahydroxy atorvastatin (C). Shown are 40 mg atorvastatin alone (open"}, {"to": "20244", "prefix": ", and parahydroxy ", "from": "20233", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " (C). Shown are 40 mg atorvastatin alone (open circles) (A to C), 10 mg atorvast"}, {"to": "20278", "prefix": ". Shown are 40 mg ", "from": "20267", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " alone (open circles) (A to C), 10 mg atorvastatin plus steady-state TPV"}, {"to": "20328", "prefix": ", 10 mg ", "from": "20317", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " plus steady-state TPV"}, {"to": "20446", "prefix": "r on single-dose ", "from": "20435", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " (ATO) Cmax, plasma drug concentration (Cp), and AUC0-"}, {"to": "20562", "prefix": ".\nTABLE 2.\nTABLE 2.\nSingle-dose PK parameters of ", "from": "20551", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": ", orthohydroxy atorvastatin, and parahydroxy atorvastatin after administration o"}, {"to": "20589", "prefix": ".\nTABLE 2.\nTABLE 2.\nSingle-dose PK parameters of atorvastatin, orthohydroxy ", "from": "20578", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": ", and parahydroxy atorvastatin after administration of atorvastatin 40 mg alone "}, {"to": "20619", "prefix": "dose PK parameters of atorvastatin, orthohydroxy atorvastatin, and parahydroxy ", "from": "20608", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " after administration of atorvastatin 40 mg alone and coadministration of atorva"}, {"to": "20656", "prefix": "rthohydroxy atorvastatin, and parahydroxy atorvastatin after administration of ", "from": "20645", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " 40 mg alone and coadministration of atorvastatin 10 mg and steady-state TPV"}, {"to": "20705", "prefix": "tatin after administration of atorvastatin 40 mg alone and coadministration of ", "from": "20694", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " 10 mg and steady-state TPV"}, {"to": "20794", "prefix": " ...\nSingle-dose ", "from": "20783", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " did not affect the steady-state PKs of tipranavir (Table "}, {"to": "20991", "prefix": "200 mg twice daily alone and in the presence of single-dose ", "from": "20980", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " was well tolerated in this study. There were no study discontinuations due to A"}, {"to": "23511", "prefix": " of ", "from": "23500", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": ". However, the atorvastatin AUC increase was significantly higher. The different"}, {"to": "23538", "prefix": " of atorvastatin. However, the ", "from": "23527", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " AUC increase was significantly higher. The differential effect of TPV"}, {"to": "23654", "prefix": "r on the PKs of rosuvastatin and ", "from": "23643", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " may be due to the difference in the mechanisms of interaction.\n\nRosuvastatin is"}, {"to": "24200", "prefix": "i.e., pravastatin, cerivastatin, ", "from": "24189", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": ", and rosuvastatin) (7, 10). BCRP is expressed in many tissue barriers throughou"}, {"to": "25249", "prefix": " in healthy volunteers was associated with significant increased ", "from": "25238", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " and rosuvastatin AUC values of 72% and 100%, respectively (13). Cyclosporine, a"}, {"to": "25412", "prefix": "orine, an OATP1B1 and BCRP inhibitor, significantly increases rosuvastatin and ", "from": "25401", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " serum concentrations, by 11-fold and 8-fold, respectively (8, 24). Tipranavir, "}, {"to": "25986", "prefix": "ion of OATP1B1 may lead to a decrease in hepatocyte uptake of rosuvastatin and ", "from": "25975", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": ", whereas inhibition of BCRP decreases hepatobiliary excretion and increases ros"}, {"to": "26092", "prefix": "ition of BCRP decreases hepatobiliary excretion and increases rosuvastatin and ", "from": "26081", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " absorption.\n\nIn addition to OATP1B1 and BCRP transporter-mediated interaction, "}, {"to": "26223", "prefix": " BCRP transporter-mediated interaction, inhibition of first-pass metabolism of ", "from": "26212", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": ", rather than inhibition of its systemic metabolism, may explain the 8.6-fold in"}, {"to": "26325", "prefix": "an inhibition of its systemic metabolism, may explain the 8.6-fold increase in ", "from": "26314", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " Cmax (an 8.6-fold increase) without an effect on the t1"}, {"to": "26434", "prefix": "2. The absolute oral bioavailability of ", "from": "26423", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " is low (14%), which is likely a result of the combined effects of intestinal me"}, {"to": "26650", "prefix": ". Assuming the linear PKs of ", "from": "26639", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " (23), coincidentally, the formation of orthohydroxy and parahydroxy atorvastati"}, {"to": "26731", "prefix": ", coincidentally, the formation of orthohydroxy and parahydroxy ", "from": "26720", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " was inhibited. The AUC0-"}, {"to": "26999", "prefix": " and may thus increase the bioavailability of ", "from": "26988", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": ", as suggested in the current study. Previous studies have reported an increased"}, {"to": "27256", "prefix": ". Similarly near-complete absorption of ", "from": "27245", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " in the presence of TPV"}, {"to": "28057", "prefix": ". Similar to the results of the current ", "from": "28046", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " study, the t1"}, {"to": "28885", "prefix": ". Increased exposure to ", "from": "28874", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " has previously been observed in combination with other HIV PIs, which are all s"}, {"to": "29077", "prefix": "100 mg twice daily increased the ", "from": "29066", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " (20 mg once daily) AUC0-24 and Cmax by 5.9- and 4.7-fold, respectively, and inc"}, {"to": "29557", "prefix": "400 mg twice daily increased the median ", "from": "29546", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " (40 mg) AUC0-24 by 3.5-fold and the AUC0-24 of the total HMG-CoA reductase inhi"}, {"to": "29877", "prefix": "nhibitory activity by 1.7- and 2.2-fold, respectively, after administration of ", "from": "29866", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " 10 mg once daily for 14 days (11). The combination of darunavir-ritonavir 300 m"}, {"to": "29995", "prefix": "100 mg twice daily with ", "from": "29984", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " 10 mg daily resulted in an AUC0-24 that was 15% lower than the AUC0-24 of atorv"}, {"to": "30082", "prefix": "atin 10 mg daily resulted in an AUC0-24 that was 15% lower than the AUC0-24 of ", "from": "30071", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " 40 mg daily alone, suggesting an almost fourfold increase in the atorvastatin A"}, {"to": "30160", "prefix": " atorvastatin 40 mg daily alone, suggesting an almost fourfold increase in the ", "from": "30149", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " AUC0-24 (R. M. W. Hoetelmans, A. Lasure, A. Koester, M. de Pauw, B. van Baelen,"}, {"to": "30832", "prefix": ". Several cases of ", "from": "30821", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": "-associated rhabdomyolysis have been reported in patients using atorvastatin in "}, {"to": "30908", "prefix": "of atorvastatin-associated rhabdomyolysis have been reported in patients using ", "from": "30897", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " in combination with CYP3A4 inhibitors, such as cyclosporine or delavirdine (3, "}, {"to": "31058", "prefix": ". Although the safety and efficacy of rosuvastatin and ", "from": "31047", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " could not be assessed by these single-dose studies, to minimize the risk of rha"}, {"to": "31399", "prefix": "\nIn conclusion, we observed a clinically relevant increase in rosuvastatin and ", "from": "31388", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " concentrations during coadministration of TPV"}, {"to": "31557", "prefix": " and ", "from": "31546", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": " (10 mg) is recommended when combined with TPV"}, {"to": "31672", "prefix": "r, with careful clinical monitoring of rosuvastatin- or ", "from": "31661", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2764168", "exact": "atorvastatin", "suffix": "-related AEs, such as myopathy.\n\nGo to:\nACKNOWLEDGMENTS\nThe study participants a"}, {"to": "2743", "prefix": "e.g., atorvastatin [", "from": "2737", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "PMC2764168", "exact": "Lipitor", "suffix": "; Pfizer, Inc., New York, NY] and rosuvastatin [Crestor; AstraZeneca Pharmaceuti"}, {"to": "1491", "prefix": " that include increased triglycerides and ", "from": "1481", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC2764168", "exact": "cholesterol", "suffix": ". NIAID Division of AIDS (DAIDS) grade 3 to 4 cholesterol elevation ("}, {"to": "1548", "prefix": " grade 3 to 4 ", "from": "1538", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC2764168", "exact": "cholesterol", "suffix": " elevation ("}, {"to": "1768", "prefix": ". Grade 3 to 4 ", "from": "1758", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC2764168", "exact": "cholesterol", "suffix": " elevation was 4.3 versus 0.6"}, {"to": "5668", "prefix": " starting 5 days prior to the first study day. ", "from": "5655", "name": "methylxanthine", "fullId": "http://purl.bioontology.org/ontology/MESH/C008514", "setId": "PMC2764168", "exact": "Methylxanthine", "suffix": "-containing foods or drinks were not allowed within 72 h prior to and during PK "}, {"to": "6626", "prefix": " served to subjects within 30 min before morning medication administration. No ", "from": "6619", "name": "Caffeine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002110", "setId": "PMC2764168", "exact": "caffeine", "suffix": " or food was allowed until 5 h postdose. No grapefruit juice was allowed on PK s"}, {"to": "8277", "prefix": "sis of atorvastatin and hydroxy metabolites were collected on days 1 and 20 in ", "from": "8274", "name": "Edetic Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D004492", "setId": "PMC2764168", "exact": "EDTA", "suffix": "-containing tubes by an indwelling catheter or the venipuncture of a forearm vei"}, {"to": "10905", "prefix": "l of ", "from": "10902", "name": "Edetic Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D004492", "setId": "PMC2764168", "exact": "EDTA", "suffix": " plasma by solid-phase extraction using C8 cartridges. After isolation and evapo"}, {"to": "11609", "prefix": ". In general terms, ritonavir, tipranavir, and an IS are extracted from ", "from": "11606", "name": "Edetic Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D004492", "setId": "PMC2764168", "exact": "EDTA", "suffix": " human plasma by a two-step liquid-liquid extraction using an ethyl acetate-hexa"}, {"to": "9733", "prefix": " for the analysis of rosuvastatin in human plasma containing ", "from": "9718", "name": "edetate dipotassium anhydrous", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1540526", "setId": "PMC2764168", "exact": "dipotassium EDTA", "suffix": ". A 200-"}, {"to": "9904", "prefix": "l of ", "from": "9893", "name": "acetonitrile", "fullId": "http://purl.bioontology.org/ontology/MESH/C032159", "setId": "PMC2764168", "exact": "acetonitrile", "suffix": ". Sample extraction steps were controlled and automated using a Quadra 96 model "}, {"to": "10203", "prefix": "l of 20:80:0.1 ", "from": "10192", "name": "acetonitrile", "fullId": "http://purl.bioontology.org/ontology/MESH/C032159", "setId": "PMC2764168", "exact": "acetonitrile", "suffix": "-water-formic acid (vol"}, {"to": "11895", "prefix": " with a formic acid-acetic acid-", "from": "11884", "name": "acetonitrile", "fullId": "http://purl.bioontology.org/ontology/MESH/C032159", "setId": "PMC2764168", "exact": "acetonitrile", "suffix": " mobile phase. For the atorvastatin study, tipranavir and an IS (PNU-109011) wer"}, {"to": "22038", "prefix": "h the exception of one subject with an asymptomatic DAIDS grade 3 elevation in ", "from": "22032", "name": "Alanine", "fullId": "http://purl.bioontology.org/ontology/MESH/D000409", "setId": "PMC2764168", "exact": "alanine", "suffix": " aminotransferase, there were no clinically relevant changes (grade 3 or higher)"}, {"to": "22242", "prefix": "argest deviations from the median baseline were observed for triglycerides and ", "from": "22236", "name": "Alanine", "fullId": "http://purl.bioontology.org/ontology/MESH/D000409", "setId": "PMC2764168", "exact": "alanine", "suffix": " aminotransferase levels, which increased by 1.7-fold and 3.1-fold, respectively"}, {"to": "23057", "prefix": " plus ritonavir 200 mg twice daily did not affect concentrations of plasma S-", "from": "23050", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2764168", "exact": "warfarin", "suffix": ", a CYP2C9 substrate (M. Vourvahis, presented at the Eighth International Worksh"}, {"to": "24172", "prefix": "i.e., ", "from": "24162", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC2764168", "exact": "pravastatin", "suffix": ", cerivastatin, atorvastatin, and rosuvastatin) (7, 10). BCRP is expressed in ma"}, {"to": "24186", "prefix": "i.e., pravastatin, ", "from": "24175", "name": "cerivastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C086276", "setId": "PMC2764168", "exact": "cerivastatin", "suffix": ", atorvastatin, and rosuvastatin) (7, 10). BCRP is expressed in many tissue barr"}, {"to": "24925", "prefix": "s demonstrated in a BCRP 1 knockout murine model. The plasma concentrations of ", "from": "24912", "name": "Nitrofurantoin", "fullId": "http://purl.bioontology.org/ontology/MESH/D009582", "setId": "PMC2764168", "exact": "nitrofurantoin", "suffix": ", a substrate of BCRP, were increased by fourfold and twofold compared with thos"}, {"to": "25326", "prefix": ". ", "from": "25315", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "PMC2764168", "exact": "Cyclosporine", "suffix": ", an OATP1B1 and BCRP inhibitor, significantly increases rosuvastatin and atorva"}, {"to": "30968", "prefix": " in patients using atorvastatin in combination with CYP3A4 inhibitors, such as ", "from": "30957", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "PMC2764168", "exact": "cyclosporine", "suffix": " or delavirdine (3, 18). Although the safety and efficacy of rosuvastatin and at"}, {"to": "25516", "prefix": ". Tipranavir, ritonavir, and ", "from": "25508", "name": "Lopinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D061466", "setId": "PMC2764168", "exact": "lopinavir", "suffix": " are also BCRP inhibitors in vitro (19, 27). Concentration-dependent inhibition "}, {"to": "27753", "prefix": "nt with those of drug interaction studies evaluating the effect of another PI, ", "from": "27745", "name": "Lopinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D061466", "setId": "PMC2764168", "exact": "lopinavir", "suffix": "-ritonavir (LPV"}, {"to": "28290", "prefix": " This effect may be due to the higher inhibitory potency of BCRP observed with ", "from": "28282", "name": "Lopinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D061466", "setId": "PMC2764168", "exact": "lopinavir", "suffix": " in vitro (27). Coadministration of atazanavir-ritonavir with rosuvastatin was f"}, {"to": "25612", "prefix": ". Concentration-dependent inhibition of [3H]", "from": "25604", "name": "Estradiol", "fullId": "http://purl.bioontology.org/ontology/MESH/D004958", "setId": "PMC2764168", "exact": "estradiol", "suffix": "-17"}, {"to": "27179", "prefix": "e.g., ", "from": "27173", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "PMC2764168", "exact": "digoxin", "suffix": " and saquinavir) (22, 26). Similarly near-complete absorption of atorvastatin in"}, {"to": "27194", "prefix": "e.g., digoxin and ", "from": "27185", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83395", "setId": "PMC2764168", "exact": "saquinavir", "suffix": ") (22, 26). Similarly near-complete absorption of atorvastatin in the presence o"}, {"to": "29487", "prefix": ". The combination of ", "from": "29478", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83395", "setId": "PMC2764168", "exact": "saquinavir", "suffix": "-ritonavir 400 mg"}, {"to": "28336", "prefix": ". Coadministration of ", "from": "28327", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "PMC2764168", "exact": "atazanavir", "suffix": "-ritonavir with rosuvastatin was found to result in a 210% increase in the rosuv"}, {"to": "28496", "prefix": "in the rosuvastatin AUC; however, no significant interaction was observed with ", "from": "28484", "name": "fosamprenavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/358262", "setId": "PMC2764168", "exact": "fosamprenavir", "suffix": "-ritonavir (2). The lack of interaction observed with fosamprenavir-ritonavir ma"}, {"to": "28563", "prefix": ". The lack of interaction observed with ", "from": "28551", "name": "fosamprenavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/358262", "setId": "PMC2764168", "exact": "fosamprenavir", "suffix": "-ritonavir may be due to its low BCRP and OATP1B1 inhibitory potential (V. E. Th"}, {"to": "29680", "prefix": ". ", "from": "29671", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC2764168", "exact": "Nelfinavir", "suffix": ", a moderately strong inhibitor of CYP3A4, increased the AUC0-24 and Cmax of the"}, {"to": "29941", "prefix": ". The combination of ", "from": "29933", "name": "darunavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C482292", "setId": "PMC2764168", "exact": "darunavir", "suffix": "-ritonavir 300 mg"}, {"to": "30983", "prefix": "ng atorvastatin in combination with CYP3A4 inhibitors, such as cyclosporine or ", "from": "30973", "name": "Delavirdine", "fullId": "http://purl.bioontology.org/ontology/MESH/D020008", "setId": "PMC2764168", "exact": "delavirdine", "suffix": " (3, 18). Although the safety and efficacy of rosuvastatin and atorvastatin coul"}, {"to": "54", "prefix": "Abstract\nAims\n\nPrevious work has shown that ", "from": "45", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": ", a potent inducer of several cytochrome P450 (CYP) enzymes and transporters, de"}, {"to": "270", "prefix": "n acid by more than 90%. This study was conducted to investigate the effect of ", "from": "261", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " on the pharmacokinetics of pravastatin.\n\nMethods\n\nIn a randomised, cross-over t"}, {"to": "459", "prefix": "a washout of 4 weeks, 10 healthy volunteers received a 5-day pretreatment with ", "from": "450", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " (600 mg daily) or placebo. On day 6, a single 40 mg dose of pravastatin was adm"}, {"to": "682", "prefix": " were measured up to 12 h by a sensitive LC-MS-MS method.\n\nResults\n\nDuring the ", "from": "673", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " phase, the mean total area under the plasma concentration-time curve of pravast"}, {"to": "1007", "prefix": " of pravastatin during the ", "from": "998", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " phase was 50% or less of that during the placebo phase. Rifampicin had no signi"}, {"to": "1074", "prefix": " during the rifampicin phase was 50% or less of that during the placebo phase. ", "from": "1065", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "Rifampicin", "suffix": " had no significant effect on the peak concentration, elimination half-life or r"}, {"to": "1209", "prefix": "ration, elimination half-life or renal clearance of pravastatin.\n\nConclusions\n\n", "from": "1200", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "Rifampicin", "suffix": " caused a statistically significant decrease in the plasma concentration of prav"}, {"to": "1379", "prefix": "statin given as a single oral dose to healthy subjects. However, the effect of ", "from": "1370", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " varied greatly between subjects. The mean rifampicin-induced decrease in pravas"}, {"to": "1432", "prefix": "s. However, the effect of rifampicin varied greatly between subjects. The mean ", "from": "1423", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": "-induced decrease in pravastatin concentration was considerably smaller than tha"}, {"to": "1598", "prefix": "that observed previously for simvastatin.\n\nKeywords: interaction, pravastatin, ", "from": "1589", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": "\nGo to:\nIntroduction\nRifampicin is a potent inducer of several cytochrome P450 ("}, {"to": "1629", "prefix": "mvastatin.\n\nKeywords: interaction, pravastatin, rifampicin\nGo to:\nIntroduction\n", "from": "1620", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "Rifampicin", "suffix": " is a potent inducer of several cytochrome P450 (CYP) enzymes both in the intest"}, {"to": "1750", "prefix": "3]. ", "from": "1741", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "Rifampicin", "suffix": " also induces the expression of some drug transporters, for example the efflux t"}, {"to": "1999", "prefix": " [5]. Induction of CYP enzymes and drug transporters by ", "from": "1990", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " is mediated by the activation of the nuclear pregnane X receptor (PXR) [6, 7]. "}, {"to": "2218", "prefix": " can mediate the uptake of ", "from": "2209", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " into liver cells, and thus facilitate rifampicin mediated PXR activation [8]. R"}, {"to": "2267", "prefix": " can mediate the uptake of rifampicin into liver cells, and thus facilitate ", "from": "2258", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " mediated PXR activation [8]. Recently we showed that rifampicin decreases the t"}, {"to": "2331", "prefix": "hus facilitate rifampicin mediated PXR activation [8]. Recently we showed that ", "from": "2322", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " decreases the total area under the plasma concentration-time curve (AUC) and pe"}, {"to": "3452", "prefix": " transporters are largely unknown. Thus, the extent of any interaction between ", "from": "3443", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " and pravastatin cannot be inferred from previous work. The aim of this study wa"}, {"to": "3578", "prefix": "rom previous work. The aim of this study was to examine the possible effect of ", "from": "3569", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " on the pharmacokinetics of pravastatin in healthy volunteers, using an identica"}, {"to": "4970", "prefix": "h-out period between the phases was 4 weeks. Subjects were given either 600 mg ", "from": "4961", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " (Rifarm, Pharmacal, Helsinki, Finland) or matched placebo orally once daily at "}, {"to": "5258", "prefix": "nistered orally with 150 ml water at 9 AM, that is 17 h after the last dose of ", "from": "5249", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": ". The subjects had fasted overnight, and a standard meal was served 3 and 7 h af"}, {"to": "5594", "prefix": "eks before test days. The study design was otherwise identical to our previous ", "from": "5585", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": "-simvastatin study [9].\n\nBlood and urine sampling\n\nBlood samples (10 ml each) we"}, {"to": "7668", "prefix": "ence intervals were calculated on the mean differences between the placebo and ", "from": "7659", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " phases for AUC(0"}, {"to": "8068", "prefix": "Whitney U-test was used to compare the effect of ", "from": "8059", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " on the AUC(0"}, {"to": "8300", "prefix": "0.05.\n\nGo to:\nResults\nDuring the ", "from": "8291", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " phase, the mean AUC(0"}, {"to": "8528", "prefix": ". However, there were large interindividual differences in the effect of ", "from": "8519", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": ". Thus, the AUC(0"}, {"to": "8752", "prefix": ". ", "from": "8743", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "Rifampicin", "suffix": " tended to decrease the Cmax of pravastatin, on average by 21%, but the differen"}, {"to": "8896", "prefix": ". ", "from": "8887", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "Rifampicin", "suffix": " had no statistically significant effect on the tmax (P "}, {"to": "9121", "prefix": " cumulative excretion of pravastatin into the urine were largely unaffected by ", "from": "9112", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " (P "}, {"to": "9329", "prefix": "jects after the ingestion of 40 mg pravastatin following treatment with 600 mg ", "from": "9320", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " or placebo twice daily for 5 days\nFigure 1\nFigure 1\nPlasma concentrations (mean"}, {"to": "9547", "prefix": "s after administration of 40 mg pravastatin following pretreatment with 600 mg ", "from": "9538", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " ("}, {"to": "9896", "prefix": "subjects after ingestion of 40 mg pravastatin following ...\nThe mean effect of ", "from": "9887", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " on the AUC of pravastatin in the present study was considerably smaller and mor"}, {"to": "10136", "prefix": " [9]. The difference in the effect of ", "from": "10127", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " on the AUC(0"}, {"to": "10317", "prefix": ".\n\nFigure 3\nFigure 3\nEffect of an identical pretreatment with 600 mg ", "from": "10308", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " once daily for five days on the areas under the plasma concentration-time curve"}, {"to": "10630", "prefix": "a concentrations of pravastatin were moderately decreased by pretreatment with ", "from": "10621", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": ". The mean AUC(0"}, {"to": "10817", "prefix": " of pravastatin during the ", "from": "10808", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " phase was 50% or less of that during the placebo phase. However, in three subje"}, {"to": "10973", "prefix": "n three subjects the plasma concentrations of pravastatin increased during the ", "from": "10964", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " phase. The other pharmacokinetic variables studied were not altered to a statis"}, {"to": "11114", "prefix": "were not altered to a statistically significant degree. Although the effect of ", "from": "11105", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " was statistically significant, the possibility of chance finding cannot be excl"}, {"to": "11301", "prefix": " carry over or period effects did not explain the observations.\n\nThe effect of ", "from": "11292", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " on pravastatin pharmacokinetics is not likely to be caused by induction of CYP3"}, {"to": "11781", "prefix": "r can affect the absorption, tissue uptake and elimination of substrate drugs. ", "from": "11772", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "Rifampicin", "suffix": " is known to induce duodenal MRP2 mRNA and MRP2 protein [5], which may result in"}, {"to": "11961", "prefix": "d exposure to substrates of this transporter. Induction of canalicular MRP2 by ", "from": "11952", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " might also decrease systemic pravastatin absorption by enhancing first-pass bil"}, {"to": "12179", "prefix": "pravastatin interaction is a consequence of an effect of ", "from": "12170", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " on MRP2 or other transporting proteins. Fromm et al. [5] observed that rifampic"}, {"to": "12261", "prefix": "ampicin on MRP2 or other transporting proteins. Fromm et al. [5] observed that ", "from": "12252", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " induced duodenal MRP2 protein in only 10 out of the 16 subjects [5], which is i"}, {"to": "12380", "prefix": " in only 10 out of the 16 subjects [5], which is in line with our results that ", "from": "12371", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " only decreased pravastatin AUC in 7 out of 10 subjects (Figure 2). There are se"}, {"to": "12614", "prefix": "xpressed exclusively in the liver sinusoidal membrane, which decrease cellular ", "from": "12605", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " retention and thus could cause interindividual variability in the activation of"}, {"to": "12912", "prefix": " be the inhibition of OATP2-mediated uptake of pravastatin into hepatocytes by ", "from": "12903", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " [8]. However, it is likely that the concentrations of rifampicin in the liver w"}, {"to": "12977", "prefix": "epatocytes by rifampicin [8]. However, it is likely that the concentrations of ", "from": "12968", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " in the liver were very low at the time of pravastatin administration, because t"}, {"to": "13083", "prefix": "e very low at the time of pravastatin administration, because the last dose of ", "from": "13074", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " was administered 17 h earlier. Accordingly, it is also possible that the increa"}, {"to": "13406", "prefix": "ears to be one of the predominant pathways of pravastatin metabolism [12], and ", "from": "13397", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " is also known to induce the phase II enzymes, such as UDP-glucuronosyltransfera"}, {"to": "13619", "prefix": " clearance and elimination half-life of pravastatin were largely unaffected by ", "from": "13610", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": ", it is reasonable to assume that the interaction occurred primarily during the "}, {"to": "13828", "prefix": "hase.\n\nRecently, we showed that using an identical protocol, pretreatment with ", "from": "13819", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " greatly decreased the AUC(0"}, {"to": "14634", "prefix": "astatin is less susceptible to pharmacokinetic interactions than simvastatin.\n\n", "from": "14625", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "Rifampicin", "suffix": " decreases the total AUC of fluvastatin, a CYP2C9 substrate [28], by about 50% ["}, {"to": "14765", "prefix": " CYP2C9 substrate [28], by about 50% [23]. Preliminary data also indicate that ", "from": "14756", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " decreases the AUC of atorvastatin by a mean of 78% compared to placebo [30]. Be"}, {"to": "14993", "prefix": "e lovastatin closely resemble those of simvastatin [31, 32], it is likely that ", "from": "14984", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " will induce the metabolism of lovastatin and lovastatin acid as well. Of the st"}, {"to": "15183", "prefix": " pravastatin appears to be least susceptible to the potent inducing effects of ", "from": "15174", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": ", and therefore seems most suited for use in combination with inducers of CYP en"}, {"to": "15347", "prefix": "YP enzymes or P-glycoprotein. However, the decrease in pravastatin exposure by ", "from": "15338", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " might be clinically significant in some individuals, and the dose of pravastati"}, {"to": "15478", "prefix": "ndividuals, and the dose of pravastatin might need adjustment.\n\nIn conclusion, ", "from": "15469", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " had a relatively small but highly variable effect on the pharmacokinetics of pr"}, {"to": "15673", "prefix": "vastatin might need adjustment in some individuals if long-term treatment with ", "from": "15664", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1884432", "exact": "rifampicin", "suffix": " is needed.\n\nGo to:\nAcknowledgments\nWe thank Mr Jouko Laitila, Mrs Kerttu M"}, {"to": "309", "prefix": "s conducted to investigate the effect of rifampicin on the pharmacokinetics of ", "from": "299", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": ".\n\nMethods\n\nIn a randomised, cross-over two-phase study with a washout of 4 week"}, {"to": "531", "prefix": " or placebo. On day 6, a single 40 mg dose of ", "from": "521", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " was administered orally. Plasma concentrations of pravastatin were measured up "}, {"to": "593", "prefix": "le 40 mg dose of pravastatin was administered orally. Plasma concentrations of ", "from": "583", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " were measured up to 12 h by a sensitive LC-MS-MS method.\n\nResults\n\nDuring the r"}, {"to": "766", "prefix": "mpicin phase, the mean total area under the plasma concentration-time curve of ", "from": "756", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " [AUC(0"}, {"to": "985", "prefix": " of ", "from": "975", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " during the rifampicin phase was 50% or less of that during the placebo phase. R"}, {"to": "1183", "prefix": " effect on the peak concentration, elimination half-life or renal clearance of ", "from": "1173", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": ".\n\nConclusions\n\nRifampicin caused a statistically significant decrease in the pl"}, {"to": "1296", "prefix": "cin caused a statistically significant decrease in the plasma concentration of ", "from": "1286", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " given as a single oral dose to healthy subjects. However, the effect of rifampi"}, {"to": "1464", "prefix": "picin varied greatly between subjects. The mean rifampicin-induced decrease in ", "from": "1454", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " concentration was considerably smaller than that observed previously for simvas"}, {"to": "1586", "prefix": "smaller than that observed previously for simvastatin.\n\nKeywords: interaction, ", "from": "1576", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": ", rifampicin\nGo to:\nIntroduction\nRifampicin is a potent inducer of several cytoc"}, {"to": "2588", "prefix": " about one tenth of control values [9].\n\nUnlike simvastatin, the metabolism of ", "from": "2578", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " is not significantly mediated by CYP enzymes [10"}, {"to": "2663", "prefix": "12]. However, ", "from": "2653", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " is a substrate of MRP2 and the uptake transporter OATP2 [13"}, {"to": "2959", "prefix": " of simvastatin acid at least tenfold but had no significant effect on that of ", "from": "2949", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " [16]. Furthermore, combination therapy with the HIV protease inhibitors ritonav"}, {"to": "3145", "prefix": " of simvastatin 30-fold, but decreased that of ", "from": "3135", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " by 50% [17]. Pravastatin is a substrate of both influx and efflux transporters,"}, {"to": "3170", "prefix": " of simvastatin 30-fold, but decreased that of pravastatin by 50% [17]. ", "from": "3160", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "Pravastatin", "suffix": " is a substrate of both influx and efflux transporters, and although significant"}, {"to": "3300", "prefix": "x transporters, and although significant interactions mediated by induction of ", "from": "3290", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " metabolism are not likely, the in vivo effects of induction of transporters are"}, {"to": "3468", "prefix": "re largely unknown. Thus, the extent of any interaction between rifampicin and ", "from": "3458", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " cannot be inferred from previous work. The aim of this study was to examine the"}, {"to": "3617", "prefix": "dy was to examine the possible effect of rifampicin on the pharmacokinetics of ", "from": "3607", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " in healthy volunteers, using an identical study design as in the previous study"}, {"to": "3778", "prefix": "ous study to allow comparison of the interaction potentials of simvastatin and ", "from": "3768", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " [9].\n\nGo to:\nMethods\nSubjects\n\nTen healthy nonsmoking volunteers (age range, 19"}, {"to": "4511", "prefix": "ical power was estimated to be sufficient to detect a 50% change in the AUC of ", "from": "4501", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " with a power of 80% (alpha-level 5%).\n\nTable 1\nTable 1\nCharacteristics of the s"}, {"to": "5090", "prefix": " or matched placebo orally once daily at 4 p.m. for 5 days. On day 6, ", "from": "5080", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " (a single Pravachol 40 mg tablet, Bristol-Myers Squibb, New York, NY) was admin"}, {"to": "5110", "prefix": "a single ", "from": "5102", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "Pravachol", "suffix": " 40 mg tablet, Bristol-Myers Squibb, New York, NY) was administered orally with "}, {"to": "5375", "prefix": "vernight, and a standard meal was served 3 and 7 h after the administration of ", "from": "5365", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": ". Alcohol or strenuous exercise was not allowed for two days and subjects didn't"}, {"to": "5752", "prefix": " were drawn from a cannulated forearm vein prior to administration of ", "from": "5742", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 12 h later, and were collected in "}, {"to": "6046", "prefix": "12 h after the administration of ", "from": "6036", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": ".\n\nDetermination of pravastatin\n\nThe concentrations of pravastatin in plasma and"}, {"to": "6077", "prefix": "12 h after the administration of pravastatin.\n\nDetermination of ", "from": "6067", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": "\n\nThe concentrations of pravastatin in plasma and urine were measured by liquid "}, {"to": "6112", "prefix": "istration of pravastatin.\n\nDetermination of pravastatin\n\nThe concentrations of ", "from": "6102", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " in plasma and urine were measured by liquid chromatography-ionspray tandem mass"}, {"to": "7296", "prefix": " of ", "from": "7286", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " was calculated from CLrenal 0"}, {"to": "7385", "prefix": ", where Ae is the amount of ", "from": "7375", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " excreted into urine within 12 h.\n\nStatistical analysis\n\nResults are expressed a"}, {"to": "8099", "prefix": " of ", "from": "8089", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " and simvastatin acid [9]. The analysis was performed with Systat for Windows, V"}, {"to": "8340", "prefix": " of ", "from": "8330", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " was 69% (range 24"}, {"to": "8563", "prefix": " of ", "from": "8553", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " decreased in 7 and increased in 3 of the 10 subjects. This effect was not relat"}, {"to": "8671", "prefix": "d increased in 3 of the 10 subjects. This effect was not related to the AUC of ", "from": "8661", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " during the placebo phase or to the gender of the subjects (Figure 2). Rifampici"}, {"to": "8795", "prefix": ". Rifampicin tended to decrease the Cmax of ", "from": "8785", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": ", on average by 21%, but the difference did not reach statistical significance ("}, {"to": "8993", "prefix": " of ", "from": "8983", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " (Table 2). The renal clearance and the cumulative excretion of pravastatin into"}, {"to": "9068", "prefix": ". The renal clearance and the cumulative excretion of ", "from": "9058", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " into the urine were largely unaffected by rifampicin (P "}, {"to": "9222", "prefix": ".\n\nTable 2\nTable 2\nThe pharmacokinetic variables of ", "from": "9212", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " in 10 healthy subjects after the ingestion of 40 mg pravastatin following treat"}, {"to": "9286", "prefix": "c variables of pravastatin in 10 healthy subjects after the ingestion of 40 mg ", "from": "9276", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " following treatment with 600 mg rifampicin or placebo twice daily for 5 days\nFi"}, {"to": "9436", "prefix": " of ", "from": "9426", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " in 10 healthy subjects after administration of 40 mg pravastatin following pret"}, {"to": "9501", "prefix": " of pravastatin in 10 healthy subjects after administration of 40 mg ", "from": "9491", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " following pretreatment with 600 mg rifampicin ("}, {"to": "9792", "prefix": " values of ", "from": "9782", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " in 10 healthy subjects after ingestion of 40 mg pravastatin following ...\nThe m"}, {"to": "9852", "prefix": " values of pravastatin in 10 healthy subjects after ingestion of 40 mg ", "from": "9842", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " following ...\nThe mean effect of rifampicin on the AUC of pravastatin in the pr"}, {"to": "9922", "prefix": "of 40 mg pravastatin following ...\nThe mean effect of rifampicin on the AUC of ", "from": "9912", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " in the present study was considerably smaller and more variable than that on th"}, {"to": "10167", "prefix": " of ", "from": "10157", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " compared to simvastatin acid was statistically significant (P "}, {"to": "10444", "prefix": "] of simvastatin acid and ", "from": "10434", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " as percent of control values. The simvastatin acid ...\nGo to:\nDiscussion\nIn thi"}, {"to": "10572", "prefix": "vastatin acid ...\nGo to:\nDiscussion\nIn this study the plasma concentrations of ", "from": "10562", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " were moderately decreased by pretreatment with rifampicin. The mean AUC(0"}, {"to": "10664", "prefix": " of ", "from": "10654", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " was decreased by 31%, but there was considerable interindividual variation. In "}, {"to": "10795", "prefix": " of ", "from": "10785", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " during the rifampicin phase was 50% or less of that during the placebo phase. H"}, {"to": "10941", "prefix": "ing the placebo phase. However, in three subjects the plasma concentrations of ", "from": "10931", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " increased during the rifampicin phase. The other pharmacokinetic variables stud"}, {"to": "11316", "prefix": " period effects did not explain the observations.\n\nThe effect of rifampicin on ", "from": "11306", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " pharmacokinetics is not likely to be caused by induction of CYP3A4 or P-glycopr"}, {"to": "11422", "prefix": "s is not likely to be caused by induction of CYP3A4 or P-glycoprotein, because ", "from": "11412", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " is not a substrate of P-glycoprotein, CYP3A4 or other CYP enzymes [10, 11, 19"}, {"to": "11526", "prefix": "21]. However, ", "from": "11516", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " is a substrate of canalicular multispecific organic anion transporter (cMOAT or"}, {"to": "12002", "prefix": "rter. Induction of canalicular MRP2 by rifampicin might also decrease systemic ", "from": "11992", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " absorption by enhancing first-pass biliary excretion. Therefore, it is possible"}, {"to": "12407", "prefix": "subjects [5], which is in line with our results that rifampicin only decreased ", "from": "12397", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " AUC in 7 out of 10 subjects (Figure 2). There are several allelic variants of O"}, {"to": "12785", "prefix": "PXR receptors and consequent induction [8]. An explanation for the increase in ", "from": "12775", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " concentrations in some subjects might be the inhibition of OATP2-mediated uptak"}, {"to": "12881", "prefix": "ntrations in some subjects might be the inhibition of OATP2-mediated uptake of ", "from": "12871", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " into hepatocytes by rifampicin [8]. However, it is likely that the concentratio"}, {"to": "13031", "prefix": "hat the concentrations of rifampicin in the liver were very low at the time of ", "from": "13021", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " administration, because the last dose of rifampicin was administered 17 h earli"}, {"to": "13180", "prefix": "ministered 17 h earlier. Accordingly, it is also possible that the increase in ", "from": "13170", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " concentrations in some subjects was the result of the inherent variability of p"}, {"to": "13270", "prefix": " concentrations in some subjects was the result of the inherent variability of ", "from": "13260", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " AUC within an individual.\n\nGlucuronidation appears to be one of the predominant"}, {"to": "13374", "prefix": " individual.\n\nGlucuronidation appears to be one of the predominant pathways of ", "from": "13364", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " metabolism [12], and rifampicin is also known to induce the phase II enzymes, s"}, {"to": "13581", "prefix": "26]. Nevertheless, because the renal clearance and elimination half-life of ", "from": "13571", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " were largely unaffected by rifampicin, it is reasonable to assume that the inte"}, {"to": "14012", "prefix": "studied [9]. This effect was much greater than that on the pharmacokinetics of ", "from": "14002", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " observed in the present study. In other work, itraconazole was found to increas"}, {"to": "14224", "prefix": " and Cmax of ", "from": "14214", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " was not statistically significant [16]. Furthermore, a 14-day pretreatment with"}, {"to": "14459", "prefix": " of simvastatin acid by 52%, but had no effect on that of ", "from": "14449", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " [27]. These results are in agreement with the present findings and indicate tha"}, {"to": "14552", "prefix": "7]. These results are in agreement with the present findings and indicate that ", "from": "14542", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " is less susceptible to pharmacokinetic interactions than simvastatin.\n\nRifampic"}, {"to": "15106", "prefix": "lism of lovastatin and lovastatin acid as well. Of the statins studied so far, ", "from": "15096", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " appears to be least susceptible to the potent inducing effects of rifampicin, a"}, {"to": "15324", "prefix": "ation with inducers of CYP enzymes or P-glycoprotein. However, the decrease in ", "from": "15314", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " exposure by rifampicin might be clinically significant in some individuals, and"}, {"to": "15428", "prefix": "ifampicin might be clinically significant in some individuals, and the dose of ", "from": "15418", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " might need adjustment.\n\nIn conclusion, rifampicin had a relatively small but hi"}, {"to": "15567", "prefix": "n had a relatively small but highly variable effect on the pharmacokinetics of ", "from": "15557", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": ". The dose of pravastatin might need adjustment in some individuals if long-term"}, {"to": "15592", "prefix": "but highly variable effect on the pharmacokinetics of pravastatin. The dose of ", "from": "15582", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1884432", "exact": "pravastatin", "suffix": " might need adjustment in some individuals if long-term treatment with rifampici"}, {"to": "1549", "prefix": "tatin concentration was considerably smaller than that observed previously for ", "from": "1539", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC1884432", "exact": "simvastatin", "suffix": ".\n\nKeywords: interaction, pravastatin, rifampicin\nGo to:\nIntroduction\nRifampicin"}, {"to": "2471", "prefix": " of the HMG-CoA inhibitor ", "from": "2461", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC1884432", "exact": "simvastatin", "suffix": " and its acid metabolite to about one tenth of control values [9].\n\nUnlike simva"}, {"to": "2557", "prefix": "atin and its acid metabolite to about one tenth of control values [9].\n\nUnlike ", "from": "2547", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC1884432", "exact": "simvastatin", "suffix": ", the metabolism of pravastatin is not significantly mediated by CYP enzymes [10"}, {"to": "3102", "prefix": " of ", "from": "3092", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC1884432", "exact": "simvastatin", "suffix": " 30-fold, but decreased that of pravastatin by 50% [17]. Pravastatin is a substr"}, {"to": "3762", "prefix": " as in the previous study to allow comparison of the interaction potentials of ", "from": "3752", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC1884432", "exact": "simvastatin", "suffix": " and pravastatin [9].\n\nGo to:\nMethods\nSubjects\n\nTen healthy nonsmoking volunteer"}, {"to": "5606", "prefix": "test days. The study design was otherwise identical to our previous rifampicin-", "from": "5596", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC1884432", "exact": "simvastatin", "suffix": " study [9].\n\nBlood and urine sampling\n\nBlood samples (10 ml each) were drawn fro"}, {"to": "13874", "prefix": " of ", "from": "13864", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC1884432", "exact": "simvastatin", "suffix": " and simvastatin acid in all of the 10 subjects studied [9]. This effect was muc"}, {"to": "14621", "prefix": "cate that pravastatin is less susceptible to pharmacokinetic interactions than ", "from": "14611", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC1884432", "exact": "simvastatin", "suffix": ".\n\nRifampicin decreases the total AUC of fluvastatin, a CYP2C9 substrate [28], b"}, {"to": "14954", "prefix": "inetic properties of the CYP3A4 substrate lovastatin closely resemble those of ", "from": "14944", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC1884432", "exact": "simvastatin", "suffix": " [31, 32], it is likely that rifampicin will induce the metabolism of lovastatin"}, {"to": "2851", "prefix": " differences in the interaction potential of the different statin drugs. Thus, ", "from": "2840", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1884432", "exact": "itraconazole", "suffix": " increased the AUC of simvastatin acid at least tenfold but had no significant e"}, {"to": "14071", "prefix": " pharmacokinetics of pravastatin observed in the present study. In other work, ", "from": "14060", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1884432", "exact": "itraconazole", "suffix": " was found to increase the AUC(0"}, {"to": "3041", "prefix": "statin [16]. Furthermore, combination therapy with the HIV protease inhibitors ", "from": "3033", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC1884432", "exact": "ritonavir", "suffix": " and saquinavir increased the median AUC(0"}, {"to": "3056", "prefix": "urthermore, combination therapy with the HIV protease inhibitors ritonavir and ", "from": "3047", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83395", "setId": "PMC1884432", "exact": "saquinavir", "suffix": " increased the median AUC(0"}, {"to": "6514", "prefix": "1, 2.6% ", "from": "6510", "name": "Dihydrotachysterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D004097", "setId": "PMC1884432", "exact": "at 10", "suffix": " ng ml"}, {"to": "14673", "prefix": "okinetic interactions than simvastatin.\n\nRifampicin decreases the total AUC of ", "from": "14663", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1884432", "exact": "fluvastatin", "suffix": ", a CYP2C9 substrate [28], by about 50% [23]. Preliminary data also indicate tha"}, {"to": "14799", "prefix": " 50% [23]. Preliminary data also indicate that rifampicin decreases the AUC of ", "from": "14788", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC1884432", "exact": "atorvastatin", "suffix": " by a mean of 78% compared to placebo [30]. Because the pharmacokinetic properti"}, {"to": "14916", "prefix": "o placebo [30]. Because the pharmacokinetic properties of the CYP3A4 substrate ", "from": "14907", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1884432", "exact": "lovastatin", "suffix": " closely resemble those of simvastatin [31, 32], it is likely that rifampicin wi"}, {"to": "15034", "prefix": "mvastatin [31, 32], it is likely that rifampicin will induce the metabolism of ", "from": "15025", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1884432", "exact": "lovastatin", "suffix": " and lovastatin acid as well. Of the statins studied so far, pravastatin appears"}, {"to": "15049", "prefix": "32], it is likely that rifampicin will induce the metabolism of lovastatin and ", "from": "15040", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1884432", "exact": "lovastatin", "suffix": " acid as well. Of the statins studied so far, pravastatin appears to be least su"}, {"to": "44", "prefix": "Abstract\nAims\n\nThe anticoagulant ", "from": "34", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " is an oral, direct Factor Xa inhibitor for the management of thromboembolic dis"}, {"to": "432", "prefix": " on ", "from": "422", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " were studied in healthy volunteers.\n\nResults\n\nRivaroxaban did not interact with"}, {"to": "490", "prefix": " on rivaroxaban were studied in healthy volunteers.\n\nResults\n\n", "from": "480", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "Rivaroxaban", "suffix": " did not interact with midazolam (CYP3A4 probe substrate). Exposure to rivaroxab"}, {"to": "572", "prefix": ". Exposure to ", "from": "562", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " when co-administered with midazolam was slightly decreased by 11% (95% confiden"}, {"to": "704", "prefix": " compared with ", "from": "694", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " alone. The following drugs moderately affected rivaroxaban exposure, but not to"}, {"to": "763", "prefix": " compared with rivaroxaban alone. The following drugs moderately affected ", "from": "753", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " exposure, but not to a clinically relevant extent: erythromycin (moderate CYP3A"}, {"to": "1118", "prefix": ". A significant increase in ", "from": "1108", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " exposure was demonstrated with the strong CYP3A4, P-gp"}, {"to": "1407", "prefix": ".\n\nConclusions\n\nResults suggest that ", "from": "1397", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " may be co-administered with CYP3A4 and"}, {"to": "1699", "prefix": ", which are multi-pathway inhibitors of ", "from": "1689", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " clearance and elimination.\n\nKeywords: cytochrome P450, drug interactions, healt"}, {"to": "1819", "prefix": "eywords: cytochrome P450, drug interactions, healthy subjects, P-glycoprotein, ", "from": "1809", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": "\nWHAT IS ALREADY KNOWN ABOUT THIS SUBJECT\n\nRivaroxaban, an oral, direct Factor X"}, {"to": "1873", "prefix": "ubjects, P-glycoprotein, rivaroxaban\nWHAT IS ALREADY KNOWN ABOUT THIS SUBJECT\n\n", "from": "1863", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "Rivaroxaban", "suffix": ", an oral, direct Factor Xa inhibitor, is metabolized and excreted via mechanism"}, {"to": "2097", "prefix": "ever, the pharmacokinetic effects and implications of the co-administration of ", "from": "2087", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " and medications that interfere with these elimination pathways require characte"}, {"to": "2279", "prefix": "AT THIS STUDY ADDS\n\nThis paper reports on a series of interaction studies with ", "from": "2269", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " in healthy volunteers, the results of which suggest that rivaroxaban can be adm"}, {"to": "2348", "prefix": "dies with rivaroxaban in healthy volunteers, the results of which suggest that ", "from": "2338", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " can be administered in conjunction with substrates or moderate inhibitors of CY"}, {"to": "2687", "prefix": "zole-antimycotics and HIV protease inhibitors, cause a significant increase in ", "from": "2677", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " exposure that could increase the risk of bleeding. The exception is fluconazole"}, {"to": "3086", "prefix": "are taking concomitant medications.\nGo to:\nIntroduction\nThe oral anticoagulant ", "from": "3076", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " is a highly selective, direct Factor Xa inhibitor for the prevention and treatm"}, {"to": "3344", "prefix": " independently of antithrombin [1]. In vitro, ", "from": "3334", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " has been shown to inhibit thrombin generation and prolong clotting times [1, 2]"}, {"to": "3489", "prefix": "ong clotting times [1, 2]. Results of in vivo animal model studies showed that ", "from": "3479", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " was effective in the prevention and treatment of venous thrombosis [1, 3], as w"}, {"to": "3790", "prefix": "OCKET AF [8] and ATLAS ACS 2 TIMI 51 [9] phase III clinical trial programmes.\n\n", "from": "3780", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "Rivaroxaban", "suffix": " is approved for the prevention of venous thromboembolism (or deep vein thrombos"}, {"to": "4324", "prefix": " and secondary prevention of DVT and pulmonary embolism after acute DVT [10].\n\n", "from": "4314", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "Rivaroxaban", "suffix": " has a dual mode of elimination. Approximately two-thirds of the administered do"}, {"to": "4734", "prefix": " mainly via active renal secretion [12]. When comparing the renal clearance of ", "from": "4724", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " (approximately 30"}, {"to": "4910", "prefix": "erular filtration rate, taking into account the high plasma protein binding of ", "from": "4900", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " (approximately 92"}, {"to": "5227", "prefix": " as the responsible active renal transporters [15].\n\n", "from": "5217", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "Rivaroxaban", "suffix": " is metabolized via cytochrome P450 (CYP) 3A4"}, {"to": "5497", "prefix": "s are the major pathways of biotransformation [18]. After a 10 mg oral dose of ", "from": "5487", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": ", the metabolite profile in human plasma shows that unchanged rivaroxaban is the"}, {"to": "5570", "prefix": "se of rivaroxaban, the metabolite profile in human plasma shows that unchanged ", "from": "5560", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " is the main compound, with no major or active circulating metabolites present ["}, {"to": "5719", "prefix": "1, ", "from": "5709", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " can be classified as a low clearance drug, lacking relevant presystemic first p"}, {"to": "6037", "prefix": " [10]. Owing to the involvement of both CYP3A4 and CYP2J2 in ", "from": "6027", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " biotransformation and of transport proteins P-gp and Bcrp (ABCG2) in active ren"}, {"to": "6144", "prefix": " in active renal secretion of ", "from": "6134", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": ", it was important to determine the potential of rivaroxaban to interact with dr"}, {"to": "6204", "prefix": "renal secretion of rivaroxaban, it was important to determine the potential of ", "from": "6194", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " to interact with drugs that are substrates for, or known inhibitors of, these p"}, {"to": "6358", "prefix": "tors of, these pathways.\n\nIn vitro studies showed that the active transport of ", "from": "6348", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " was unaffected by substrates of P-gp and Bcrp (ABCG2). However, these studies s"}, {"to": "6580", "prefix": ", such as ketoconazole and ritonavir, may reduce the renal clearance of ", "from": "6570", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " [15]. Further in vitro interaction studies showed that the biotransformation of"}, {"to": "6672", "prefix": "15]. Further in vitro interaction studies showed that the biotransformation of ", "from": "6662", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " was affected by therapeutically relevant concentrations of ketoconazole and rit"}, {"to": "7193", "prefix": ". Using appropriate probe drugs and in vitro test systems, ", "from": "7183", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " itself (at concentrations up to more than 100-fold higher than therapeutic plas"}, {"to": "7483", "prefix": "ated transport [10, 11, 15, 17], rendering clinically relevant interactions of ", "from": "7473", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " with co-medications unlikely. Clinically relevant drug"}, {"to": "7576", "prefix": "drug interactions between ", "from": "7566", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " and substrates of CYP enzymes are unlikely, because no significant influence of"}, {"to": "7668", "prefix": "nd substrates of CYP enzymes are unlikely, because no significant influence of ", "from": "7658", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " on biotransformation reactions catalysed by relevant CYP isoforms was observed "}, {"to": "8179", "prefix": "dertaken to determine the clinical extent of any potential interaction between ", "from": "8169", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " and substrates for, or inhibitors of, CYP3A4 and"}, {"to": "8312", "prefix": ". Previously, ", "from": "8302", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " has demonstrated a lack of mutual interaction with the P-gp probe substrate dig"}, {"to": "8534", "prefix": "rate atorvastatin [26, 27]. Here, interaction studies were carried out between ", "from": "8524", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " and the following drugs:\n\nA sensitive probe substrate for CYP3A4 only "}, {"to": "9160", "prefix": "ertaken to determine the extent of potential interactions with single doses of ", "from": "9150", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " (10 mg or 20 mg) and steady-state ketoconazole (200 mg once daily), steady-stat"}, {"to": "9582", "prefix": "taken to determine the extent of the possible interaction between steady-state ", "from": "9572", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " (10 mg once daily) and high dose, steady-state ketoconazole (400 mg once daily)"}, {"to": "10368", "prefix": "drug administration. In the study investigating potential interactions between ", "from": "10358", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " and steady-state ketoconazole 200 mg, subjects received ketoconazole for 72 h a"}, {"to": "10980", "prefix": " for routine laboratory tests and to determine the pharmacokinetics of ", "from": "10970", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " and, where necessary, the pharmacokinetics of the potential interacting drug.\n\n"}, {"to": "11489", "prefix": "\nMidazolam\n\nA study was undertaken to determine potential interactions between ", "from": "11479", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " and a sensitive probe substrate for CYP3A4 alone, midazolam [24, 28].\n\nIn an op"}, {"to": "11670", "prefix": "hree way crossover study, subjects were randomized to receive a single dose of ", "from": "11660", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " 20 mg alone, a single dose of midazolam 7.5 mg alone or the combination. All st"}, {"to": "12187", "prefix": "s were undertaken to determine the extent of the potential interaction between ", "from": "12177", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " and strong inhibitors of CYP3A4"}, {"to": "12422", "prefix": "eraction study investigated the potential interaction between a single dose of ", "from": "12412", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " and steady-state ketoconazole 200 mg once daily. In this open label, two way cr"}, {"to": "12581", "prefix": " two way crossover study, subjects were randomized to receive a single dose of ", "from": "12571", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " 10 mg, alone or with ketoconazole (4 days of oral ketoconazole 200 mg once dail"}, {"to": "12679", "prefix": "4 days of oral ketoconazole 200 mg once daily with ", "from": "12669", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " given on day 4). Rivaroxaban was given under fasting conditions and ketoconazol"}, {"to": "12708", "prefix": ". ", "from": "12698", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "Rivaroxaban", "suffix": " was given under fasting conditions and ketoconazole was given with food, except"}, {"to": "12826", "prefix": "ditions and ketoconazole was given with food, except when co-administered with ", "from": "12816", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": ". After completion of this study, a publication suggested that ketoconazole 400 "}, {"to": "13074", "prefix": "stigating the maximum extent of the potential interaction between steady-state ", "from": "13064", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " and steady-state ketoconazole 400 mg once daily. This was a non-randomized, ope"}, {"to": "13211", "prefix": "y. This was a non-randomized, open label study in which subjects received oral ", "from": "13201", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " 10 mg once daily alone for 5 days, with concomitant ketoconazole 400 mg once da"}, {"to": "13933", "prefix": " 10.9 kg.\n\nRitonavir\n\nThe potential interaction between a single dose of ", "from": "13923", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " and steady-state ritonavir was investigated in a non-randomized, open label stu"}, {"to": "14063", "prefix": "ated in a non-randomized, open label study. Subjects received a single dose of ", "from": "14053", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " 10 mg on day 1, ritonavir 600 mg twice daily on days 3"}, {"to": "14188", "prefix": "7, and ritonavir 600 mg twice daily plus a single dose of ", "from": "14178", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " on day 8. All study drugs were administered with food.\n\nEighteen subjects were "}, {"to": "14672", "prefix": " 16 subjects were valid for the safety analysis. All received a single dose of ", "from": "14662", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " 10 mg on day 1 and at least one dose of ritonavir (600 mg). Twelve subjects rec"}, {"to": "14788", "prefix": ". Twelve subjects received the combination of ", "from": "14778", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " and ritonavir on day 8. However, none of the subjects received the second dose "}, {"to": "15292", "prefix": "\nClarithromycin\n\nA single study investigated the potential interaction between ", "from": "15282", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " and clarithromycin, classified as a strong inhibitor of CYP3A4, and considered "}, {"to": "15532", "prefix": " two way crossover study, subjects were randomized to receive a single dose of ", "from": "15522", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " 10 mg alone, or clarithromycin 500 mg twice daily for a period of 4 days under "}, {"to": "16194", "prefix": ".\n\nErythromycin\n\nA single study investigated the potential interaction between ", "from": "16184", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " and erythromycin, classified as a moderate inhibitor of CYP3A4, and considered "}, {"to": "16435", "prefix": " two way crossover study, subjects were randomized to receive a single dose of ", "from": "16425", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " 10 mg alone, or erythromycin 500 mg three times daily given for 4 days, with a "}, {"to": "16565", "prefix": "ee times daily given for 4 days, with a single 500 mg dose given on day 5 with ", "from": "16555", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " 10 mg. All study drugs were administered with food and there was a 14 day washo"}, {"to": "17093", "prefix": "s.\n\nFluconazole\n\nA single study investigated the potential interaction between ", "from": "17083", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " and fluconazole, classified as a potent inhibitor of CYP2C9 (rivaroxaban is not"}, {"to": "17166", "prefix": "", "from": "17156", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " is not metabolized via CYP2C9), a moderate inhibitor of CYP3A4, and also report"}, {"to": "17403", "prefix": " two way crossover study, subjects were randomized to receive a single dose of ", "from": "17393", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " 20 mg alone, or fluconazole 400 mg once daily given for 6 days, with a concomit"}, {"to": "17522", "prefix": "400 mg once daily given for 6 days, with a concomitant administration of 20 mg ", "from": "17512", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " given on day 5. All study drugs were administered with food and there was a 14 "}, {"to": "18539", "prefix": "\n\nSample collection and analysis\n\nPharmacokinetic parameters were derived from ", "from": "18529", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " plasma concentration"}, {"to": "18798", "prefix": " predefined time intervals after drug administration. Quantitative analysis of ", "from": "18788", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " concentrations (plasma and urine) was performed using a fully validated high pe"}, {"to": "19409", "prefix": ".\n\nThe following ", "from": "19399", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " plasma pharmacokinetic parameters were assessed: area under the plasma concentr"}, {"to": "19589", "prefix": " in the ketoconazole 400 mg study, in which multiple doses of ", "from": "19579", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " were given. Maximum drug concentration in plasma (Cmax), time to maximum drug p"}, {"to": "20248", "prefix": " for ", "from": "20238", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " is high ("}, {"to": "20342", "prefix": " for the 10 mg dose [14] used in most of the studies. The amount of ", "from": "20332", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " excreted in the urine was used to determine the renal clearance (CLR). Non-rena"}, {"to": "20708", "prefix": " for ", "from": "20698", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " was determined using equilibrium dialysis of total plasma concentrations at thr"}, {"to": "21015", "prefix": "ne measurements and urinary creatinine data collected in parallel to amount of ", "from": "21005", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " excreted in the urine. This allowed the splitting of rivaroxaban CLR into clear"}, {"to": "21080", "prefix": " to amount of rivaroxaban excreted in the urine. This allowed the splitting of ", "from": "21070", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " CLR into clearance by renal filtration (CLRF, calculated by CLCR "}, {"to": "21804", "prefix": "-hydroxy-midazolam [28], the effect of ", "from": "21794", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " on the pharmacokinetics of this CYP3A4-mediated metabolite was also analyzed.\n\n"}, {"to": "22076", "prefix": "udies using a crossover design, the pharmacokinetic parameters AUC and Cmax of ", "from": "22066", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " were analyzed assuming log-normally distributed data. To compare the pharmacoki"}, {"to": "22177", "prefix": "zed assuming log-normally distributed data. To compare the pharmacokinetics of ", "from": "22167", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " in the absence and presence of the potential interacting drug, the logarithms o"}, {"to": "22685", "prefix": ", in the absence or presence of ", "from": "22675", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": ", were also analyzed using the same method.\n\nIn the ketoconazole 400 mg once dai"}, {"to": "22880", "prefix": " both using sequential designs, the pharmacokinetic parameters AUC and Cmax of ", "from": "22870", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " were analyzed assuming log-normally distributed data. Student's paired t-tests "}, {"to": "23222", "prefix": "ed by retransformation of the logarithmic results. Derived clearance values of ", "from": "23212", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " (CL"}, {"to": "23387", "prefix": "teraction study with a substrate of CYP3A4\n\nMidazolam\n\nThe pharmacokinetics of ", "from": "23377", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": ", midazolam and its CYP3A4-mediated metabolite, "}, {"to": "23472", "prefix": "-hydroxy-midazolam, when ", "from": "23462", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " 20 mg and midazolam 7.5 mg were administered alone and in combination are summa"}, {"to": "23636", "prefix": " summarized in Table 1. Co-administration with midazolam led to an increase in ", "from": "23626", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " median tmax from 1.5 h to 4.0 h and slightly decreased the rivaroxaban mean Cma"}, {"to": "23707", "prefix": "ease in rivaroxaban median tmax from 1.5 h to 4.0 h and slightly decreased the ", "from": "23697", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " mean Cmax by 12% compared with rivaroxaban alone, a change that was not statist"}, {"to": "23750", "prefix": "to 4.0 h and slightly decreased the rivaroxaban mean Cmax by 12% compared with ", "from": "23740", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " alone, a change that was not statistically significant (90% CI "}, {"to": "23836", "prefix": ". ", "from": "23826", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "Rivaroxaban", "suffix": " mean AUC remained almost unchanged. Co-administration with rivaroxaban slightly"}, {"to": "23907", "prefix": ". Rivaroxaban mean AUC remained almost unchanged. Co-administration with ", "from": "23897", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " slightly decreased the mean AUC of midazolam by 11% compared with midazolam alo"}, {"to": "24203", "prefix": "-hydroxy-midazolam remained almost the same with co-administration of ", "from": "24193", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " and midazolam compared with midazolam alone, but the mean Cmax was increased by"}, {"to": "24463", "prefix": "of midazolam and its metabolite remained similar in the presence or absence of ", "from": "24453", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": ".\n\nTable 1\nTable 1\nPharmacokinetic parameters of rivaroxaban administered alone "}, {"to": "24523", "prefix": "ence or absence of rivaroxaban.\n\nTable 1\nTable 1\nPharmacokinetic parameters of ", "from": "24513", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " administered alone or in combination with midazolam 7.5 mg (mean"}, {"to": "24896", "prefix": "\n\nKetoconazole 200 mg once daily\n\nThe pharmacokinetic parameters of ", "from": "24886", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " 10 mg administered alone or in combination with ketoconazole 200 mg once daily "}, {"to": "25128", "prefix": "conazole significantly increased the plasma concentrations of a single dose of ", "from": "25118", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " 10 mg compared with rivaroxaban alone. The mean AUC increased by 82% (90% CI 59"}, {"to": "25160", "prefix": " the plasma concentrations of a single dose of rivaroxaban 10 mg compared with ", "from": "25150", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " alone. The mean AUC increased by 82% (90% CI 59%, 108%) and the mean Cmax incre"}, {"to": "25348", "prefix": " of ", "from": "25338", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " was significantly reduced by a mean of 45% (90% CI "}, {"to": "25441", "prefix": " with combined vs. ", "from": "25431", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " alone.\n\nTable 2\nTable 2\nPharmacokinetic parameters of rivaroxaban (10 mg) admin"}, {"to": "25507", "prefix": "combined vs. rivaroxaban alone.\n\nTable 2\nTable 2\nPharmacokinetic parameters of ", "from": "25497", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " (10 mg) administered alone or in combination with ketoconazole 200 mg once dail"}, {"to": "25801", "prefix": "ly or ...\nKetoconazole 400 mg once daily\n\nThe pharmacokinetics of steady-state ", "from": "25791", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " 10 mg (day 5) were compared with those of steady-state rivaroxaban 10 mg in com"}, {"to": "25868", "prefix": " were compared with those of steady-state ", "from": "25858", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " 10 mg in combination with steady-state ketoconazole 400 mg once daily (day 10)."}, {"to": "26027", "prefix": ". Co-administration with ketoconazole 400 mg significantly increased ", "from": "26017", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " plasma concentrations (Figure 1A). The mean AUC for the actual dose interval (A"}, {"to": "26243", "prefix": " with the combination compared with ", "from": "26233", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " alone (Table 2). The mean CL"}, {"to": "26544", "prefix": "time profile of ", "from": "26534", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " (20 mg [fluconazole study] or 10 mg [all other studies] once daily) in the abse"}, {"to": "26832", "prefix": " that holds a picture, illustration, etc.\nObject name is bcp0076-0455-mu1.jpg, ", "from": "26822", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " ...\nRitonavir\n\nThe pharmacokinetics of rivaroxaban 10 mg were compared after a "}, {"to": "26883", "prefix": "me is bcp0076-0455-mu1.jpg, rivaroxaban ...\nRitonavir\n\nThe pharmacokinetics of ", "from": "26873", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " 10 mg were compared after a single dose (day 1) with those of a single dose of "}, {"to": "27117", "prefix": "the pharmacokinetics of ritonavir were compared in the absence and presence of ", "from": "27107", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " (days 7 and 8, respectively). Steady-state ritonavir significantly increased th"}, {"to": "27226", "prefix": ". Steady-state ritonavir significantly increased the AUC and Cmax of ", "from": "27216", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": ". The mean AUC increased by 153% (90% CI 134%, 174%) and the mean Cmax increased"}, {"to": "27357", "prefix": " compared with ", "from": "27347", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " alone (Table 2). Mean plasma concentrations of rivaroxaban were shown to increa"}, {"to": "27416", "prefix": ". Mean plasma concentrations of ", "from": "27406", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " were shown to increase with the combined regimen (Figure 1B). Ritonavir signifi"}, {"to": "27536", "prefix": "F of ", "from": "27526", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " by 60% (90% CI "}, {"to": "27603", "prefix": " without affecting the fu of ", "from": "27593", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": ". CLRS was significantly reduced by 82% (90% CI "}, {"to": "27771", "prefix": "P-gp inhibitors\n\nClarithromycin\n\nThe pharmacokinetics of ", "from": "27761", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " were compared after a single dose of rivaroxaban 10 mg was administered alone a"}, {"to": "27820", "prefix": "ycin\n\nThe pharmacokinetics of rivaroxaban were compared after a single dose of ", "from": "27810", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " 10 mg was administered alone and co-administered with clarithromycin 500 mg aft"}, {"to": "28081", "prefix": "arithromycin significantly increased the primary pharmacokinetic parameters of ", "from": "28071", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " (Table 2, Figure 1C). Both the mean AUC and Cmax were significantly increased, "}, {"to": "28257", "prefix": ", respectively, in comparison with ", "from": "28247", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " alone. Co-administration significantly decreased the mean CL"}, {"to": "28335", "prefix": "F of ", "from": "28325", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " from plasma by 35% (90% CI "}, {"to": "28514", "prefix": ".\n\nErythromycin\n\nThe pharmacokinetic effects of ", "from": "28504", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " 10 mg administered alone (day 5) and in combination with steady-state erythromy"}, {"to": "28794", "prefix": "with steady-state erythromycin significantly increased the pharmacokinetics of ", "from": "28784", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " (Table 2, Figure 1D). The mean AUC and Cmax both significantly increased (by 34"}, {"to": "28960", "prefix": " compared with ", "from": "28950", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " alone. The mean CL"}, {"to": "28996", "prefix": "F of ", "from": "28986", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " was significantly decreased by 25% (90% CI "}, {"to": "29180", "prefix": " and the fu of ", "from": "29170", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " showed a slight increase of 6%.\n\nFluconazole\n\nThe pharmacokinetics of rivaroxab"}, {"to": "29262", "prefix": "aroxaban showed a slight increase of 6%.\n\nFluconazole\n\nThe pharmacokinetics of ", "from": "29252", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " were compared after a single dose of rivaroxaban 20 mg was administered alone a"}, {"to": "29311", "prefix": "zole\n\nThe pharmacokinetics of rivaroxaban were compared after a single dose of ", "from": "29301", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " 20 mg was administered alone and co-administered with fluconazole 400 mg after "}, {"to": "29562", "prefix": " fluconazole significantly increased the primary pharmacokinetic parameters of ", "from": "29552", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " (Table 2, Figure 1E). Both the mean AUC and mean Cmax increased (by 42% [90% CI"}, {"to": "29724", "prefix": " in comparison with ", "from": "29714", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " alone. Co-administration significantly decreased the CL"}, {"to": "29797", "prefix": "F of ", "from": "29787", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " from plasma by 29% (90% CI "}, {"to": "30171", "prefix": "4 events, none of which was serious, were considered to be possibly related to ", "from": "30161", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " alone or a combination involving rivaroxaban. Of these, headache (32 events) an"}, {"to": "30216", "prefix": "sidered to be possibly related to rivaroxaban alone or a combination involving ", "from": "30206", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": ". Of these, headache (32 events) and fatigue (13 events) were the most common. N"}, {"to": "30579", "prefix": "lts of these specific interaction studies in healthy subjects demonstrate that ", "from": "30569", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " does not interact with a probe substrate for CYP3A4 (midazolam). Co-administrat"}, {"to": "30677", "prefix": ". Co-administration of ", "from": "30667", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " with a moderate CYP3A4 and P-gp inhibitor (erythromycin), a moderate inhibitor "}, {"to": "30950", "prefix": ", led to a statistically significant increase in ", "from": "30940", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " exposure. Of note, active renal secretion (CLRS) was reduced to a moderate but "}, {"to": "31275", "prefix": " pronounced and statistically significant interaction was demonstrated between ", "from": "31265", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " and strong inhibitors of CYP3A4 (and possibly CYP2J2), P-gp and Bcrp (ABCG2, ke"}, {"to": "31419", "prefix": ".\n\nThe co-administration of ", "from": "31409", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " with midazolam had no effect on the pharmacokinetics of rivaroxaban, or on the "}, {"to": "31487", "prefix": "tration of rivaroxaban with midazolam had no effect on the pharmacokinetics of ", "from": "31477", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": ", or on the pharmacokinetics of midazolam or its CYP3A4-mediated metabolites. Pr"}, {"to": "31821", "prefix": "ubjects demonstrated no effect on the pharmacokinetics and pharmacodynamics of ", "from": "31811", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": ", or on the pharmacokinetics of digoxin or atorvastatin [25, 27]. This lack of i"}, {"to": "31968", "prefix": "25, 27]. This lack of interaction confirms previous in vitro observations that ", "from": "31958", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " does not induce or inhibit any major CYP isoforms, including CYP3A4, or P-gp"}, {"to": "32161", "prefix": ", 15, 17]. This information is of further value because the concomitant use of ", "from": "32151", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " and these drugs is highly likely. Rivaroxaban is now in use for the prevention "}, {"to": "32207", "prefix": "e because the concomitant use of rivaroxaban and these drugs is highly likely. ", "from": "32197", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "Rivaroxaban", "suffix": " is now in use for the prevention of stroke in patients with atrial fibrillation"}, {"to": "32565", "prefix": "r medications, such as digoxin and statins [36, 37].\n\nThe co-administration of ", "from": "32555", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " and the frequently used antibiotic erythromycin, a moderate CYP inhibitor and w"}, {"to": "32741", "prefix": " moderate P-gp inhibitor, led to a 34% and 38% increase in the AUC and Cmax of ", "from": "32731", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": ", respectively. However, as with other studies reporting similar statistically s"}, {"to": "33098", "prefix": "hey were similar in magnitude to the inter-individual variability expected for ", "from": "33088", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " in patients [20, 40]. The decreased clearance and slightly increased active ren"}, {"to": "33205", "prefix": " 40]. The decreased clearance and slightly increased active renal secretion of ", "from": "33195", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " when it was co-administered with steady-state erythromycin may be partially exp"}, {"to": "33498", "prefix": ". The interaction between ", "from": "33488", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " and another frequently used antibiotic, clarithromycin, classified as a strong "}, {"to": "33740", "prefix": "mean increases of 54% and 40% in ", "from": "33730", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " AUC and Cmax, respectively), with a minimal decrease in active renal secretion."}, {"to": "33899", "prefix": " secretion.\n\nThese results, combined with in vitro data [15, 17], suggest that ", "from": "33889", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " has the potential to interact to a clinically relevant extent with strong inhib"}, {"to": "34359", "prefix": ". There were significant increases in exposure to ", "from": "34349", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " when it was co-administered with ketoconazole and ritonavir, with a more than t"}, {"to": "34581", "prefix": " clearance of ", "from": "34571", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " (derived from data in Table 2) and a 44% mean inhibition of active renal secret"}, {"to": "35023", "prefix": " and, as a result, the concomitant administration of ", "from": "35013", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " with these drugs should be avoided because of a potential increase in the risk "}, {"to": "35382", "prefix": "ent study, the quantitative assumption for the interaction of fluconazole with ", "from": "35372", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " was moderate (mean increases of 42% and 28% in rivaroxaban AUC and Cmax, respec"}, {"to": "35441", "prefix": "mean increases of 42% and 28% in ", "from": "35431", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " AUC and Cmax, respectively).\n\nBased on excretion and metabolite data derived fr"}, {"to": "35662", "prefix": "18], the clearance pathways of ", "from": "35652", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " have been quantified to the following average values. The contribution of CYP3A"}, {"to": "35832", "prefix": "3A5 accounts for approximately 18% and CYP2J2 for approximately 14% of total ", "from": "35822", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " elimination. In addition to this oxidative biotransformation, non-CYP-mediated "}, {"to": "36317", "prefix": "n studies are in accordance with the contributions of the respective routes of ", "from": "36307", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " multi-pathway clearance and the inhibitory potential of the specific inhibitors"}, {"to": "36534", "prefix": "blished mechanistic understanding of the clearance and elimination profile for ", "from": "36524", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " and its potential for drug"}, {"to": "36700", "prefix": "ivo data. Of note, although the studies described here involve single doses of ", "from": "36690", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": ", no relevant accumulation was observed in a multiple dose escalation study [41]"}, {"to": "36835", "prefix": "multiple dose escalation study [41]. This indicates that the concentrations of ", "from": "36825", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " observed after single dose administration can be considered representative for "}, {"to": "37018", "prefix": "conditions.\n\nFigure 2\nFigure 2\nMetabolic clearance and elimination pathways of ", "from": "37008", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " based on in vitro investigations [16"}, {"to": "37269", "prefix": ", are involved in the elimination of ", "from": "37259", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": ". Therefore, it was important to determine the clinical extent of any potential "}, {"to": "37380", "prefix": "mportant to determine the clinical extent of any potential interaction between ", "from": "37370", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " and drugs that are substrates for and"}, {"to": "37542", "prefix": "The results of these studies suggest that the oral, direct Factor Xa inhibitor ", "from": "37532", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " does not interact to a clinically relevant extent with substrates for, or inhib"}, {"to": "37884", "prefix": "ntimycotics and the HIV protease inhibitors. Therefore, the concomitant use of ", "from": "37874", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " with these agents should be avoided. The exception may be fluconazole, which is"}, {"to": "38008", "prefix": "ed. The exception may be fluconazole, which is expected to have less effect on ", "from": "37998", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3769672", "exact": "rivaroxaban", "suffix": " exposure and can be co-administered with caution [10, 11].\n\nGo to:\nAcknowledgme"}, {"to": "522", "prefix": "ere studied in healthy volunteers.\n\nResults\n\nRivaroxaban did not interact with ", "from": "514", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3769672", "exact": "midazolam", "suffix": " (CYP3A4 probe substrate). Exposure to rivaroxaban when co-administered with mid"}, {"to": "608", "prefix": ". Exposure to rivaroxaban when co-administered with ", "from": "600", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3769672", "exact": "midazolam", "suffix": " was slightly decreased by 11% (95% confidence interval [CI] "}, {"to": "6915", "prefix": "including ", "from": "6907", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3769672", "exact": "midazolam", "suffix": ") or moderate to strong inhibitors of CYP3A4 only (erythromycin and clarithromyc"}, {"to": "8616", "prefix": " ", "from": "8608", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3769672", "exact": "midazolam", "suffix": " [24, 28]\nStrong inhibitors of CYP3A4 (and possibly CYP2J2), P-gp and Bcrp (ABCG"}, {"to": "9452", "prefix": " or a single dose of ", "from": "9444", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3769672", "exact": "midazolam", "suffix": " (7.5 mg). An additional study was undertaken to determine the extent of the pos"}, {"to": "11409", "prefix": "their informed written consent.\n\nInteraction study with a substrate of CYP3A4\n\n", "from": "11401", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3769672", "exact": "Midazolam", "suffix": "\n\nA study was undertaken to determine potential interactions between rivaroxaban"}, {"to": "11549", "prefix": "ractions between rivaroxaban and a sensitive probe substrate for CYP3A4 alone, ", "from": "11541", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3769672", "exact": "midazolam", "suffix": " [24, 28].\n\nIn an open label, three way crossover study, subjects were randomize"}, {"to": "11710", "prefix": "ndomized to receive a single dose of rivaroxaban 20 mg alone, a single dose of ", "from": "11702", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3769672", "exact": "midazolam", "suffix": " 7.5 mg alone or the combination. All study drugs were given under fasting condi"}, {"to": "21724", "prefix": "alone, and in combination with the potential interacting drug. In addition, as ", "from": "21716", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3769672", "exact": "midazolam", "suffix": " is metabolized by CYP3A4 to "}, {"to": "21772", "prefix": "-hydroxy-", "from": "21764", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3769672", "exact": "midazolam", "suffix": " [28], the effect of rivaroxaban on the pharmacokinetics of this CYP3A4-mediated"}, {"to": "22604", "prefix": "calculated by retransformation of the logarithmic results. The AUC and Cmax of ", "from": "22596", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3769672", "exact": "midazolam", "suffix": " (and its CYP3A4-mediated metabolites), in the absence or presence of rivaroxaba"}, {"to": "23350", "prefix": "he same methods.\n\nGo to:\nResults\nInteraction study with a substrate of CYP3A4\n\n", "from": "23342", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3769672", "exact": "Midazolam", "suffix": "\n\nThe pharmacokinetics of rivaroxaban, midazolam and its CYP3A4-mediated metabol"}, {"to": "23398", "prefix": "dy with a substrate of CYP3A4\n\nMidazolam\n\nThe pharmacokinetics of rivaroxaban, ", "from": "23390", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3769672", "exact": "midazolam", "suffix": " and its CYP3A4-mediated metabolite, "}, {"to": "23454", "prefix": "-hydroxy-", "from": "23446", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3769672", "exact": "midazolam", "suffix": ", when rivaroxaban 20 mg and midazolam 7.5 mg were administered alone and in com"}, {"to": "23492", "prefix": "-hydroxy-midazolam, when rivaroxaban 20 mg and ", "from": "23484", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3769672", "exact": "midazolam", "suffix": " 7.5 mg were administered alone and in combination are summarized in Table 1. Co"}, {"to": "23602", "prefix": "red alone and in combination are summarized in Table 1. Co-administration with ", "from": "23594", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3769672", "exact": "midazolam", "suffix": " led to an increase in rivaroxaban median tmax from 1.5 h to 4.0 h and slightly "}, {"to": "23952", "prefix": "changed. Co-administration with rivaroxaban slightly decreased the mean AUC of ", "from": "23944", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3769672", "exact": "midazolam", "suffix": " by 11% compared with midazolam alone, but this was not statistically significan"}, {"to": "23983", "prefix": " rivaroxaban slightly decreased the mean AUC of midazolam by 11% compared with ", "from": "23975", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3769672", "exact": "midazolam", "suffix": " alone, but this was not statistically significant (90% CI "}, {"to": "24140", "prefix": "-hydroxy-", "from": "24132", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3769672", "exact": "midazolam", "suffix": " remained almost the same with co-administration of rivaroxaban and midazolam co"}, {"to": "24217", "prefix": "y-midazolam remained almost the same with co-administration of rivaroxaban and ", "from": "24209", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3769672", "exact": "midazolam", "suffix": " compared with midazolam alone, but the mean Cmax was increased by 11%. This cha"}, {"to": "24241", "prefix": "ost the same with co-administration of rivaroxaban and midazolam compared with ", "from": "24233", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3769672", "exact": "midazolam", "suffix": " alone, but the mean Cmax was increased by 11%. This change was not statisticall"}, {"to": "24385", "prefix": "2 of ", "from": "24377", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3769672", "exact": "midazolam", "suffix": " and its metabolite remained similar in the presence or absence of rivaroxaban.\n"}, {"to": "24575", "prefix": "acokinetic parameters of rivaroxaban administered alone or in combination with ", "from": "24567", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3769672", "exact": "midazolam", "suffix": " 7.5 mg (mean"}, {"to": "30642", "prefix": "", "from": "30634", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3769672", "exact": "midazolam", "suffix": "). Co-administration of rivaroxaban with a moderate CYP3A4 and P-gp inhibitor (e"}, {"to": "31434", "prefix": ".\n\nThe co-administration of rivaroxaban with ", "from": "31426", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3769672", "exact": "midazolam", "suffix": " had no effect on the pharmacokinetics of rivaroxaban, or on the pharmacokinetic"}, {"to": "31528", "prefix": "o effect on the pharmacokinetics of rivaroxaban, or on the pharmacokinetics of ", "from": "31520", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3769672", "exact": "midazolam", "suffix": " or its CYP3A4-mediated metabolites. Previous interaction studies with digoxin ("}, {"to": "827", "prefix": "rately affected rivaroxaban exposure, but not to a clinically relevant extent: ", "from": "816", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "PMC3769672", "exact": "erythromycin", "suffix": " (moderate CYP3A4"}, {"to": "6978", "prefix": "", "from": "6967", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "PMC3769672", "exact": "erythromycin", "suffix": " and clarithromycin) did not reveal any significant interactions (unpublished da"}, {"to": "8894", "prefix": " ", "from": "8883", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "PMC3769672", "exact": "erythromycin", "suffix": " [24, 33]\nA moderate inhibitor of CYP3A4, also reported to potentially inhibit B"}, {"to": "9349", "prefix": ", steady-state ", "from": "9338", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "PMC3769672", "exact": "erythromycin", "suffix": " (500 mg three times daily), steady-state fluconazole (400 mg once daily) or a s"}, {"to": "10652", "prefix": "in-house for 92 h after administration of the drug combinations, except in the ", "from": "10641", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "PMC3769672", "exact": "erythromycin", "suffix": " interaction study, in which subjects were discharged 72 h after receiving the c"}, {"to": "16119", "prefix": "sis. The remaining 15 subjects were included in the pharmacokinetic analyses.\n\n", "from": "16108", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "PMC3769672", "exact": "Erythromycin", "suffix": "\n\nA single study investigated the potential interaction between rivaroxaban and "}, {"to": "16211", "prefix": "\nA single study investigated the potential interaction between rivaroxaban and ", "from": "16200", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "PMC3769672", "exact": "erythromycin", "suffix": ", classified as a moderate inhibitor of CYP3A4, and considered to be a weak to m"}, {"to": "16464", "prefix": "bjects were randomized to receive a single dose of rivaroxaban 10 mg alone, or ", "from": "16453", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "PMC3769672", "exact": "erythromycin", "suffix": " 500 mg three times daily given for 4 days, with a single 500 mg dose given on d"}, {"to": "20612", "prefix": "in the ketoconazole, ritonavir, clarithromycin, ", "from": "20601", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "PMC3769672", "exact": "erythromycin", "suffix": " and fluconazole studies), the fraction of free (unbound) drug in plasma (fu, %)"}, {"to": "25688", "prefix": "g once daily, ritonavir 600 mg twice daily, clarithromycin 500 mg twice daily, ", "from": "25677", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "PMC3769672", "exact": "erythromycin", "suffix": " 500 mg three times daily or ...\nKetoconazole 400 mg once daily\n\nThe pharmacokin"}, {"to": "28470", "prefix": ".\n\n", "from": "28459", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "PMC3769672", "exact": "Erythromycin", "suffix": "\n\nThe pharmacokinetic effects of rivaroxaban 10 mg administered alone (day 5) an"}, {"to": "28597", "prefix": " and in combination with steady-state ", "from": "28586", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "PMC3769672", "exact": "erythromycin", "suffix": " (500 mg three times daily for 4 days with a single 500 mg dose on day 5) were a"}, {"to": "28734", "prefix": " were analyzed. Co-administration with steady-state ", "from": "28723", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "PMC3769672", "exact": "erythromycin", "suffix": " significantly increased the pharmacokinetics of rivaroxaban (Table 2, Figure 1D"}, {"to": "30733", "prefix": "", "from": "30722", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "PMC3769672", "exact": "erythromycin", "suffix": "), a moderate inhibitor of CYP3A4 and potentially Bcrp (ABCG2, fluconazole), and"}, {"to": "31111", "prefix": "erate but statistically significant extent with fluconazole but minimally with ", "from": "31100", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "PMC3769672", "exact": "erythromycin", "suffix": " and clarithromycin. As expected from in vitro studies [15, 24, 29, 30], a prono"}, {"to": "32613", "prefix": " 37].\n\nThe co-administration of rivaroxaban and the frequently used antibiotic ", "from": "32602", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "PMC3769672", "exact": "erythromycin", "suffix": ", a moderate CYP inhibitor and weak to moderate P-gp inhibitor, led to a 34% and"}, {"to": "32928", "prefix": "or decreases in these parameters when drugs were co-administered with ", "from": "32917", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "PMC3769672", "exact": "erythromycin", "suffix": " [38, 39], these changes were not considered to be clinically relevant because t"}, {"to": "33264", "prefix": "e renal secretion of rivaroxaban when it was co-administered with steady-state ", "from": "33253", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "PMC3769672", "exact": "erythromycin", "suffix": " may be partially explained by the observed mean difference in CLcr between the "}, {"to": "908", "prefix": ", ", "from": "895", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3769672", "exact": "clarithromycin", "suffix": " (strong CYP3A4"}, {"to": "6997", "prefix": "erythromycin and ", "from": "6984", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3769672", "exact": "clarithromycin", "suffix": ") did not reveal any significant interactions (unpublished data on file, Bayer H"}, {"to": "8830", "prefix": " ", "from": "8817", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3769672", "exact": "clarithromycin", "suffix": " [24, 32]\nA moderate inhibitor of CYP3A4 and P-gp "}, {"to": "9301", "prefix": ", steady-state ", "from": "9288", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3769672", "exact": "clarithromycin", "suffix": " (500 mg twice daily), steady-state erythromycin (500 mg three times daily), ste"}, {"to": "15217", "prefix": "P-gp inhibitors\n\n", "from": "15204", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3769672", "exact": "Clarithromycin", "suffix": "\n\nA single study investigated the potential interaction between rivaroxaban and "}, {"to": "15311", "prefix": "\nA single study investigated the potential interaction between rivaroxaban and ", "from": "15298", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3769672", "exact": "clarithromycin", "suffix": ", classified as a strong inhibitor of CYP3A4, and considered to be a weak to mod"}, {"to": "15563", "prefix": "bjects were randomized to receive a single dose of rivaroxaban 10 mg alone, or ", "from": "15550", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3769672", "exact": "clarithromycin", "suffix": " 500 mg twice daily for a period of 4 days under steady-state conditions, follow"}, {"to": "20598", "prefix": "in the ketoconazole, ritonavir, ", "from": "20585", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3769672", "exact": "clarithromycin", "suffix": ", erythromycin and fluconazole studies), the fraction of free (unbound) drug in "}, {"to": "25655", "prefix": "conazole 200 mg once daily or 400 mg once daily, ritonavir 600 mg twice daily, ", "from": "25642", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3769672", "exact": "clarithromycin", "suffix": " 500 mg twice daily, erythromycin 500 mg three times daily or ...\nKetoconazole 4"}, {"to": "27734", "prefix": "P-gp inhibitors\n\n", "from": "27721", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3769672", "exact": "Clarithromycin", "suffix": "\n\nThe pharmacokinetics of rivaroxaban were compared after a single dose of rivar"}, {"to": "27889", "prefix": "ngle dose of rivaroxaban 10 mg was administered alone and co-administered with ", "from": "27876", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3769672", "exact": "clarithromycin", "suffix": " 500 mg after 4 days of pretreatment with clarithromycin 500 mg twice daily. Co-"}, {"to": "27945", "prefix": "d co-administered with clarithromycin 500 mg after 4 days of pretreatment with ", "from": "27932", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3769672", "exact": "clarithromycin", "suffix": " 500 mg twice daily. Co-administration with clarithromycin significantly increas"}, {"to": "28003", "prefix": "of pretreatment with clarithromycin 500 mg twice daily. Co-administration with ", "from": "27990", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3769672", "exact": "clarithromycin", "suffix": " significantly increased the primary pharmacokinetic parameters of rivaroxaban ("}, {"to": "30889", "prefix": "", "from": "30876", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3769672", "exact": "clarithromycin", "suffix": "), led to a statistically significant increase in rivaroxaban exposure. Of note,"}, {"to": "31130", "prefix": "ically significant extent with fluconazole but minimally with erythromycin and ", "from": "31117", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3769672", "exact": "clarithromycin", "suffix": ". As expected from in vitro studies [15, 24, 29, 30], a pronounced and statistic"}, {"to": "33553", "prefix": ". The interaction between rivaroxaban and another frequently used antibiotic, ", "from": "33540", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3769672", "exact": "clarithromycin", "suffix": ", classified as a strong inhibitor of CYP3A4 only, but reported also to possess "}, {"to": "996", "prefix": " and ", "from": "986", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3769672", "exact": "fluconazole", "suffix": " (moderate CYP3A4, possible Bcrp [ABCG2] inhibitor; 42% increase [95% CI 29%, 56"}, {"to": "1618", "prefix": "mainly comprising azole-antimycotics, apart from ", "from": "1608", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3769672", "exact": "fluconazole", "suffix": ", and HIV protease inhibitors), which are multi-pathway inhibitors of rivaroxaba"}, {"to": "2767", "prefix": "ivaroxaban exposure that could increase the risk of bleeding. The exception is ", "from": "2757", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3769672", "exact": "fluconazole", "suffix": ", an azole-antimycotic, which interacted to a lesser degree and could, therefore"}, {"to": "8999", "prefix": " ", "from": "8989", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3769672", "exact": "fluconazole", "suffix": " [24, 30]\nGo to:\nMethods\nIn total, seven single centre studies were undertaken t"}, {"to": "9402", "prefix": ", steady-state ", "from": "9392", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3769672", "exact": "fluconazole", "suffix": " (400 mg once daily) or a single dose of midazolam (7.5 mg). An additional study"}, {"to": "17018", "prefix": "event. Consequently, 15 subjects were valid for the pharmacokinetic analyses.\n\n", "from": "17008", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3769672", "exact": "Fluconazole", "suffix": "\n\nA single study investigated the potential interaction between rivaroxaban and "}, {"to": "17109", "prefix": "\nA single study investigated the potential interaction between rivaroxaban and ", "from": "17099", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3769672", "exact": "fluconazole", "suffix": ", classified as a potent inhibitor of CYP2C9 (rivaroxaban is not metabolized via"}, {"to": "17431", "prefix": "bjects were randomized to receive a single dose of rivaroxaban 20 mg alone, or ", "from": "17421", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3769672", "exact": "fluconazole", "suffix": " 400 mg once daily given for 6 days, with a concomitant administration of 20 mg "}, {"to": "20628", "prefix": "in the ketoconazole, ritonavir, clarithromycin, erythromycin and ", "from": "20618", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3769672", "exact": "fluconazole", "suffix": " studies), the fraction of free (unbound) drug in plasma (fu, %) for rivaroxaban"}, {"to": "26564", "prefix": "20 mg [", "from": "26554", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3769672", "exact": "fluconazole", "suffix": " study] or 10 mg [all other studies] once daily) in the absence and presence of "}, {"to": "29225", "prefix": " and the fu of rivaroxaban showed a slight increase of 6%.\n\n", "from": "29215", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3769672", "exact": "Fluconazole", "suffix": "\n\nThe pharmacokinetics of rivaroxaban were compared after a single dose of rivar"}, {"to": "29377", "prefix": "ngle dose of rivaroxaban 20 mg was administered alone and co-administered with ", "from": "29367", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3769672", "exact": "fluconazole", "suffix": " 400 mg after 4 days of pretreatment with fluconazole 400 mg once daily. Co-admi"}, {"to": "29430", "prefix": " and co-administered with fluconazole 400 mg after 4 days of pretreatment with ", "from": "29420", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3769672", "exact": "fluconazole", "suffix": " 400 mg once daily. Co-administration with fluconazole significantly increased t"}, {"to": "29484", "prefix": "ays of pretreatment with fluconazole 400 mg once daily. Co-administration with ", "from": "29474", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3769672", "exact": "fluconazole", "suffix": " significantly increased the primary pharmacokinetic parameters of rivaroxaban ("}, {"to": "30807", "prefix": "ABCG2, ", "from": "30797", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3769672", "exact": "fluconazole", "suffix": "), and a strong inhibitor of CYP3A4 and moderate inhibitor of P-gp (clarithromyc"}, {"to": "31079", "prefix": " was reduced to a moderate but statistically significant extent with ", "from": "31069", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3769672", "exact": "fluconazole", "suffix": " but minimally with erythromycin and clarithromycin. As expected from in vitro s"}, {"to": "35178", "prefix": "se in the risk of bleeding [10, 11]. An exception may be the azole-antimycotic ", "from": "35168", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3769672", "exact": "fluconazole", "suffix": ", which is classified as a strong CYP2C9 inhibitor with only moderate inhibitory"}, {"to": "35365", "prefix": "P3A4. In the present study, the quantitative assumption for the interaction of ", "from": "35355", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3769672", "exact": "fluconazole", "suffix": " with rivaroxaban was moderate (mean increases of 42% and 28% in rivaroxaban AUC"}, {"to": "37954", "prefix": "t use of rivaroxaban with these agents should be avoided. The exception may be ", "from": "37944", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3769672", "exact": "fluconazole", "suffix": ", which is expected to have less effect on rivaroxaban exposure and can be co-ad"}, {"to": "1244", "prefix": " ", "from": "1233", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "ketoconazole", "suffix": " (158% increase [95% CI 136%, 182%] for a 400 mg once daily dose) and ritonavir "}, {"to": "6519", "prefix": ", such as ", "from": "6508", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "ketoconazole", "suffix": " and ritonavir, may reduce the renal clearance of rivaroxaban [15]. Further in v"}, {"to": "6744", "prefix": "tion of rivaroxaban was affected by therapeutically relevant concentrations of ", "from": "6733", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "ketoconazole", "suffix": " and ritonavir, both of which are not only strong inhibitors of CYP3A4 [21, 22],"}, {"to": "8713", "prefix": " ", "from": "8702", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "ketoconazole", "suffix": " [24, 29, 30] and ritonavir [24, 29, 31]\nA strong inhibitor of CYP3A4 and modera"}, {"to": "9207", "prefix": " and steady-state ", "from": "9196", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "ketoconazole", "suffix": " (200 mg once daily), steady-state ritonavir (600 mg twice daily), steady-state "}, {"to": "9642", "prefix": " and high dose, steady-state ", "from": "9631", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "ketoconazole", "suffix": " (400 mg once daily).\n\nHealthy male subjects aged 18"}, {"to": "10398", "prefix": "tudy investigating potential interactions between rivaroxaban and steady-state ", "from": "10387", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "ketoconazole", "suffix": " 200 mg, subjects received ketoconazole for 72 h as outpatients. Subjects were k"}, {"to": "10437", "prefix": "ns between rivaroxaban and steady-state ketoconazole 200 mg, subjects received ", "from": "10426", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "ketoconazole", "suffix": " for 72 h as outpatients. Subjects were kept in-house for 72 h after administrat"}, {"to": "12260", "prefix": ", ", "from": "12249", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "ketoconazole", "suffix": " and ritonavir [24, 29, 30].\n\nKetoconazole\n\nThe initial ketoconazole interaction"}, {"to": "12302", "prefix": ", ketoconazole and ritonavir [24, 29, 30].\n\n", "from": "12291", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "Ketoconazole", "suffix": "\n\nThe initial ketoconazole interaction study investigated the potential interact"}, {"to": "12328", "prefix": ", ketoconazole and ritonavir [24, 29, 30].\n\nKetoconazole\n\nThe initial ", "from": "12317", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "ketoconazole", "suffix": " interaction study investigated the potential interaction between a single dose "}, {"to": "12452", "prefix": "he potential interaction between a single dose of rivaroxaban and steady-state ", "from": "12441", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "ketoconazole", "suffix": " 200 mg once daily. In this open label, two way crossover study, subjects were r"}, {"to": "12615", "prefix": "s were randomized to receive a single dose of rivaroxaban 10 mg, alone or with ", "from": "12604", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "ketoconazole", "suffix": " (4 days of oral ketoconazole 200 mg once daily with rivaroxaban given on day 4)"}, {"to": "12644", "prefix": "4 days of oral ", "from": "12633", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "ketoconazole", "suffix": " 200 mg once daily with rivaroxaban given on day 4). Rivaroxaban was given under"}, {"to": "12760", "prefix": ". Rivaroxaban was given under fasting conditions and ", "from": "12749", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "ketoconazole", "suffix": " was given with food, except when co-administered with rivaroxaban. After comple"}, {"to": "12901", "prefix": "with rivaroxaban. After completion of this study, a publication suggested that ", "from": "12890", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "ketoconazole", "suffix": " 400 mg may lead to higher inhibition of CYP 34, which prompted a second study i"}, {"to": "13104", "prefix": "of the potential interaction between steady-state rivaroxaban and steady-state ", "from": "13093", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "ketoconazole", "suffix": " 400 mg once daily. This was a non-randomized, open label study in which subject"}, {"to": "13276", "prefix": " received oral rivaroxaban 10 mg once daily alone for 5 days, with concomitant ", "from": "13265", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "ketoconazole", "suffix": " 400 mg once daily for a further 5 days. All study drugs were administered with "}, {"to": "13382", "prefix": "ily for a further 5 days. All study drugs were administered with food.\n\nIn the ", "from": "13371", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "ketoconazole", "suffix": " 200 mg study, 12 subjects were enrolled. All completed the study and were inclu"}, {"to": "13618", "prefix": " 9.2 kg. In the ", "from": "13607", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "ketoconazole", "suffix": " 400 mg study, a total of 20 subjects were enrolled. All completed the study and"}, {"to": "19536", "prefix": " in the ", "from": "19525", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "ketoconazole", "suffix": " 400 mg study, in which multiple doses of rivaroxaban were given. Maximum drug c"}, {"to": "20571", "prefix": "in the ", "from": "20560", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "ketoconazole", "suffix": ", ritonavir, clarithromycin, erythromycin and fluconazole studies), the fraction"}, {"to": "22749", "prefix": " or presence of rivaroxaban, were also analyzed using the same method.\n\nIn the ", "from": "22738", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "ketoconazole", "suffix": " 400 mg once daily and ritonavir studies, both using sequential designs, the pha"}, {"to": "24831", "prefix": "\n\n", "from": "24820", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "Ketoconazole", "suffix": " 200 mg once daily\n\nThe pharmacokinetic parameters of rivaroxaban 10 mg administ"}, {"to": "24957", "prefix": "etic parameters of rivaroxaban 10 mg administered alone or in combination with ", "from": "24946", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "ketoconazole", "suffix": " 200 mg once daily are shown in Table 2. Co-administration with steady-state ket"}, {"to": "25046", "prefix": "le 200 mg once daily are shown in Table 2. Co-administration with steady-state ", "from": "25035", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "ketoconazole", "suffix": " significantly increased the plasma concentrations of a single dose of rivaroxab"}, {"to": "25570", "prefix": " administered alone or in combination with ", "from": "25559", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "ketoconazole", "suffix": " 200 mg once daily or 400 mg once daily, ritonavir 600 mg twice daily, clarithro"}, {"to": "25733", "prefix": "larithromycin 500 mg twice daily, erythromycin 500 mg three times daily or ...\n", "from": "25722", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "Ketoconazole", "suffix": " 400 mg once daily\n\nThe pharmacokinetics of steady-state rivaroxaban 10 mg (day "}, {"to": "25920", "prefix": " with those of steady-state rivaroxaban 10 mg in combination with steady-state ", "from": "25909", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "ketoconazole", "suffix": " 400 mg once daily (day 10). Co-administration with ketoconazole 400 mg signific"}, {"to": "25984", "prefix": ". Co-administration with ", "from": "25973", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "ketoconazole", "suffix": " 400 mg significantly increased rivaroxaban plasma concentrations (Figure 1A). T"}, {"to": "26673", "prefix": " steady-state ", "from": "26662", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "ketoconazole", "suffix": " (400 mg once daily given concomitantly for 5 days), An external file that holds"}, {"to": "31365", "prefix": "ABCG2, ", "from": "31354", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "ketoconazole", "suffix": " and ritonavir).\n\nThe co-administration of rivaroxaban with midazolam had no eff"}, {"to": "34101", "prefix": ". This was confirmed in the studies with ", "from": "34090", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "ketoconazole", "suffix": " and ritonavir, both strong inhibitors of CYP3A4 (and possibly CYP2J2 based on i"}, {"to": "34405", "prefix": "nificant increases in exposure to rivaroxaban when it was co-administered with ", "from": "34394", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "ketoconazole", "suffix": " and ritonavir, with a more than two-fold increase in the AUC. Ketoconazole 400 "}, {"to": "34480", "prefix": "ith ketoconazole and ritonavir, with a more than two-fold increase in the AUC. ", "from": "34469", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3769672", "exact": "Ketoconazole", "suffix": " 400 mg led to an approximately 70% mean inhibition of non-renal (metabolic) cle"}, {"to": "1323", "prefix": " and ", "from": "1315", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC3769672", "exact": "ritonavir", "suffix": " (153% increase [95% CI 134%, 174%]).\n\nConclusions\n\nResults suggest that rivarox"}, {"to": "6533", "prefix": ", such as ketoconazole and ", "from": "6525", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC3769672", "exact": "ritonavir", "suffix": ", may reduce the renal clearance of rivaroxaban [15]. Further in vitro interacti"}, {"to": "6758", "prefix": "an was affected by therapeutically relevant concentrations of ketoconazole and ", "from": "6750", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC3769672", "exact": "ritonavir", "suffix": ", both of which are not only strong inhibitors of CYP3A4 [21, 22], but also pote"}, {"to": "8740", "prefix": " ketoconazole [24, 29, 30] and ", "from": "8732", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC3769672", "exact": "ritonavir", "suffix": " [24, 29, 31]\nA strong inhibitor of CYP3A4 and moderate inhibitor of P-gp "}, {"to": "9251", "prefix": ", steady-state ", "from": "9243", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC3769672", "exact": "ritonavir", "suffix": " (600 mg twice daily), steady-state clarithromycin (500 mg twice daily), steady-"}, {"to": "12274", "prefix": ", ketoconazole and ", "from": "12266", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC3769672", "exact": "ritonavir", "suffix": " [24, 29, 30].\n\nKetoconazole\n\nThe initial ketoconazole interaction study investi"}, {"to": "13869", "prefix": " 10.9 kg.\n\n", "from": "13861", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC3769672", "exact": "Ritonavir", "suffix": "\n\nThe potential interaction between a single dose of rivaroxaban and steady-stat"}, {"to": "13960", "prefix": "he potential interaction between a single dose of rivaroxaban and steady-state ", "from": "13952", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC3769672", "exact": "ritonavir", "suffix": " was investigated in a non-randomized, open label study. Subjects received a sin"}, {"to": "14089", "prefix": "en label study. Subjects received a single dose of rivaroxaban 10 mg on day 1, ", "from": "14081", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC3769672", "exact": "ritonavir", "suffix": " 600 mg twice daily on days 3"}, {"to": "14135", "prefix": "7, and ", "from": "14127", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC3769672", "exact": "ritonavir", "suffix": " 600 mg twice daily plus a single dose of rivaroxaban on day 8. All study drugs "}, {"to": "14722", "prefix": " received a single dose of rivaroxaban 10 mg on day 1 and at least one dose of ", "from": "14714", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC3769672", "exact": "ritonavir", "suffix": " (600 mg). Twelve subjects received the combination of rivaroxaban and ritonavir"}, {"to": "14802", "prefix": ". Twelve subjects received the combination of rivaroxaban and ", "from": "14794", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC3769672", "exact": "ritonavir", "suffix": " on day 8. However, none of the subjects received the second dose of ritonavir o"}, {"to": "14880", "prefix": " ritonavir on day 8. However, none of the subjects received the second dose of ", "from": "14872", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC3769672", "exact": "ritonavir", "suffix": " on day 8 because of tolerability issues, which were considered to be related to"}, {"to": "14970", "prefix": "n day 8 because of tolerability issues, which were considered to be related to ", "from": "14962", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC3769672", "exact": "ritonavir", "suffix": ". Four subjects withdrew from the study owing to adverse events while receiving "}, {"to": "15059", "prefix": " Four subjects withdrew from the study owing to adverse events while receiving ", "from": "15051", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC3769672", "exact": "ritonavir", "suffix": " alone (see below). Therefore, 12 subjects were valid for the pharmacokinetic an"}, {"to": "20582", "prefix": "in the ketoconazole, ", "from": "20574", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC3769672", "exact": "ritonavir", "suffix": ", clarithromycin, erythromycin and fluconazole studies), the fraction of free (u"}, {"to": "22781", "prefix": "lso analyzed using the same method.\n\nIn the ketoconazole 400 mg once daily and ", "from": "22773", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC3769672", "exact": "ritonavir", "suffix": " studies, both using sequential designs, the pharmacokinetic parameters AUC and "}, {"to": "25620", "prefix": "ne or in combination with ketoconazole 200 mg once daily or 400 mg once daily, ", "from": "25612", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC3769672", "exact": "ritonavir", "suffix": " 600 mg twice daily, clarithromycin 500 mg twice daily, erythromycin 500 mg thre"}, {"to": "26846", "prefix": "cture, illustration, etc.\nObject name is bcp0076-0455-mu1.jpg, rivaroxaban ...\n", "from": "26838", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC3769672", "exact": "Ritonavir", "suffix": "\n\nThe pharmacokinetics of rivaroxaban 10 mg were compared after a single dose (d"}, {"to": "26985", "prefix": " with those of a single dose of steady-state ", "from": "26977", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC3769672", "exact": "ritonavir", "suffix": " 600 mg twice daily (day 8). In addition, the pharmacokinetics of ritonavir were"}, {"to": "27060", "prefix": ". In addition, the pharmacokinetics of ", "from": "27052", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC3769672", "exact": "ritonavir", "suffix": " were compared in the absence and presence of rivaroxaban (days 7 and 8, respect"}, {"to": "27170", "prefix": ". Steady-state ", "from": "27162", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC3769672", "exact": "ritonavir", "suffix": " significantly increased the AUC and Cmax of rivaroxaban. The mean AUC increased"}, {"to": "27488", "prefix": ". ", "from": "27480", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC3769672", "exact": "Ritonavir", "suffix": " significantly decreased the CL"}, {"to": "30388", "prefix": "inically relevant changes in ECG or vital signs were observed. Subjects taking ", "from": "30380", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC3769672", "exact": "ritonavir", "suffix": " exhibited adverse events consistent with its established safety profile.\n\nGo to"}, {"to": "31379", "prefix": "ABCG2, ketoconazole and ", "from": "31371", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC3769672", "exact": "ritonavir", "suffix": ").\n\nThe co-administration of rivaroxaban with midazolam had no effect on the pha"}, {"to": "34115", "prefix": ". This was confirmed in the studies with ketoconazole and ", "from": "34107", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC3769672", "exact": "ritonavir", "suffix": ", both strong inhibitors of CYP3A4 (and possibly CYP2J2 based on in vitro data ["}, {"to": "34419", "prefix": "s in exposure to rivaroxaban when it was co-administered with ketoconazole and ", "from": "34411", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC3769672", "exact": "ritonavir", "suffix": ", with a more than two-fold increase in the AUC. Ketoconazole 400 mg led to an a"}, {"to": "34683", "prefix": " and a 44% mean inhibition of active renal secretion, whereas ", "from": "34675", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC3769672", "exact": "ritonavir", "suffix": " led to a reduction of metabolic clearance by approximately 50% and of active re"}, {"to": "3379", "prefix": "pendently of antithrombin [1]. In vitro, rivaroxaban has been shown to inhibit ", "from": "3372", "name": "Thrombin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10528", "setId": "PMC3769672", "exact": "thrombin", "suffix": " generation and prolong clotting times [1, 2]. Results of in vivo animal model s"}, {"to": "8396", "prefix": "an has demonstrated a lack of mutual interaction with the P-gp probe substrate ", "from": "8390", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "PMC3769672", "exact": "digoxin", "suffix": " [24, 25], as well as with the CYP3A4"}, {"to": "31606", "prefix": "idazolam or its CYP3A4-mediated metabolites. Previous interaction studies with ", "from": "31600", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "PMC3769672", "exact": "digoxin", "suffix": " (a pure P-gp substrate with a narrow therapeutic window) and atorvastatin (a su"}, {"to": "31860", "prefix": "acokinetics and pharmacodynamics of rivaroxaban, or on the pharmacokinetics of ", "from": "31854", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "PMC3769672", "exact": "digoxin", "suffix": " or atorvastatin [25, 27]. This lack of interaction confirms previous in vitro o"}, {"to": "32505", "prefix": "itions are likely to be taking concomitant cardiovascular medications, such as ", "from": "32499", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "PMC3769672", "exact": "digoxin", "suffix": " and statins [36, 37].\n\nThe co-administration of rivaroxaban and the frequently "}, {"to": "8461", "prefix": "P-gp substrate ", "from": "8450", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3769672", "exact": "atorvastatin", "suffix": " [26, 27]. Here, interaction studies were carried out between rivaroxaban and th"}, {"to": "31680", "prefix": " and ", "from": "31669", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3769672", "exact": "atorvastatin", "suffix": " (a substrate of both CYP3A4 and P-gp) in healthy subjects demonstrated no effec"}, {"to": "31876", "prefix": " and pharmacodynamics of rivaroxaban, or on the pharmacokinetics of digoxin or ", "from": "31865", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3769672", "exact": "atorvastatin", "suffix": " [25, 27]. This lack of interaction confirms previous in vitro observations that"}, {"to": "20834", "prefix": "lysis of total plasma concentrations at three predefined sampling time points. ", "from": "20825", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003404", "setId": "PMC3769672", "exact": "Creatinine", "suffix": " clearance (CLcr), as a marker of glomerular filtration, was determined from ser"}, {"to": "20927", "prefix": ", as a marker of glomerular filtration, was determined from serum ", "from": "20918", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003404", "setId": "PMC3769672", "exact": "creatinine", "suffix": " measurements and urinary creatinine data collected in parallel to amount of riv"}, {"to": "20963", "prefix": "ular filtration, was determined from serum creatinine measurements and urinary ", "from": "20954", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003404", "setId": "PMC3769672", "exact": "creatinine", "suffix": " data collected in parallel to amount of rivaroxaban excreted in the urine. This"}, {"to": "104", "prefix": "\n\nTo compare the lipid-regulating effects and steady-state pharmacokinetics of ", "from": "93", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": ", a new synthetic hydroxy methylglutaryl-coenzyme A (HMG-CoA) reductase inhibito"}, {"to": "470", "prefix": "two-way crossover trial 24 healthy adult volunteers were randomized to receive ", "from": "459", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " 10 mg orally each morning (07.00 h) or evening (18.00 h) for 14 days. After a 4"}, {"to": "641", "prefix": " week washout period, volunteers received the alternative regimen for 14 days. ", "from": "630", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "Rosuvastatin", "suffix": " was administered in the absence of food.\n\nResults\n\nReductions from baseline in "}, {"to": "1231", "prefix": ". The steady-state pharmacokinetics of ", "from": "1220", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " were very similar following the morning and evening dosing regimens. The Cmax v"}, {"to": "1527", "prefix": "tion, respectively. There were no serious adverse events during the trial, and ", "from": "1516", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " was well tolerated after morning and evening administration.\n\nConclusions\n\nThe "}, {"to": "1667", "prefix": "inistration.\n\nConclusions\n\nThe pharmacodynamic effects and pharmacokinetics of ", "from": "1656", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " are not dependent on time of dosing. Morning or evening administration is equal"}, {"to": "1852", "prefix": "evening dosing, ", "from": "1841", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": "\nGo to:\nIntroduction\nHydroxy methylglutaryl-coenzyme A (HMG-CoA) reductase inhib"}, {"to": "3101", "prefix": "d are less pronounced following morning compared with evening administration.\n\n", "from": "3090", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "Rosuvastatin", "suffix": " (Crestor"}, {"to": "3110", "prefix": "", "from": "3104", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "Crestor", "suffix": ""}, {"to": "3306", "prefix": "elopment for the treatment of patients with dyslipidaemia. In clinical trials, ", "from": "3295", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " (1"}, {"to": "3503", "prefix": "18].\n\nThe pharmacokinetics of ", "from": "3492", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " following single- and multiple-dose administration of the drug to healthy volun"}, {"to": "3716", "prefix": " ]. Following multiple oral doses of ", "from": "3705", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " (20, 40, and 80 mg) AUC(0,24 h) and Cmax were essentially dose proportional, ti"}, {"to": "4014", "prefix": "onducted to compare the pharmacodynamics and multiple-dose pharmacokinetics of ", "from": "4003", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " following morning and evening administration in healthy adult volunteers.\n\nGo t"}, {"to": "5393", "prefix": " period.\n\nEligible volunteers were randomized to receive a single oral dose of ", "from": "5382", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " (10 mg) each morning (approximately 07.00 h) or evening (approximately 18.00 h)"}, {"to": "5758", "prefix": "r. Volunteers were required to fast for a minimum of 2 h before and after each ", "from": "5747", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " dose, and for at least 12 h (overnight) before collection of blood samples for "}, {"to": "6285", "prefix": "asting serum lipid concentrations before administration of the morning dose of ", "from": "6274", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " (morning dosing) or before the morning meal (evening dosing). Serum LDL-C (the "}, {"to": "7454", "prefix": "etermined over a 24 h period before the first dose and after the final dose of ", "from": "7443", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " in each treatment period. Heparinized plasma samples and urine samples were sto"}, {"to": "8449", "prefix": " for determination of plasma ", "from": "8438", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " concentrations were collected at 0.5 h predose and at fixed intervals (0.5, 1, "}, {"to": "8613", "prefix": " after administration of ", "from": "8602", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " on treatment day 14. Blood samples were also collected at 0.5 h pre-dose on tre"}, {"to": "9033", "prefix": "C prior to analysis. Plasma concentrations of ", "from": "9022", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " were determined using a validated h.p.l.c."}, {"to": "9161", "prefix": "MS assay [24] at Quintiles, Edinburgh, UK. Correlation coefficients for ", "from": "9150", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " were 0.994"}, {"to": "9355", "prefix": " 8%, respectively. The limit of quantification for ", "from": "9344", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " in this trial was 0.2 ng ml"}, {"to": "9407", "prefix": "1.\n\nPlasma ", "from": "9396", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " concentration-time data were analysed by standard noncompartmental pharmacokine"}, {"to": "11370", "prefix": "etion of MVA and expressed as morning-evening differences with 90% CIs. Plasma ", "from": "11359", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " exposure was compared using least square geometric means generated by anova of "}, {"to": "11478", "prefix": "pared using least square geometric means generated by anova of log-transformed ", "from": "11467", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " AUC(0,24 h) and Cmax values and expressed as morning"}, {"to": "12048", "prefix": "reductions in serum LDL-C were obtained following once daily administration of ", "from": "12037", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " 10 mg in the morning or evening. After 14 days of treatment, the mean reduction"}, {"to": "12466", "prefix": "pid and lipoprotein concentrations after morning and evening administration of ", "from": "12455", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": ".\nLikewise, the reductions in serum TC ("}, {"to": "12911", "prefix": "ons from baseline in LDL-C, TC, TG, and ApoB are consistent with the effect of ", "from": "12900", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": ". The small reductions in HDL-C and ApoA-I are atypical.\n\nSummary statistics for"}, {"to": "13181", "prefix": "nd urine mevalonic acid parameters after morning and evening administration of ", "from": "13170", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": ".\nDuring the course of the 14 day treatment period, the mean percent reduction i"}, {"to": "13718", "prefix": "oncentration-time profiles before, after morning and evening administration of ", "from": "13707", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": ". "}, {"to": "14273", "prefix": ".\n\nPharmacokinetics\n\nFrom inspection of trough plasma ", "from": "14262", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " concentration-time profiles, it was apparent that steady state was attained wit"}, {"to": "14401", "prefix": "apparent that steady state was attained within 8 days of initiating once-daily ", "from": "14390", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " administration (with both morning and evening dosing regimens). Under steady-st"}, {"to": "14532", "prefix": ". Under steady-state conditions, the mean trough plasma ", "from": "14521", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " concentration was approximately 0.6 ng ml"}, {"to": "14786", "prefix": ".\n\nFigure 2\nFigure 2\nGeometric mean plasma ", "from": "14775", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " concentration-time profiles on day 14 after morning ("}, {"to": "14889", "prefix": " administration of ", "from": "14878", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": ".\nThe apparent rate of absorption of rosuvastatin was essentially the same follo"}, {"to": "14938", "prefix": " administration of rosuvastatin.\nThe apparent rate of absorption of ", "from": "14927", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " was essentially the same following morning and evening dosing (median tmax 3.0 "}, {"to": "15377", "prefix": ", supporting no diurnal variation in the disposition of ", "from": "15366", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": ".\n\nTable 3\nTable 3\nSummary of pharmacokinetic parameters for rosuvastatin after "}, {"to": "15450", "prefix": "on of rosuvastatin.\n\nTable 3\nTable 3\nSummary of pharmacokinetic parameters for ", "from": "15439", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " after morning and evening administration of rosuvastatin.\nAny difference greate"}, {"to": "15507", "prefix": "inetic parameters for rosuvastatin after morning and evening administration of ", "from": "15496", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": ".\nAny difference greater than 2% in the pharmacokinetic parameters (Cmax and AUC"}, {"to": "15613", "prefix": " for ", "from": "15602", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " between the morning and evening dosing regimens was excluded by the 90% CIs (Ta"}, {"to": "15739", "prefix": ".\n\nSafety and tolerability\n\n", "from": "15728", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "Rosuvastatin", "suffix": " proved to be well tolerated over the two 14 day treatment periods, with no sign"}, {"to": "16107", "prefix": ", which occurred 3.5 h after the first dose of ", "from": "16096", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": ". The volunteer was asymptomatic and the T-wave abnormality resolved within 15 h"}, {"to": "16572", "prefix": "onducted to compare the pharmacodynamics and multiple-dose pharmacokinetics of ", "from": "16561", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " following morning and evening administration in healthy volunteers. The results"}, {"to": "16675", "prefix": "orning and evening administration in healthy volunteers. The results show that ", "from": "16664", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " was equally effective in lowering serum LDL-C concentrations after morning or e"}, {"to": "16857", "prefix": "nistration. In keeping with this finding, the steady-state pharmacokinetics of ", "from": "16846", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " were very similar after morning and evening administration. This characteristic"}, {"to": "17038", "prefix": "ime independence for both pharmacodynamics and pharmacokinetics differentiates ", "from": "17027", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " from other marketed statins.\n\nFluvastatin [10], lovastatin [11], pravastatin [1"}, {"to": "17319", "prefix": "ening administration. Atorvastatin appears to be the only statin to share with ", "from": "17308", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " the characteristic of dose-time independence for pharmacodynamics [26]. The fac"}, {"to": "17440", "prefix": "me independence for pharmacodynamics [26]. The fact that both atorvastatin and ", "from": "17429", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " have relatively long plasma half-lives may be of relevance to this common chara"}, {"to": "17573", "prefix": "y be of relevance to this common characteristic. However, atorvastatin, unlike ", "from": "17562", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": ", shows diurnal differences in plasma exposure: lower systemic bioavailability ("}, {"to": "17940", "prefix": "atch those obtained in hypercholesterolaemic patients following treatment with ", "from": "17929", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " 10 mg once daily for 6 weeks (approximately "}, {"to": "18121", "prefix": "d ApoB concentrations observed in this trial are consistent with the effect of ", "from": "18110", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " on LDL-C, the small reductions in HDL-C and ApoA-I concentrations are less read"}, {"to": "18297", "prefix": "18] trials show that ", "from": "18286", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " (1"}, {"to": "19090", "prefix": "conclusion, the results of this trial indicate that the therapeutic benefit of ", "from": "19079", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " is not dose-time de-pendent, and that morning or evening administration is equa"}, {"to": "19261", "prefix": "lly effective in regulating lipid levels. In addition, the pharmacokinetics of ", "from": "19250", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1874466", "exact": "rosuvastatin", "suffix": " were independent of time of dosing.\n\nGo to:\nAcknowledgments\nThe authors thank E"}, {"to": "309", "prefix": "vening administration in volunteers with fasting serum low-density lipoprotein ", "from": "299", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC1874466", "exact": "cholesterol", "suffix": " (LDL-C) concentrations "}, {"to": "808", "prefix": ", total ", "from": "798", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC1874466", "exact": "cholesterol", "suffix": " ("}, {"to": "2069", "prefix": "lipid-regulating therapy, and are the most effective agents for reducing serum ", "from": "2059", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC1874466", "exact": "cholesterol", "suffix": " concentrations and cardiovascular mortality [1"}, {"to": "2225", "prefix": " inhibitors of HMG-CoA reductase, statins block an early rate-limiting step in ", "from": "2215", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC1874466", "exact": "cholesterol", "suffix": " biosynthesis: the conversion of HMG-CoA to mevalonate [4]. Inhibition of hepati"}, {"to": "2318", "prefix": "osynthesis: the conversion of HMG-CoA to mevalonate [4]. Inhibition of hepatic ", "from": "2308", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC1874466", "exact": "cholesterol", "suffix": " production results in up-regulation of hepatic low-density lipoprotein receptor"}, {"to": "2491", "prefix": "which are responsible for the clearance of circulating low-density lipoprotein ", "from": "2481", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC1874466", "exact": "cholesterol", "suffix": " (LDL-C), and reduced hepatic secretion of very-low-density lipoprotein particle"}, {"to": "2641", "prefix": "7].\n\nSince hepatic HMG-CoA reductase activity [8] and ", "from": "2631", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC1874466", "exact": "cholesterol", "suffix": " biosynthesis [9] are greatest at night (circadian variation) it is generally re"}, {"to": "3364", "prefix": " produced reductions in LDL-C, total ", "from": "3354", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC1874466", "exact": "cholesterol", "suffix": " (TC), and triglycerides (TG), and increases in high-density lipoprotein cholest"}, {"to": "3448", "prefix": ", and increases in high-density lipoprotein ", "from": "3438", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC1874466", "exact": "cholesterol", "suffix": " (HDL-C) [14"}, {"to": "2891", "prefix": " including ", "from": "2881", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1874466", "exact": "fluvastatin", "suffix": " [10], lovastatin [11], pravastatin [12], and simvastatin [13]"}, {"to": "17080", "prefix": "and pharmacokinetics differentiates rosuvastatin from other marketed statins.\n\n", "from": "17070", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1874466", "exact": "Fluvastatin", "suffix": " [10], lovastatin [11], pravastatin [12], and simvastatin [13] all exert less pr"}, {"to": "2908", "prefix": " including fluvastatin [10], ", "from": "2899", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1874466", "exact": "lovastatin", "suffix": " [11], pravastatin [12], and simvastatin [13]"}, {"to": "17097", "prefix": "cs differentiates rosuvastatin from other marketed statins.\n\nFluvastatin [10], ", "from": "17088", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1874466", "exact": "lovastatin", "suffix": " [11], pravastatin [12], and simvastatin [13] all exert less pronounced LDL-C-re"}, {"to": "2926", "prefix": " including fluvastatin [10], lovastatin [11], ", "from": "2916", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1874466", "exact": "pravastatin", "suffix": " [12], and simvastatin [13]"}, {"to": "17115", "prefix": " rosuvastatin from other marketed statins.\n\nFluvastatin [10], lovastatin [11], ", "from": "17105", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1874466", "exact": "pravastatin", "suffix": " [12], and simvastatin [13] all exert less pronounced LDL-C-regulating effects f"}, {"to": "2948", "prefix": " including fluvastatin [10], lovastatin [11], pravastatin [12], and ", "from": "2938", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC1874466", "exact": "simvastatin", "suffix": " [13]"}, {"to": "17137", "prefix": "er marketed statins.\n\nFluvastatin [10], lovastatin [11], pravastatin [12], and ", "from": "17127", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC1874466", "exact": "simvastatin", "suffix": " [13] all exert less pronounced LDL-C-regulating effects following morning compa"}, {"to": "8939", "prefix": "1 for 10 min. The derived plasma samples were diluted 1 : 1 with 0.1 m ", "from": "8926", "name": "Sodium Acetate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/56443", "setId": "PMC1874466", "exact": "sodium acetate", "suffix": " buffer (pH 4.0) and stored at "}, {"to": "17262", "prefix": "L-C-regulating effects following morning compared with evening administration. ", "from": "17251", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC1874466", "exact": "Atorvastatin", "suffix": " appears to be the only statin to share with rosuvastatin the characteristic of "}, {"to": "17423", "prefix": "ristic of dose-time independence for pharmacodynamics [26]. The fact that both ", "from": "17412", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC1874466", "exact": "atorvastatin", "suffix": " and rosuvastatin have relatively long plasma half-lives may be of relevance to "}, {"to": "17552", "prefix": " plasma half-lives may be of relevance to this common characteristic. However, ", "from": "17541", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC1874466", "exact": "atorvastatin", "suffix": ", unlike rosuvastatin, shows diurnal differences in plasma exposure: lower syste"}, {"to": "138", "prefix": " inhibit the metabolism of ", "from": "128", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2598705", "exact": "simvastatin", "suffix": ", and co"}, {"to": "260", "prefix": "aindicated. Despite this, we have seen a recent cluster of patients prescribed ", "from": "250", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2598705", "exact": "simvastatin", "suffix": " whilst on PIs.\n\nA 58"}, {"to": "481", "prefix": ", stating that ", "from": "471", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2598705", "exact": "simvastatin", "suffix": " is not recommended with his antiretroviral combination, but low dose atorvastat"}, {"to": "599", "prefix": " antiretroviral combination, but low dose atorvastatin or pravastatin is safe. ", "from": "589", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2598705", "exact": "Simvastatin", "suffix": " was prescribed by the GP.\n\nA 52"}, {"to": "895", "prefix": "ted her medications and mentioned that her cholesterol was 8.5. Her GP started ", "from": "885", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2598705", "exact": "simvastatin", "suffix": ". The patient took the first dose but stopped after reading the medication inser"}, {"to": "1210", "prefix": "tten regularly to his GP about current medications. Pravastatin was changed to ", "from": "1200", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2598705", "exact": "simvastatin", "suffix": " by his GP 6"}, {"to": "1351", "prefix": " have recently been switched to ", "from": "1341", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2598705", "exact": "simvastatin", "suffix": " by GPs. None have suffered adverse consequences, although similar cases have re"}, {"to": "1618", "prefix": " 3A4 activity, which metabolises ", "from": "1608", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2598705", "exact": "simvastatin", "suffix": " and atorvastatin. Simvastatin exposure is increased by up to 3000% by PIs,2 and"}, {"to": "1648", "prefix": " 3A4 activity, which metabolises simvastatin and atorvastatin. ", "from": "1638", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2598705", "exact": "Simvastatin", "suffix": " exposure is increased by up to 3000% by PIs,2 and co"}, {"to": "2114", "prefix": ", is an inducer of CYP3A4 metabolism, and reduces the concentrations of active ", "from": "2104", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2598705", "exact": "simvastatin", "suffix": ", atorvastatin and pravastatin by 58%, 34% and 40%, respectively.3\n\nGPs, and all"}, {"to": "2320", "prefix": "rescribe cheaper medications where possible, and this is driving the switch to ", "from": "2310", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2598705", "exact": "simvastatin", "suffix": ". Simvastatin is also available without prescription in pharmacies. These cases "}, {"to": "2333", "prefix": "per medications where possible, and this is driving the switch to simvastatin. ", "from": "2323", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2598705", "exact": "Simvastatin", "suffix": " is also available without prescription in pharmacies. These cases highlight the"}, {"to": "2613", "prefix": "ications but also about potential drug interactions. Where PIs are being used, ", "from": "2603", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2598705", "exact": "simvastatin", "suffix": " must be avoided."}, {"to": "314", "prefix": "old man was taking ", "from": "307", "name": "abacavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/190521", "setId": "PMC2598705", "exact": "abacavir", "suffix": ", lamivudine, atazanavir and ritonavir. His HIV physician noted raised cholester"}, {"to": "326", "prefix": "old man was taking abacavir, ", "from": "317", "name": "Lamivudine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/68244", "setId": "PMC2598705", "exact": "lamivudine", "suffix": ", atazanavir and ritonavir. His HIV physician noted raised cholesterol and wrote"}, {"to": "1037", "prefix": "old man was taking stavudine, ", "from": "1028", "name": "Lamivudine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/68244", "setId": "PMC2598705", "exact": "lamivudine", "suffix": " and nelfinavir. Pravastatin was started by his HIV physician, and letters were "}, {"to": "338", "prefix": "old man was taking abacavir, lamivudine, ", "from": "329", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "PMC2598705", "exact": "atazanavir", "suffix": " and ritonavir. His HIV physician noted raised cholesterol and wrote to the pati"}, {"to": "691", "prefix": "old woman was taking didanosine, efavirenz, ", "from": "682", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "PMC2598705", "exact": "atazanavir", "suffix": " and ritonavir, as well as gliclazide, doxazosin and bendrofluazide. A letter fr"}, {"to": "1505", "prefix": "r cases have resulted in rhabdomyolysis and death.1\n\nPIs, including ritonavir, ", "from": "1496", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "PMC2598705", "exact": "atazanavir", "suffix": ", lopinavir, saquinavir and nelfinavir, inhibit cytochrome P450 (CYP) 3A4 activi"}, {"to": "352", "prefix": "old man was taking abacavir, lamivudine, atazanavir and ", "from": "344", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC2598705", "exact": "ritonavir", "suffix": ". His HIV physician noted raised cholesterol and wrote to the patient and his ge"}, {"to": "705", "prefix": "old woman was taking didanosine, efavirenz, atazanavir and ", "from": "697", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC2598705", "exact": "ritonavir", "suffix": ", as well as gliclazide, doxazosin and bendrofluazide. A letter from her HIV phy"}, {"to": "1493", "prefix": "ough similar cases have resulted in rhabdomyolysis and death.1\n\nPIs, including ", "from": "1485", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC2598705", "exact": "ritonavir", "suffix": ", atazanavir, lopinavir, saquinavir and nelfinavir, inhibit cytochrome P450 (CYP"}, {"to": "396", "prefix": "abacavir, lamivudine, atazanavir and ritonavir. His HIV physician noted raised ", "from": "386", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC2598705", "exact": "cholesterol", "suffix": " and wrote to the patient and his general practitioner (GP), stating that simvas"}, {"to": "859", "prefix": "from her HIV physician to her GP listed her medications and mentioned that her ", "from": "849", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC2598705", "exact": "cholesterol", "suffix": " was 8.5. Her GP started simvastatin. The patient took the first dose but stoppe"}, {"to": "563", "prefix": "mvastatin is not recommended with his antiretroviral combination, but low dose ", "from": "552", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2598705", "exact": "atorvastatin", "suffix": " or pravastatin is safe. Simvastatin was prescribed by the GP.\n\nA 52"}, {"to": "1635", "prefix": " 3A4 activity, which metabolises simvastatin and ", "from": "1624", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2598705", "exact": "atorvastatin", "suffix": ". Simvastatin exposure is increased by up to 3000% by PIs,2 and co"}, {"to": "1749", "prefix": "administration is contraindicated. ", "from": "1738", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2598705", "exact": "Atorvastatin", "suffix": " concentrations are increased by a much smaller margin, and atorvastatin may be "}, {"to": "1821", "prefix": "cated. Atorvastatin concentrations are increased by a much smaller margin, and ", "from": "1810", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2598705", "exact": "atorvastatin", "suffix": " may be used cautiously. Pravastatin and rosuvastatin are not metabolised by CYP"}, {"to": "2128", "prefix": "er of CYP3A4 metabolism, and reduces the concentrations of active simvastatin, ", "from": "2117", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2598705", "exact": "atorvastatin", "suffix": " and pravastatin by 58%, 34% and 40%, respectively.3\n\nGPs, and all physicians, a"}, {"to": "578", "prefix": " recommended with his antiretroviral combination, but low dose atorvastatin or ", "from": "568", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC2598705", "exact": "pravastatin", "suffix": " is safe. Simvastatin was prescribed by the GP.\n\nA 52"}, {"to": "1065", "prefix": "old man was taking stavudine, lamivudine and nelfinavir. ", "from": "1055", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC2598705", "exact": "Pravastatin", "suffix": " was started by his HIV physician, and letters were written regularly to his GP "}, {"to": "1183", "prefix": "ician, and letters were written regularly to his GP about current medications. ", "from": "1173", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC2598705", "exact": "Pravastatin", "suffix": " was changed to simvastatin by his GP 6"}, {"to": "1857", "prefix": "e increased by a much smaller margin, and atorvastatin may be used cautiously. ", "from": "1847", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC2598705", "exact": "Pravastatin", "suffix": " and rosuvastatin are not metabolised by CYP3A4 and are safe to use with PIs.\n\nI"}, {"to": "2144", "prefix": "bolism, and reduces the concentrations of active simvastatin, atorvastatin and ", "from": "2134", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC2598705", "exact": "pravastatin", "suffix": " by 58%, 34% and 40%, respectively.3\n\nGPs, and all physicians, are under pressur"}, {"to": "668", "prefix": "old woman was taking ", "from": "659", "name": "Didanosine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016049", "setId": "PMC2598705", "exact": "didanosine", "suffix": ", efavirenz, atazanavir and ritonavir, as well as gliclazide, doxazosin and bend"}, {"to": "679", "prefix": "old woman was taking didanosine, ", "from": "671", "name": "efavirenz", "fullId": "http://purl.bioontology.org/ontology/RXNORM/195085", "setId": "PMC2598705", "exact": "efavirenz", "suffix": ", atazanavir and ritonavir, as well as gliclazide, doxazosin and bendrofluazide."}, {"to": "1974", "prefix": "abolised by CYP3A4 and are safe to use with PIs.\n\nIt should also be noted that ", "from": "1966", "name": "efavirenz", "fullId": "http://purl.bioontology.org/ontology/RXNORM/195085", "setId": "PMC2598705", "exact": "efavirenz", "suffix": ", a non"}, {"to": "728", "prefix": "d woman was taking didanosine, efavirenz, atazanavir and ritonavir, as well as ", "from": "719", "name": "Gliclazide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4816", "setId": "PMC2598705", "exact": "gliclazide", "suffix": ", doxazosin and bendrofluazide. A letter from her HIV physician to her GP listed"}, {"to": "739", "prefix": "taking didanosine, efavirenz, atazanavir and ritonavir, as well as gliclazide, ", "from": "731", "name": "Doxazosin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017292", "setId": "PMC2598705", "exact": "doxazosin", "suffix": " and bendrofluazide. A letter from her HIV physician to her GP listed her medica"}, {"to": "758", "prefix": "ine, efavirenz, atazanavir and ritonavir, as well as gliclazide, doxazosin and ", "from": "745", "name": "Bendroflumethiazide", "fullId": "http://purl.bioontology.org/ontology/MESH/D001539", "setId": "PMC2598705", "exact": "bendrofluazide", "suffix": ". A letter from her HIV physician to her GP listed her medications and mentioned"}, {"to": "1025", "prefix": "old man was taking ", "from": "1017", "name": "Stavudine", "fullId": "http://purl.bioontology.org/ontology/MESH/D018119", "setId": "PMC2598705", "exact": "stavudine", "suffix": ", lamivudine and nelfinavir. Pravastatin was started by his HIV physician, and l"}, {"to": "1052", "prefix": "old man was taking stavudine, lamivudine and ", "from": "1043", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC2598705", "exact": "nelfinavir", "suffix": ". Pravastatin was started by his HIV physician, and letters were written regular"}, {"to": "1543", "prefix": "s and death.1\n\nPIs, including ritonavir, atazanavir, lopinavir, saquinavir and ", "from": "1534", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC2598705", "exact": "nelfinavir", "suffix": ", inhibit cytochrome P450 (CYP) 3A4 activity, which metabolises simvastatin and "}, {"to": "1516", "prefix": " resulted in rhabdomyolysis and death.1\n\nPIs, including ritonavir, atazanavir, ", "from": "1508", "name": "Lopinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D061466", "setId": "PMC2598705", "exact": "lopinavir", "suffix": ", saquinavir and nelfinavir, inhibit cytochrome P450 (CYP) 3A4 activity, which m"}, {"to": "1528", "prefix": "n rhabdomyolysis and death.1\n\nPIs, including ritonavir, atazanavir, lopinavir, ", "from": "1519", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83395", "setId": "PMC2598705", "exact": "saquinavir", "suffix": " and nelfinavir, inhibit cytochrome P450 (CYP) 3A4 activity, which metabolises s"}, {"to": "1874", "prefix": " much smaller margin, and atorvastatin may be used cautiously. Pravastatin and ", "from": "1863", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC2598705", "exact": "rosuvastatin", "suffix": " are not metabolised by CYP3A4 and are safe to use with PIs.\n\nIt should also be "}, {"to": "60", "prefix": "Abstract\nAims\n\nTo examine in vivo the effect of ", "from": "49", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " on the pharmacokinetics of rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme "}, {"to": "319", "prefix": " received ", "from": "308", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " 200 mg or placebo twice daily for 7 days, and rosuvastatin 80 mg was coadminist"}, {"to": "602", "prefix": "s were measured up to 96 h postdose.\n\nResults\n\nFollowing coadministration with ", "from": "591", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": ", rosuvastatin geometric least square mean AUC(0,t) and Cmax were unchanged comp"}, {"to": "957", "prefix": " of the total inhibitors. ", "from": "946", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "Ketoconazole", "suffix": " did not affect the proportion of circulating active or total inhibitors account"}, {"to": "1099", "prefix": "e or total inhibitors accounted for by circulating rosuvastatin.\n\nConclusions\n\n", "from": "1088", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "Ketoconazole", "suffix": " did not produce any change in rosuvastatin pharmacokinetics in healthy subjects"}, {"to": "1338", "prefix": "d transport contributes to the elimination of rosuvastatin.\n\nKeywords: CYP3A4, ", "from": "1327", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": ", P-glycoprotein, rosuvastatin\nGo to:\nIntroduction\nRosuvastatin (Crestor"}, {"to": "3748", "prefix": "excluded. Accordingly, the present study was conducted to assess the effect of ", "from": "3737", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " (a potent CYP3A4 inhibitor [15]) on the pharmacokinetics of rosuvastatin.\n\nKeto"}, {"to": "3836", "prefix": " on the pharmacokinetics of rosuvastatin.\n\n", "from": "3825", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "Ketoconazole", "suffix": " is also known to inhibit the activity of transport protein P-glycoprotein (P-gp"}, {"to": "6024", "prefix": ". Volunteers were randomized to receive daily oral doses of ", "from": "6013", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " 400 mg (1 "}, {"to": "6336", "prefix": " with the morning dose of ", "from": "6325", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " or placebo. Volunteers then remained in the Clinical Pharmacology Unit for the "}, {"to": "7308", "prefix": "dose. Additional samples were taken before administration of the first dose of ", "from": "7297", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " or placebo on day 1 of the second dosing period. Blood samples were collected i"}, {"to": "10874", "prefix": ", respectively.\n\nDetermination of ", "from": "10863", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " plasma concentrations\n\nBlood samples (10 ml) were taken before and 2 h after ad"}, {"to": "11000", "prefix": " were taken before and 2 h after administration of the first dose of ", "from": "10989", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " or placebo on days 4, 5, 6 and 7 of each dosing period. Blood samples were coll"}, {"to": "11842", "prefix": " of rosuvastatin after dosing with ", "from": "11831", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " compared with placebo. If less than 12 volunteers had AUC data available from b"}, {"to": "12388", "prefix": "ctive and total HMG-CoA reductase inhibitors, and plasma drug concentration of ", "from": "12377", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " before and 2 h after administration of the first dose on days 4"}, {"to": "13121", "prefix": " ", "from": "13110", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": ""}, {"to": "14224", "prefix": " rosuvastatin over time were similar when rosuvastatin was coadministered with ", "from": "14213", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " and placebo (Figure 1). As AUC data from both dosing periods were available for"}, {"to": "14673", "prefix": "acement for AUC in the assessment of exposure. Following coadministration with ", "from": "14662", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": ", rosuvastatin glsmean AUC(0,t) and Cmax were unchanged compared with placebo (T"}, {"to": "14887", "prefix": "1.43, so it was concluded that ", "from": "14876", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " had no effect on the pharmacokinetics of rosuvastatin.\n\nFigure 1\nFigure 1\nGeome"}, {"to": "15062", "prefix": " mean plasma concentrations of rosuvastatin over time when coadministered with ", "from": "15051", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " or placebo. "}, {"to": "15105", "prefix": " ", "from": "15094", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": "; "}, {"to": "15328", "prefix": " and Cmax of rosuvastatin, when coadministered with ", "from": "15317", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " and placebo\nComparison of areas under the plasma concentration-time curves meas"}, {"to": "15821", "prefix": ". ", "from": "15810", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "Ketoconazole", "suffix": " did not affect the proportion of circulating active or total HMG-CoA reductase "}, {"to": "16141", "prefix": "nhibitors and rosuvastatin over time when rosuvastatin was coadministered with ", "from": "16130", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": ". A similar pattern was seen when rosuvastatin was coadministered with placebo. "}, {"to": "16275", "prefix": ", ...\nThe gmean plasma concentrations of ", "from": "16264", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " before administration of the first dose on days 4"}, {"to": "16501", "prefix": "astatin and was maintained during sampling. The gmean plasma concentrations of ", "from": "16490", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " 2 h after administration of the first dose on days 4"}, {"to": "16701", "prefix": "ted that concentrations fell within the range anticipated for a 200-mg dose of ", "from": "16690", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": ".\n\nRosuvastatin and ketoconazole were well tolerated when coadministered. There "}, {"to": "16733", "prefix": "hin the range anticipated for a 200-mg dose of ketoconazole.\n\nRosuvastatin and ", "from": "16722", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " were well tolerated when coadministered. There were no serious adverse events a"}, {"to": "17040", "prefix": "o:\nDiscussion\nCoadministration of rosuvastatin and the potent CYP3A4 inhibitor ", "from": "17029", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " did not produce any change in pharmacokinetics of the former. Furthermore, the "}, {"to": "17153", "prefix": "hange in pharmacokinetics of the former. Furthermore, the results suggest that ", "from": "17142", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " had no effect on the systemic clearance of rosuvastatin, as individual plasma c"}, {"to": "19354", "prefix": " result of competition for, or induction or inhibition of, transport proteins. ", "from": "19343", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "Ketoconazole", "suffix": " is known to have inhibitory effects on the transport protein P-gp [16]. Active-"}, {"to": "19786", "prefix": "ase in rosuvastatin exposure would be expected following coadministration with ", "from": "19775", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": ". The potency of ketoconazole to inhibit P-gp has been assessed in cell-based as"}, {"to": "19815", "prefix": "would be expected following coadministration with ketoconazole. The potency of ", "from": "19804", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " to inhibit P-gp has been assessed in cell-based assays and in vivo animal exper"}, {"to": "19981", "prefix": "experiments [16]. Based on these data, it is likely that the concentrations of ", "from": "19970", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " achieved in the present study would have caused a degree of P-gp inhibition [16"}, {"to": "20322", "prefix": "in on the pharmacokinetics of the P-gp substrate digoxin [21].\n\nIn conclusion, ", "from": "20311", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " did not affect the pharmacokinetics of rosuvastatin in healthy subjects. Theref"}, {"to": "20439", "prefix": "cokinetics of rosuvastatin in healthy subjects. Therefore, coadministration of ", "from": "20428", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " and rosuvastatin is unlikely to increase the risk of toxicity at therapeutic do"}, {"to": "21005", "prefix": " for performing the ", "from": "20994", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " assays, Olise M. Nwose MB BS for his support of this trial, and Elizabeth Eaton"}, {"to": "100", "prefix": "Aims\n\nTo examine in vivo the effect of ketoconazole on the pharmacokinetics of ", "from": "89", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ", a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor.\n\nMethod"}, {"to": "378", "prefix": " received ketoconazole 200 mg or placebo twice daily for 7 days, and ", "from": "367", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " 80 mg was coadministered on day 4 of dosing. Plasma concentrations of rosuvasta"}, {"to": "461", "prefix": "vastatin 80 mg was coadministered on day 4 of dosing. Plasma concentrations of ", "from": "450", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ", and active and total HMG-CoA reductase inhibitors were measured up to 96 h pos"}, {"to": "616", "prefix": "d up to 96 h postdose.\n\nResults\n\nFollowing coadministration with ketoconazole, ", "from": "605", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " geometric least square mean AUC(0,t) and Cmax were unchanged compared with plac"}, {"to": "817", "prefix": ". ", "from": "806", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "Rosuvastatin", "suffix": " accounted for essentially all of the circulating active HMG-CoA reductase inhib"}, {"to": "1071", "prefix": "portion of circulating active or total inhibitors accounted for by circulating ", "from": "1060", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ".\n\nConclusions\n\nKetoconazole did not produce any change in rosuvastatin pharmaco"}, {"to": "1142", "prefix": "ulating rosuvastatin.\n\nConclusions\n\nKetoconazole did not produce any change in ", "from": "1131", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " pharmacokinetics in healthy subjects. The data suggest that neither cytochrome "}, {"to": "1305", "prefix": "ochrome P450 3A4 nor P-gp-mediated transport contributes to the elimination of ", "from": "1294", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ".\n\nKeywords: CYP3A4, ketoconazole, P-glycoprotein, rosuvastatin\nGo to:\nIntroduct"}, {"to": "1368", "prefix": " elimination of rosuvastatin.\n\nKeywords: CYP3A4, ketoconazole, P-glycoprotein, ", "from": "1357", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": "\nGo to:\nIntroduction\nRosuvastatin (Crestor"}, {"to": "1401", "prefix": "ywords: CYP3A4, ketoconazole, P-glycoprotein, rosuvastatin\nGo to:\nIntroduction\n", "from": "1390", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "Rosuvastatin", "suffix": " (Crestor"}, {"to": "1410", "prefix": "", "from": "1404", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "Crestor", "suffix": ""}, {"to": "1644", "prefix": "ffective for the treatment of patients with dyslipidaemia. In clinical trials, ", "from": "1633", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " (1-80 mg) produced highly significant dose-dependent reductions in low-density "}, {"to": "1825", "prefix": " and was well-tolerated [1].\n\nThe pharmacokinetics of ", "from": "1814", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " following single- and multiple-dose administration of the drug to healthy volun"}, {"to": "2332", "prefix": "80 mg, and the elimination half-life was about 20 h.\n\nElimination of ", "from": "2321", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " is primarily via the liver. In a clinical trial [3], 90% of an orally administe"}, {"to": "2454", "prefix": " a clinical trial [3], 90% of an orally administered dose of 14C-radiolabelled ", "from": "2443", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " was recovered in faeces as unchanged drug, a result consistent with metabolism "}, {"to": "2683", "prefix": "man hepatic microsomes and hepatocytes demonstrated only limited metabolism of ", "from": "2672", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " [4], and cytochrome P450 2C9 (CYP2C9) appeared to be the principal enzyme invol"}, {"to": "2842", "prefix": "enzyme involved [4], with minor roles for CYP3A4 and CYP2C19 [4]. In addition, ", "from": "2831", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " had no significant inhibitory effect on the major CYP isoforms in human hepatic"}, {"to": "3576", "prefix": "ata suggest that CYP3A4 metabolism is not an important clearance mechanism for ", "from": "3565", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ", an in vivo interaction with coadministered drugs that inhibit CYP3A4 cannot be"}, {"to": "3821", "prefix": " on the pharmacokinetics of ", "from": "3810", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ".\n\nKetoconazole is also known to inhibit the activity of transport protein P-gly"}, {"to": "4032", "prefix": "tated-transport processes may have a role in the absorption and disposition of ", "from": "4021", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ". Thus, studies with rats have demonstrated selective hepatic uptake of rosuvast"}, {"to": "4116", "prefix": "astatin. Thus, studies with rats have demonstrated selective hepatic uptake of ", "from": "4105", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " by an active transport process [17], and rosuvastatin was shown to be a ligand "}, {"to": "4170", "prefix": "ective hepatic uptake of rosuvastatin by an active transport process [17], and ", "from": "4159", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " was shown to be a ligand for a liver-specific human organic-anion-transporting "}, {"to": "4527", "prefix": "dy may provide an indication of whether P-gp-mediated transport contributes to ", "from": "4516", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " disposition.\n\nGo to:\nMethods\nThis trial was conducted in accordance with good c"}, {"to": "5679", "prefix": "", "from": "5668", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " "}, {"to": "6260", "prefix": "s. On day 4 of each dosing period, volunteers were given a single oral dose of ", "from": "6249", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " 80 mg (1 "}, {"to": "6639", "prefix": "ed from 96 h before the first dose on day 1 until 96 h after administration of ", "from": "6628", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " in each dosing period), the consumption of caffeine-containing drinks"}, {"to": "6817", "prefix": "none permitted from midnight before day 1 until 96 h after administration of ", "from": "6806", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " in each dosing period), and concomitant medications (none permitted from 96 h b"}, {"to": "6994", "prefix": ".\n\nDetermination of ", "from": "6983", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " plasma concentrations\n\nBlood samples (9 ml) for rosuvastatin assay were taken b"}, {"to": "7055", "prefix": " for ", "from": "7044", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " assay were taken before administration of rosuvastatin on day 4 of each dosing "}, {"to": "7110", "prefix": " for rosuvastatin assay were taken before administration of ", "from": "7099", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " on day 4 of each dosing period and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 30"}, {"to": "7797", "prefix": " [19]. Briefly, ", "from": "7786", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " was extracted from the samples by automated solid-phase extraction on 96-well p"}, {"to": "8286", "prefix": ". ", "from": "8275", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "Rosuvastatin", "suffix": " was detected using a PE-Sciex API 365 triple quadruple mass spectrometer fitted"}, {"to": "8452", "prefix": " of ", "from": "8441", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " was verified as 0.1 ng ml"}, {"to": "8704", "prefix": " 20%. Correlation coefficients for ", "from": "8693", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " calibration curves were 0.996-0.999. Mean imprecision values and inaccuracy lev"}, {"to": "9426", "prefix": "or total inhibition.\n\nThe blood samples taken for ", "from": "9415", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " assay were also used to obtain plasma for active and total inhibitor assays. Sa"}, {"to": "10605", "prefix": "o construct a standard curve. Concentrations are reported as ng equivalents of ", "from": "10594", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " ml"}, {"to": "11811", "prefix": " of ", "from": "11800", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " after dosing with ketoconazole compared with placebo. If less than 12 volunteer"}, {"to": "12235", "prefix": " of ", "from": "12224", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ", area under the plasma concentration-time curve and Cmax of active and total HM"}, {"to": "13106", "prefix": "", "from": "13095", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " "}, {"to": "13134", "prefix": "", "from": "13123", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " "}, {"to": "13209", "prefix": " for ", "from": "13198", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " AUC [or AUC(0,t)] was contained within the interval of 0.7"}, {"to": "13453", "prefix": "his prespecified interval, the absence of an interaction was assumed [20].\n\nAs ", "from": "13442", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " AUC [or AUC(0,t)] and Cmax were the primary parameters upon which sizing of the"}, {"to": "14146", "prefix": " plasma concentrations of ", "from": "14135", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " over time were similar when rosuvastatin was coadministered with ketoconazole a"}, {"to": "14187", "prefix": " plasma concentrations of rosuvastatin over time were similar when ", "from": "14176", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " was coadministered with ketoconazole and placebo (Figure 1). As AUC data from b"}, {"to": "14687", "prefix": "C in the assessment of exposure. Following coadministration with ketoconazole, ", "from": "14676", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " glsmean AUC(0,t) and Cmax were unchanged compared with placebo (Table 1). The 9"}, {"to": "14941", "prefix": "so it was concluded that ketoconazole had no effect on the pharmacokinetics of ", "from": "14930", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ".\n\nFigure 1\nFigure 1\nGeometric mean plasma concentrations of rosuvastatin over t"}, {"to": "15014", "prefix": "cs of rosuvastatin.\n\nFigure 1\nFigure 1\nGeometric mean plasma concentrations of ", "from": "15003", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " over time when coadministered with ketoconazole or placebo. "}, {"to": "15090", "prefix": ", ", "from": "15079", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "Rosuvastatin", "suffix": " "}, {"to": "15122", "prefix": ", ", "from": "15111", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " "}, {"to": "15200", "prefix": " placebo.\nTable 1\nTable 1\nSummary pharmacokinetic parameters of ", "from": "15189", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ", and results of the statistical analysis of the plasma AUC(0,t) and Cmax of ros"}, {"to": "15289", "prefix": " and Cmax of ", "from": "15278", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ", when coadministered with ketoconazole and placebo\nComparison of areas under th"}, {"to": "15447", "prefix": "reas under the plasma concentration-time curves measured to a common point for ", "from": "15436", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " and active and total HMG-CoA reductase inhibitors indicated that, within the ac"}, {"to": "15583", "prefix": "itors indicated that, within the accuracy and precision s of the methods used, ", "from": "15572", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " accounted for essentially all of the circulating active inhibitors and most ("}, {"to": "15953", "prefix": "ting active or total HMG-CoA reductase inhibitors accounted for by circulating ", "from": "15942", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ".\n\nFigure 2\nFigure 2\nGeometric mean plasma concentrations of active and total HM"}, {"to": "16076", "prefix": "ean plasma concentrations of active and total HMG-CoA reductase inhibitors and ", "from": "16065", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " over time when rosuvastatin was coadministered with ketoconazole. A similar pat"}, {"to": "16104", "prefix": " active and total HMG-CoA reductase inhibitors and rosuvastatin over time when ", "from": "16093", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " was coadministered with ketoconazole. A similar pattern was seen when rosuvasta"}, {"to": "16187", "prefix": "vastatin was coadministered with ketoconazole. A similar pattern was seen when ", "from": "16176", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " was coadministered with placebo. "}, {"to": "16417", "prefix": " indicated that steady state was achieved before dosing with ", "from": "16406", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " and was maintained during sampling. The gmean plasma concentrations of ketocona"}, {"to": "16716", "prefix": "trations fell within the range anticipated for a 200-mg dose of ketoconazole.\n\n", "from": "16705", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "Rosuvastatin", "suffix": " and ketoconazole were well tolerated when coadministered. There were no serious"}, {"to": "16995", "prefix": "medical examinations during this trial.\n\nGo to:\nDiscussion\nCoadministration of ", "from": "16984", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " and the potent CYP3A4 inhibitor ketoconazole did not produce any change in phar"}, {"to": "17209", "prefix": "e results suggest that ketoconazole had no effect on the systemic clearance of ", "from": "17198", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ", as individual plasma concentration profiles, including the terminal eliminatio"}, {"to": "17379", "prefix": ", were similar between dosing periods.\n\nIn contrast to ", "from": "17368", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ", atorvastatin [5], simvastatin [6], and lovastatin [7] are cleared primarily by"}, {"to": "17905", "prefix": "ductase inhibitor concentrations were measured in this trial. The finding that ", "from": "17894", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " accounted for essentially all of the circulating active inhibitors suggests the"}, {"to": "18114", "prefix": ". The finding that the active inhibitors, and therefore ", "from": "18103", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ", constituted the majority of the total inhibitors indicates the presence of onl"}, {"to": "18430", "prefix": "esults provide good support for previous data indicating limited metabolism of ", "from": "18419", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " [3, 4].\n\nOther HMG-CoA reductase inhibitors have circulating metabolites that c"}, {"to": "19535", "prefix": "tated-transport processes may have a role in the absorption and disposition of ", "from": "19524", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " [17, 18]. The identity of the rosuvastatin transporters that interact with rosu"}, {"to": "19578", "prefix": "n the absorption and disposition of rosuvastatin [17, 18]. The identity of the ", "from": "19567", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " transporters that interact with rosuvastatin has not been clearly defined, but "}, {"to": "19623", "prefix": "tin [17, 18]. The identity of the rosuvastatin transporters that interact with ", "from": "19612", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " has not been clearly defined, but if it were a P-gp substrate, an increase in r"}, {"to": "19714", "prefix": " has not been clearly defined, but if it were a P-gp substrate, an increase in ", "from": "19703", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " exposure would be expected following coadministration with ketoconazole. The po"}, {"to": "20112", "prefix": "e caused a degree of P-gp inhibition [16]. Therefore, our results suggest that ", "from": "20101", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " is not a ligand for P-gp. This finding is in agreement with the results of a st"}, {"to": "20233", "prefix": "s finding is in agreement with the results of a study that showed no effect of ", "from": "20222", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " on the pharmacokinetics of the P-gp substrate digoxin [21].\n\nIn conclusion, ket"}, {"to": "20374", "prefix": "oxin [21].\n\nIn conclusion, ketoconazole did not affect the pharmacokinetics of ", "from": "20363", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " in healthy subjects. Therefore, coadministration of ketoconazole and rosuvastat"}, {"to": "20456", "prefix": "uvastatin in healthy subjects. Therefore, coadministration of ketoconazole and ", "from": "20445", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " is unlikely to increase the risk of toxicity at therapeutic doses of rosuvastat"}, {"to": "20538", "prefix": "uvastatin is unlikely to increase the risk of toxicity at therapeutic doses of ", "from": "20527", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ". The data suggest that neither cytochrome P450 3A4 nor P-gp-mediated transport "}, {"to": "20664", "prefix": "ochrome P450 3A4 nor P-gp-mediated transport contributes to the elimination of ", "from": "20653", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ".\n\nGo to:\nAcknowledgments\nThe authors thank Quintiles Scotland Ltd (Edinburgh, U"}, {"to": "20778", "prefix": " for performing the ", "from": "20767", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " assays, Medical Research Laboratories (Highland Heights, Kentucky, USA) for per"}, {"to": "1530", "prefix": " reductase, the rate-limiting enzyme in ", "from": "1520", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC1884190", "exact": "cholesterol", "suffix": " biosynthesis, and is effective for the treatment of patients with dyslipidaemia"}, {"to": "1747", "prefix": "oduced highly significant dose-dependent reductions in low-density lipoprotein ", "from": "1737", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC1884190", "exact": "cholesterol", "suffix": " (up to 65%) and was well-tolerated [1].\n\nThe pharmacokinetics of rosuvastatin f"}, {"to": "3000", "prefix": "", "from": "2989", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC1884190", "exact": "atorvastatin", "suffix": " [5], simvastatin [6], and lovastatin [7]) are cleared primarily by metabolism i"}, {"to": "3268", "prefix": "ered drugs affecting CYP3A4 activity. It has been shown that the metabolism of ", "from": "3257", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC1884190", "exact": "atorvastatin", "suffix": " [8"}, {"to": "17393", "prefix": ", were similar between dosing periods.\n\nIn contrast to rosuvastatin, ", "from": "17382", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC1884190", "exact": "atorvastatin", "suffix": " [5], simvastatin [6], and lovastatin [7] are cleared primarily by metabolism in"}, {"to": "18799", "prefix": "rent compound and its metabolites may be affected. For example, in the case of ", "from": "18788", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC1884190", "exact": "atorvastatin", "suffix": ", following coadministration with itraconazole, the mean AUC(0,72) of the active"}, {"to": "18982", "prefix": " of ", "from": "18971", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC1884190", "exact": "atorvastatin", "suffix": " acid and lactone was increased 3.2- and 4.1-fold, respectively; and the mean AU"}, {"to": "3017", "prefix": "atorvastatin [5], ", "from": "3007", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC1884190", "exact": "simvastatin", "suffix": " [6], and lovastatin [7]) are cleared primarily by metabolism involving CYP3A4. "}, {"to": "3288", "prefix": "10], ", "from": "3278", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC1884190", "exact": "simvastatin", "suffix": " [11, 12], and lovastatin [13, 14] is inhibited by erythromycin and itraconazole"}, {"to": "17410", "prefix": "imilar between dosing periods.\n\nIn contrast to rosuvastatin, atorvastatin [5], ", "from": "17400", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC1884190", "exact": "simvastatin", "suffix": " [6], and lovastatin [7] are cleared primarily by metabolism involving CYP3A4 an"}, {"to": "3037", "prefix": "atorvastatin [5], simvastatin [6], and ", "from": "3028", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1884190", "exact": "lovastatin", "suffix": " [7]) are cleared primarily by metabolism involving CYP3A4. Thus, there is poten"}, {"to": "3313", "prefix": "10], simvastatin [11, 12], and ", "from": "3304", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1884190", "exact": "lovastatin", "suffix": " [13, 14] is inhibited by erythromycin and itraconazole, leading to increased se"}, {"to": "17430", "prefix": " periods.\n\nIn contrast to rosuvastatin, atorvastatin [5], simvastatin [6], and ", "from": "17421", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1884190", "exact": "lovastatin", "suffix": " [7] are cleared primarily by metabolism involving CYP3A4 and are known to inter"}, {"to": "3351", "prefix": "10], simvastatin [11, 12], and lovastatin [13, 14] is inhibited by ", "from": "3340", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "PMC1884190", "exact": "erythromycin", "suffix": " and itraconazole, leading to increased serum"}, {"to": "3368", "prefix": "simvastatin [11, 12], and lovastatin [13, 14] is inhibited by erythromycin and ", "from": "3357", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1884190", "exact": "itraconazole", "suffix": ", leading to increased serum"}, {"to": "18845", "prefix": "ted. For example, in the case of atorvastatin, following coadministration with ", "from": "18834", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1884190", "exact": "itraconazole", "suffix": ", the mean AUC(0,72) of the active and total inhibitors was increased 1.6- and 1"}, {"to": "5174", "prefix": "clinical chemistry, haematology, or urinalysis results, or if total bilirubin, ", "from": "5168", "name": "Alanine", "fullId": "http://purl.bioontology.org/ontology/MESH/D000409", "setId": "PMC1884190", "exact": "alanine", "suffix": " aminotransferase, aspartate aminotransferase, alkaline phosphatase, or creatine"}, {"to": "6691", "prefix": ", the consumption of ", "from": "6684", "name": "Caffeine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002110", "setId": "PMC1884190", "exact": "caffeine", "suffix": "-containing drinks"}, {"to": "7424", "prefix": "cond dosing period. Blood samples were collected into tubes containing lithium ", "from": "7418", "name": "Heparin", "fullId": "http://purl.bioontology.org/ontology/MESH/D006493", "setId": "PMC1884190", "exact": "heparin", "suffix": " anticoagulant and centrifuged within 30 min. Plasma was then harvested from the"}, {"to": "7543", "prefix": "uged within 30 min. Plasma was then harvested from the samples, mixed 1:1 with ", "from": "7530", "name": "Sodium Acetate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/56443", "setId": "PMC1884190", "exact": "sodium acetate", "suffix": " buffer 0.1 m pH 4.0, and stored at "}, {"to": "9725", "prefix": ". Briefly, drug-related components were isolated from plasma by using ", "from": "9714", "name": "acetonitrile", "fullId": "http://purl.bioontology.org/ontology/MESH/C032159", "setId": "PMC1884190", "exact": "acetonitrile", "suffix": " : acetone (95 : 5) to precipitate plasma proteins. The supernatant was assayed "}, {"to": "9735", "prefix": "fly, drug-related components were isolated from plasma by using acetonitrile : ", "from": "9729", "name": "Acetone", "fullId": "http://purl.bioontology.org/ontology/MESH/D000096", "setId": "PMC1884190", "exact": "acetone", "suffix": " (95 : 5) to precipitate plasma proteins. The supernatant was assayed following "}, {"to": "10313", "prefix": "e enzyme reaction was separated from the substrate, after lactonization to 14C-", "from": "10299", "name": "mevalonolactone", "fullId": "http://purl.bioontology.org/ontology/MESH/C015367", "setId": "PMC1884190", "exact": "mevalonolactone", "suffix": " by hydrochloric acid, on a small ion-exchange column. The effluent from the col"}, {"to": "10437", "prefix": "which contained the 14C-", "from": "10423", "name": "mevalonolactone", "fullId": "http://purl.bioontology.org/ontology/MESH/C015367", "setId": "PMC1884190", "exact": "mevalonolactone", "suffix": ") was collected into scintillation vials and counted. The results were used to c"}, {"to": "11112", "prefix": "nd 7 of each dosing period. Blood samples were collected into tubes containing ", "from": "11109", "name": "Edetic Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D004492", "setId": "PMC1884190", "exact": "EDTA", "suffix": " anticoagulant and centrifuged. Plasma was then harvested from the samples and s"}, {"to": "20287", "prefix": "showed no effect of rosuvastatin on the pharmacokinetics of the P-gp substrate ", "from": "20281", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "PMC1884190", "exact": "digoxin", "suffix": " [21].\n\nIn conclusion, ketoconazole did not affect the pharmacokinetics of rosuv"}, {"to": "305", "prefix": "oncentrations in patients.\n\nMethods and Results\n\nIn total, 299 patients taking ", "from": "294", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " or rosuvastatin were prospectively recruited at an outpatient referral center. "}, {"to": "872", "prefix": ". ", "from": "861", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "Atorvastatin", "suffix": " concentration was associated with SLCO1B1 c.388A"}, {"to": "1700", "prefix": "hisms. An algorithm incorporating genomic and clinical variables to avoid high ", "from": "1689", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " and rosuvastatin levels is described; further study will determine if this appr"}, {"to": "4299", "prefix": " taking ", "from": "4288", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " or rosuvastatin daily to participate. Patients were excluded if they were takin"}, {"to": "4393", "prefix": " rosuvastatin daily to participate. Patients were excluded if they were taking ", "from": "4382", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " or rosuvastatin in an alternate day dosing regimen, or if they had not taken th"}, {"to": "4494", "prefix": "statin in an alternate day dosing regimen, or if they had not taken their last ", "from": "4483", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " or rosuvastatin dose within 24 hours of their clinic visit and blood draw. All "}, {"to": "4611", "prefix": "in 24 hours of their clinic visit and blood draw. All patients had been taking ", "from": "4600", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " or rosuvastatin at the same dose for at least six weeks prior to participation,"}, {"to": "6864", "prefix": "L acetonitrile containing internal standard d5-", "from": "6853", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " or d6-rosuvastatin, and centrifuged at 14,000 rpm for 20 minutes at 4 "}, {"to": "7215", "prefix": "f 70:30, with a gradient to ratio of 10:90. Concentrations of rosuvastatin and ", "from": "7204", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " were measured by liquid chromatography-mass spectrometry (LCMS) instrumentation"}, {"to": "10175", "prefix": ". For the ", "from": "10164", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " group, polymorphisms in the drug metabolizing enzymes CYP3A4 (rs35599367) and C"}, {"to": "12020", "prefix": "A, respectively. For log-transformed ", "from": "12009", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " concentration, the effect sizes detectable with a power of 0.80 or higher are 0"}, {"to": "12431", "prefix": "1.5 hours and 4.0 hours for ", "from": "12420", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " and rosuvastatin, respectively11). Different genetic models"}, {"to": "14133", "prefix": " linear regression models. The 90th percentile was determined by adjusting the ", "from": "14122", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " or rosuvastatin concentrations measured in our population to the concentration "}, {"to": "14315", "prefix": "11.5 hours for ", "from": "14304", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " and 12.9 hours for rosuvastatin). For covariates that were not significant in t"}, {"to": "14617", "prefix": "m2 for ", "from": "14606", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " and 30.1 kg"}, {"to": "14668", "prefix": ", and for ", "from": "14657", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": ", average 4"}, {"to": "14960", "prefix": "in Table 1. In total, 299 patients were enrolled in the study, with 134 taking ", "from": "14949", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " and 165 patients on rosuvastatin therapy. Of these patients, 3 taking rosuvasta"}, {"to": "15069", "prefix": "on rosuvastatin therapy. Of these patients, 3 taking rosuvastatin and 6 taking ", "from": "15058", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " had undetectable statin levels, and were excluded from further analysis. Two pa"}, {"to": "15470", "prefix": " Table 2.\n\nTable 1\nTable 1\nPopulation characteristics of prospective cohort of ", "from": "15459", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": "- and rosuvastatin-treated patients\nRosuvastatin concentration\n\nWe observed up t"}, {"to": "16147", "prefix": ".\n\nFigure 1\nFigure 1\nProspective analysis of ", "from": "16136", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " (A) plasma concentrations in patients taking 10, 20, 40, or 80 mg daily, and ro"}, {"to": "17584", "prefix": "tin concentration linear regression model coefficients from prospective cohort\n", "from": "17573", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "Atorvastatin", "suffix": " concentration\n\nSimilar to rosuvastatin, we observed 45-fold or higher variabili"}, {"to": "17714", "prefix": ", we observed 45-fold or higher variability between patients on the same daily ", "from": "17703", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " dose (Figure 1B). In patients taking 10, 20, 40, or 80 mg atorvastatin daily, m"}, {"to": "17785", "prefix": ". In patients taking 10, 20, 40, or 80 mg ", "from": "17774", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " daily, mean plasma concentration of atorvastatin was 0.9 ng"}, {"to": "17834", "prefix": "s taking 10, 20, 40, or 80 mg atorvastatin daily, mean plasma concentration of ", "from": "17823", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " was 0.9 ng"}, {"to": "17985", "prefix": ", respectively. There was a significant difference in plasma ", "from": "17974", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " concentration between those taking 20 mg, 40 mg, or 80 mg vs. 10 mg (p "}, {"to": "18239", "prefix": ".\n\nMultiple linear regression analysis indicated that plasma ", "from": "18228", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " concentration was higher in individuals with the SLCO1B1 c.521C allele (p "}, {"to": "18546", "prefix": ". In addition, age was a significant predictor of ", "from": "18535", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " level (p "}, {"to": "18970", "prefix": "ncentration, accounted for an additional 30% of the explainable variability in ", "from": "18959", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " concentration. A list of CYP3A inhibitors and inducers prescribed to patients t"}, {"to": "19068", "prefix": "tration. A list of CYP3A inhibitors and inducers prescribed to patients taking ", "from": "19057", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " is provided in Supplemental Table 6. Similar results were obtained when 4"}, {"to": "19283", "prefix": "al cholesterol. The following variables were not significantly associated with ", "from": "19272", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " concentration: gender, ethnicity, BMI, and SLCO1B3, SLCO2B1, ABCB1, ABCC2, ABCG"}, {"to": "19488", "prefix": "thosterol concentration\n\nThe mean lathosterol concentration in patients taking ", "from": "19477", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " was 3.9 "}, {"to": "19581", "prefix": ". In patients taking ", "from": "19570", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": ", lathosterol concentration was lower in patients taking a higher dose of atorva"}, {"to": "19667", "prefix": "tatin, lathosterol concentration was lower in patients taking a higher dose of ", "from": "19656", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " (p "}, {"to": "19762", "prefix": ", however, there was no significant association between rosuvastatin or ", "from": "19751", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " concentrations and lathosterol concentration detected in this population. In bo"}, {"to": "20038", "prefix": ". The adjusted R2 value of the model of lathosterol concentration in ", "from": "20027", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": "-treated patients was 0.08; for rosuvastatin-treated patients the adjusted R2 va"}, {"to": "21654", "prefix": "Statin dosing algorithm\n\nIn Figure 2, we summarize recommendations for maximum ", "from": "21643", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " and rosuvastatin doses, based on a patient's age and transporter genotype, and "}, {"to": "22044", "prefix": "perience statin-related muscle complaints.\n\nFigure 2\nFigure 2\nRosuvastatin and ", "from": "22033", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " dosing decision support algorithm. Doses are the maximum doses that result in a"}, {"to": "22163", "prefix": "orithm. Doses are the maximum doses that result in a predicted rosuvastatin or ", "from": "22152", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " concentration that is less than the 90th percentile. In patients taking atorvas"}, {"to": "22248", "prefix": "statin concentration that is less than the 90th percentile. In patients taking ", "from": "22237", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": ", dose should be lowered ...\nRetrospective analysis of statin dosing\n\nWe further"}, {"to": "22515", "prefix": ". The first cohort contained 224 patients taking ", "from": "22504", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " and 37 patients taking rosuvastatin in the context of routine clinical care at "}, {"to": "22692", "prefix": "e academic center in the U.S.; the second cohort contained 121 patients taking ", "from": "22681", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " and 198 patients taking rosuvastatin treated in a lipid clinic at a large acade"}, {"to": "23059", "prefix": "ribed in Table 4.\n\nTable 4\nTable 4\nPopulation characteristics of retrospective ", "from": "23048", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " and rosuvastatin dosing cohort\nFor these clinical practice-based cohorts, the r"}, {"to": "23995", "prefix": ".\n\nFigure 3\nFigure 3\nDistribution of transporter genotypes and age among ", "from": "23984", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " (A) doses of 10, 20, 40, or 80 mg daily and rosuvastatin (B) doses of 5, 10, 20"}, {"to": "24275", "prefix": "h ...\nTable 5\nTable 5\nAccuracy of dose prediction in retrospective analysis of ", "from": "24264", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " and rosuvastatin dosing\nAmong 67 patients on high-dose rosuvastatin (40 mg) or "}, {"to": "24367", "prefix": " or ", "from": "24356", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " (80 mg), nearly 50% exceeded the maximum dose recommended by our model, suggest"}, {"to": "24549", "prefix": "ny were at risk of developing intolerance. Of the 16 patients taking high-dose ", "from": "24538", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " (80 mg) within our cohort derived from an EMR-linked biobank, 9 exceeded the ma"}, {"to": "24714", "prefix": "the maximum recommended dose, and only 7 of these patients were still on 80 mg ", "from": "24703", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " one year later. Conversely, all (7 of 7) subjects predicted by our algorithm to"}, {"to": "24846", "prefix": " subjects predicted by our algorithm to tolerate 80 mg were still on high-dose ", "from": "24835", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " one year later, however, this result was not statistically significant (p "}, {"to": "25275", "prefix": "hip between common drug transporter polymorphisms and plasma concentrations of ", "from": "25264", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " and rosuvastatin in a real world population. We found a marked, 45-fold interpa"}, {"to": "25867", "prefix": "O1B1 and the efflux transporter ABCG2. In contrast, explainable variability in ", "from": "25856", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " level is almost equally divided between two polymorphisms in SLCO1B1, and the a"}, {"to": "26092", "prefix": "concentration. Taking our findings together, we propose a dosing algorithm for ", "from": "26081", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " and rosuvastatin that, based on our data regarding the association between tran"}, {"to": "26786", "prefix": "oring certain SLCO1B1 SNPs had higher plasma concentrations of such statins as ", "from": "26775", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": ", rosuvastatin, simvastatin, pravastatin, and pitavastatin19-22. Importantly, a "}, {"to": "27439", "prefix": ", healthy volunteer studies to be associated with a trend towards lower plasma ", "from": "27428", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " level22, 24. Interestingly, the SEARCH study showed a link between this SNP and"}, {"to": "29545", "prefix": "-hydroxycholesterol level was associated with higher ", "from": "29534", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " but not rosuvastatin concentration. Rosuvastatin concentration was also not ass"}, {"to": "29908", "prefix": "d reduced CYP3A function with higher creatine kinase levels in patients taking ", "from": "29897", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": ", suggesting these individuals are prone to more severe myopathy31-32. Numerous "}, {"to": "30175", "prefix": "omitant use of CYP3A inhibitors and statins metabolized by CYP3A, particularly ", "from": "30164", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " and simvastatin. The US Food and Drug Administration (US FDA) recommendations a"}, {"to": "30526", "prefix": "udy identified age as a significant factor in predicting the concentrations of ", "from": "30515", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " and rosuvastatin in patients. Age has been recognized as a clinical risk factor"}, {"to": "31096", "prefix": "ations, though the number of co-medications was not a significant predictor of ", "from": "31085", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " or rosuvastatin concentrations in our population.\n\nLathosterol is a late interm"}, {"to": "31359", "prefix": "HMG-CoA reductase inhibition37-38. In our population, plasma concentrations of ", "from": "31348", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " and rosuvastatin did not correlate with lathosterol levels. This suggests stati"}, {"to": "32456", "prefix": "wering the dose.\n\nAt the highest available dose, nearly 50% of patients taking ", "from": "32445", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " or rosuvastatin exceeded the maximum genotype-based dose recommended by our alg"}, {"to": "32899", "prefix": "etic testing may be most useful when a patient is starting the highest dose of ", "from": "32888", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " or rosuvastatin, bearing in mind that SLCO1B1 c.521 T"}, {"to": "33108", "prefix": "her doses as a result of reduced hepatic uptake.\n\nHere we present the range of ", "from": "33097", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3922121", "exact": "atorvastatin", "suffix": " and rosuvastatin concentrations in a patient population, providing a framework "}, {"to": "321", "prefix": " patients.\n\nMethods and Results\n\nIn total, 299 patients taking atorvastatin or ", "from": "310", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " were prospectively recruited at an outpatient referral center. The contribution"}, {"to": "803", "prefix": " were important to ", "from": "792", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " concentration (adjusted R2 "}, {"to": "1717", "prefix": "hm incorporating genomic and clinical variables to avoid high atorvastatin and ", "from": "1706", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " levels is described; further study will determine if this approach reduces inci"}, {"to": "4315", "prefix": " taking atorvastatin or ", "from": "4304", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " daily to participate. Patients were excluded if they were taking atorvastatin o"}, {"to": "4409", "prefix": "ily to participate. Patients were excluded if they were taking atorvastatin or ", "from": "4398", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " in an alternate day dosing regimen, or if they had not taken their last atorvas"}, {"to": "4510", "prefix": "ernate day dosing regimen, or if they had not taken their last atorvastatin or ", "from": "4499", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " dose within 24 hours of their clinic visit and blood draw. All patients had bee"}, {"to": "4627", "prefix": "heir clinic visit and blood draw. All patients had been taking atorvastatin or ", "from": "4616", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " at the same dose for at least six weeks prior to participation, with the except"}, {"to": "6883", "prefix": "L acetonitrile containing internal standard d5-atorvastatin or d6-", "from": "6872", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": ", and centrifuged at 14,000 rpm for 20 minutes at 4 "}, {"to": "7198", "prefix": "ting at a ratio of 70:30, with a gradient to ratio of 10:90. Concentrations of ", "from": "7187", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " and atorvastatin were measured by liquid chromatography-mass spectrometry (LCMS"}, {"to": "10320", "prefix": " were also assessed. Patients in the ", "from": "10309", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " group were also genotyped for CYP2C9 "}, {"to": "11812", "prefix": "sing the proportion contributed by the genetic variables.\n\nFor log-transformed ", "from": "11801", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " concentration, the effect sizes detectable with a power of 0.80 or higher are 0"}, {"to": "12448", "prefix": "1.5 hours and 4.0 hours for atorvastatin and ", "from": "12437", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": ", respectively11). Different genetic models"}, {"to": "14149", "prefix": "on models. The 90th percentile was determined by adjusting the atorvastatin or ", "from": "14138", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " concentrations measured in our population to the concentration predicted at the"}, {"to": "14347", "prefix": "11.5 hours for atorvastatin and 12.9 hours for ", "from": "14336", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": "). For covariates that were not significant in the model, we substituted the ave"}, {"to": "14645", "prefix": "m2 ", "from": "14634", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": "), and for atorvastatin, average 4"}, {"to": "14993", "prefix": "s were enrolled in the study, with 134 taking atorvastatin and 165 patients on ", "from": "14982", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " therapy. Of these patients, 3 taking rosuvastatin and 6 taking atorvastatin had"}, {"to": "15043", "prefix": "vastatin and 165 patients on rosuvastatin therapy. Of these patients, 3 taking ", "from": "15032", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " and 6 taking atorvastatin had undetectable statin levels, and were excluded fro"}, {"to": "15175", "prefix": "le statin levels, and were excluded from further analysis. Two patients taking ", "from": "15164", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " were excluded from lathosterol-related analysis, due to inability to measure la"}, {"to": "15488", "prefix": "\nTable 1\nPopulation characteristics of prospective cohort of atorvastatin- and ", "from": "15477", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": "-treated patients\nRosuvastatin concentration\n\nWe observed up to 45-fold variabil"}, {"to": "15518", "prefix": "stics of prospective cohort of atorvastatin- and rosuvastatin-treated patients\n", "from": "15507", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "Rosuvastatin", "suffix": " concentration\n\nWe observed up to 45-fold variability in plasma rosuvastatin con"}, {"to": "15594", "prefix": "ts\nRosuvastatin concentration\n\nWe observed up to 45-fold variability in plasma ", "from": "15583", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " concentration among individuals on the same dose (Figure 1A). In patients takin"}, {"to": "15708", "prefix": ". In patients taking 5, 10, 20, or 40 mg ", "from": "15697", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " daily, mean plasma concentration of rosuvastatin was 1.6 ng"}, {"to": "15757", "prefix": "ts taking 5, 10, 20, or 40 mg rosuvastatin daily, mean plasma concentration of ", "from": "15746", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " was 1.6 ng"}, {"to": "15908", "prefix": ", respectively. There was a significant difference in plasma ", "from": "15897", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " concentration between those taking 5 mg vs. 10 mg, 20 mg or 40 mg (p "}, {"to": "16237", "prefix": " plasma concentrations in patients taking 10, 20, 40, or 80 mg daily, and ", "from": "16226", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " (B) plasma concentrations in patients taking 5, 10, 20, or 40 mg daily. Rosuvas"}, {"to": "16322", "prefix": " plasma concentrations in patients taking 5, 10, 20, or 40 mg daily. ", "from": "16311", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "Rosuvastatin", "suffix": " concentrations were collected within 0 ...\nIn order to assess the association o"}, {"to": "16464", "prefix": "r to assess the association of clinical and pharmacogenetic variables with the ", "from": "16453", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " levels observed, we performed multiple linear regression analysis. Only those p"}, {"to": "16728", "prefix": ". Multiple linear regression analysis indicated that plasma ", "from": "16717", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " concentration was higher in individuals with the reduced function hepatic uptak"}, {"to": "16983", "prefix": ". Age also contributed to plasma ", "from": "16972", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " level (p "}, {"to": "17450", "prefix": "O2B1, ABCB1, ABCC2, and CYP2C9 genotype were not significantly associated with ", "from": "17439", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " concentration.\n\nTable 2\nTable 2\nPlasma statin concentration linear regression m"}, {"to": "17623", "prefix": "el coefficients from prospective cohort\nAtorvastatin concentration\n\nSimilar to ", "from": "17612", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": ", we observed 45-fold or higher variability between patients on the same daily a"}, {"to": "18729", "prefix": ". In contrast to ", "from": "18718", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": ", the genetic component of the model contributed only 38% of the explainable var"}, {"to": "19528", "prefix": " and ", "from": "19517", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " was 3.4 "}, {"to": "19746", "prefix": ", however, there was no significant association between ", "from": "19735", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " or atorvastatin concentrations and lathosterol concentration detected in this p"}, {"to": "20082", "prefix": "el of lathosterol concentration in atorvastatin-treated patients was 0.08; for ", "from": "20071", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": "-treated patients the adjusted R2 value was 0.39.\n\nTable 3\nTable 3\nLathosterol p"}, {"to": "20282", "prefix": "gression model coefficients from prospective cohort\nLDL-C lowering response to ", "from": "20271", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": "\n\nDespite the lack of association between lathosterol level and statin level, so"}, {"to": "20522", "prefix": "lowering response in combination with plasma statin concentration. We examined ", "from": "20511", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " acid concentrations in patients taking 40 mg rosuvastatin daily, for whom no hi"}, {"to": "20580", "prefix": "tration. We examined rosuvastatin acid concentrations in patients taking 40 mg ", "from": "20569", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " daily, for whom no higher dose or more potent statin is available, and included"}, {"to": "20916", "prefix": " had a mean plasma ", "from": "20905", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " concentration of 9.183 ng"}, {"to": "21671", "prefix": "orithm\n\nIn Figure 2, we summarize recommendations for maximum atorvastatin and ", "from": "21660", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " doses, based on a patient's age and transporter genotype, and the linear regres"}, {"to": "22027", "prefix": "dividuals will experience statin-related muscle complaints.\n\nFigure 2\nFigure 2\n", "from": "22016", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "Rosuvastatin", "suffix": " and atorvastatin dosing decision support algorithm. Doses are the maximum doses"}, {"to": "22147", "prefix": "sion support algorithm. Doses are the maximum doses that result in a predicted ", "from": "22136", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " or atorvastatin concentration that is less than the 90th percentile. In patient"}, {"to": "22551", "prefix": "first cohort contained 224 patients taking atorvastatin and 37 patients taking ", "from": "22540", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " in the context of routine clinical care at a large academic center in the U.S.;"}, {"to": "22729", "prefix": "cond cohort contained 121 patients taking atorvastatin and 198 patients taking ", "from": "22718", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " treated in a lipid clinic at a large academic center in Canada. Thus, we were a"}, {"to": "23076", "prefix": "\n\nTable 4\nTable 4\nPopulation characteristics of retrospective atorvastatin and ", "from": "23065", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " dosing cohort\nFor these clinical practice-based cohorts, the relationship betwe"}, {"to": "23285", "prefix": "in dose has been summarized in Figure 3. We observed that patients taking 5 mg ", "from": "23274", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " were older than those taking 10 mg and 40 mg (p "}, {"to": "24052", "prefix": " doses of 10, 20, 40, or 80 mg daily and ", "from": "24041", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " (B) doses of 5, 10, 20, or 40 mg daily in retrospective analysis of statin-trea"}, {"to": "24292", "prefix": "le 5\nAccuracy of dose prediction in retrospective analysis of atorvastatin and ", "from": "24281", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " dosing\nAmong 67 patients on high-dose rosuvastatin (40 mg) or atorvastatin (80 "}, {"to": "24343", "prefix": "nalysis of atorvastatin and rosuvastatin dosing\nAmong 67 patients on high-dose ", "from": "24332", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " (40 mg) or atorvastatin (80 mg), nearly 50% exceeded the maximum dose recommend"}, {"to": "25292", "prefix": "n drug transporter polymorphisms and plasma concentrations of atorvastatin and ", "from": "25281", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " in a real world population. We found a marked, 45-fold interpatient variability"}, {"to": "25660", "prefix": "e change in statin level. Indeed, nearly 90% of the explainable variability in ", "from": "25649", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " concentration can be accounted for by two reduced function transporter polymorp"}, {"to": "26109", "prefix": "king our findings together, we propose a dosing algorithm for atorvastatin and ", "from": "26098", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " that, based on our data regarding the association between transporter genotype,"}, {"to": "26800", "prefix": "SLCO1B1 SNPs had higher plasma concentrations of such statins as atorvastatin, ", "from": "26789", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": ", simvastatin, pravastatin, and pitavastatin19-22. Importantly, a genome-wide an"}, {"to": "27157", "prefix": "C has also been associated with reduced LDL-C lowering response to ", "from": "27146", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " therapy23. The other SLCO1B1 polymorphism genotyped, c.388A"}, {"to": "28024", "prefix": " efflux transporter ABCG2 have been associated with higher ", "from": "28013", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " concentration in healthy volunteers25 and recently, with improved lipid lowerin"}, {"to": "28223", "prefix": "s26 and Caucasians23, 27. The effect of reduced activity ABCG2 polymorphism on ", "from": "28212", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " concentration suggests increased statin exposure is the mechanism resulting in "}, {"to": "28806", "prefix": "y 24. Moreover, in Asian countries such as Japan, the maximum approved dose of ", "from": "28795", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " is 20 mg"}, {"to": "28920", "prefix": "day in North American and European countries. Since the increase in ", "from": "28909", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " exposure is not strictly related to environment 24, physicians in North America"}, {"to": "29566", "prefix": "-hydroxycholesterol level was associated with higher atorvastatin but not ", "from": "29555", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " concentration. Rosuvastatin concentration was also not associated with CYP2C9 "}, {"to": "29594", "prefix": "el was associated with higher atorvastatin but not rosuvastatin concentration. ", "from": "29583", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "Rosuvastatin", "suffix": " concentration was also not associated with CYP2C9 "}, {"to": "29744", "prefix": "3 genotypes, consistent with previous studies which have indicated that ", "from": "29733", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " is predominantly eliminated unchanged30. Previous reports have associated reduc"}, {"to": "30543", "prefix": "e as a significant factor in predicting the concentrations of atorvastatin and ", "from": "30532", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " in patients. Age has been recognized as a clinical risk factor for statin-induc"}, {"to": "30780", "prefix": " associated with increased exposure to atorvastatin35, but not rosuvastatin36. ", "from": "30769", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "Rosuvastatin", "suffix": " clearance, however, is partially mediated by tubular secretion in the kidney, t"}, {"to": "31112", "prefix": "he number of co-medications was not a significant predictor of atorvastatin or ", "from": "31101", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " concentrations in our population.\n\nLathosterol is a late intermediate in choles"}, {"to": "31376", "prefix": " inhibition37-38. In our population, plasma concentrations of atorvastatin and ", "from": "31365", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " did not correlate with lathosterol levels. This suggests statin concentration i"}, {"to": "32472", "prefix": "\n\nAt the highest available dose, nearly 50% of patients taking atorvastatin or ", "from": "32461", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " exceeded the maximum genotype-based dose recommended by our algorithm. At lower"}, {"to": "32915", "prefix": " be most useful when a patient is starting the highest dose of atorvastatin or ", "from": "32904", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": ", bearing in mind that SLCO1B1 c.521 T"}, {"to": "33125", "prefix": "sult of reduced hepatic uptake.\n\nHere we present the range of atorvastatin and ", "from": "33114", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " concentrations in a patient population, providing a framework by which to asses"}, {"to": "33388", "prefix": "xposure and common statin transporter polymorphisms. In the clinical review of ", "from": "33377", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " originally submitted to the US FDA, all patients with serious adverse events fo"}, {"to": "33531", "prefix": " had high ", "from": "33520", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "rosuvastatin", "suffix": " concentrations ("}, {"to": "33629", "prefix": "", "from": "33623", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3922121", "exact": "Crestor", "suffix": ""}, {"to": "2170", "prefix": "ascular event risk by lowering plasma concentration of low-density lipoprotein ", "from": "2160", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3922121", "exact": "cholesterol", "suffix": " (LDL-C)1. A recent report indicates that 25% of Americans over age 45 takes a s"}, {"to": "3911", "prefix": "ncentration to assess the efficacy of statin-mediated inhibition of endogenous ", "from": "3901", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3922121", "exact": "cholesterol", "suffix": " synthesis, as well as its relationship to statin concentration. Taken together,"}, {"to": "4830", "prefix": "witched from 40 mg to 80 mg one week prior to blood sampling to achieve better ", "from": "4820", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3922121", "exact": "cholesterol", "suffix": " lowering. The study was conducted between August 2009 and May 2011. A detailed "}, {"to": "9259", "prefix": "-hydroxycholesterol, at relevant concentrations.\n\nDetermination of total ", "from": "9249", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3922121", "exact": "cholesterol", "suffix": "\n\nTotal cholesterol was measured by the enzymatic colorimetric method, using the"}, {"to": "9278", "prefix": "sterol, at relevant concentrations.\n\nDetermination of total cholesterol\n\nTotal ", "from": "9268", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3922121", "exact": "cholesterol", "suffix": " was measured by the enzymatic colorimetric method, using the Cholesterol E kit "}, {"to": "9351", "prefix": "Total cholesterol was measured by the enzymatic colorimetric method, using the ", "from": "9341", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3922121", "exact": "Cholesterol", "suffix": " E kit from Wako (Richmond, VA). Samples were measured in triplicate using the m"}, {"to": "15285", "prefix": "lathosterol-related analysis, due to inability to measure lathosterol or total ", "from": "15275", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3922121", "exact": "cholesterol", "suffix": ". A list of the concomitant medications observed in our population is provided i"}, {"to": "19206", "prefix": "-hydroxycholesterol levels were normalized by total ", "from": "19196", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3922121", "exact": "cholesterol", "suffix": ". The following variables were not significantly associated with atorvastatin co"}, {"to": "19902", "prefix": "cted in this population. In both groups, lathosterol was associated with total ", "from": "19892", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3922121", "exact": "cholesterol", "suffix": ", and was higher in patients taking ezetimibe (Table 3). The adjusted R2 value o"}, {"to": "29384", "prefix": "-hydroxycholesterol is produced by CYP3A enzymes from ", "from": "29374", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3922121", "exact": "cholesterol", "suffix": ", and has been proposed to be a marker of CYP3A activity in vivo28-29. In our po"}, {"to": "31197", "prefix": "tatin concentrations in our population.\n\nLathosterol is a late intermediate in ", "from": "31187", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3922121", "exact": "cholesterol", "suffix": " synthesis that can be used to measure the efficacy of statin-mediated HMG-CoA r"}, {"to": "31592", "prefix": "tant factor in determining the inhibition of HMG-CoA reductase. Ezetimibe is a ", "from": "31582", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3922121", "exact": "cholesterol", "suffix": " absorption inhibitor that has been previously associated with lathosterol level"}, {"to": "5471", "prefix": ".\n\nSample collection\n\nA single venous 8 mL blood sample was drawn into ", "from": "5468", "name": "Edetic Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D004492", "setId": "PMC3922121", "exact": "EDTA", "suffix": "-containing tubes, and placed immediately on ice. Samples were centrifuged 2,000"}, {"to": "6819", "prefix": "L ", "from": "6808", "name": "acetonitrile", "fullId": "http://purl.bioontology.org/ontology/MESH/C032159", "setId": "PMC3922121", "exact": "acetonitrile", "suffix": " containing internal standard d5-atorvastatin or d6-rosuvastatin, and centrifuge"}, {"to": "7101", "prefix": "arated using mobile phases 0.05% formic acid in water and 0.05% formic acid in ", "from": "7090", "name": "acetonitrile", "fullId": "http://purl.bioontology.org/ontology/MESH/C032159", "setId": "PMC3922121", "exact": "acetonitrile", "suffix": ", starting at a ratio of 70:30, with a gradient to ratio of 10:90. Concentration"}, {"to": "8958", "prefix": ". Analytes were separated and eluted with a gradient from 80% to 98% methanol:", "from": "8947", "name": "acetonitrile", "fullId": "http://purl.bioontology.org/ontology/MESH/C032159", "setId": "PMC3922121", "exact": "acetonitrile", "suffix": " (1:1). The transition used for lathosterol was m"}, {"to": "7995", "prefix": "L of plasma or standard curve were saponified in 1 mL of 1M KOH in ", "from": "7989", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/448", "setId": "PMC3922121", "exact": "ethanol", "suffix": " for 1 hour at 37 "}, {"to": "8334", "prefix": "L ", "from": "8322", "name": "triethylamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1307097", "setId": "PMC3922121", "exact": "triethylamine", "suffix": ". Samples were incubated with the derivatization reagents at 80 "}, {"to": "13148", "prefix": "ozygous genotypes were coded as 1, and homozygous variant genotypes were coded ", "from": "13145", "name": "Aligeron", "fullId": "http://purl.bioontology.org/ontology/MESH/C021591", "setId": "PMC3922121", "exact": "as 2", "suffix": ". Regression analysis was performed by a step-wise search. All models were adjus"}, {"to": "13539", "prefix": " the number of concomitant medications or presence of the specific medications ", "from": "13531", "name": "ezetimibe", "fullId": "http://purl.bioontology.org/ontology/MESH/C108606", "setId": "PMC3922121", "exact": "ezetimibe", "suffix": ", niacin, and fibrate were assessed for their contribution to the model and reta"}, {"to": "19947", "prefix": "terol was associated with total cholesterol, and was higher in patients taking ", "from": "19939", "name": "ezetimibe", "fullId": "http://purl.bioontology.org/ontology/MESH/C108606", "setId": "PMC3922121", "exact": "ezetimibe", "suffix": " (Table 3). The adjusted R2 value of the model of lathosterol concentration in a"}, {"to": "31575", "prefix": " the most important factor in determining the inhibition of HMG-CoA reductase. ", "from": "31567", "name": "ezetimibe", "fullId": "http://purl.bioontology.org/ontology/MESH/C108606", "setId": "PMC3922121", "exact": "Ezetimibe", "suffix": " is a cholesterol absorption inhibitor that has been previously associated with "}, {"to": "31757", "prefix": "vel39; here we observed that lathosterol level is increased in patients taking ", "from": "31749", "name": "ezetimibe", "fullId": "http://purl.bioontology.org/ontology/MESH/C108606", "setId": "PMC3922121", "exact": "ezetimibe", "suffix": " even when they are concurrently taking statins, which limit lathosterol synthes"}, {"to": "13547", "prefix": " of concomitant medications or presence of the specific medications ezetimibe, ", "from": "13542", "name": "Niacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D009525", "setId": "PMC3922121", "exact": "niacin", "suffix": ", and fibrate were assessed for their contribution to the model and retained if "}, {"to": "26813", "prefix": "ad higher plasma concentrations of such statins as atorvastatin, rosuvastatin, ", "from": "26803", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3922121", "exact": "simvastatin", "suffix": ", pravastatin, and pitavastatin19-22. Importantly, a genome-wide analysis reveal"}, {"to": "26982", "prefix": "led an association between susceptibility to biochemical myopathy on high-dose ", "from": "26972", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3922121", "exact": "simvastatin", "suffix": " and a common reduced-function variant in SLCO1B1, namely c.521T"}, {"to": "27548", "prefix": "estingly, the SEARCH study showed a link between this SNP and reduced risk for ", "from": "27538", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3922121", "exact": "simvastatin", "suffix": "-associated myopathy4. In our population, the SLCO1B1 c.521T"}, {"to": "30191", "prefix": "P3A inhibitors and statins metabolized by CYP3A, particularly atorvastatin and ", "from": "30181", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3922121", "exact": "simvastatin", "suffix": ". The US Food and Drug Administration (US FDA) recommendations advocate for a re"}, {"to": "26826", "prefix": "sma concentrations of such statins as atorvastatin, rosuvastatin, simvastatin, ", "from": "26816", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC3922121", "exact": "pravastatin", "suffix": ", and pitavastatin19-22. Importantly, a genome-wide analysis revealed an associa"}, {"to": "1716", "prefix": "gh triglyceride and fasting blood glucose levels, low high-density lipoprotein ", "from": "1706", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3571969", "exact": "cholesterol", "suffix": " (HDL-C), raised blood pressure and the presence of treated hypertension or type"}, {"to": "2893", "prefix": "", "from": "2883", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3571969", "exact": "cholesterol", "suffix": ", LDL-C, triglycerides, HDL-C), which appears to confer additional cardiovascula"}, {"to": "5268", "prefix": ".\n\nHis values were: total ", "from": "5258", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3571969", "exact": "cholesterol", "suffix": " 277.7 mg"}, {"to": "7596", "prefix": ", but ", "from": "7586", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3571969", "exact": "cholesterol", "suffix": " showed further increase (310.5 mg"}, {"to": "7971", "prefix": "ptomatic at the second control. This time both the values of triglycerides and ", "from": "7961", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3571969", "exact": "cholesterol", "suffix": " showed improvement, 154.1 and 249.8 mg"}, {"to": "9711", "prefix": ". Serum ", "from": "9701", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3571969", "exact": "cholesterol", "suffix": " level remained elevated (257.2 mg"}, {"to": "10737", "prefix": "total ", "from": "10727", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3571969", "exact": "cholesterol", "suffix": " and triglycerides levels were 238.3 and 216.1 mg"}, {"to": "16484", "prefix": "of the more, than 3-fold higher triglyceride and the moderately elevated total ", "from": "16474", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3571969", "exact": "cholesterol", "suffix": " at the beginning. Third, unfortunately at the first blood test LDL-cholesterol "}, {"to": "16563", "prefix": "cholesterol at the beginning. Third, unfortunately at the first blood test LDL-", "from": "16553", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3571969", "exact": "cholesterol", "suffix": " could not have been evaluated because of the disturbing effect of raised trigly"}, {"to": "16706", "prefix": "ing effect of raised triglyceride. Later at the control blood tests only total ", "from": "16696", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3571969", "exact": "cholesterol", "suffix": " was measured. LDL-cholesterol is an essential parameter of cardiovascular risk "}, {"to": "16736", "prefix": "ide. Later at the control blood tests only total cholesterol was measured. LDL-", "from": "16726", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3571969", "exact": "cholesterol", "suffix": " is an essential parameter of cardiovascular risk stratification and must be the"}, {"to": "17961", "prefix": "ns\nMetS: Metabolic syndrome; TG: Triglyceride; HDL-C: High-density lipoprotein ", "from": "17951", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3571969", "exact": "cholesterol", "suffix": "; ESC"}, {"to": "3122", "prefix": "rapy is especially recommended in MetS and diabetes with the administration of ", "from": "3112", "name": "Fenofibrate", "fullId": "http://purl.bioontology.org/ontology/MESH/D011345", "setId": "PMC3571969", "exact": "fenofibrate", "suffix": " besides the statins [4].\n\nAlthough the use of statins considered to be safe, so"}, {"to": "6973", "prefix": "he high triglycerides and lack of lifestyle modification possibilities, 160 mg ", "from": "6963", "name": "Fenofibrate", "fullId": "http://purl.bioontology.org/ontology/MESH/D011345", "setId": "PMC3571969", "exact": "fenofibrate", "suffix": " per day was applied. The patient was also informed about the possible side-effe"}, {"to": "12407", "prefix": "e main cause of it was probably the atrovastatin as compared with gemfibrozil, ", "from": "12397", "name": "Fenofibrate", "fullId": "http://purl.bioontology.org/ontology/MESH/D011345", "setId": "PMC3571969", "exact": "fenofibrate", "suffix": " were found to be less prone to make complications when used together with stati"}, {"to": "12547", "prefix": " when used together with statins [28]. However, the pathophysiological role of ", "from": "12537", "name": "Fenofibrate", "fullId": "http://purl.bioontology.org/ontology/MESH/D011345", "setId": "PMC3571969", "exact": "fenofibrate", "suffix": " or the exaggerating effect in the extent of CK elevation cannot be excluded.\n\nO"}, {"to": "13929", "prefix": " [33]. ", "from": "13919", "name": "Fenofibrate", "fullId": "http://purl.bioontology.org/ontology/MESH/D011345", "setId": "PMC3571969", "exact": "Fenofibrate", "suffix": " is also glucuronidated by this enzyme [34]. Thus a varenicline-fenofibrate inte"}, {"to": "14004", "prefix": "3]. Fenofibrate is also glucuronidated by this enzyme [34]. Thus a varenicline-", "from": "13994", "name": "Fenofibrate", "fullId": "http://purl.bioontology.org/ontology/MESH/D011345", "setId": "PMC3571969", "exact": "fenofibrate", "suffix": " interaction is theoretically possible. In our case, 3 weeks after starting the "}, {"to": "14264", "prefix": " took altogether a 2-week dose of varenicline where in the second week he took ", "from": "14254", "name": "Fenofibrate", "fullId": "http://purl.bioontology.org/ontology/MESH/D011345", "setId": "PMC3571969", "exact": "fenofibrate", "suffix": " and atorvastatin, as well. The symptoms started two weeks after the stop of var"}, {"to": "16277", "prefix": "in the office of a general practitioner sometimes limit our success. Secondly, ", "from": "16267", "name": "Fenofibrate", "fullId": "http://purl.bioontology.org/ontology/MESH/D011345", "setId": "PMC3571969", "exact": "fenofibrate", "suffix": " was administered first instead of atrovastatin. This choice also can be debated"}, {"to": "16913", "prefix": "f the general laboratory protocol.\n\nGo to:\nConclusions\nIn conclusion, although ", "from": "16903", "name": "Fenofibrate", "fullId": "http://purl.bioontology.org/ontology/MESH/D011345", "setId": "PMC3571969", "exact": "fenofibrate", "suffix": " and statin combination therapy is supposed to be safe, myopathy, myositis and r"}, {"to": "5112", "prefix": "per week. His hypertension started 10 years ago and was controlled with 2.5 mg ", "from": "5104", "name": "nebivolol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/31555", "setId": "PMC3571969", "exact": "nebivolol", "suffix": " per day. He was a blue-collar worker in a storehouse, and sometimes did manual "}, {"to": "14594", "prefix": "at are metabolized through CYP 450. [4] Although the aromatic hydroxylation of ", "from": "14586", "name": "nebivolol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/31555", "setId": "PMC3571969", "exact": "nebivolol", "suffix": " takes place in CYP 2D6 [35], a single nucleotid polymorphism of this type of cy"}, {"to": "14848", "prefix": "h statin-induced muscle effects [36]. Although interaction between statins and ", "from": "14840", "name": "nebivolol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/31555", "setId": "PMC3571969", "exact": "nebivolol", "suffix": " has not been published yet, nebivolol might have influenced the development of "}, {"to": "14886", "prefix": "Although interaction between statins and nebivolol has not been published yet, ", "from": "14878", "name": "nebivolol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/31555", "setId": "PMC3571969", "exact": "nebivolol", "suffix": " might have influenced the development of rhabdomyolysis in our patient. Unfortu"}, {"to": "17368", "prefix": "e safe together with lipid lowering medications. The incidental interaction of ", "from": "17360", "name": "nebivolol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/31555", "setId": "PMC3571969", "exact": "nebivolol", "suffix": " with statins or fibrates is also need to be clarified in the future. Moreover, "}, {"to": "5778", "prefix": ", ", "from": "5772", "name": "Alanine", "fullId": "http://purl.bioontology.org/ontology/MESH/D000409", "setId": "PMC3571969", "exact": "alanine", "suffix": " transaminase (ALT) and gamma glutamyl transpeptidase (GGT) were in the normal r"}, {"to": "18107", "prefix": "therosclerosis Society; CK: Creatine kinase; AST: Aspartate transaminase; ALT: ", "from": "18101", "name": "Alanine", "fullId": "http://purl.bioontology.org/ontology/MESH/D000409", "setId": "PMC3571969", "exact": "Alanine", "suffix": " transaminases; GGT: Gamma glutamyl transpeptidase; LDH: Lactate dehydrogenase; "}, {"to": "5941", "prefix": "blood ", "from": "5938", "name": "Urea", "fullId": "http://purl.bioontology.org/ontology/MESH/D014508", "setId": "PMC3571969", "exact": "urea", "suffix": " nitrogen: 7.6 mmol"}, {"to": "5980", "prefix": "l, serum ", "from": "5971", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003404", "setId": "PMC3571969", "exact": "creatinine", "suffix": ": 97 "}, {"to": "6469", "prefix": "except for ", "from": "6463", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "PMC3571969", "exact": "aspirin", "suffix": ", because of bad family experience). About lifestyle modifications he did not se"}, {"to": "7119", "prefix": "t the possible side-effects of the lipid-lowering therapy. Because of smoking, ", "from": "7109", "name": "varenicline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/591622", "setId": "PMC3571969", "exact": "varenicline", "suffix": " therapy was prescribed as well, as the patient previously failed to give up smo"}, {"to": "7376", "prefix": "one-month control without any symptoms, and mentioned that he had begun taking ", "from": "7366", "name": "varenicline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/591622", "setId": "PMC3571969", "exact": "varenicline", "suffix": " only one week earlier. Laboratory parameters revealed the efficacy of the thera"}, {"to": "8594", "prefix": "At the time of the control he had no muscle complaints.\n\nHe had stopped taking ", "from": "8584", "name": "varenicline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/591622", "setId": "PMC3571969", "exact": "varenicline", "suffix": " after 2 weeks, and had taken the three types of medicines together (statin, fib"}, {"to": "8694", "prefix": "statin, fibrate and ", "from": "8684", "name": "varenicline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/591622", "setId": "PMC3571969", "exact": "varenicline", "suffix": ") only one week long. He did not smoke since then. The irregular moderate alcoho"}, {"to": "10990", "prefix": ", takes 1 gram omega-3 fatty acid per day, and thanks to the ", "from": "10980", "name": "varenicline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/591622", "setId": "PMC3571969", "exact": "varenicline", "suffix": " therapy he does not smoke.\n\nThe diagnosis of drug-induced myositis was reported"}, {"to": "13650", "prefix": "hether the statin-fibrate therapy-induced rhabdomyolysis could be connected to ", "from": "13640", "name": "varenicline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/591622", "setId": "PMC3571969", "exact": "varenicline", "suffix": " intake. The theoretical background of this interaction is based on the observat"}, {"to": "13809", "prefix": "he observation of Obrach et al., who found two metabolites in human excreta of ", "from": "13799", "name": "varenicline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/591622", "setId": "PMC3571969", "exact": "varenicline", "suffix": ": one of them is the N-carbamoylglucuronide, catalyzed by the UDP-glucuronosyltr"}, {"to": "13992", "prefix": " [33]. Fenofibrate is also glucuronidated by this enzyme [34]. Thus a ", "from": "13982", "name": "varenicline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/591622", "setId": "PMC3571969", "exact": "varenicline", "suffix": "-fenofibrate interaction is theoretically possible. In our case, 3 weeks after s"}, {"to": "14137", "prefix": "our case, 3 weeks after starting the fibrate therapy the patient began to take ", "from": "14127", "name": "varenicline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/591622", "setId": "PMC3571969", "exact": "varenicline", "suffix": ", and one week later atorvastatin. He took altogether a 2-week dose of varenicli"}, {"to": "14219", "prefix": "enicline, and one week later atorvastatin. He took altogether a 2-week dose of ", "from": "14209", "name": "varenicline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/591622", "setId": "PMC3571969", "exact": "varenicline", "suffix": " where in the second week he took fenofibrate and atorvastatin, as well. The sym"}, {"to": "14352", "prefix": "te and atorvastatin, as well. The symptoms started two weeks after the stop of ", "from": "14342", "name": "varenicline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/591622", "setId": "PMC3571969", "exact": "varenicline", "suffix": ", so it probably had no role in the side effect.\n\nStatin-fibrate combination sho"}, {"to": "7758", "prefix": " high cardiovascular risk of the patient due to MetS into consideration, 20 mg ", "from": "7747", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3571969", "exact": "atorvastatin", "suffix": " per day was added to the therapy. Similarly, a control laboratory test was set "}, {"to": "14170", "prefix": " the fibrate therapy the patient began to take varenicline, and one week later ", "from": "14159", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3571969", "exact": "atorvastatin", "suffix": ". He took altogether a 2-week dose of varenicline where in the second week he to"}, {"to": "14281", "prefix": " a 2-week dose of varenicline where in the second week he took fenofibrate and ", "from": "14270", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3571969", "exact": "atorvastatin", "suffix": ", as well. The symptoms started two weeks after the stop of varenicline, so it p"}, {"to": "9345", "prefix": ". The ", "from": "9339", "name": "Lactate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114202", "setId": "PMC3571969", "exact": "lactate", "suffix": " dehydrogenase (LDH) level was also increased, 463 U"}, {"to": "18171", "prefix": "saminase; ALT: Alanine transaminases; GGT: Gamma glutamyl transpeptidase; LDH: ", "from": "18165", "name": "Lactate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114202", "setId": "PMC3571969", "exact": "Lactate", "suffix": " dehydrogenase; CYP: Cytochrome P enzyme; GFR: Glomerular filtration rate.\n\nGo t"}, {"to": "9938", "prefix": "", "from": "9912", "name": "Thyrotropin", "fullId": "http://purl.bioontology.org/ontology/MESH/D013972", "setId": "PMC3571969", "exact": "thyroid-stimulating hormone", "suffix": " 1.42 "}, {"to": "12394", "prefix": "tarted but the main cause of it was probably the atrovastatin as compared with ", "from": "12384", "name": "Gemfibrozil", "fullId": "http://purl.bioontology.org/ontology/MESH/D015248", "setId": "PMC3571969", "exact": "gemfibrozil", "suffix": ", fenofibrate were found to be less prone to make complications when used togeth"}, {"to": "13480", "prefix": "12.7-38.1 ml of ", "from": "13474", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/448", "setId": "PMC3571969", "exact": "ethanol", "suffix": " per day in men) it was not found to be harmful [24].\n\nAnother question arises w"}, {"to": "32", "prefix": "Abstract\nBackground\n\n", "from": "22", "name": "sitagliptin", "fullId": "http://purl.bioontology.org/ontology/MESH/C496398", "setId": "PMC2602841", "exact": "Sitagliptin", "suffix": " is a new oral glucose lowering medication which acts via the incretin hormone s"}, {"to": "514", "prefix": "ped leg pain, weakness, and tenderness after starting treatment with high dose ", "from": "504", "name": "sitagliptin", "fullId": "http://purl.bioontology.org/ontology/MESH/C496398", "setId": "PMC2602841", "exact": "sitagliptin", "suffix": " while on simvastatin. The patient had acute renal failure and rhabdomyolysis wh"}, {"to": "636", "prefix": "nt had acute renal failure and rhabdomyolysis which resolved with cessation of ", "from": "626", "name": "sitagliptin", "fullId": "http://purl.bioontology.org/ontology/MESH/C496398", "setId": "PMC2602841", "exact": "sitagliptin", "suffix": ", simvastatin, ezetimibe, diuretics and olmesartan. All drugs except sitagliptin"}, {"to": "716", "prefix": "itagliptin, simvastatin, ezetimibe, diuretics and olmesartan. All drugs except ", "from": "706", "name": "sitagliptin", "fullId": "http://purl.bioontology.org/ontology/MESH/C496398", "setId": "PMC2602841", "exact": "sitagliptin", "suffix": " and ezetimibe, simvastatin were resumed, and the patient was subsequently start"}, {"to": "890", "prefix": "n lovastatin without recurrence of rhabdomyolysis.\n\nConclusions\n\nHigh doses of ", "from": "880", "name": "sitagliptin", "fullId": "http://purl.bioontology.org/ontology/MESH/C496398", "setId": "PMC2602841", "exact": "sitagliptin", "suffix": " may have worsened this patient's renal failure and precipitated rhabdomyolysis "}, {"to": "1061", "prefix": "y increasing circulating levels of simvastatin. Given the high likelihood that ", "from": "1051", "name": "sitagliptin", "fullId": "http://purl.bioontology.org/ontology/MESH/C496398", "setId": "PMC2602841", "exact": "sitagliptin", "suffix": " will be co-administered with statins and renally active medications, further st"}, {"to": "1179", "prefix": "h statins and renally active medications, further study of long-term safety of ", "from": "1169", "name": "sitagliptin", "fullId": "http://purl.bioontology.org/ontology/MESH/C496398", "setId": "PMC2602841", "exact": "sitagliptin", "suffix": " in renal sufficiency may be warranted.\n\nGo to:\nIntroduction\nSitagliptin, a new "}, {"to": "1251", "prefix": "ety of sitagliptin in renal sufficiency may be warranted.\n\nGo to:\nIntroduction\n", "from": "1241", "name": "sitagliptin", "fullId": "http://purl.bioontology.org/ontology/MESH/C496398", "setId": "PMC2602841", "exact": "Sitagliptin", "suffix": ", a new oral glucose lowering medication, is already used widely for treatment o"}, {"to": "1610", "prefix": "n secretion and decreased glucagon production. The most common side effects of ", "from": "1600", "name": "sitagliptin", "fullId": "http://purl.bioontology.org/ontology/MESH/C496398", "setId": "PMC2602841", "exact": "sitagliptin", "suffix": " include headache and pharyngitis, and few serious adverse events were observed "}, {"to": "2074", "prefix": "nstration of safety in renal insufficiency. Single dose studies suggested that ", "from": "2064", "name": "sitagliptin", "fullId": "http://purl.bioontology.org/ontology/MESH/C496398", "setId": "PMC2602841", "exact": "sitagliptin", "suffix": " may be used in the setting of renal insufficiency, but data regarding its long-"}, {"to": "2344", "prefix": "developed acute renal failure and rhabdomyolysis after starting treatment with ", "from": "2334", "name": "sitagliptin", "fullId": "http://purl.bioontology.org/ontology/MESH/C496398", "setId": "PMC2602841", "exact": "sitagliptin", "suffix": ".\n\nHistory and Examination\n\nA 76 year-old man presented to clinic with 2 weeks o"}, {"to": "2995", "prefix": "mg daily and ezetimibe 10 mg daily was added without incident. He began taking ", "from": "2985", "name": "sitagliptin", "fullId": "http://purl.bioontology.org/ontology/MESH/C496398", "setId": "PMC2602841", "exact": "sitagliptin", "suffix": " 50 mg daily 6 weeks prior to presentation, increasing his dose 3 weeks later to"}, {"to": "3120", "prefix": "ntation, increasing his dose 3 weeks later to 100 mg daily. One week after the ", "from": "3110", "name": "sitagliptin", "fullId": "http://purl.bioontology.org/ontology/MESH/C496398", "setId": "PMC2602841", "exact": "sitagliptin", "suffix": " dose was increased, he noted the onset of pain and tenderness in both thighs. T"}, {"to": "3609", "prefix": "habdomyolysis and acute renal failure, and olmesartan, bumetanide, metolazone, ", "from": "3599", "name": "sitagliptin", "fullId": "http://purl.bioontology.org/ontology/MESH/C496398", "setId": "PMC2602841", "exact": "sitagliptin", "suffix": ", simvastatin, and ezetimibe were all stopped. His creatine kinase levels fell, "}, {"to": "3844", "prefix": "e within 7 days. He resumed all medications except simvastatin, ezetimibe, and ", "from": "3834", "name": "sitagliptin", "fullId": "http://purl.bioontology.org/ontology/MESH/C496398", "setId": "PMC2602841", "exact": "sitagliptin", "suffix": ". He later started lovastatin which was increased to a dose of 10 mg daily witho"}, {"to": "4043", "prefix": "is.\n\nGo to:\nDiscussion\nRhabdomyolysis was not reported in clinical trials with ", "from": "4033", "name": "sitagliptin", "fullId": "http://purl.bioontology.org/ontology/MESH/C496398", "setId": "PMC2602841", "exact": "sitagliptin", "suffix": ", although it is a well-documented side effect of statins. The reaction is thoug"}, {"to": "4332", "prefix": " increase the risk of myopathy. At presentation, the patient was taking 100 mg ", "from": "4322", "name": "sitagliptin", "fullId": "http://purl.bioontology.org/ontology/MESH/C496398", "setId": "PMC2602841", "exact": "sitagliptin", "suffix": ", double the recommended dose given his renal function. (1) High serum concentra"}, {"to": "4432", "prefix": " High serum concentrations of ", "from": "4422", "name": "sitagliptin", "fullId": "http://purl.bioontology.org/ontology/MESH/C496398", "setId": "PMC2602841", "exact": "sitagliptin", "suffix": " were achieved following single doses in healthy patients without adverse effect"}, {"to": "4620", "prefix": "hase II trials. Drug half-life was observed to decrease and renal clearance of ", "from": "4610", "name": "sitagliptin", "fullId": "http://purl.bioontology.org/ontology/MESH/C496398", "setId": "PMC2602841", "exact": "sitagliptin", "suffix": " was preserved. (2) However, both the maximum serum concentration and terminal h"}, {"to": "4723", "prefix": " However, both the maximum serum concentration and terminal half-life of ", "from": "4713", "name": "sitagliptin", "fullId": "http://purl.bioontology.org/ontology/MESH/C496398", "setId": "PMC2602841", "exact": "sitagliptin", "suffix": " are increased in renal insufficiency, and the maximum recommended doses are 50 "}, {"to": "5070", "prefix": " suggesting that elevated doses of ", "from": "5060", "name": "sitagliptin", "fullId": "http://purl.bioontology.org/ontology/MESH/C496398", "setId": "PMC2602841", "exact": "sitagliptin", "suffix": " may result in renal injury in humans. We suspect that initiation of sitagliptin"}, {"to": "5150", "prefix": "itagliptin may result in renal injury in humans. We suspect that initiation of ", "from": "5140", "name": "sitagliptin", "fullId": "http://purl.bioontology.org/ontology/MESH/C496398", "setId": "PMC2602841", "exact": "sitagliptin", "suffix": " and escalation of dose in this patient may have produced prolonged, elevated si"}, {"to": "5239", "prefix": "n and escalation of dose in this patient may have produced prolonged, elevated ", "from": "5229", "name": "sitagliptin", "fullId": "http://purl.bioontology.org/ontology/MESH/C496398", "setId": "PMC2602841", "exact": "sitagliptin", "suffix": " levels resulting in decreased renal function and precipitating rhabdomyolysis b"}, {"to": "5395", "prefix": "abdomyolysis by increasing circulating simvastatin levels.\n\nThe association of ", "from": "5385", "name": "sitagliptin", "fullId": "http://purl.bioontology.org/ontology/MESH/C496398", "setId": "PMC2602841", "exact": "sitagliptin", "suffix": " and renal insufficiency in this case is classified as "}, {"to": "5588", "prefix": " There is no published data regarding the safety of chronic administration of ", "from": "5578", "name": "sitagliptin", "fullId": "http://purl.bioontology.org/ontology/MESH/C496398", "setId": "PMC2602841", "exact": "sitagliptin", "suffix": " with renal insufficiency in humans, but analysis of reports involving sitaglipt"}, {"to": "5670", "prefix": "agliptin with renal insufficiency in humans, but analysis of reports involving ", "from": "5660", "name": "sitagliptin", "fullId": "http://purl.bioontology.org/ontology/MESH/C496398", "setId": "PMC2602841", "exact": "sitagliptin", "suffix": " submitted through the FDA's Adverse Event Reporting System (AERS) until Septemb"}, {"to": "5963", "prefix": " cases involving renal injury, ", "from": "5953", "name": "sitagliptin", "fullId": "http://purl.bioontology.org/ontology/MESH/C496398", "setId": "PMC2602841", "exact": "sitagliptin", "suffix": " was designated as the "}, {"to": "6076", "prefix": " drug. Patients' condition improved with discontinuation of ", "from": "6066", "name": "sitagliptin", "fullId": "http://purl.bioontology.org/ontology/MESH/C496398", "setId": "PMC2602841", "exact": "sitagliptin", "suffix": " in 20 cases and returned on rechallenge in 1 case. In 40"}, {"to": "6755", "prefix": "s renal function, suggesting that this event was precipitated by initiation of ", "from": "6745", "name": "sitagliptin", "fullId": "http://purl.bioontology.org/ontology/MESH/C496398", "setId": "PMC2602841", "exact": "sitagliptin", "suffix": " therapy.\n\nGo to:\nConclusions\nGiven the high likelihood that sitagliptin will be"}, {"to": "6827", "prefix": "ion of sitagliptin therapy.\n\nGo to:\nConclusions\nGiven the high likelihood that ", "from": "6817", "name": "sitagliptin", "fullId": "http://purl.bioontology.org/ontology/MESH/C496398", "setId": "PMC2602841", "exact": "sitagliptin", "suffix": " will be co-administered with renally active drugs and statins in many diabetic "}, {"to": "7007", "prefix": "our findings suggest that additional studies regarding the long-term safety of ", "from": "6997", "name": "sitagliptin", "fullId": "http://purl.bioontology.org/ontology/MESH/C496398", "setId": "PMC2602841", "exact": "sitagliptin", "suffix": " in renal insufficiency may be warranted.\n\nGo to:\nAcknowledgements\nDavid Kao is "}, {"to": "535", "prefix": "s, and tenderness after starting treatment with high dose sitagliptin while on ", "from": "525", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2602841", "exact": "simvastatin", "suffix": ". The patient had acute renal failure and rhabdomyolysis which resolved with ces"}, {"to": "649", "prefix": "renal failure and rhabdomyolysis which resolved with cessation of sitagliptin, ", "from": "639", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2602841", "exact": "simvastatin", "suffix": ", ezetimibe, diuretics and olmesartan. All drugs except sitagliptin and ezetimib"}, {"to": "743", "prefix": "etimibe, diuretics and olmesartan. All drugs except sitagliptin and ezetimibe, ", "from": "733", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2602841", "exact": "simvastatin", "suffix": " were resumed, and the patient was subsequently started on lovastatin without re"}, {"to": "1017", "prefix": "al failure and precipitated rhabdomyolysis by increasing circulating levels of ", "from": "1007", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2602841", "exact": "simvastatin", "suffix": ". Given the high likelihood that sitagliptin will be co-administered with statin"}, {"to": "2799", "prefix": "edilol, insulin, metolazone, amiodarone, bumetanide, glipizide, levothyroxine, ", "from": "2789", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2602841", "exact": "simvastatin", "suffix": ", and ezetimibe. Four months prior to presentation, his simvastatin dose had bee"}, {"to": "2866", "prefix": "othyroxine, simvastatin, and ezetimibe. Four months prior to presentation, his ", "from": "2856", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2602841", "exact": "simvastatin", "suffix": " dose had been increased from 40 to 80 mg daily and ezetimibe 10 mg daily was ad"}, {"to": "3622", "prefix": " and acute renal failure, and olmesartan, bumetanide, metolazone, sitagliptin, ", "from": "3612", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2602841", "exact": "simvastatin", "suffix": ", and ezetimibe were all stopped. His creatine kinase levels fell, his symptoms "}, {"to": "3816", "prefix": "function returned to baseline within 7 days. He resumed all medications except ", "from": "3806", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2602841", "exact": "simvastatin", "suffix": ", ezetimibe, and sitagliptin. He later started lovastatin which was increased to"}, {"to": "5355", "prefix": "ased renal function and precipitating rhabdomyolysis by increasing circulating ", "from": "5345", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2602841", "exact": "simvastatin", "suffix": " levels.\n\nThe association of sitagliptin and renal insufficiency in this case is"}, {"to": "6579", "prefix": "ncurrent medications had been stable for months, and the patient had tolerated ", "from": "6569", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2602841", "exact": "simvastatin", "suffix": " and ezetemibe for at least 4 months prior to the onset of symptoms or worsening"}, {"to": "660", "prefix": " and rhabdomyolysis which resolved with cessation of sitagliptin, simvastatin, ", "from": "652", "name": "ezetimibe", "fullId": "http://purl.bioontology.org/ontology/MESH/C108606", "setId": "PMC2602841", "exact": "ezetimibe", "suffix": ", diuretics and olmesartan. All drugs except sitagliptin and ezetimibe, simvasta"}, {"to": "730", "prefix": "astatin, ezetimibe, diuretics and olmesartan. All drugs except sitagliptin and ", "from": "722", "name": "ezetimibe", "fullId": "http://purl.bioontology.org/ontology/MESH/C108606", "setId": "PMC2602841", "exact": "ezetimibe", "suffix": ", simvastatin were resumed, and the patient was subsequently started on lovastat"}, {"to": "2814", "prefix": "metolazone, amiodarone, bumetanide, glipizide, levothyroxine, simvastatin, and ", "from": "2806", "name": "ezetimibe", "fullId": "http://purl.bioontology.org/ontology/MESH/C108606", "setId": "PMC2602841", "exact": "ezetimibe", "suffix": ". Four months prior to presentation, his simvastatin dose had been increased fro"}, {"to": "2927", "prefix": "esentation, his simvastatin dose had been increased from 40 to 80 mg daily and ", "from": "2919", "name": "ezetimibe", "fullId": "http://purl.bioontology.org/ontology/MESH/C108606", "setId": "PMC2602841", "exact": "ezetimibe", "suffix": " 10 mg daily was added without incident. He began taking sitagliptin 50 mg daily"}, {"to": "3637", "prefix": "failure, and olmesartan, bumetanide, metolazone, sitagliptin, simvastatin, and ", "from": "3629", "name": "ezetimibe", "fullId": "http://purl.bioontology.org/ontology/MESH/C108606", "setId": "PMC2602841", "exact": "ezetimibe", "suffix": " were all stopped. His creatine kinase levels fell, his symptoms improved, and h"}, {"to": "3827", "prefix": "rned to baseline within 7 days. He resumed all medications except simvastatin, ", "from": "3819", "name": "ezetimibe", "fullId": "http://purl.bioontology.org/ontology/MESH/C108606", "setId": "PMC2602841", "exact": "ezetimibe", "suffix": ", and sitagliptin. He later started lovastatin which was increased to a dose of "}, {"to": "686", "prefix": " resolved with cessation of sitagliptin, simvastatin, ezetimibe, diuretics and ", "from": "677", "name": "olmesartan", "fullId": "http://purl.bioontology.org/ontology/MESH/C437965", "setId": "PMC2602841", "exact": "olmesartan", "suffix": ". All drugs except sitagliptin and ezetimibe, simvastatin were resumed, and the "}, {"to": "2703", "prefix": "L. His medications included aspirin, clopidogrel, ", "from": "2694", "name": "olmesartan", "fullId": "http://purl.bioontology.org/ontology/MESH/C437965", "setId": "PMC2602841", "exact": "olmesartan", "suffix": ", carvedilol, insulin, metolazone, amiodarone, bumetanide, glipizide, levothyrox"}, {"to": "3572", "prefix": "ient was admitted to hospital with rhabdomyolysis and acute renal failure, and ", "from": "3563", "name": "olmesartan", "fullId": "http://purl.bioontology.org/ontology/MESH/C437965", "setId": "PMC2602841", "exact": "olmesartan", "suffix": ", bumetanide, metolazone, sitagliptin, simvastatin, and ezetimibe were all stopp"}, {"to": "812", "prefix": "etimibe, simvastatin were resumed, and the patient was subsequently started on ", "from": "803", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC2602841", "exact": "lovastatin", "suffix": " without recurrence of rhabdomyolysis.\n\nConclusions\n\nHigh doses of sitagliptin m"}, {"to": "3873", "prefix": "l medications except simvastatin, ezetimibe, and sitagliptin. He later started ", "from": "3864", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC2602841", "exact": "lovastatin", "suffix": " which was increased to a dose of 10 mg daily without recurrence of rhabdomyolys"}, {"to": "1463", "prefix": "ipeptidyl-peptidase IV enzyme thereby prolonging the post-prandial activity of ", "from": "1456", "name": "Glucagon", "fullId": "http://purl.bioontology.org/ontology/MESH/D005934", "setId": "PMC2602841", "exact": "glucagon", "suffix": "-like-peptide-1 (GLP-1). This results in increased insulin secretion and decreas"}, {"to": "1554", "prefix": ". This results in increased insulin secretion and decreased ", "from": "1547", "name": "Glucagon", "fullId": "http://purl.bioontology.org/ontology/MESH/D005934", "setId": "PMC2602841", "exact": "glucagon", "suffix": " production. The most common side effects of sitagliptin include headache and ph"}, {"to": "1521", "prefix": ". This results in increased ", "from": "1515", "name": "Insulin", "fullId": "http://purl.bioontology.org/ontology/MESH/D007328", "setId": "PMC2602841", "exact": "insulin", "suffix": " secretion and decreased glucagon production. The most common side effects of si"}, {"to": "2724", "prefix": "L. His medications included aspirin, clopidogrel, olmesartan, carvedilol, ", "from": "2718", "name": "Insulin", "fullId": "http://purl.bioontology.org/ontology/MESH/D007328", "setId": "PMC2602841", "exact": "insulin", "suffix": ", metolazone, amiodarone, bumetanide, glipizide, levothyroxine, simvastatin, and"}, {"to": "1912", "prefix": "dney as the primary organ of toxicity, and approval of its nearest competitor, ", "from": "1901", "name": "vildagliptin", "fullId": "http://purl.bioontology.org/ontology/MESH/C502012", "setId": "PMC2602841", "exact": "vildagliptin", "suffix": ", by the Federal Drug Administration (FDA) has been delayed pending demonstratio"}, {"to": "2630", "prefix": "rtery disease, atrial fibrillation, and chronic kidney disease with a baseline ", "from": "2621", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003404", "setId": "PMC2602841", "exact": "creatinine", "suffix": " of 204 "}, {"to": "3430", "prefix": "L, ", "from": "3421", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003404", "setId": "PMC2602841", "exact": "creatinine", "suffix": " 398 "}, {"to": "2678", "prefix": "L. His medications included ", "from": "2672", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "PMC2602841", "exact": "aspirin", "suffix": ", clopidogrel, olmesartan, carvedilol, insulin, metolazone, amiodarone, bumetani"}, {"to": "2691", "prefix": "L. His medications included aspirin, ", "from": "2681", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/MESH/C055162", "setId": "PMC2602841", "exact": "clopidogrel", "suffix": ", olmesartan, carvedilol, insulin, metolazone, amiodarone, bumetanide, glipizide"}, {"to": "2715", "prefix": "L. His medications included aspirin, clopidogrel, olmesartan, ", "from": "2706", "name": "carvedilol", "fullId": "http://purl.bioontology.org/ontology/MESH/C043211", "setId": "PMC2602841", "exact": "carvedilol", "suffix": ", insulin, metolazone, amiodarone, bumetanide, glipizide, levothyroxine, simvast"}, {"to": "2736", "prefix": "is medications included aspirin, clopidogrel, olmesartan, carvedilol, insulin, ", "from": "2727", "name": "Metolazone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6916", "setId": "PMC2602841", "exact": "metolazone", "suffix": ", amiodarone, bumetanide, glipizide, levothyroxine, simvastatin, and ezetimibe. "}, {"to": "3596", "prefix": "pital with rhabdomyolysis and acute renal failure, and olmesartan, bumetanide, ", "from": "3587", "name": "Metolazone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6916", "setId": "PMC2602841", "exact": "metolazone", "suffix": ", sitagliptin, simvastatin, and ezetimibe were all stopped. His creatine kinase "}, {"to": "2748", "prefix": "ns included aspirin, clopidogrel, olmesartan, carvedilol, insulin, metolazone, ", "from": "2739", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/MESH/D000638", "setId": "PMC2602841", "exact": "amiodarone", "suffix": ", bumetanide, glipizide, levothyroxine, simvastatin, and ezetimibe. Four months "}, {"to": "2760", "prefix": "aspirin, clopidogrel, olmesartan, carvedilol, insulin, metolazone, amiodarone, ", "from": "2751", "name": "Bumetanide", "fullId": "http://purl.bioontology.org/ontology/MESH/D002034", "setId": "PMC2602841", "exact": "bumetanide", "suffix": ", glipizide, levothyroxine, simvastatin, and ezetimibe. Four months prior to pre"}, {"to": "3584", "prefix": "itted to hospital with rhabdomyolysis and acute renal failure, and olmesartan, ", "from": "3575", "name": "Bumetanide", "fullId": "http://purl.bioontology.org/ontology/MESH/D002034", "setId": "PMC2602841", "exact": "bumetanide", "suffix": ", metolazone, sitagliptin, simvastatin, and ezetimibe were all stopped. His crea"}, {"to": "2771", "prefix": "pidogrel, olmesartan, carvedilol, insulin, metolazone, amiodarone, bumetanide, ", "from": "2763", "name": "Glipizide", "fullId": "http://purl.bioontology.org/ontology/MESH/D005913", "setId": "PMC2602841", "exact": "glipizide", "suffix": ", levothyroxine, simvastatin, and ezetimibe. Four months prior to presentation, "}, {"to": "2786", "prefix": "lmesartan, carvedilol, insulin, metolazone, amiodarone, bumetanide, glipizide, ", "from": "2774", "name": "levothyroxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10582", "setId": "PMC2602841", "exact": "levothyroxine", "suffix": ", simvastatin, and ezetimibe. Four months prior to presentation, his simvastatin"}, {"to": "3408", "prefix": "s and weakness of the proximal muscles in both legs. Laboratory tests revealed ", "from": "3405", "name": "Urea", "fullId": "http://purl.bioontology.org/ontology/MESH/D014508", "setId": "PMC2602841", "exact": "urea", "suffix": " 43 mmol"}, {"to": "94", "prefix": "P-glycoprotein inducer, ", "from": "85", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": ", on the pharmacokinetics of dabigatran following oral administration of the pro"}, {"to": "376", "prefix": "eers. Subjects received a single dose of dabigatran etexilate 150 mg on day 1, ", "from": "367", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " 600 mg once daily on days 2"}, {"to": "705", "prefix": ", administration of dabigatran etexilate following 7 days of ", "from": "696", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " (treatment B) decreased the geometric mean (gMean) area under the concentration"}, {"to": "1656", "prefix": "all safety profile of all treatments was good.\n\nCONCLUSIONS\n\nAdministration of ", "from": "1647", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " for 7 days resulted in a significant reduction in the bioavailability of dabiga"}, {"to": "1875", "prefix": "ys washout.\n\nKeywords: dabigatran etexilate, drug interaction, P-glycoprotein, ", "from": "1866", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": "\nWHAT IS ALREADY KNOWN ABOUT THIS SUBJECT\n\nDabigatran etexilate is an oral prodr"}, {"to": "2487", "prefix": "ltered by P-gp inhibitors or inducers.\nWHAT THIS STUDY ADDS\n\nAdministration of ", "from": "2478", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " (a strong P-gp inducer) for 7 days before a single dose of dabigatran etexilate"}, {"to": "2752", "prefix": "ration of dabigatran etexilate alone.\nWithin 7 days following the cessation of ", "from": "2743", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " administration, the bioavailability of dabigatran returned almost to baseline v"}, {"to": "2849", "prefix": "tration, the bioavailability of dabigatran returned almost to baseline values.\n", "from": "2840", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "Rifampicin", "suffix": " is not recommended for use with dabigatran etexilate because of the potential f"}, {"to": "4626", "prefix": "ibitors, such as quinidine, verapamil and amiodarone.\n\nThe antibacterial agent ", "from": "4617", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " (used primarily in the treatment of tuberculosis) is a strong inducer of intest"}, {"to": "4992", "prefix": "e of the trial was to determine whether, and to what extent, the P-gp inducer, ", "from": "4983", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": ", affects the plasma exposure of dabigatran by investigating the effect of multi"}, {"to": "5095", "prefix": "plasma exposure of dabigatran by investigating the effect of multiple doses of ", "from": "5086", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " 600 mg once daily on the PK parameters of dabigatran following a single dose of"}, {"to": "5386", "prefix": "hich could be interpreted as normal activity levels of P-gp after induction by ", "from": "5377", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": ". The doses selected for investigation reflect standard clinical doses of rifamp"}, {"to": "5470", "prefix": "picin. The doses selected for investigation reflect standard clinical doses of ", "from": "5461", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " and dabigatran etexilate, and were expected to allow an adequate determination "}, {"to": "5634", "prefix": "tion of the PK parameters of dabigatran after P-gp induction. The induction by ", "from": "5625", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " was to be confirmed further by measurement of a surrogate end-point, the urinar"}, {"to": "5964", "prefix": "ary objectives were to determine the safety and tolerability of dabigatran and ", "from": "5955", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " coadministration, and to determine the duration of the effect of P-gp induction"}, {"to": "6074", "prefix": "d to determine the duration of the effect of P-gp induction after cessation of ", "from": "6065", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " treatment. If an interaction between rifampicin and dabigatran was observed, it"}, {"to": "6122", "prefix": "p induction after cessation of rifampicin treatment. If an interaction between ", "from": "6113", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " and dabigatran was observed, it was expected that this would lead to decreased "}, {"to": "6519", "prefix": "atran etexilate given as single doses, either alone or after multiple doses of ", "from": "6510", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": ", or after cessation of rifampicin. Twenty-four subjects were to be enrolled, wi"}, {"to": "6553", "prefix": "ses, either alone or after multiple doses of rifampicin, or after cessation of ", "from": "6544", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": ". Twenty-four subjects were to be enrolled, with at least eight of each sex. The"}, {"to": "7192", "prefix": " was administered as 150 mg hydroxypropyl methylcellulose capsules. ", "from": "7183", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "Rifampicin", "suffix": " was administered as the commercially available Rifa"}, {"to": "7590", "prefix": ", ", "from": "7581", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " 600 mg once daily administered for 7 days (days 2"}, {"to": "7703", "prefix": " in the evening at 20.00 h, with the last dose of ", "from": "7694", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " given 12 h before dabigatran etexilate 150 mg administered on day 9 (test 1); p"}, {"to": "7900", "prefix": "gle dose of dabigatran etexilate 150 mg administered on day 16 after 7 days of ", "from": "7891", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " washout (test 2); and period 4 (treatment D), a single dose of dabigatran etexi"}, {"to": "8042", "prefix": "le dose of dabigatran etexilate 150 mg administered on day 23 after 14 days of ", "from": "8033", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " washout (test 3).\n\nFigure 1\nFigure 1\nAdministration of trial medication (upper "}, {"to": "8303", "prefix": ". Dabigatran etexilate was always given in the morning at 08.00 h. ", "from": "8294", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "Rifampicin", "suffix": " was always administered in ...\nA screening examination (visit 1) was performed "}, {"to": "9233", "prefix": "abolic, immunological or hormonal disorders, risk of bleeding, previous use of ", "from": "9224", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " or other P-gp or CYP450 inhibitors"}, {"to": "9634", "prefix": "single dose of dabigatran etexilate 150 mg after multiple doses of ", "from": "9625", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " 600 mg) vs. reference treatment A (single dose of dabigatran etexilate 150 mg b"}, {"to": "9734", "prefix": "single dose of dabigatran etexilate 150 mg before any ", "from": "9725", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " treatment), with "}, {"to": "10052", "prefix": "se of dabigatran etexilate 150 mg after 7 days of washout since last intake of ", "from": "10043", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " 600 mg) and reference treatment A, and between treatment D (single dose of dabi"}, {"to": "10213", "prefix": " of dabigatran etexilate 150 mg after 14 days washout after the last intake of ", "from": "10204", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " 600 mg) and reference treatment A.\n\nThe secondary PK end-points included AUC0"}, {"to": "10531", "prefix": "-hydroxycortisol to cortisol as a marker of induction of CYP3A4 by ", "from": "10522", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " and an evaluation of safety were other secondary end-points.\n\nPharmacokinetic d"}, {"to": "13259", "prefix": ". Samples were taken in the morning after subjects had received three doses of ", "from": "13250", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " during treatment B and before administration of dabigatran in each respective t"}, {"to": "13920", "prefix": " at all spiked concentrations. Induction of CYP3A by ", "from": "13911", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " was assessed by the change in the ratio of 6"}, {"to": "14036", "prefix": "cortisol after a 7 day treatment of 600 mg ", "from": "14027", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " once daily and after cessation of rifampicin, compared with the ratio at baseli"}, {"to": "14081", "prefix": "after a 7 day treatment of 600 mg rifampicin once daily and after cessation of ", "from": "14072", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": ", compared with the ratio at baseline before the administration of rifampicin.\n\n"}, {"to": "14158", "prefix": "f rifampicin, compared with the ratio at baseline before the administration of ", "from": "14149", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": ".\n\nSafety\n\nSafety was assessed by medical examination, pulse rate, blood pressur"}, {"to": "15662", "prefix": " and ", "from": "15653", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " 600 mg for 7 days (period 2); the other two subjects received dabigatran etexil"}, {"to": "15821", "prefix": " and ", "from": "15812", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " 600 mg for 7 days (period 2).\n\nPharmacokinetic parameters\n\nThe shapes of the pl"}, {"to": "16127", "prefix": "bigatran after administration of dabigatran etexilate 150 mg, with and without ", "from": "16118", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": ", are shown in Table 1.\n\nFigure 2\nFigure 2\nGeometric mean (gMean) plasma concent"}, {"to": "16561", "prefix": "bigatran after administration of dabigatran etexilate 150 mg, with and without ", "from": "16552", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": "\nRelative to the reference treatment (dabigatran etexilate alone), the administr"}, {"to": "16678", "prefix": ", the administration of the P-gp inducer, ", "from": "16669", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": ", over 7 days (treatment B) resulted in a significant reduction in the exposure "}, {"to": "17301", "prefix": " effect of ", "from": "17292", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " on the total dabigatran exposure.\n\nTable 2\nTable 2\nGeometric means (gMeans) and"}, {"to": "17581", "prefix": " and after administration of multiple doses of ", "from": "17572", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " (test 1; treatment B)\nThe time to peak (tmax) and the terminal half-life (t1"}, {"to": "17693", "prefix": " were not affected by ", "from": "17684", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " administration. The tmax, t1"}, {"to": "17980", "prefix": "se of 150 mg dabigatran etexilate after a 7 day washout after the last dose of ", "from": "17971", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " (treatment C, day 16), AUC0"}, {"to": "18316", "prefix": " for Cmax. Fourteen days after the last administration of ", "from": "18307", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " (treatment D, day 23), the AUC0"}, {"to": "18968", "prefix": " or 1, 7 or 14 days after the last administration of ", "from": "18959", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " ...\nFor reference treatment A (day 1), male subjects had approximately 76% of t"}, {"to": "19153", "prefix": "% of the Cmax of female subjects in the trial. Following the administration of ", "from": "19144", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " over 7 days, the reduction in total dabigatran exposure was similar in male and"}, {"to": "19441", "prefix": " was not modulated by ", "from": "19432", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " administration. Furthermore, the prodrug (dabigatran etexilate) and the interme"}, {"to": "20018", "prefix": " after administration of dabigatran etexilate 150 mg, with and without ", "from": "20009", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": "\n6"}, {"to": "20317", "prefix": ", indicating CYP450 3A induction as a result of ", "from": "20308", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " administration. The urinary 6"}, {"to": "20521", "prefix": "ut had returned to baseline by day 23, 2 weeks after the end of treatment with ", "from": "20512", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": ".\n\nSafety\n\nAll 24 subjects who received at least one dose of study drug were inc"}, {"to": "20806", "prefix": " subjects during treatment with dabigatran etexilate plus ", "from": "20797", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " and two (8.3%) subjects during treatment with rifampicin alone (Table 4). In ad"}, {"to": "20863", "prefix": " subjects during treatment with ", "from": "20854", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " alone (Table 4). In addition, one subject (4.5%; 1 of 22) reported an AE during"}, {"to": "21260", "prefix": "dabigatran, two subjects; ", "from": "21251", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": ", one subject; and dabigatran plus rifampicin, three subjects). No other AEs wer"}, {"to": "21305", "prefix": "dabigatran, two subjects; rifampicin, one subject; and dabigatran plus ", "from": "21296", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": ", three subjects). No other AEs were reported during treatment with dabigatran a"}, {"to": "21497", "prefix": " during the dabigatran plus ", "from": "21488", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " period; dizziness, nausea, oropharyngeal pain, vomiting and fatigue (one subjec"}, {"to": "21606", "prefix": " during the ", "from": "21597", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " alone period; and nausea (one subject) during the washout after period 3.\n\nAll "}, {"to": "22431", "prefix": "ran may be affected by P-gp inhibitors [23]. In this study, a 1 week course of ", "from": "22422", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": ", a potent inducer of P-gp, decreased exposure to dabigatran by 67%.\n\nThe approv"}, {"to": "22732", "prefix": "8]. The present study investigated dabigatran etexilate 150 mg with or without ", "from": "22723", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " 600 mg once daily. These doses were selected because they reflected standard cl"}, {"to": "22884", "prefix": "ected standard clinical doses, and the plasma concentrations of dabigatran and ", "from": "22875", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " in this trial represent clinically relevant drug exposure. The selected dosing "}, {"to": "22986", "prefix": "l represent clinically relevant drug exposure. The selected dosing regimen for ", "from": "22977", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " (7 day treatment with cessation of treatment the evening, i.e. 12 h, before adm"}, {"to": "23213", "prefix": " maximal induction of P-gp without interference of inhibiting effects, because ", "from": "23204", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " was stopped after the last dose given in the evening before dabigatran administ"}, {"to": "23670", "prefix": "ters of dabigatran after P-gp induction.\n\nIn this study, the administration of ", "from": "23661", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " for 7 days resulted in a significant and relevant reduction in the bioavailabil"}, {"to": "24003", "prefix": "tran etexilate in healthy volunteers. Within 7 days following the cessation of ", "from": "23994", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " administration, the bioavailability of total dabigatran returned almost to base"}, {"to": "24213", "prefix": "f free dabigatran were influenced in a similar fashion.\n\nIn the present trial, ", "from": "24204", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " administration also induced CYP3A, as shown by an elevated urinary 6"}, {"to": "24421", "prefix": "ion has been documented to dissipate in about 2 weeks after discontinuation of ", "from": "24412", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " [25]. Indeed, in this trial, the urinary 6"}, {"to": "24662", "prefix": "ad returned to baseline levels 2 weeks after discontinuation of treatment with ", "from": "24653", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": ". The effect on dabigatran was highly comparable, which seems physiologically re"}, {"to": "24932", "prefix": "regnane X receptor [26].\n\nThe reduction of the total dabigatran exposure after ", "from": "24923", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " pretreatment seen in this trial was of similar magnitude or only slightly excee"}, {"to": "25225", "prefix": " of aliskiren or a 58% reduction in Cmax of digoxin after ", "from": "25216", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " treatment, the renal clearance and half-life of these drugs always remained una"}, {"to": "25515", "prefix": "ate is assumed to be absorbed mainly in the duodenum. The pronounced effect of ", "from": "25506", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " on dabigatran kinetics might, thus, be due to a remarkable increase in duodenal"}, {"to": "25657", "prefix": " after ", "from": "25648", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": ", as reported ex vivo[27] and in vitro[26]. An approximately 66% reduction in bi"}, {"to": "26865", "prefix": " there were sex differences in exposure to total dabigatran, administration of ", "from": "26856", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " for 7 days resulted in a similar percentage reduction in total dabigatran expos"}, {"to": "27132", "prefix": "bigatran etexilate was well tolerated when given alone and in combination with ", "from": "27123", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": ". The results were in line with the known safety profile of dabigatran etexilate"}, {"to": "27300", "prefix": "e.\n\nA reduction of two-thirds in dabigatran exposure due to a 1 week course of ", "from": "27291", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " has clinically relevant consequences. Patients undergoing orthopaedic surgery w"}, {"to": "27546", "prefix": "may not achieve therapeutic concentrations of dabigatran if they have received ", "from": "27537", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " immediately before surgery. Dabigatran etexilate is also indicated for stroke p"}, {"to": "27838", "prefix": " etexilate [13], the significant decrease in dabigatran exposure observed with ", "from": "27829", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " is likely to decrease the potential for stroke prevention. Concomitant treatmen"}, {"to": "27935", "prefix": "ly to decrease the potential for stroke prevention. Concomitant treatment with ", "from": "27926", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " and dabigatran should be avoided in these patients. The effect of concomitant a"}, {"to": "28380", "prefix": " compounds increasing warfarin clearance, such as carbamazepine, barbiturates, ", "from": "28371", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " and chronic alcohol [30]. Furthermore, the new factor Xa inhibitors rivaroxaban"}, {"to": "28531", "prefix": "bitors rivaroxaban and apixaban are expected to be affected by inducers of the ", "from": "28522", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " type because their clearance is dependent to a large extent on CYP3A4 and partl"}, {"to": "28681", "prefix": "on CYP3A4 and partly also on P-gp [18, 31].\n\nIn summary, the administration of ", "from": "28672", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": ", a P-gp inducer, for 7 days resulted in a statistically significant and potenti"}, {"to": "28939", "prefix": "tran etexilate in healthy volunteers. Within 7 days following the cessation of ", "from": "28930", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " administration, the bioavailability returned almost to baseline values. Owing t"}, {"to": "29090", "prefix": "ne values. Owing to the potential for reduced systemic exposure to dabigatran, ", "from": "29081", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3477350", "exact": "rifampicin", "suffix": " and other P-gp inducers (e.g. carbamazepine and St John's wort) are not recomme"}, {"to": "133", "prefix": "P-glycoprotein inducer, rifampicin, on the pharmacokinetics of ", "from": "124", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " following oral administration of the prodrug, dabigatran etexilate.\n\nMETHODS\n\nT"}, {"to": "865", "prefix": " of total ", "from": "856", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " by 67 and 65.5%, respectively. The time to peak and the terminal half-life were"}, {"to": "1201", "prefix": " for Cmax, indicating a significant effect on total ", "from": "1192", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " exposure (total pharmacologically active dabigatran represents the sum of nonco"}, {"to": "1253", "prefix": "total pharmacologically active ", "from": "1244", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " represents the sum of nonconjugated dabigatran and dabigatran glucuronide). Aft"}, {"to": "1300", "prefix": "total pharmacologically active dabigatran represents the sum of nonconjugated ", "from": "1291", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " and dabigatran glucuronide). After a 7 day (treatment C) or 14 day washout (tre"}, {"to": "1315", "prefix": "logically active dabigatran represents the sum of nonconjugated dabigatran and ", "from": "1306", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " glucuronide). After a 7 day (treatment C) or 14 day washout (treatment D), the "}, {"to": "1424", "prefix": " and Cmax of ", "from": "1415", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " were reduced by 18 and 20%, and by 15 and 20%, respectively, compared with trea"}, {"to": "1740", "prefix": "picin for 7 days resulted in a significant reduction in the bioavailability of ", "from": "1731", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": ", which returned almost to baseline after 7 days washout.\n\nKeywords: dabigatran "}, {"to": "1997", "prefix": " SUBJECT\n\nDabigatran etexilate is an oral prodrug that is rapidly converted to ", "from": "1988", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": ", a direct and reversible thrombin inhibitor.\nDabigatran etexilate and dabigatra"}, {"to": "2078", "prefix": "bigatran, a direct and reversible thrombin inhibitor.\nDabigatran etexilate and ", "from": "2069", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " are not metabolized by the cytochrome P450 system, and dabigatran does not affe"}, {"to": "2144", "prefix": "texilate and dabigatran are not metabolized by the cytochrome P450 system, and ", "from": "2135", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " does not affect the metabolism of other drugs that utilize this system, leading"}, {"to": "2312", "prefix": "drug interactions.\nDabigatran etexilate, but not ", "from": "2303", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": ", is a P-glycoprotein (P-gp) substrate, and the bioavailability of dabigatran ma"}, {"to": "2389", "prefix": " substrate, and the bioavailability of ", "from": "2380", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " may be altered by P-gp inhibitors or inducers.\nWHAT THIS STUDY ADDS\n\nAdministra"}, {"to": "2640", "prefix": "gatran etexilate resulted in a significant reduction in the bioavailability of ", "from": "2631", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " compared with administration of dabigatran etexilate alone.\nWithin 7 days follo"}, {"to": "2802", "prefix": "s following the cessation of rifampicin administration, the bioavailability of ", "from": "2793", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " returned almost to baseline values.\nRifampicin is not recommended for use with "}, {"to": "2971", "prefix": "dabigatran etexilate because of the potential for reduced systemic exposure to ", "from": "2962", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": ".\nGo to:\nIntroduction\nDabigatran etexilate is an oral prodrug that is rapidly co"}, {"to": "3144", "prefix": "ted via two intermediates, BIBR 1087 SE and BIBR 951 BS, to the active moiety, ", "from": "3135", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": ", a direct and reversible thrombin inhibitor. Dabigatran is partly conjugated wi"}, {"to": "3200", "prefix": " to the active moiety, dabigatran, a direct and reversible thrombin inhibitor. ", "from": "3191", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "Dabigatran", "suffix": " is partly conjugated with activated glucuronic acid to form a pharmacologically"}, {"to": "3320", "prefix": "vated glucuronic acid to form a pharmacologically equipotent glucuronide. Free ", "from": "3311", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " and total dabigatran (sum of free and glucuronidated dabigatran) reach peak pla"}, {"to": "3341", "prefix": " to form a pharmacologically equipotent glucuronide. Free dabigatran and total ", "from": "3332", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " (sum of free and glucuronidated dabigatran) reach peak plasma concentrations af"}, {"to": "3384", "prefix": "sum of free and glucuronidated ", "from": "3375", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": ") reach peak plasma concentrations after approximately 1.5 h, have a half-life o"}, {"to": "4017", "prefix": "13].\n\nDabigatran etexilate and ", "from": "4008", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " are not metabolized by the cytochrome P450 (CYP) system, and dabigatran does no"}, {"to": "4089", "prefix": " system, and ", "from": "4080", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " does not affect the metabolism of other drugs that utilize this system [2, 14"}, {"to": "4271", "prefix": "but not ", "from": "4262", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": ") is a P-glycoprotein (P-gp) substrate, and therefore the bioavailability of dab"}, {"to": "4358", "prefix": " substrate, and therefore the bioavailability of ", "from": "4349", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " following oral administration of dabigatran etexilate may be altered by P-gp in"}, {"to": "5035", "prefix": "d to what extent, the P-gp inducer, rifampicin, affects the plasma exposure of ", "from": "5026", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " by investigating the effect of multiple doses of rifampicin 600 mg once daily o"}, {"to": "5148", "prefix": "fect of multiple doses of rifampicin 600 mg once daily on the PK parameters of ", "from": "5139", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " following a single dose of 150 mg dabigatran etexilate. The study also evaluate"}, {"to": "5294", "prefix": "The study also evaluated the time course of a return to normal availability of ", "from": "5285", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": ", which could be interpreted as normal activity levels of P-gp after induction b"}, {"to": "5584", "prefix": ", and were expected to allow an adequate determination of the PK parameters of ", "from": "5575", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " after P-gp induction. The induction by rifampicin was to be confirmed further b"}, {"to": "5949", "prefix": "1].\n\nThe secondary objectives were to determine the safety and tolerability of ", "from": "5940", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " and rifampicin coadministration, and to determine the duration of the effect of"}, {"to": "6137", "prefix": "er cessation of rifampicin treatment. If an interaction between rifampicin and ", "from": "6128", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " was observed, it was expected that this would lead to decreased dabigatran expo"}, {"to": "6212", "prefix": "and dabigatran was observed, it was expected that this would lead to decreased ", "from": "6203", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " exposure.\n\nGo to:\nMethods\nStudy design and treatments\n\nThis study was an open-l"}, {"to": "9484", "prefix": " of total ", "from": "9475", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " (free plus conjugated). The primary comparison was between treatment B (single "}, {"to": "10321", "prefix": " and Cmax of free ", "from": "10312", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": ", and Cmax and time from dosing to maximal plasma concentration (tmax) of total "}, {"to": "10411", "prefix": " of total ", "from": "10402", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": ". The ratio of urinary concentrations of 6"}, {"to": "10654", "prefix": "other secondary end-points.\n\nPharmacokinetic determinations\n\nBlood samples for ", "from": "10645", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " PK measurements were collected before ("}, {"to": "10907", "prefix": "exilate in each treatment period. Plasma concentrations of free, nonconjugated ", "from": "10898", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": ", total dabigatran [sum of free and conjugated dabigatran (measured after alkali"}, {"to": "10925", "prefix": "eatment period. Plasma concentrations of free, nonconjugated dabigatran, total ", "from": "10916", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " [sum of free and conjugated dabigatran (measured after alkaline cleavage of con"}, {"to": "10964", "prefix": "f free, nonconjugated dabigatran, total dabigatran [sum of free and conjugated ", "from": "10955", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " (measured after alkaline cleavage of conjugates)], the prodrug, dabigatran etex"}, {"to": "11408", "prefix": "; for the determination of free ", "from": "11399", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": ", 50 "}, {"to": "11573", "prefix": "1[13C6]", "from": "11564", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": "), mixed and centrifuged. For the determination of total dabigatran, 50 "}, {"to": "11640", "prefix": ", mixed and centrifuged. For the determination of total ", "from": "11631", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": ", 50 "}, {"to": "12199", "prefix": "mn with gradient elution.\n\nThe lowest limit of quantification of free or total ", "from": "12190", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " was 1 ng ml"}, {"to": "12284", "prefix": "1 nominal ", "from": "12275", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " concentration), and the imprecision was always "}, {"to": "12666", "prefix": "10%.\n\nIn addition, total ", "from": "12657", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " urine concentrations were measured. The calibration range was between 20 and 10"}, {"to": "13318", "prefix": "ived three doses of rifampicin during treatment B and before administration of ", "from": "13309", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " in each respective treatment period. Thus, morning spot urine samples were coll"}, {"to": "15962", "prefix": "time profiles of free and total ", "from": "15953", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " were highly comparable, as shown in Figure 2. The PK parameters of total dabiga"}, {"to": "16046", "prefix": "atran were highly comparable, as shown in Figure 2. The PK parameters of total ", "from": "16037", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " after administration of dabigatran etexilate 150 mg, with and without rifampici"}, {"to": "16285", "prefix": " and free ", "from": "16276", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " (b) after a single oral dose of 150 mg dabigatran etexilate on day 1 (reference"}, {"to": "16480", "prefix": "fter administration of ...\nTable 1\nTable 1\nPharmacokinetic parameters of total ", "from": "16471", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " after administration of dabigatran etexilate 150 mg, with and without rifampici"}, {"to": "16777", "prefix": " resulted in a significant reduction in the exposure to total ", "from": "16768", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " (67% reduction in AUC0"}, {"to": "17325", "prefix": " effect of rifampicin on the total ", "from": "17316", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " exposure.\n\nTable 2\nTable 2\nGeometric means (gMeans) and relative bioavailabilit"}, {"to": "18820", "prefix": " of total ", "from": "18811", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " after a single oral dose of 150 mg dabigatran etexilate alone on day 1 (treatme"}, {"to": "19200", "prefix": "Following the administration of rifampicin over 7 days, the reduction in total ", "from": "19191", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " exposure was similar in male and female subjects.\n\nThe PK parameters of free da"}, {"to": "19288", "prefix": "n exposure was similar in male and female subjects.\n\nThe PK parameters of free ", "from": "19279", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " followed the same trend as those of total dabigatran (Figure 2b), and the ratio"}, {"to": "19341", "prefix": "The PK parameters of free dabigatran followed the same trend as those of total ", "from": "19332", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " (Figure 2b), and the ratio between total and free dabigatran AUC0"}, {"to": "19402", "prefix": ", and the ratio between total and free ", "from": "19393", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " AUC0"}, {"to": "19613", "prefix": " were affected in the same way as ", "from": "19604", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " (Table 3). As the concentrations (only Cmax could be evaluated) were already ra"}, {"to": "21234", "prefix": "", "from": "21225", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": ", two subjects; rifampicin, one subject; and dabigatran plus rifampicin, three s"}, {"to": "21289", "prefix": "dabigatran, two subjects; rifampicin, one subject; and ", "from": "21280", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " plus rifampicin, three subjects). No other AEs were reported during treatment w"}, {"to": "21383", "prefix": ". No other AEs were reported during treatment with ", "from": "21374", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " alone. Other AEs reported were vertigo and hyperhidrosis (one subject each) dur"}, {"to": "21481", "prefix": " during the ", "from": "21472", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " plus rifampicin period; dizziness, nausea, oropharyngeal pain, vomiting and fat"}, {"to": "22185", "prefix": "but not ", "from": "22176", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " or its intermediate metabolites) is a substrate for the efflux transporter prot"}, {"to": "22345", "prefix": "rter protein P-gp. Previous investigations suggest that the bioavailability of ", "from": "22336", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " may be affected by P-gp inhibitors [23]. In this study, a 1 week course of rifa"}, {"to": "22491", "prefix": "a 1 week course of rifampicin, a potent inducer of P-gp, decreased exposure to ", "from": "22482", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " by 67%.\n\nThe approved dabigatran etexilate dose for stroke prevention in patien"}, {"to": "22869", "prefix": "cause they reflected standard clinical doses, and the plasma concentrations of ", "from": "22860", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " and rifampicin in this trial represent clinically relevant drug exposure. The s"}, {"to": "23284", "prefix": "because rifampicin was stopped after the last dose given in the evening before ", "from": "23275", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " administration. A single dose of dabigatran etexilate was considered to be repr"}, {"to": "23599", "prefix": "ed doses were expected to allow adequate determination of the PK parameters of ", "from": "23590", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " after P-gp induction.\n\nIn this study, the administration of rifampicin for 7 da"}, {"to": "23773", "prefix": "sulted in a significant and relevant reduction in the bioavailability of total ", "from": "23764", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " (67 and 65.5% reduction in AUC0"}, {"to": "23843", "prefix": " and Cmax values of total ", "from": "23834", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": ", respectively) after administering a single oral dose of 150 mg dabigatran etex"}, {"to": "24059", "prefix": "owing the cessation of rifampicin administration, the bioavailability of total ", "from": "24050", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " returned almost to baseline values. Pharmacokinetic parameters of free dabigatr"}, {"to": "24141", "prefix": "igatran returned almost to baseline values. Pharmacokinetic parameters of free ", "from": "24132", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " were influenced in a similar fashion.\n\nIn the present trial, rifampicin adminis"}, {"to": "24688", "prefix": "vels 2 weeks after discontinuation of treatment with rifampicin. The effect on ", "from": "24679", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " was highly comparable, which seems physiologically reasonable because both CYP3"}, {"to": "24906", "prefix": "the transcription factor pregnane X receptor [26].\n\nThe reduction of the total ", "from": "24897", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " exposure after rifampicin pretreatment seen in this trial was of similar magnit"}, {"to": "25406", "prefix": " 28]. This is in perfect agreement with the results reported in this study for ", "from": "25397", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": ".\n\nDabigatran etexilate is assumed to be absorbed mainly in the duodenum. The pr"}, {"to": "25529", "prefix": " to be absorbed mainly in the duodenum. The pronounced effect of rifampicin on ", "from": "25520", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " kinetics might, thus, be due to a remarkable increase in duodenal P-gp expressi"}, {"to": "26002", "prefix": "ransporter P-gp. Moreover, recent in vitro data have clearly demonstrated that ", "from": "25993", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " has no affinity to any efflux (P-gp, BCRP and MRP2) or uptake transporter (OAT1"}, {"to": "26275", "prefix": "ognized dabigatran etexilate as substrate [29]. The reduced bioavailability of ", "from": "26266", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " after P-gp induction contrasts with the effect observed (an increase in exposur"}, {"to": "26373", "prefix": " when ", "from": "26364", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " is administered with a P-gp inhibitor. For example, the administration of the s"}, {"to": "26530", "prefix": " and Cmax of ", "from": "26521", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " by approximately 150% compared with dabigatran alone [23].\n\nIn the present tria"}, {"to": "26577", "prefix": " and Cmax of dabigatran by approximately 150% compared with ", "from": "26568", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " alone [23].\n\nIn the present trial, male subjects receiving reference treatment "}, {"to": "26835", "prefix": "ubjects investigated. Although there were sex differences in exposure to total ", "from": "26826", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": ", administration of rifampicin for 7 days resulted in a similar percentage reduc"}, {"to": "26939", "prefix": "n of rifampicin for 7 days resulted in a similar percentage reduction in total ", "from": "26930", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " exposure for male and female subjects.\n\nThe overall safety profile of all treat"}, {"to": "27254", "prefix": "he known safety profile of dabigatran etexilate.\n\nA reduction of two-thirds in ", "from": "27245", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " exposure due to a 1 week course of rifampicin has clinically relevant consequen"}, {"to": "27513", "prefix": "ention of venous thromboembolism may not achieve therapeutic concentrations of ", "from": "27504", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " if they have received rifampicin immediately before surgery. Dabigatran etexila"}, {"to": "27804", "prefix": "s been demonstrated for dabigatran etexilate [13], the significant decrease in ", "from": "27795", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " exposure observed with rifampicin is likely to decrease the potential for strok"}, {"to": "27950", "prefix": "the potential for stroke prevention. Concomitant treatment with rifampicin and ", "from": "27941", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": " should be avoided in these patients. The effect of concomitant administration o"}, {"to": "29078", "prefix": "st to baseline values. Owing to the potential for reduced systemic exposure to ", "from": "29069", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3477350", "exact": "dabigatran", "suffix": ", rifampicin and other P-gp inducers (e.g. carbamazepine and St John's wort) are"}, {"to": "200", "prefix": "e pharmacokinetics of dabigatran following oral administration of the prodrug, ", "from": "181", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": ".\n\nMETHODS\n\nThis was an open-label, fixed-sequence, four-period study in healthy"}, {"to": "348", "prefix": "e, four-period study in healthy volunteers. Subjects received a single dose of ", "from": "329", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " 150 mg on day 1, rifampicin 600 mg once daily on days 2"}, {"to": "448", "prefix": "8, and single doses of ", "from": "429", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " on days 9, 16 and 23.\n\nRESULTS\n\nTwenty-four subjects were treated, of whom 22 r"}, {"to": "614", "prefix": "single dose of ", "from": "595", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " alone; treatment A), administration of dabigatran etexilate following 7 days of"}, {"to": "674", "prefix": ", administration of ", "from": "655", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " following 7 days of rifampicin (treatment B) decreased the geometric mean (gMea"}, {"to": "1829", "prefix": "dabigatran, which returned almost to baseline after 7 days washout.\n\nKeywords: ", "from": "1810", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": ", drug interaction, P-glycoprotein, rifampicin\nWHAT IS ALREADY KNOWN ABOUT THIS "}, {"to": "1938", "prefix": "eraction, P-glycoprotein, rifampicin\nWHAT IS ALREADY KNOWN ABOUT THIS SUBJECT\n\n", "from": "1919", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "Dabigatran etexilate", "suffix": " is an oral prodrug that is rapidly converted to dabigatran, a direct and revers"}, {"to": "2063", "prefix": "s rapidly converted to dabigatran, a direct and reversible thrombin inhibitor.\n", "from": "2044", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "Dabigatran etexilate", "suffix": " and dabigatran are not metabolized by the cytochrome P450 system, and dabigatra"}, {"to": "2292", "prefix": "drug interactions.\n", "from": "2273", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "Dabigatran etexilate", "suffix": ", but not dabigatran, is a P-glycoprotein (P-gp) substrate, and the bioavailabil"}, {"to": "2567", "prefix": " for 7 days before a single dose of ", "from": "2548", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " resulted in a significant reduction in the bioavailability of dabigatran compar"}, {"to": "2693", "prefix": "reduction in the bioavailability of dabigatran compared with administration of ", "from": "2674", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " alone.\nWithin 7 days following the cessation of rifampicin administration, the "}, {"to": "2902", "prefix": "returned almost to baseline values.\nRifampicin is not recommended for use with ", "from": "2883", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " because of the potential for reduced systemic exposure to dabigatran.\nGo to:\nIn"}, {"to": "3013", "prefix": "the potential for reduced systemic exposure to dabigatran.\nGo to:\nIntroduction\n", "from": "2994", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "Dabigatran etexilate", "suffix": " is an oral prodrug that is rapidly converted via two intermediates, BIBR 1087 S"}, {"to": "3556", "prefix": "6].\n\n", "from": "3537", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "Dabigatran etexilate", "suffix": " is licensed for the prevention of venous thromboembolic events following total "}, {"to": "3795", "prefix": "9]. ", "from": "3776", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "Dabigatran etexilate", "suffix": " is administered orally, is not associated with clinically relevant food interac"}, {"to": "4002", "prefix": "13].\n\n", "from": "3983", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "Dabigatran etexilate", "suffix": " and dabigatran are not metabolized by the cytochrome P450 (CYP) system, and dab"}, {"to": "4251", "prefix": "16]. However, preclinical and clinical studies have shown that ", "from": "4232", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " (but not dabigatran) is a P-glycoprotein (P-gp) substrate, and therefore the bi"}, {"to": "4412", "prefix": "d therefore the bioavailability of dabigatran following oral administration of ", "from": "4393", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " may be altered by P-gp inhibitors [17, 18]. For example, its bioavailability is"}, {"to": "5203", "prefix": "nce daily on the PK parameters of dabigatran following a single dose of 150 mg ", "from": "5184", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": ". The study also evaluated the time course of a return to normal availability of"}, {"to": "5495", "prefix": "s selected for investigation reflect standard clinical doses of rifampicin and ", "from": "5476", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": ", and were expected to allow an adequate determination of the PK parameters of d"}, {"to": "6445", "prefix": "ealthy male and female subjects to investigate the relative bioavailability of ", "from": "6426", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " given as single doses, either alone or after multiple doses of rifampicin, or a"}, {"to": "7060", "prefix": "s sponsored by Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.\n\n", "from": "7041", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "Dabigatran etexilate", "suffix": " (Pradaxa"}, {"to": "7368", "prefix": ".\n\nThe subjects received single oral doses of ", "from": "7349", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " (150 mg), always in the morning at 08.00 h, during the following four treatment"}, {"to": "7513", "prefix": ", ", "from": "7494", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " 150 mg administered on day 1 (reference); period 2 (treatment B), rifampicin 60"}, {"to": "7742", "prefix": " in the evening at 20.00 h, with the last dose of rifampicin given 12 h before ", "from": "7723", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " 150 mg administered on day 9 (test 1); period 3 (treatment C), a single dose of"}, {"to": "7843", "prefix": ", a single dose of ", "from": "7824", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " 150 mg administered on day 16 after 7 days of rifampicin washout (test 2); and "}, {"to": "7984", "prefix": ", a single dose of ", "from": "7965", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " 150 mg administered on day 23 after 14 days of rifampicin washout (test 3).\n\nFi"}, {"to": "8248", "prefix": ". ", "from": "8229", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "Dabigatran etexilate", "suffix": " was always given in the morning at 08.00 h. Rifampicin was always administered "}, {"to": "8463", "prefix": "1. Washout periods between subsequent ", "from": "8444", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " doses were included between the study days (days 1, 9, 16 and 23). The end-of-t"}, {"to": "9592", "prefix": "single dose of ", "from": "9573", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " 150 mg after multiple doses of rifampicin 600 mg) vs. reference treatment A (si"}, {"to": "9705", "prefix": "single dose of ", "from": "9686", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " 150 mg before any rifampicin treatment), with "}, {"to": "9989", "prefix": "single dose of ", "from": "9970", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " 150 mg after 7 days of washout since last intake of rifampicin 600 mg) and refe"}, {"to": "10148", "prefix": "single dose of ", "from": "10129", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " 150 mg after 14 days washout after the last intake of rifampicin 600 mg) and re"}, {"to": "10825", "prefix": ", 4, 6, 8, 10, 12, 24 and 34 h after administration of a single dose of 150 mg ", "from": "10806", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " in each treatment period. Plasma concentrations of free, nonconjugated dabigatr"}, {"to": "11049", "prefix": "], the prodrug, ", "from": "11030", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": ", and the intermediate metabolites, BIBR 1087 SE and BIBR 951 BS, were determine"}, {"to": "12421", "prefix": "", "from": "12402", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": ") and the intermediate metabolites, BIBR 1087 SE and BIBR 951 BS. The inaccuracy"}, {"to": "15596", "prefix": "nd-of-trial visit. The 22 subjects who completed treatment as planned received ", "from": "15577", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " 150 mg for 4 days (1 day in each treatment period) and rifampicin 600 mg for 7 "}, {"to": "15745", "prefix": "; the other two subjects received ", "from": "15726", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " 150 mg for 2 days (1 day in the first two treatment periods) and rifampicin 600"}, {"to": "16091", "prefix": "own in Figure 2. The PK parameters of total dabigatran after administration of ", "from": "16072", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " 150 mg, with and without rifampicin, are shown in Table 1.\n\nFigure 2\nFigure 2\nG"}, {"to": "16345", "prefix": " after a single oral dose of 150 mg ", "from": "16326", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " on day 1 (reference; treatment A), on day 9 after administration of ...\nTable 1"}, {"to": "16525", "prefix": "Table 1\nPharmacokinetic parameters of total dabigatran after administration of ", "from": "16506", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " 150 mg, with and without rifampicin\nRelative to the reference treatment (dabiga"}, {"to": "16619", "prefix": "", "from": "16600", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " alone), the administration of the P-gp inducer, rifampicin, over 7 days (treatm"}, {"to": "17480", "prefix": " relative bioavailability for intra-individual comparisons of a single dose of ", "from": "17461", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " 150 mg given alone (reference; treatment A) and after administration of multipl"}, {"to": "17924", "prefix": " curve were similar between treatments A and B.\n\nFor the single dose of 150 mg ", "from": "17905", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " after a 7 day washout after the last dose of rifampicin (treatment C, day 16), "}, {"to": "18876", "prefix": " of total dabigatran after a single oral dose of 150 mg ", "from": "18857", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " alone on day 1 (treatment A) or 1, 7 or 14 days after the last administration o"}, {"to": "19504", "prefix": "", "from": "19485", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": ") and the intermediate metabolites (BIBR 951 BS and BIBR 1087 SE) were affected "}, {"to": "19876", "prefix": "", "from": "19857", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": ") and intermediate metabolites (BIBR 1087 SE and BIBR 951 BS) after administrati"}, {"to": "19982", "prefix": " after administration of ", "from": "19963", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " 150 mg, with and without rifampicin\n6"}, {"to": "20718", "prefix": " subjects reported any AEs during treatment with ", "from": "20699", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " alone, four (16.7%) subjects during treatment with dabigatran etexilate plus ri"}, {"to": "20790", "prefix": " subjects during treatment with ", "from": "20771", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " plus rifampicin and two (8.3%) subjects during treatment with rifampicin alone "}, {"to": "21100", "prefix": " of subjects with adverse events reported during treatment with ", "from": "21081", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " (excluding washout periods)\nThe most frequently reported AEs were nervous syste"}, {"to": "22165", "prefix": "in all subjects.\n\nGo to:\nDiscussion\nPreclinical investigations have shown that ", "from": "22146", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " (but not dabigatran or its intermediate metabolites) is a substrate for the eff"}, {"to": "22534", "prefix": "potent inducer of P-gp, decreased exposure to dabigatran by 67%.\n\nThe approved ", "from": "22515", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " dose for stroke prevention in patients with atrial fibrillation is 150 mg twice"}, {"to": "22698", "prefix": "is 150 mg twice daily for most patients [7, 8]. The present study investigated ", "from": "22679", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " 150 mg with or without rifampicin 600 mg once daily. These doses were selected "}, {"to": "23101", "prefix": "t with cessation of treatment the evening, i.e. 12 h, before administration of ", "from": "23082", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": ") allowed for a test of maximal induction of P-gp without interference of inhibi"}, {"to": "23338", "prefix": "t dose given in the evening before dabigatran administration. A single dose of ", "from": "23319", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " was considered to be representative of the effect following multiple dosing, po"}, {"to": "23928", "prefix": " after administering a single oral dose of 150 mg ", "from": "23909", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " in healthy volunteers. Within 7 days following the cessation of rifampicin admi"}, {"to": "25429", "prefix": " in perfect agreement with the results reported in this study for dabigatran.\n\n", "from": "25410", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "Dabigatran etexilate", "suffix": " is assumed to be absorbed mainly in the duodenum. The pronounced effect of rifa"}, {"to": "25826", "prefix": "tion in bioavailability by P-gp induction may be physiologically plausible for ", "from": "25807", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": ", whose absorption (besides solubility limitations) is solely dependent on the e"}, {"to": "26214", "prefix": ", and that among intestinal transporters, P-gp only recognized ", "from": "26195", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " as substrate [29]. The reduced bioavailability of dabigatran after P-gp inducti"}, {"to": "27061", "prefix": "female subjects.\n\nThe overall safety profile of all treatments was favourable. ", "from": "27042", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "Dabigatran etexilate", "suffix": " was well tolerated when given alone and in combination with rifampicin. The res"}, {"to": "27212", "prefix": "ion with rifampicin. The results were in line with the known safety profile of ", "from": "27193", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": ".\n\nA reduction of two-thirds in dabigatran exposure due to a 1 week course of ri"}, {"to": "27411", "prefix": "lly relevant consequences. Patients undergoing orthopaedic surgery who receive ", "from": "27392", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " for the prevention of venous thromboembolism may not achieve therapeutic concen"}, {"to": "27595", "prefix": "ons of dabigatran if they have received rifampicin immediately before surgery. ", "from": "27576", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "Dabigatran etexilate", "suffix": " is also indicated for stroke prevention in patients with atrial fibrillation. A"}, {"to": "27759", "prefix": "response in stroke reduction has been demonstrated for ", "from": "27740", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " [13], the significant decrease in dabigatran exposure observed with rifampicin "}, {"to": "28052", "prefix": "ould be avoided in these patients. The effect of concomitant administration of ", "from": "28033", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " with other P-gp inducers, such as carbamazepine, diphenylhydantoin and St John'"}, {"to": "28864", "prefix": " clinically relevant reduction in the bioavailability of a single oral dose of ", "from": "28845", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " in healthy volunteers. Within 7 days following the cessation of rifampicin admi"}, {"to": "29208", "prefix": " are not recommended for use with ", "from": "29189", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037042", "setId": "PMC3477350", "exact": "dabigatran etexilate", "suffix": " [32].\n\nGo to:\nAcknowledgments\nThe study was exclusively sponsored by Boehringer"}, {"to": "7069", "prefix": "", "from": "7063", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "PMC3477350", "exact": "Pradaxa", "suffix": ""}, {"to": "2031", "prefix": " oral prodrug that is rapidly converted to dabigatran, a direct and reversible ", "from": "2024", "name": "Thrombin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10528", "setId": "PMC3477350", "exact": "thrombin", "suffix": " inhibitor.\nDabigatran etexilate and dabigatran are not metabolized by the cytoc"}, {"to": "3178", "prefix": " SE and BIBR 951 BS, to the active moiety, dabigatran, a direct and reversible ", "from": "3171", "name": "Thrombin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10528", "setId": "PMC3477350", "exact": "thrombin", "suffix": " inhibitor. Dabigatran is partly conjugated with activated glucuronic acid to fo"}, {"to": "3252", "prefix": " reversible thrombin inhibitor. Dabigatran is partly conjugated with activated ", "from": "3238", "name": "Glucuronic Acid", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1426906", "setId": "PMC3477350", "exact": "glucuronic acid", "suffix": " to form a pharmacologically equipotent glucuronide. Free dabigatran and total d"}, {"to": "4563", "prefix": "ioavailability is increased in patients taking strong P-gp inhibitors, such as ", "from": "4555", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "PMC3477350", "exact": "quinidine", "suffix": ", verapamil and amiodarone.\n\nThe antibacterial agent rifampicin (used primarily "}, {"to": "4574", "prefix": "ity is increased in patients taking strong P-gp inhibitors, such as quinidine, ", "from": "4566", "name": "Verapamil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11170", "setId": "PMC3477350", "exact": "verapamil", "suffix": " and amiodarone.\n\nThe antibacterial agent rifampicin (used primarily in the trea"}, {"to": "4589", "prefix": "ed in patients taking strong P-gp inhibitors, such as quinidine, verapamil and ", "from": "4580", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/MESH/D000638", "setId": "PMC3477350", "exact": "amiodarone", "suffix": ".\n\nThe antibacterial agent rifampicin (used primarily in the treatment of tuberc"}, {"to": "5743", "prefix": "", "from": "5736", "name": "Hydrocortisone", "fullId": "http://purl.bioontology.org/ontology/MESH/D006854", "setId": "PMC3477350", "exact": "cortisol", "suffix": " ratio. This ratio is thought to reflect the CYP3A activity and has proved to be"}, {"to": "10482", "prefix": "-hydroxycortisol to ", "from": "10475", "name": "Hydrocortisone", "fullId": "http://purl.bioontology.org/ontology/MESH/D006854", "setId": "PMC3477350", "exact": "cortisol", "suffix": " as a marker of induction of CYP3A4 by rifampicin and an evaluation of safety we"}, {"to": "12891", "prefix": "", "from": "12884", "name": "Hydrocortisone", "fullId": "http://purl.bioontology.org/ontology/MESH/D006854", "setId": "PMC3477350", "exact": "cortisol", "suffix": " ratio, an established marker of human hepatic CYP450 3A induction (but not a ma"}, {"to": "13536", "prefix": ".\n\nUrinary concentrations of ", "from": "13529", "name": "Hydrocortisone", "fullId": "http://purl.bioontology.org/ontology/MESH/D006854", "setId": "PMC3477350", "exact": "cortisol", "suffix": " and 6"}, {"to": "13697", "prefix": "-hydroxycortisol and ", "from": "13690", "name": "Hydrocortisone", "fullId": "http://purl.bioontology.org/ontology/MESH/D006854", "setId": "PMC3477350", "exact": "cortisol", "suffix": " ranged between 1"}, {"to": "13856", "prefix": "", "from": "13849", "name": "Hydrocortisone", "fullId": "http://purl.bioontology.org/ontology/MESH/D006854", "setId": "PMC3477350", "exact": "cortisol", "suffix": ") at all spiked concentrations. Induction of CYP3A by rifampicin was assessed by"}, {"to": "13991", "prefix": "", "from": "13984", "name": "Hydrocortisone", "fullId": "http://purl.bioontology.org/ontology/MESH/D006854", "setId": "PMC3477350", "exact": "cortisol", "suffix": " after a 7 day treatment of 600 mg rifampicin once daily and after cessation of "}, {"to": "20046", "prefix": "", "from": "20039", "name": "Hydrocortisone", "fullId": "http://purl.bioontology.org/ontology/MESH/D006854", "setId": "PMC3477350", "exact": "cortisol", "suffix": " urine ratios\n\nCompared with day 1, the urinary 6"}, {"to": "20121", "prefix": "", "from": "20114", "name": "Hydrocortisone", "fullId": "http://purl.bioontology.org/ontology/MESH/D006854", "setId": "PMC3477350", "exact": "cortisol", "suffix": " ratio on day 9 was increased approximately 5.6-fold, from a gMean (gCV %) 6"}, {"to": "20223", "prefix": "", "from": "20216", "name": "Hydrocortisone", "fullId": "http://purl.bioontology.org/ontology/MESH/D006854", "setId": "PMC3477350", "exact": "cortisol", "suffix": " ratio of 3.92 (65.3) to 22.0 (48.5), indicating CYP450 3A induction as a result"}, {"to": "20373", "prefix": "", "from": "20366", "name": "Hydrocortisone", "fullId": "http://purl.bioontology.org/ontology/MESH/D006854", "setId": "PMC3477350", "exact": "cortisol", "suffix": " ratio was still slightly elevated on day 16 ("}, {"to": "24308", "prefix": "", "from": "24301", "name": "Hydrocortisone", "fullId": "http://purl.bioontology.org/ontology/MESH/D006854", "setId": "PMC3477350", "exact": "cortisol", "suffix": " ratio [24]. Such induction has been documented to dissipate in about 2 weeks af"}, {"to": "24490", "prefix": "", "from": "24483", "name": "Hydrocortisone", "fullId": "http://purl.bioontology.org/ontology/MESH/D006854", "setId": "PMC3477350", "exact": "cortisol", "suffix": " ratio was found to be only 1.2-fold higher than baseline values after 1 week an"}, {"to": "11328", "prefix": "eutschland GmbH & Co. KG, Neu-Ulm, Germany.\n\nBriefly, plasma was prepared from ", "from": "11325", "name": "Edetic Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D004492", "setId": "PMC3477350", "exact": "EDTA", "suffix": " blood (at 2000g"}, {"to": "25048", "prefix": "al was of similar magnitude or only slightly exceeded the effects reported for ", "from": "25042", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "PMC3477350", "exact": "digoxin", "suffix": " [27], a prototypical P-gp substrate, or aliskiren [28]. Interestingly, despite "}, {"to": "25208", "prefix": " of aliskiren or a 58% reduction in Cmax of ", "from": "25202", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "PMC3477350", "exact": "digoxin", "suffix": " after rifampicin treatment, the renal clearance and half-life of these drugs al"}, {"to": "25098", "prefix": "eeded the effects reported for digoxin [27], a prototypical P-gp substrate, or ", "from": "25090", "name": "aliskiren", "fullId": "http://purl.bioontology.org/ontology/RXNORM/325646", "setId": "PMC3477350", "exact": "aliskiren", "suffix": " [28]. Interestingly, despite a 56% reduction in the AUC0"}, {"to": "25170", "prefix": " of ", "from": "25162", "name": "aliskiren", "fullId": "http://purl.bioontology.org/ontology/RXNORM/325646", "setId": "PMC3477350", "exact": "aliskiren", "suffix": " or a 58% reduction in Cmax of digoxin after rifampicin treatment, the renal cle"}, {"to": "26486", "prefix": "a P-gp inhibitor. For example, the administration of the strong P-gp inhibitor ", "from": "26475", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3477350", "exact": "ketoconazole", "suffix": " increased the AUC0"}, {"to": "28100", "prefix": "itant administration of dabigatran etexilate with other P-gp inducers, such as ", "from": "28088", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "PMC3477350", "exact": "carbamazepine", "suffix": ", diphenylhydantoin and St John's wort has not been tested. However, it should b"}, {"to": "28354", "prefix": "ties when coadministered with compounds increasing warfarin clearance, such as ", "from": "28342", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "PMC3477350", "exact": "carbamazepine", "suffix": ", barbiturates, rifampicin and chronic alcohol [30]. Furthermore, the new factor"}, {"to": "29134", "prefix": "e.g. ", "from": "29122", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "PMC3477350", "exact": "carbamazepine", "suffix": " and St John's wort) are not recommended for use with dabigatran etexilate [32]."}, {"to": "28119", "prefix": "ation of dabigatran etexilate with other P-gp inducers, such as carbamazepine, ", "from": "28103", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/MESH/D010672", "setId": "PMC3477350", "exact": "diphenylhydantoin", "suffix": " and St John's wort has not been tested. However, it should be emphasized that v"}, {"to": "28207", "prefix": " and St John's wort has not been tested. However, it should be emphasized that ", "from": "28199", "name": "Vitamin K", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11258", "setId": "PMC3477350", "exact": "vitamin K", "suffix": " antagonists, such as warfarin, show comparable liabilities when coadministered "}, {"to": "28237", "prefix": "n tested. However, it should be emphasized that vitamin K antagonists, such as ", "from": "28230", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3477350", "exact": "warfarin", "suffix": ", show comparable liabilities when coadministered with compounds increasing warf"}, {"to": "28321", "prefix": "rin, show comparable liabilities when coadministered with compounds increasing ", "from": "28314", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3477350", "exact": "warfarin", "suffix": " clearance, such as carbamazepine, barbiturates, rifampicin and chronic alcohol "}, {"to": "28460", "prefix": "rifampicin and chronic alcohol [30]. Furthermore, the new factor Xa inhibitors ", "from": "28450", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "PMC3477350", "exact": "rivaroxaban", "suffix": " and apixaban are expected to be affected by inducers of the rifampicin type bec"}, {"to": "28473", "prefix": "hronic alcohol [30]. Furthermore, the new factor Xa inhibitors rivaroxaban and ", "from": "28466", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C522181", "setId": "PMC3477350", "exact": "apixaban", "suffix": " are expected to be affected by inducers of the rifampicin type because their cl"}, {"to": "181", "prefix": "aim of this study was to determine the importance of inhibitory metabolites of ", "from": "170", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC3056523", "exact": "itraconazole", "suffix": " (ITZ) in in vivo cytochrome p450 (CYP) 3A4 inhibition. The pharmacokinetics of "}, {"to": "1483", "prefix": "s with circulating inhibitory metabolites include three potent CYP inhibitors: ", "from": "1472", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC3056523", "exact": "itraconazole", "suffix": " (ITZ),3 fluoxetine,4 and bupropion.5 Norfluoxetine, the primary circulating met"}, {"to": "5563", "prefix": "g doses of ITZ, respectively.\n\nFigure 1\nFigure 1\nEffect of escalating doses of ", "from": "5552", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC3056523", "exact": "itraconazole", "suffix": " (ITZ) on disposition of oral midazolam (MDZ). Panel a shows the plasma concentr"}, {"to": "7521", "prefix": " for ", "from": "7510", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC3056523", "exact": "itraconazole", "suffix": " (ITZ) in the six study subjects. The subjects are labeled "}, {"to": "12442", "prefix": "y was observed.\n\nFigure 3\nFigure 3\nPredicted vs. observed interactions between ", "from": "12431", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC3056523", "exact": "itraconazole", "suffix": " (ITZ) and midazolam after escalating doses of ITZ. The circles represent data f"}, {"to": "278", "prefix": " 3A4 inhibition. The pharmacokinetics of ITZ and ", "from": "270", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3056523", "exact": "midazolam", "suffix": " (MDZ) were determined in six healthy volunteers in four sessions after administ"}, {"to": "3711", "prefix": "e study. An additional female subject was enrolled, but she withdrew after the ", "from": "3703", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3056523", "exact": "midazolam", "suffix": " (MDZ) control session because of nausea and vomiting. No other side effects or "}, {"to": "5602", "prefix": " on disposition of oral ", "from": "5594", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3056523", "exact": "midazolam", "suffix": " (MDZ). Panel a shows the plasma concentration"}, {"to": "5674", "prefix": "time curves for ", "from": "5666", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3056523", "exact": "midazolam", "suffix": " in the control session and three ITZ sessions. MDZ was administered 4 h after t"}, {"to": "10894", "prefix": " of oral ", "from": "10886", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3056523", "exact": "midazolam", "suffix": " calculated using Eqs. 2, 4, and 6, considering ITZ alone or both ITZ and its me"}, {"to": "12462", "prefix": " and ", "from": "12454", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3056523", "exact": "midazolam", "suffix": " after escalating doses of ITZ. The circles represent data from each individual "}, {"to": "1502", "prefix": ",3 ", "from": "1493", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4493", "setId": "PMC3056523", "exact": "fluoxetine", "suffix": ",4 and bupropion.5 Norfluoxetine, the primary circulating metabolite of fluoxeti"}, {"to": "1584", "prefix": "oxetine,4 and bupropion.5 Norfluoxetine, the primary circulating metabolite of ", "from": "1575", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4493", "setId": "PMC3056523", "exact": "fluoxetine", "suffix": ", has been shown to be responsible for the persistent CYP2D6 inhibition after ad"}, {"to": "1690", "prefix": "to be responsible for the persistent CYP2D6 inhibition after administration of ", "from": "1681", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4493", "setId": "PMC3056523", "exact": "fluoxetine", "suffix": ",6 although no quantitative prediction of CYP2D6 inhibition by norfluoxetine as "}, {"to": "1794", "prefix": "quantitative prediction of CYP2D6 inhibition by norfluoxetine as compared with ", "from": "1785", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4493", "setId": "PMC3056523", "exact": "fluoxetine", "suffix": " was shown. Using atomoxetine as an example, quantitative predictions of the con"}, {"to": "1518", "prefix": ",3 fluoxetine,4 and ", "from": "1510", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "PMC3056523", "exact": "bupropion", "suffix": ".5 Norfluoxetine, the primary circulating metabolite of fluoxetine, has been sho"}, {"to": "1534", "prefix": ",3 fluoxetine,4 and bupropion.5 ", "from": "1522", "name": "norfluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C036139", "setId": "PMC3056523", "exact": "Norfluoxetine", "suffix": ", the primary circulating metabolite of fluoxetine, has been shown to be respons"}, {"to": "1766", "prefix": "on of fluoxetine,6 although no quantitative prediction of CYP2D6 inhibition by ", "from": "1754", "name": "norfluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C036139", "setId": "PMC3056523", "exact": "norfluoxetine", "suffix": " as compared with fluoxetine was shown. Using atomoxetine as an example, quantit"}, {"to": "1823", "prefix": "YP2D6 inhibition by norfluoxetine as compared with fluoxetine was shown. Using ", "from": "1813", "name": "atomoxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/38400", "setId": "PMC3056523", "exact": "atomoxetine", "suffix": " as an example, quantitative predictions of the contribution of metabolites to i"}, {"to": "2015", "prefix": "rmed, and, despite the overall weak in vivo inhibition of CYP3A4 and CYP2D6 by ", "from": "2005", "name": "atomoxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/38400", "setId": "PMC3056523", "exact": "atomoxetine", "suffix": ", the metabolites were predicted to be mainly responsible for the interaction.7\n"}, {"to": "15758", "prefix": "gated the effect of ingestion time interval on the interaction between ITZ and ", "from": "15750", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D014229", "setId": "PMC3056523", "exact": "triazolam", "suffix": ", a larger magnitude of inhibition was observed when ITZ and triazolam doses wer"}, {"to": "15828", "prefix": " ITZ and triazolam, a larger magnitude of inhibition was observed when ITZ and ", "from": "15820", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D014229", "setId": "PMC3056523", "exact": "triazolam", "suffix": " doses were separated by 3 or 12 h as compared with administering them simultane"}, {"to": "18711", "prefix": "inhibition plateau with increasing ITZ doses has previously been observed with ", "from": "18703", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D014229", "setId": "PMC3056523", "exact": "triazolam", "suffix": " when triazolam was administered 3 h after a 200- or 400-mg oral dose of ITZ. On"}, {"to": "18726", "prefix": "eau with increasing ITZ doses has previously been observed with triazolam when ", "from": "18718", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D014229", "setId": "PMC3056523", "exact": "triazolam", "suffix": " was administered 3 h after a 200- or 400-mg oral dose of ITZ. Only a marginal ("}, {"to": "19041", "prefix": "that ITZ inhibits only CYP3A and no alternative elimination pathways of MDZ or ", "from": "19033", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D014229", "setId": "PMC3056523", "exact": "triazolam", "suffix": ".\n\nThe use of in vivo Ki has been proposed as a method for comparing an inhibito"}, {"to": "24064", "prefix": "and grapefruit products for the duration of the study and to avoid alcohol and ", "from": "24057", "name": "Caffeine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002110", "setId": "PMC3056523", "exact": "caffeine", "suffix": " from 1 day before through the end of each urine-collection period. The study wa"}, {"to": "24734", "prefix": "rations, blood samples were collected through indwelling venous catheters into ", "from": "24731", "name": "Edetic Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D004492", "setId": "PMC3056523", "exact": "EDTA", "suffix": "-containing tubes (BD Vacutainer; BD Biosciences, Franklin Lakes, NJ) before MDZ"}, {"to": "26", "prefix": "Abstract\nAIMS\n\n", "from": "16", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "Ambrisentan", "suffix": " is an oral, propanoic acid-based endothelin receptor antagonist often co-admini"}, {"to": "244", "prefix": "arterial hypertension. The aim of this study was to evaluate the potential for ", "from": "234", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " to affect warfarin pharmacokinetics and pharmacodynamics.\n\nMETHODS\n\nIn this ope"}, {"to": "456", "prefix": "cts received a single dose of racemic warfarin 25 mg alone and after 8 days of ", "from": "446", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " 10 mg once daily. Assessments included exposure (AUC0"}, {"to": "727", "prefix": ". The effects of warfarin on ", "from": "717", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " steady-state pharmacokinetics and the safety of ambrisentan"}, {"to": "787", "prefix": "cts of warfarin on ambrisentan steady-state pharmacokinetics and the safety of ", "from": "777", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": ""}, {"to": "896", "prefix": "stration were assessed. Data are presented as geometric mean ratios.\n\nRESULTS\n\n", "from": "886", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "Ambrisentan", "suffix": " had no significant effects on the AUC0"}, {"to": "1071", "prefix": ". Similarly, ", "from": "1061", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " had no significant effects on the Cmax of R-warfarin (91.6; 90% CI 86.2, 97.4) "}, {"to": "1421", "prefix": ". In addition, co-administration of warfarin did not alter ", "from": "1411", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " steady-state pharmacokinetics. Adverse events were infrequent, and there were n"}, {"to": "1571", "prefix": "nt, and there were no bleeding adverse events.\n\nCONCLUSIONS\n\nMultiple doses of ", "from": "1561", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " had no clinically relevant effects on the pharmacokinetics and pharmacodynamics"}, {"to": "1811", "prefix": " of either drug are unlikely to be required with co-administration.\n\nKeywords: ", "from": "1801", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": ", endothelin receptor antagonist, International Normalized Ratio, pharmacodynami"}, {"to": "2181", "prefix": " to reduce the risk of thrombosis and embolism.\n", "from": "2171", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "Ambrisentan", "suffix": " is an orally active, propanoic acid-based endothelin receptor antagonist that i"}, {"to": "2730", "prefix": "rtaken in healthy subjects to identify any potential drug interactions between ", "from": "2720", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " and warfarin.\nMultiple doses of ambrisentan had no clinically relevant effects "}, {"to": "2774", "prefix": "otential drug interactions between ambrisentan and warfarin.\nMultiple doses of ", "from": "2764", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " had no clinically relevant effects on the pharmacokinetics or pharmacodynamics "}, {"to": "2991", "prefix": "rin had no clinically relevant effects on the steady-state pharmacokinetics of ", "from": "2981", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": ".\nTherefore, co-administration of ambrisentan with warfarin should not require a"}, {"to": "3036", "prefix": " steady-state pharmacokinetics of ambrisentan.\nTherefore, co-administration of ", "from": "3026", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " with warfarin should not require adjustment of the therapeutically effective do"}, {"to": "5011", "prefix": "n to alter warfarin metabolism by affecting the activity of CYP3A4 and CYP2C9. ", "from": "5001", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "Ambrisentan", "suffix": " is a once-daily, orally active, propanoic acid-based, receptor subtype A (ETA) "}, {"to": "5159", "prefix": " selective ERA that is approved for the treatment of PAH. ", "from": "5149", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "Ambrisentan", "suffix": " has been shown to improve exercise capacity, delay time to clinical worsening, "}, {"to": "5380", "prefix": "12]. Unlike bosentan and sitaxsentan, ", "from": "5370", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " does not induce or inhibit CYP2C9 or CYP3A4 and is therefore unlikely to have d"}, {"to": "5616", "prefix": "s [11]. This study was undertaken to evaluate the effects of multiple doses of ", "from": "5606", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " on the pharmacokinetics and pharmacodynamics of a single racemic dose of warfar"}, {"to": "5796", "prefix": "l as to assess the effects of warfarin on the steady-state pharmacokinetics of ", "from": "5786", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": ". In addition, the safety and tolerability of ambrisentan and warfarin co-admini"}, {"to": "5853", "prefix": "e pharmacokinetics of ambrisentan. In addition, the safety and tolerability of ", "from": "5843", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " and warfarin co-administration were evaluated.\n\nGo to:\nMethods\nSubjects\n\nMen an"}, {"to": "6973", "prefix": " history of alcohol dependence, bleeding disorders, sensitivity to warfarin or ", "from": "6963", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": ", or significant allergies. Subjects were also excluded if they had donated or r"}, {"to": "7679", "prefix": "or pharmacodynamic interaction of multiple doses of ", "from": "7669", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " with a single dose of warfarin in healthy subjects (Figure 1). Following a scre"}, {"to": "7973", "prefix": " on day 1. On days 5 to 16, subjects received a single daily dose of ", "from": "7963", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " 10 mg (Gilead Sciences, Inc., formerly Myogen, Inc., Westminster, CO, USA). On "}, {"to": "8122", "prefix": ". On day 13, subjects were administered a single 10-mg dose of ", "from": "8112", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " together with a single 25-mg dose of warfarin. All study medications were admin"}, {"to": "8571", "prefix": "Single doses of racemic warfarin 25 mg were administered on days 1 and 13, and ", "from": "8561", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " 10 mg was administered once daily from day 5 to day 16. OD, once daily; PK, pha"}, {"to": "9015", "prefix": "2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72 and 96 h postdose. Blood samples for ", "from": "9005", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " pharmacokinetic assessments were collected relative to the day 12 and day 13 am"}, {"to": "9104", "prefix": "n pharmacokinetic assessments were collected relative to the day 12 and day 13 ", "from": "9094", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " doses: predose ("}, {"to": "9218", "prefix": ", and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 18 and 24 h postdose. Steady-state ", "from": "9208", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " concentrations were determined from samples collected at trough (predose) on da"}, {"to": "9871", "prefix": "1[13]. Plasma concentrations of ", "from": "9861", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " were determined by a validated LC"}, {"to": "10004", "prefix": "1. The precision of the ", "from": "9994", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " assay was "}, {"to": "10153", "prefix": "variation and the accuracy of the assay was within 15% of the actual value for ", "from": "10143", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": ". Pharmacokinetic analyses were performed using WinNonlin"}, {"to": "10353", "prefix": ". Estimated plasma pharmacokinetic parameters for ", "from": "10343", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " and warfarin enantiomers included area under the concentration"}, {"to": "10652", "prefix": " were also determined for the steady-state pharmacokinetic analysis of ", "from": "10642", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": ". Prothrombin times, presented as INR, were characterized using area under the e"}, {"to": "10951", "prefix": ".\n\nSafety\n\nThe safety and tolerability of ", "from": "10941", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " and warfarin co-administration was assessed through adverse events (AEs), vital"}, {"to": "12058", "prefix": "re calculated using the trapezoidal rule.\n\nTo assess the effect of concomitant ", "from": "12048", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " dosing on warfarin pharmacokinetics and pharmacodynamics, individual within-sub"}, {"to": "12198", "prefix": " ", "from": "12188", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": ") vs. day 1 (warfarin alone) were summarized for the natural logarithms of Cmax "}, {"to": "13086", "prefix": "rfarin concentrations.\n\nTo assess the effect of concomitant warfarin dosing on ", "from": "13076", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " pharmacokinetics, individual within-subject pair-wise differences of day 13 (wa"}, {"to": "13186", "prefix": " ", "from": "13176", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": ") vs. day 12 (ambrisentan alone) were summarized for the natural logarithms of a"}, {"to": "13211", "prefix": "", "from": "13201", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " alone) were summarized for the natural logarithms of ambrisentan Cmin,ss,Cmax,s"}, {"to": "13276", "prefix": " were summarized for the natural logarithms of ", "from": "13266", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " Cmin,ss,Cmax,ss and AUC0"}, {"to": "13618", "prefix": "rank test was evaluated for the differences in tmax between treatment days for ", "from": "13608", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " concentrations.\n\nA total of 22 subjects were enrolled to ensure that 18 subject"}, {"to": "13836", "prefix": "", "from": "13826", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": ") and day 1 (warfarin alone), and a "}, {"to": "14408", "prefix": " the protocol and received two doses of racemic warfarin 25 mg and 12 doses of ", "from": "14398", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " 10 mg; therefore, all were included in the safety, pharmacokinetic and pharmaco"}, {"to": "14611", "prefix": "armacokinetics\n\nThere were no clinically relevant effects of multiple doses of ", "from": "14601", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " on the concentration"}, {"to": "14973", "prefix": " of ", "from": "14963", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": ". Following multiple doses of ambrisentan, the observed mean AUC0"}, {"to": "15014", "prefix": " of ambrisentan. Following multiple doses of ", "from": "15004", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": ", the observed mean AUC0"}, {"to": "15539", "prefix": "tmax values for both enantiomers were comparable in the presence or absence of ", "from": "15529", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": ".\n\nTable 1\nTable 1\nEffect of ambrisentan on R-and S-warfarin pharmacokinetics\nFi"}, {"to": "15579", "prefix": "mparable in the presence or absence of ambrisentan.\n\nTable 1\nTable 1\nEffect of ", "from": "15569", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " on R-and S-warfarin pharmacokinetics\nFigure 2\nFigure 2\nMean plasma concentratio"}, {"to": "15833", "prefix": " and in the presence of multiple doses of ", "from": "15823", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " ("}, {"to": "15977", "prefix": "rmacodynamics\n\nAdministration of warfarin in the presence of multiple doses of ", "from": "15967", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " (Figure 3) resulted in a 14.7% decrease in INRmax (85.3; 95% CI 82.4, 88.2) and"}, {"to": "16255", "prefix": ". No effect of ", "from": "16245", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " on median tmax of INR was observed.\n\nTable 2\nTable 2\nEffect of ambrisentan on w"}, {"to": "16330", "prefix": " of ambrisentan on median tmax of INR was observed.\n\nTable 2\nTable 2\nEffect of ", "from": "16320", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " on warfarin pharmacodynamics\nFigure 3\nFigure 3\nMean effect vs. time profile of "}, {"to": "16558", "prefix": " and in the presence of multiple doses of ", "from": "16548", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " ("}, {"to": "16628", "prefix": " standard ...\n", "from": "16618", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "Ambrisentan", "suffix": " pharmacokinetics\n\nRacemic warfarin had little effect on the steady-state plasma"}, {"to": "16750", "prefix": "time profile of ", "from": "16740", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " (Figure 4). In the presence of warfarin, steady-state ambrisentan Cmax and Cmin"}, {"to": "16816", "prefix": ". In the presence of warfarin, steady-state ", "from": "16806", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " Cmax and Cmin decreased by 2.0% (98.0; 90% CI 87.6, 109.5) and 9.3% (90.7; 90% "}, {"to": "17089", "prefix": ". The 90% CIs for all ", "from": "17079", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " pharmacokinetic parameters were within the predefined no effect boundaries. Med"}, {"to": "17279", "prefix": "ble between day 12 and day 13.\n\nTable 3\nTable 3\nEffects of racemic warfarin on ", "from": "17269", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " steady-state pharmacokinetics\nFigure 4\nFigure 4\nMean plasma concentration"}, {"to": "17382", "prefix": "time profiles of ", "from": "17372", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " following multiple doses of ambrisentan alone ("}, {"to": "17422", "prefix": "time profiles of ambrisentan following multiple doses of ", "from": "17412", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " alone ("}, {"to": "18062", "prefix": "bly related to study drug.\n\nGo to:\nDiscussion\nIn this study, multiple doses of ", "from": "18052", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " 10 mg once daily resulted in slight to modest changes in R-and S-warfarin pharm"}, {"to": "18313", "prefix": "125%, suggesting that ", "from": "18303", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " did not have a clinically relevant effect on warfarin metabolism or the resulti"}, {"to": "20052", "prefix": "cessive anticoagulation and the potential for serious bleeding episodes [16].\n\n", "from": "20042", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "Ambrisentan", "suffix": " is primarily metabolized via hepatic glucuronidation [10"}, {"to": "20236", "prefix": " phase I metabolism by CYP pathways. In addition,in vitro studies suggest that ", "from": "20226", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " does not alter the expression or activity of CYP enzymes, thus minimizing the r"}, {"to": "20426", "prefix": "teractions with other agents metabolized by CYP family members. In this study, ", "from": "20416", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " decreased INRmax and INRAUC(0"}, {"to": "20914", "prefix": "s on warfarin dose or prothrombin time. The lack of a drug interaction between ", "from": "20904", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " and warfarin has been corroborated in ambrisentan clinical studies that permitt"}, {"to": "20964", "prefix": "f a drug interaction between ambrisentan and warfarin has been corroborated in ", "from": "20954", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " clinical studies that permitted the use of warfarin or warfarin-like anticoagul"}, {"to": "21114", "prefix": "arin-like anticoagulants as concomitant medications [10].\n\nIn this study, both ", "from": "21104", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " and warfarin were administered at clinically effective doses, and no significan"}, {"to": "21551", "prefix": " this study alone regarding the safety profile of chronic co-administration of ", "from": "21541", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " and warfarin. Of note, clinical studies in patients with PAH, such as those men"}, {"to": "21708", "prefix": " as those mentioned above, have demonstrated that chronic co-administration of ", "from": "21698", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " and warfarin does not appear to be associated with any specific safety concerns"}, {"to": "22070", "prefix": "row therapeutic window; therefore, caution should be exercised when initiating ", "from": "22060", "name": "ambrisentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C467894", "setId": "PMC2686069", "exact": "ambrisentan", "suffix": " therapy in patients receiving warfarin."}, {"to": "126", "prefix": "propanoic acid-based endothelin receptor antagonist often co-administered with ", "from": "119", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " to patients with pulmonary arterial hypertension. The aim of this study was to "}, {"to": "263", "prefix": " The aim of this study was to evaluate the potential for ambrisentan to affect ", "from": "256", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " pharmacokinetics and pharmacodynamics.\n\nMETHODS\n\nIn this open-label cross-over "}, {"to": "412", "prefix": "-label cross-over study, 22 healthy subjects received a single dose of racemic ", "from": "405", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " 25 mg alone and after 8 days of ambrisentan 10 mg once daily. Assessments inclu"}, {"to": "577", "prefix": " for R-and S-", "from": "570", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": ", and International Normalized Ratio maximum observed value (INRmax) and area un"}, {"to": "712", "prefix": ". The effects of ", "from": "705", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " on ambrisentan steady-state pharmacokinetics and the safety of ambrisentan"}, {"to": "796", "prefix": "", "from": "789", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " co-administration were assessed. Data are presented as geometric mean ratios.\n\n"}, {"to": "954", "prefix": "last of R-", "from": "947", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " [104.7; 90% confidence interval (CI) 101.7, 107.7) or S-warfarin (101.6; 90% CI"}, {"to": "1019", "prefix": " or S-", "from": "1012", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " (101.6; 90% CI 98.4, 105.0). Similarly, ambrisentan had no significant effects "}, {"to": "1124", "prefix": ". Similarly, ambrisentan had no significant effects on the Cmax of R-", "from": "1117", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " (91.6; 90% CI 86.2, 97.4) or S-warfarin (89.9; 90% CI 84.8, 95.3). Consistent w"}, {"to": "1164", "prefix": " or S-", "from": "1157", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " (89.9; 90% CI 84.8, 95.3). Consistent with these observations, little pharmacod"}, {"to": "1395", "prefix": ". In addition, co-administration of ", "from": "1388", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " did not alter ambrisentan steady-state pharmacokinetics. Adverse events were in"}, {"to": "1680", "prefix": "evant effects on the pharmacokinetics and pharmacodynamics of a single dose of ", "from": "1673", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": ". Therefore, significant dose adjustments of either drug are unlikely to be requ"}, {"to": "1956", "prefix": " Ratio, pharmacodynamics, pharmacokinetics, pulmonary arterial hypertension, R-", "from": "1949", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": ", S-warfarin\nWHAT IS ALRADY KNOWN ABOUT THIS SUBJECT\n\nWarfarin anticoagulation t"}, {"to": "1968", "prefix": "macodynamics, pharmacokinetics, pulmonary arterial hypertension, R-warfarin, S-", "from": "1961", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": "\nWHAT IS ALRADY KNOWN ABOUT THIS SUBJECT\n\nWarfarin anticoagulation therapy is co"}, {"to": "2018", "prefix": " hypertension, R-warfarin, S-warfarin\nWHAT IS ALRADY KNOWN ABOUT THIS SUBJECT\n\n", "from": "2011", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "Warfarin", "suffix": " anticoagulation therapy is commonly administered to patients with pulmonary art"}, {"to": "2305", "prefix": "based endothelin receptor antagonist that is likely to be co-administered with ", "from": "2298", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " to PAH patients.\nConcomitant therapies that induce or inhibit warfarin metaboli"}, {"to": "2376", "prefix": "ed with warfarin to PAH patients.\nConcomitant therapies that induce or inhibit ", "from": "2369", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " metabolism may alter the systemic exposure of warfarin and significantly alter "}, {"to": "2431", "prefix": " that induce or inhibit warfarin metabolism may alter the systemic exposure of ", "from": "2424", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " and significantly alter clotting time, as measured by prothrombin time and Inte"}, {"to": "2592", "prefix": "d International Normalized Ratio, thereby requiring substantial adjustments to ", "from": "2585", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " dose.\nWHAT THIS STUDY ADDS\n\nThis study was undertaken in healthy subjects to id"}, {"to": "2743", "prefix": "y subjects to identify any potential drug interactions between ambrisentan and ", "from": "2736", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": ".\nMultiple doses of ambrisentan had no clinically relevant effects on the pharma"}, {"to": "2865", "prefix": " no clinically relevant effects on the pharmacokinetics or pharmacodynamics of ", "from": "2858", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": "; conversely, a single dose of warfarin had no clinically relevant effects on th"}, {"to": "2904", "prefix": "pharmacokinetics or pharmacodynamics of warfarin; conversely, a single dose of ", "from": "2897", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " had no clinically relevant effects on the steady-state pharmacokinetics of ambr"}, {"to": "3050", "prefix": "rmacokinetics of ambrisentan.\nTherefore, co-administration of ambrisentan with ", "from": "3043", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " should not require adjustment of the therapeutically effective dosing regimen f"}, {"to": "3697", "prefix": "let activity, are characteristic of PAH [2]; therefore, anticoagulants such as ", "from": "3690", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " are commonly administered to prevent thrombus formation in this patient populat"}, {"to": "3826", "prefix": "mbus formation in this patient population [4]. The pharmacodynamic response to ", "from": "3819", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " includes increased prothrombin time (PT), which is often expressed as an Intern"}, {"to": "3950", "prefix": " [5]. ", "from": "3943", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "Warfarin", "suffix": " is administered as a racemic mixture of R("}, {"to": "4161", "prefix": "re potent than the R-enantiomer with respect to coagulation activity [6]. Both ", "from": "4154", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " enantiomers are metabolized in the liver by cytochrome P450 (CYP) isoenzymes: R"}, {"to": "4250", "prefix": " isoenzymes: R-", "from": "4243", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " is primarily metabolized by CYP1A2 and CYP3A4, whereas S-warfarin is primarily "}, {"to": "4316", "prefix": "soenzymes: R-warfarin is primarily metabolized by CYP1A2 and CYP3A4, whereas S-", "from": "4309", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " is primarily metabolized by CYP2C9 [7]. Concomitant therapies that alter CYP en"}, {"to": "4462", "prefix": "ies that alter CYP enzyme activities may alter the pharmacokinetic exposure of ", "from": "4455", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " and significantly affect clotting time as measured by INR. Decreased INR could "}, {"to": "4940", "prefix": "n the treatment of PAH [[8], [9]; however, both drugs have been shown to alter ", "from": "4933", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " metabolism by affecting the activity of CYP3A4 and CYP2C9. Ambrisentan is a onc"}, {"to": "5495", "prefix": "drug interactions with ", "from": "5488", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " and other CYP-metabolized drugs [11]. This study was undertaken to evaluate the"}, {"to": "5698", "prefix": "entan on the pharmacokinetics and pharmacodynamics of a single racemic dose of ", "from": "5691", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": ", as well as to assess the effects of warfarin on the steady-state pharmacokinet"}, {"to": "5744", "prefix": "mics of a single racemic dose of warfarin, as well as to assess the effects of ", "from": "5737", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " on the steady-state pharmacokinetics of ambrisentan. In addition, the safety an"}, {"to": "5866", "prefix": "cs of ambrisentan. In addition, the safety and tolerability of ambrisentan and ", "from": "5859", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " co-administration were evaluated.\n\nGo to:\nMethods\nSubjects\n\nMen and women aged "}, {"to": "6958", "prefix": " evidence or history of alcohol dependence, bleeding disorders, sensitivity to ", "from": "6951", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " or ambrisentan, or significant allergies. Subjects were also excluded if they h"}, {"to": "7710", "prefix": "macodynamic interaction of multiple doses of ambrisentan with a single dose of ", "from": "7703", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " in healthy subjects (Figure 1). Following a screening period of 21 days, subjec"}, {"to": "7844", "prefix": "reening period of 21 days, subjects were administered a single dose of racemic ", "from": "7837", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " 25 mg (Bristol-Myers Squibb, Princeton, NJ, USA) on day 1. On days 5 to 16, sub"}, {"to": "8168", "prefix": "stered a single 10-mg dose of ambrisentan together with a single 25-mg dose of ", "from": "8161", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": ". All study medications were administered under fasted conditions and under the "}, {"to": "8513", "prefix": "re 1\nStudy dosing regimen and blood sampling schedule. Single doses of racemic ", "from": "8506", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " 25 mg were administered on days 1 and 13, and ambrisentan 10 mg was administere"}, {"to": "8800", "prefix": "pharmacodynamics\n\nBlood samples for the pharmacokinetic assessments of R-and S-", "from": "8793", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " were collected at the following times relative to the day 1 and day 13 warfarin"}, {"to": "8880", "prefix": "arfarin were collected at the following times relative to the day 1 and day 13 ", "from": "8873", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " doses: predose ("}, {"to": "9680", "prefix": "C until analysis. Plasma concentrations of R-and S-", "from": "9673", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " were determined by a validated liquid chromatography tandem mass spectrometry ("}, {"to": "10366", "prefix": ". Estimated plasma pharmacokinetic parameters for ambrisentan and ", "from": "10359", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " enantiomers included area under the concentration"}, {"to": "10964", "prefix": ".\n\nSafety\n\nThe safety and tolerability of ambrisentan and ", "from": "10957", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " co-administration was assessed through adverse events (AEs), vital signs, clini"}, {"to": "12077", "prefix": "e trapezoidal rule.\n\nTo assess the effect of concomitant ambrisentan dosing on ", "from": "12070", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " pharmacokinetics and pharmacodynamics, individual within-subject pair-wise diff"}, {"to": "12184", "prefix": "", "from": "12177", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " "}, {"to": "12219", "prefix": "", "from": "12212", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " alone) were summarized for the natural logarithms of Cmax and AUC0"}, {"to": "12312", "prefix": "last for R-and S-", "from": "12305", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": ", and the natural logarithms of INRmax and INRAUC(0"}, {"to": "13002", "prefix": "aluated for the differences in tmax between treatment days for INR and R-and S-", "from": "12995", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " concentrations.\n\nTo assess the effect of concomitant warfarin dosing on ambrise"}, {"to": "13064", "prefix": " INR and R-and S-warfarin concentrations.\n\nTo assess the effect of concomitant ", "from": "13057", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " dosing on ambrisentan pharmacokinetics, individual within-subject pair-wise dif"}, {"to": "13172", "prefix": "", "from": "13165", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " "}, {"to": "13823", "prefix": "", "from": "13816", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " "}, {"to": "13857", "prefix": "", "from": "13850", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " alone), and a "}, {"to": "14374", "prefix": "ompleted the study according to the protocol and received two doses of racemic ", "from": "14367", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " 25 mg and 12 doses of ambrisentan 10 mg; therefore, all were included in the sa"}, {"to": "14518", "prefix": "were included in the safety, pharmacokinetic and pharmacodynamic assessments.\n\n", "from": "14511", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "Warfarin", "suffix": " pharmacokinetics\n\nThere were no clinically relevant effects of multiple doses o"}, {"to": "14666", "prefix": "time profiles of R-and S-", "from": "14659", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " (Figure 2). Both R-and S-warfarin were detectable at the first postdose samplin"}, {"to": "14700", "prefix": ". Both R-and S-", "from": "14693", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " were detectable at the first postdose sampling time (0.5 h) and reached peak co"}, {"to": "14872", "prefix": "time profiles of both ", "from": "14865", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " enantiomers were virtually superimposable in the presence (day 13) or absence ("}, {"to": "15071", "prefix": "last values for R-and S-", "from": "15064", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " increased by 4.7% (GMR 104.7; 90% CI 101.7, 107.7) and 1.6% (101.6; 90% CI 98.4"}, {"to": "15366", "prefix": ". The 90% CIs of the GMRs for R-and S-", "from": "15359", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " Cmax were within the predefined 80"}, {"to": "15599", "prefix": "e or absence of ambrisentan.\n\nTable 1\nTable 1\nEffect of ambrisentan on R-and S-", "from": "15592", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " pharmacokinetics\nFigure 2\nFigure 2\nMean plasma concentration vs. time profiles "}, {"to": "15692", "prefix": "acokinetics\nFigure 2\nFigure 2\nMean plasma concentration vs. time profiles of R-", "from": "15685", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " (a) and S-warfarin (b) following a single oral dose of racemic warfarin 25 mg a"}, {"to": "15711", "prefix": " and S-", "from": "15704", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " (b) following a single oral dose of racemic warfarin 25 mg alone ("}, {"to": "15764", "prefix": " following a single oral dose of racemic ", "from": "15757", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " 25 mg alone ("}, {"to": "15883", "prefix": " in 22 healthy subjects. Data are ...\n", "from": "15876", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "Warfarin", "suffix": " pharmacodynamics\n\nAdministration of warfarin in the presence of multiple doses "}, {"to": "15928", "prefix": "22 healthy subjects. Data are ...\nWarfarin pharmacodynamics\n\nAdministration of ", "from": "15921", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " in the presence of multiple doses of ambrisentan (Figure 3) resulted in a 14.7%"}, {"to": "16342", "prefix": " on median tmax of INR was observed.\n\nTable 2\nTable 2\nEffect of ambrisentan on ", "from": "16335", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " pharmacodynamics\nFigure 3\nFigure 3\nMean effect vs. time profile of Internationa"}, {"to": "16495", "prefix": "f International Normalized Ratio following a single oral dose of 25 mg racemic ", "from": "16488", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " alone ("}, {"to": "16663", "prefix": " standard ...\nAmbrisentan pharmacokinetics\n\nRacemic ", "from": "16656", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " had little effect on the steady-state plasma concentration"}, {"to": "16790", "prefix": ". In the presence of ", "from": "16783", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": ", steady-state ambrisentan Cmax and Cmin decreased by 2.0% (98.0; 90% CI 87.6, 1"}, {"to": "17264", "prefix": " was comparable between day 12 and day 13.\n\nTable 3\nTable 3\nEffects of racemic ", "from": "17257", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " on ambrisentan steady-state pharmacokinetics\nFigure 4\nFigure 4\nMean plasma conc"}, {"to": "17481", "prefix": " and in the presence of a single dose of ", "from": "17474", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " ("}, {"to": "18136", "prefix": "f ambrisentan 10 mg once daily resulted in slight to modest changes in R-and S-", "from": "18129", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " pharmacokinetic (AUC0"}, {"to": "18367", "prefix": "125%, suggesting that ambrisentan did not have a clinically relevant effect on ", "from": "18360", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " metabolism or the resulting therapeutic effects of warfarin. Nonetheless, warfa"}, {"to": "18427", "prefix": "relevant effect on warfarin metabolism or the resulting therapeutic effects of ", "from": "18420", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": ". Nonetheless, warfarin is a drug with a narrow therapeutic index, so that even "}, {"to": "18450", "prefix": "arin metabolism or the resulting therapeutic effects of warfarin. Nonetheless, ", "from": "18443", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " is a drug with a narrow therapeutic index, so that even slight changes must be "}, {"to": "18611", "prefix": "st be considered in the context of clinical relevance.\n\nDrug interactions with ", "from": "18604", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " have been previously demonstrated for the ERAs bosentan and sitaxsentan [9,14"}, {"to": "18907", "prefix": "sentan, and these two enzymes are also primarily responsible for metabolism of ", "from": "18900", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": ". Bosentan, which is primarily metabolized by CYP2C9 and CYP3A4, also induces th"}, {"to": "19090", "prefix": "vity of these enzymes. As a result, co-administration of bosentan with racemic ", "from": "19083", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " in healthy subjects decreased the systemic exposure (AUC) to the R-and S-enanti"}, {"to": "19407", "prefix": ". However, clinical experience with concomitant administration of bosentan and ", "from": "19400", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " in patients with PAH does not appear to result in any clinically relevant chang"}, {"to": "19508", "prefix": "ith PAH does not appear to result in any clinically relevant changes in INR or ", "from": "19501", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " dose [17]. Sitaxsentan also has an interaction with warfarin due to sitaxsentan"}, {"to": "19569", "prefix": "changes in INR or warfarin dose [17]. Sitaxsentan also has an interaction with ", "from": "19562", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " due to sitaxsentan-mediated inhibition of CYP2C9 that increases the pharmacokin"}, {"to": "19674", "prefix": "n-mediated inhibition of CYP2C9 that increases the pharmacokinetic exposure of ", "from": "19667", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": ", prolonging its effects on coagulation [16]. The increase in INR observed with "}, {"to": "19844", "prefix": "axsentan co-administration requires substantial reduction in the daily dose of ", "from": "19837", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": ". For example, an 80% reduction in warfarin dose was required during the clinica"}, {"to": "19887", "prefix": "tial reduction in the daily dose of warfarin. For example, an 80% reduction in ", "from": "19880", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " dose was required during the clinical studies of sitaxsentan to prevent excessi"}, {"to": "20552", "prefix": "last for R-and S-", "from": "20545", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " of 4.7 and 1.6%, respectively. The mechanism of these minor interactions remain"}, {"to": "20837", "prefix": "ved in this study are unlikely to result in any clinically relevant effects on ", "from": "20830", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " dose or prothrombin time. The lack of a drug interaction between ambrisentan an"}, {"to": "20927", "prefix": "se or prothrombin time. The lack of a drug interaction between ambrisentan and ", "from": "20920", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " has been corroborated in ambrisentan clinical studies that permitted the use of"}, {"to": "21016", "prefix": "as been corroborated in ambrisentan clinical studies that permitted the use of ", "from": "21009", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " or warfarin-like anticoagulants as concomitant medications [10].\n\nIn this study"}, {"to": "21028", "prefix": "oborated in ambrisentan clinical studies that permitted the use of warfarin or ", "from": "21021", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": "-like anticoagulants as concomitant medications [10].\n\nIn this study, both ambri"}, {"to": "21127", "prefix": "agulants as concomitant medications [10].\n\nIn this study, both ambrisentan and ", "from": "21120", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " were administered at clinically effective doses, and no significant changes in "}, {"to": "21259", "prefix": "ses, and no significant changes in the pharmacokinetics or pharmacodynamics of ", "from": "21252", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " were observed with co-administration. However, because of the small sample size"}, {"to": "21564", "prefix": "e regarding the safety profile of chronic co-administration of ambrisentan and ", "from": "21557", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": ". Of note, clinical studies in patients with PAH, such as those mentioned above,"}, {"to": "21721", "prefix": "ned above, have demonstrated that chronic co-administration of ambrisentan and ", "from": "21714", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " does not appear to be associated with any specific safety concerns or need for "}, {"to": "21959", "prefix": " study in healthy volunteers are consistent with that conclusion. Nonetheless, ", "from": "21952", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": " is a drug with a narrow therapeutic window; therefore, caution should be exerci"}, {"to": "22109", "prefix": " should be exercised when initiating ambrisentan therapy in patients receiving ", "from": "22102", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2686069", "exact": "warfarin", "suffix": "."}, {"to": "2497", "prefix": "mic exposure of warfarin and significantly alter clotting time, as measured by ", "from": "2487", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "PMC2686069", "exact": "prothrombin", "suffix": " time and International Normalized Ratio, thereby requiring substantial adjustme"}, {"to": "3857", "prefix": "nt population [4]. The pharmacodynamic response to warfarin includes increased ", "from": "3847", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "PMC2686069", "exact": "prothrombin", "suffix": " time (PT), which is often expressed as an International Normalized Ratio (INR) "}, {"to": "10665", "prefix": " also determined for the steady-state pharmacokinetic analysis of ambrisentan. ", "from": "10655", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "PMC2686069", "exact": "Prothrombin", "suffix": " times, presented as INR, were characterized using area under the effect"}, {"to": "20857", "prefix": " are unlikely to result in any clinically relevant effects on warfarin dose or ", "from": "20847", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "PMC2686069", "exact": "prothrombin", "suffix": " time. The lack of a drug interaction between ambrisentan and warfarin has been "}, {"to": "4780", "prefix": " have emerged as a promising class of therapeutic agents for PAH [4]. ", "from": "4773", "name": "bosentan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/75207", "setId": "PMC2686069", "exact": "Bosentan", "suffix": " and sitaxsentan are sulphonamide-based ERAs that have proven effective in the t"}, {"to": "5351", "prefix": "12]. Unlike ", "from": "5344", "name": "bosentan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/75207", "setId": "PMC2686069", "exact": "bosentan", "suffix": " and sitaxsentan, ambrisentan does not induce or inhibit CYP2C9 or CYP3A4 and is"}, {"to": "18667", "prefix": "Drug interactions with warfarin have been previously demonstrated for the ERAs ", "from": "18660", "name": "bosentan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/75207", "setId": "PMC2686069", "exact": "bosentan", "suffix": " and sitaxsentan [9,14"}, {"to": "18799", "prefix": "s have been attributed to alterations in the activity of CYP2C9 and CYP3A4 for ", "from": "18792", "name": "bosentan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/75207", "setId": "PMC2686069", "exact": "bosentan", "suffix": " and CYP2C9 for sitaxsentan, and these two enzymes are also primarily responsibl"}, {"to": "18917", "prefix": "d these two enzymes are also primarily responsible for metabolism of warfarin. ", "from": "18910", "name": "bosentan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/75207", "setId": "PMC2686069", "exact": "Bosentan", "suffix": ", which is primarily metabolized by CYP2C9 and CYP3A4, also induces the metaboli"}, {"to": "19068", "prefix": "ces the metabolic activity of these enzymes. As a result, co-administration of ", "from": "19061", "name": "bosentan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/75207", "setId": "PMC2686069", "exact": "bosentan", "suffix": " with racemic warfarin in healthy subjects decreased the systemic exposure (AUC)"}, {"to": "19394", "prefix": "d 38% [14,15]. However, clinical experience with concomitant administration of ", "from": "19387", "name": "bosentan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/75207", "setId": "PMC2686069", "exact": "bosentan", "suffix": " and warfarin in patients with PAH does not appear to result in any clinically r"}, {"to": "20723", "prefix": "known, but is unlikely to be due to CYP inhibition or induction. Compared with ", "from": "20716", "name": "bosentan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/75207", "setId": "PMC2686069", "exact": "bosentan", "suffix": ", the smaller effects observed in this study are unlikely to result in any clini"}, {"to": "4796", "prefix": "e emerged as a promising class of therapeutic agents for PAH [4]. Bosentan and ", "from": "4786", "name": "sitaxsentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C106276", "setId": "PMC2686069", "exact": "sitaxsentan", "suffix": " are sulphonamide-based ERAs that have proven effective in the treatment of PAH "}, {"to": "5367", "prefix": "12]. Unlike bosentan and ", "from": "5357", "name": "sitaxsentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C106276", "setId": "PMC2686069", "exact": "sitaxsentan", "suffix": ", ambrisentan does not induce or inhibit CYP2C9 or CYP3A4 and is therefore unlik"}, {"to": "18683", "prefix": "ions with warfarin have been previously demonstrated for the ERAs bosentan and ", "from": "18673", "name": "sitaxsentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C106276", "setId": "PMC2686069", "exact": "sitaxsentan", "suffix": " [9,14"}, {"to": "18826", "prefix": "o alterations in the activity of CYP2C9 and CYP3A4 for bosentan and CYP2C9 for ", "from": "18816", "name": "sitaxsentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C106276", "setId": "PMC2686069", "exact": "sitaxsentan", "suffix": ", and these two enzymes are also primarily responsible for metabolism of warfari"}, {"to": "19531", "prefix": "ear to result in any clinically relevant changes in INR or warfarin dose [17]. ", "from": "19521", "name": "sitaxsentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C106276", "setId": "PMC2686069", "exact": "Sitaxsentan", "suffix": " also has an interaction with warfarin due to sitaxsentan-mediated inhibition of"}, {"to": "19588", "prefix": "r warfarin dose [17]. Sitaxsentan also has an interaction with warfarin due to ", "from": "19578", "name": "sitaxsentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C106276", "setId": "PMC2686069", "exact": "sitaxsentan", "suffix": "-mediated inhibition of CYP2C9 that increases the pharmacokinetic exposure of wa"}, {"to": "19765", "prefix": " prolonging its effects on coagulation [16]. The increase in INR observed with ", "from": "19755", "name": "sitaxsentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C106276", "setId": "PMC2686069", "exact": "sitaxsentan", "suffix": " co-administration requires substantial reduction in the daily dose of warfarin."}, {"to": "19948", "prefix": " an 80% reduction in warfarin dose was required during the clinical studies of ", "from": "19938", "name": "sitaxsentan", "fullId": "http://purl.bioontology.org/ontology/MESH/C106276", "setId": "PMC2686069", "exact": "sitaxsentan", "suffix": " to prevent excessive anticoagulation and the potential for serious bleeding epi"}, {"to": "6337", "prefix": " were required to be nontobacco users, and agreed to discontinue the intake of ", "from": "6330", "name": "Caffeine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002110", "setId": "PMC2686069", "exact": "caffeine", "suffix": ", alcohol, grapefruit products, liver, and leafy green vegetables. At screening,"}, {"to": "6567", "prefix": "plastin time values within normal limits, serum aspartate aminotransferase and ", "from": "6561", "name": "Alanine", "fullId": "http://purl.bioontology.org/ontology/MESH/D000409", "setId": "PMC2686069", "exact": "alanine", "suffix": " aminotransferase concentrations "}, {"to": "45", "prefix": "Abstract\nAims\n\nStatins reduce LDL ", "from": "35", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3612775", "exact": "cholesterol", "suffix": " (LDL-C) and the risk of vascular events, but it remains uncertain whether there"}, {"to": "2166", "prefix": "ed, and effective approach to lowering blood levels of low-density lipoprotein ", "from": "2156", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3612775", "exact": "cholesterol", "suffix": " (LDL-C) and the risk of vascular events.1 Standard statin regimens typically re"}, {"to": "4916", "prefix": ". Participants were eligible for inclusion if they had non-fasting blood total ", "from": "4906", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3612775", "exact": "cholesterol", "suffix": " concentrations of at least 3.5 mmol"}, {"to": "6210", "prefix": "oanalysers used standard spectrophotometric enzymatic methods to measure total ", "from": "6200", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3612775", "exact": "cholesterol", "suffix": " and lipid fractions (including LDL-C directly) and immunoturbidometric methods "}, {"to": "12545", "prefix": " LDL ", "from": "12535", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3612775", "exact": "cholesterol", "suffix": " response and (B) apolipoprotein B response to 40 mg simvastatin daily in 3895 i"}, {"to": "22390", "prefix": " particles, but statin therapy does not reduce the number or ", "from": "22380", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3612775", "exact": "cholesterol", "suffix": " content of Lp(a) particles.33 LPA variant carriers have higher Lp(a) levels and"}, {"to": "22671", "prefix": "-", "from": "22661", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3612775", "exact": "cholesterol", "suffix": " content are needed to clarify the impact of LPA genotype on the lipid response "}, {"to": "297", "prefix": "individuals aims to identify genetic variants related to the lipid response to ", "from": "287", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3612775", "exact": "simvastatin", "suffix": " and assess their impact on vascular risk response.\n\nMethods and results\n\nA geno"}, {"to": "461", "prefix": " response to 40 mg ", "from": "451", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3612775", "exact": "simvastatin", "suffix": " daily was performed in 3895 participants in the Heart Protection Study, and the"}, {"to": "1670", "prefix": " a few per cent, and there were similar large reductions in vascular risk with ", "from": "1660", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3612775", "exact": "simvastatin", "suffix": " irrespective of genotypes associated with the lipid response to simvastatin. Co"}, {"to": "1746", "prefix": "th simvastatin irrespective of genotypes associated with the lipid response to ", "from": "1736", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3612775", "exact": "simvastatin", "suffix": ". Consequently, their value for informing clinical decisions related to maximizi"}, {"to": "4010", "prefix": "udes genome-wide association analyses of the LDL-C and ApoB responses to 40 mg ", "from": "4000", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3612775", "exact": "simvastatin", "suffix": " daily in 3895 participants in the Heart Protection Study and independent testin"}, {"to": "4463", "prefix": "tatin therapy were assessed among 18 705 genotyped patients randomly allocated ", "from": "4453", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3612775", "exact": "simvastatin", "suffix": " vs. placebo for an average of 5 years.\n\nGo to:\nMethods\nThe design of the study "}, {"to": "5402", "prefix": "6 weeks of 40 mg ", "from": "5392", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3612775", "exact": "simvastatin", "suffix": " daily, after which fully compliant individuals were randomly allocated to 40 mg"}, {"to": "5494", "prefix": "aily, after which fully compliant individuals were randomly allocated to 40 mg ", "from": "5484", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3612775", "exact": "simvastatin", "suffix": " daily or matching placebo for "}, {"to": "5684", "prefix": "i.e. while on 40 mg ", "from": "5674", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3612775", "exact": "simvastatin", "suffix": " daily). The pre-specified primary outcome for assessing the effect of statin th"}, {"to": "7186", "prefix": "5 for associations with either the LDL-C or the ApoB response to ", "from": "7176", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3612775", "exact": "simvastatin", "suffix": " therapy, or if P "}, {"to": "9233", "prefix": "6 weeks on 40 mg ", "from": "9223", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3612775", "exact": "simvastatin", "suffix": " daily ("}, {"to": "10516", "prefix": "used to estimate the effects of genotypes on the proportional risk response to ", "from": "10506", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3612775", "exact": "simvastatin", "suffix": " during the randomized phase of the Heart Protection Study. Differences in the p"}, {"to": "10982", "prefix": ". On average, compliance with 40 mg ", "from": "10972", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3612775", "exact": "simvastatin", "suffix": " daily for 4"}, {"to": "12609", "prefix": " apolipoprotein B response to 40 mg ", "from": "12599", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3612775", "exact": "simvastatin", "suffix": " daily in 3895 individuals. Single nucleotide polymorphisms with P "}, {"to": "17792", "prefix": "L reduction in LDL-C between participants allocated 40 mg ", "from": "17782", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3612775", "exact": "simvastatin", "suffix": " daily vs. placebo.25 In the genotyped participants, random allocation to 40 mg "}, {"to": "17883", "prefix": "daily vs. placebo.25 In the genotyped participants, random allocation to 40 mg ", "from": "17873", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3612775", "exact": "simvastatin", "suffix": " daily reduced the proportional 5-year risk of major vascular events by 23.3% (9"}, {"to": "18633", "prefix": ".\n\nFigure 4\nFigure 4\nEffects of ", "from": "18623", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3612775", "exact": "simvastatin", "suffix": " on major vascular events by genotype. Proportional and absolute risk reduction "}, {"to": "18956", "prefix": "iscussion\nThe present study identified associations with the lipid response to ", "from": "18946", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3612775", "exact": "simvastatin", "suffix": " for SNPs in three genes"}, {"to": "19780", "prefix": "f these variants with the proportional or absolute risk reductions produced by ", "from": "19770", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3612775", "exact": "simvastatin", "suffix": " therapy, suggesting that the clinical relevance of these variants for guiding s"}, {"to": "21788", "prefix": "lute risk and absolute LDL-C reduction associated with some of these variants, ", "from": "21778", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3612775", "exact": "simvastatin", "suffix": " therapy produced large and significant reductions in vascular risk irrespective"}, {"to": "23943", "prefix": "yopathy.19 The increase in myopathy risk seen with this variant in patients on ", "from": "23933", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3612775", "exact": "simvastatin", "suffix": " makes knowledge of this genotype of potential value in guiding statin choice (e"}, {"to": "24578", "prefix": " to be limited.\n\nLimitations\n\nThe present large study of the lipid response to ", "from": "24568", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3612775", "exact": "simvastatin", "suffix": " therapy was undertaken in a fully compliant population with individual-level re"}, {"to": "25656", "prefix": "y. With 4261 major vascular events among genotyped patients randomized between ", "from": "25646", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3612775", "exact": "simvastatin", "suffix": " vs. placebo for 5 years, this is the largest single study of the effects of gen"}, {"to": "26803", "prefix": "manufacturers of ", "from": "26793", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3612775", "exact": "simvastatin", "suffix": "), and Roche Vitamins Ltd (manufacturers of vitamins). Genotyping was supported "}, {"to": "6578", "prefix": "ker measurements were selected, and genotypes measured using the Illumina 610K ", "from": "6575", "name": "stribild", "fullId": "http://purl.bioontology.org/ontology/MESH/C575085", "setId": "PMC3612775", "exact": "Quad", "suffix": " panel. Genome-wide data were available for 3895 individuals after quality contr"}, {"to": "116", "prefix": "drug interactions between ", "from": "107", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "dabigatran", "suffix": " and P-gp modulators, using the example of clarithromycin, a strong inhibitor of"}, {"to": "554", "prefix": "rithromycin on the fourth day, or the same treatments in the reverse sequence. ", "from": "545", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "Dabigatran", "suffix": " plasma concentration and ecarin clotting time (ECT) were measured on 11 blood s"}, {"to": "850", "prefix": "se Gaussian absorption process with two compartments. The relationship between ", "from": "841", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "dabigatran", "suffix": " concentration and ECT was implemented as a linear function. No continuous covar"}, {"to": "1348", "prefix": "ively.\n\nConclusion\n\nThe model proposed effectively describes the complex PK of ", "from": "1339", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "dabigatran", "suffix": " and takes into account drug"}, {"to": "1504", "prefix": "odulators, such as clarithromycin.\n\nKeywords: bioavailability, clarithromycin, ", "from": "1495", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "dabigatran", "suffix": ", drug"}, {"to": "1874", "prefix": "ts reflux can be modulated by other drugs.\nP-gp inhibitors increase the AUC of ", "from": "1865", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "dabigatran", "suffix": " from about 50% to over 200%.\nWHAT THIS STUDY ADDS\n\nThe pharmacokinetics and pha"}, {"to": "1981", "prefix": " over 200%.\nWHAT THIS STUDY ADDS\n\nThe pharmacokinetics and pharmacodynamics of ", "from": "1972", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "dabigatran", "suffix": " were described by a two compartment model with an absorption following an inver"}, {"to": "2241", "prefix": "xplained solely by an increase in bioavailability from 6.5 to 10%.\nExposure to ", "from": "2232", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "dabigatran", "suffix": " is increased by 50% in the presence of clarithromycin and is characterized by s"}, {"to": "2683", "prefix": "c, orally administered prodrug that is rapidly converted into the active drug, ", "from": "2674", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "dabigatran", "suffix": ", by a serum esterase. It exerts its activity by direct competitive inhibition o"}, {"to": "3116", "prefix": "teral to the apical side, could be involved in the excretion of DE in the gut. ", "from": "3107", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "Dabigatran", "suffix": " is not metabolized by the cytochrome P450 enzyme system and 80% of the dose adm"}, {"to": "3280", "prefix": "e administered is directly excreted by the kidneys 3, 5. In clinical practice, ", "from": "3271", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "dabigatran", "suffix": " can be given as a fixed dose without monitoring.\n\nCompared with other anticoagu"}, {"to": "3413", "prefix": "ring.\n\nCompared with other anticoagulant drugs, such as vitamin K antagonists, ", "from": "3404", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "dabigatran", "suffix": " has a low potential for drug"}, {"to": "3661", "prefix": "rs can, respectively, decrease or increase its bioavailability. An increase in ", "from": "3652", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "dabigatran", "suffix": " area under the concentration vs. time curve (AUC), ranging from near 50% to ove"}, {"to": "4205", "prefix": "drug interactions between ", "from": "4196", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "dabigatran", "suffix": " and P-gp modulators, using clarithromycin, a strong inhibitor of P-gp, as an ex"}, {"to": "6926", "prefix": "and 23.5 h after DE administration for measurement of plasma concentrations of ", "from": "6917", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "dabigatran", "suffix": ". All analyses were performed on venous blood samples collected by venipuncture,"}, {"to": "7109", "prefix": "lood collected in citrate tubes for PD and heparinized tubes for PK analysis.\n\n", "from": "7100", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "Dabigatran", "suffix": " plasma concentrations were determined using the validated liquid chromatography"}, {"to": "7413", "prefix": "1.\n\nThe anticoagulant effect of ", "from": "7404", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "dabigatran", "suffix": " was measured by an ecarin clotting time (ECT) assay, as described by Nowak 7. T"}, {"to": "7615", "prefix": " values were below 2.5%. ECT is the reference coagulation test for analysis of ", "from": "7606", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "dabigatran", "suffix": "'s anticoagulant effect 8.\n\nModel development and evaluation\n\nData analysis was "}, {"to": "8375", "prefix": "ral steps. The first step consisted in identifying the structural PK model for ", "from": "8366", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "dabigatran", "suffix": " without clarithromycin. The second step comprised the estimation of PK"}, {"to": "9983", "prefix": "model were evaluated to describe the relationship between the concentration of ", "from": "9974", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "dabigatran", "suffix": " and its effect 8.\n\nCovariate model\n\nBody mass index, weight, lean body weight, "}, {"to": "10454", "prefix": "n the absorption model in order to test the presence of an interaction between ", "from": "10445", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "dabigatran", "suffix": " and clarithromycin:\n\nequation image\nwhere "}, {"to": "14012", "prefix": "PD model corresponded to a linear relationship between ", "from": "14003", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "dabigatran", "suffix": " concentration and its anticoagulant effect, based on the ECT, implemented as fo"}, {"to": "14236", "prefix": "fficient, ECT0 is the baseline ECT value and CDabi the plasma concentration of ", "from": "14227", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "dabigatran", "suffix": ". Random effect was tested only on K. The error model was proportional. The valu"}, {"to": "14832", "prefix": ". The modification of the absorption rate of ", "from": "14823", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "dabigatran", "suffix": " and its variability in the presence of clarithromycin is illustrated in Figure "}, {"to": "15326", "prefix": " with clarithromycin.\n\nFigure 1\nFigure 1\nAbsorption rate of ", "from": "15317", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "dabigatran", "suffix": " with and without clarithromycin. The solid black line represents the median abs"}, {"to": "15432", "prefix": " clarithromycin. The solid black line represents the median absorption rate of ", "from": "15423", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "dabigatran", "suffix": " without clarithromycin (A) and with clarithromycin (B). The dashed lines indica"}, {"to": "16308", "prefix": "d that the best model to describe the pharmacokinetics and pharmacodynamics of ", "from": "16299", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "dabigatran", "suffix": " in healthy volunteers was a two compartment model with an absorption following "}, {"to": "16975", "prefix": " sampling did not allow relevant characterization of the complex absorption of ", "from": "16966", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "dabigatran", "suffix": " DE 8, 15, 16.\n\nConcerning methodology, we employed an original and powerful sta"}, {"to": "17827", "prefix": "another P-gp substrate 12.\n\nIn our study, clarithromycin increased exposure to ", "from": "17818", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "dabigatran", "suffix": " (AUC) by more than 50%. This increase resulted in a proportional prolongation o"}, {"to": "18738", "prefix": "which limits the biotransformation of the drug's oral etexilate form to active ", "from": "18729", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "dabigatran", "suffix": ". In a recent follow-up subanalysis of the RE-LY study (atrial fibrillation trea"}, {"to": "19111", "prefix": " were significantly associated with higher ", "from": "19102", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "dabigatran", "suffix": " peak concentrations.\n\nFigure 3\nFigure 3\nPharmacokinetic profiles of three volun"}, {"to": "19215", "prefix": "tions.\n\nFigure 3\nFigure 3\nPharmacokinetic profiles of three volunteers. Fit of ", "from": "19206", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "dabigatran", "suffix": " plasma concentration with (solid line) and without (dashed line) clarithromycin"}, {"to": "19518", "prefix": "sion, the proposed model effectively describes the complex pharmacokinetics of ", "from": "19509", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "dabigatran", "suffix": ", allowing drug"}, {"to": "19660", "prefix": "ulation to be taken into account. Using this model, we showed that exposure to ", "from": "19651", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "dabigatran", "suffix": " is increased by 50% in the presence of clarithromycin and is characterized by s"}, {"to": "19920", "prefix": "drug interactions with ", "from": "19911", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1546356", "setId": "PMC3703233", "exact": "dabigatran", "suffix": " concerning P-gp inhibitors, inductors or substrates.\n\nGo to:\nAcknowledgments\nTh"}, {"to": "173", "prefix": "drug interactions between dabigatran and P-gp modulators, using the example of ", "from": "160", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": ", a strong inhibitor of P-gp.\n\nMethods\n\nTen healthy male volunteers were randomi"}, {"to": "404", "prefix": " and in the second treatment period 500 mg ", "from": "391", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": " twice daily during 3 days and then 300 mg DE plus 500 mg clarithromycin on the "}, {"to": "476", "prefix": "500 mg clarithromycin twice daily during 3 days and then 300 mg DE plus 500 mg ", "from": "463", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": " on the fourth day, or the same treatments in the reverse sequence. Dabigatran p"}, {"to": "1053", "prefix": "nificant decrease in the objective function. The concomitant administration of ", "from": "1040", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": " induced a significant change only in DE bioavailability, which increased from 6"}, {"to": "1179", "prefix": "y in DE bioavailability, which increased from 6.5% to 10.1% in the presence of ", "from": "1166", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": ". Clarithromycin increased peak concentration and AUC by 60.2% and 49.1% respect"}, {"to": "1195", "prefix": "ability, which increased from 6.5% to 10.1% in the presence of clarithromycin. ", "from": "1182", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "Clarithromycin", "suffix": " increased peak concentration and AUC by 60.2% and 49.1% respectively.\n\nConclusi"}, {"to": "1448", "prefix": "drug interactions with P-gp activity modulators, such as ", "from": "1435", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": ".\n\nKeywords: bioavailability, clarithromycin, dabigatran, drug"}, {"to": "1492", "prefix": " P-gp activity modulators, such as clarithromycin.\n\nKeywords: bioavailability, ", "from": "1479", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": ", dabigatran, drug"}, {"to": "2295", "prefix": "from 6.5 to 10%.\nExposure to dabigatran is increased by 50% in the presence of ", "from": "2282", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": " and is characterized by substantial variability.\nGo to:\nIntroduction\nDabigatran"}, {"to": "4247", "prefix": "drug interactions between dabigatran and P-gp modulators, using ", "from": "4234", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": ", a strong inhibitor of P-gp, as an example.\n\nGo to:\nMethods\nStudy design\n\nThis "}, {"to": "5401", "prefix": "ceding the study, were excluded. Subjects with known hypersensitivity to DE or ", "from": "5388", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": ", or who had taken any medicine during the week before the study were also exclu"}, {"to": "5750", "prefix": "ndomized 1:1 to receive either first DE alone and then a combination of DE and ", "from": "5737", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": ", or first the combination treatment and then DE alone. The two treatment period"}, {"to": "6087", "prefix": ". During the DE plus ", "from": "6074", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": " treatment period, volunteers received on the first 3 days 500 mg clarithromycin"}, {"to": "6167", "prefix": "larithromycin treatment period, volunteers received on the first 3 days 500 mg ", "from": "6154", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": " (Zeclar"}, {"to": "6324", "prefix": ". On the 4th day they received 300 mg of DE plus 500 mg of ", "from": "6311", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": " at t0 (07.30 h). The clarithromycin administration regimen was chosen on the gr"}, {"to": "6360", "prefix": ". The ", "from": "6347", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": " administration regimen was chosen on the grounds of its relevance to clinical p"}, {"to": "8398", "prefix": "t step consisted in identifying the structural PK model for dabigatran without ", "from": "8385", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": ". The second step comprised the estimation of PK"}, {"to": "8614", "prefix": "with and without ", "from": "8601", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": "). Finally, drug"}, {"to": "10322", "prefix": "tes on absorption and structural parameters. The concomitant administration of ", "from": "10309", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": ", was included as a categorical covariate in the absorption model in order to te"}, {"to": "10473", "prefix": "n model in order to test the presence of an interaction between dabigatran and ", "from": "10460", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": ":\n\nequation image\nwhere "}, {"to": "10837", "prefix": "s bcp0076-0107-mu4.jpg is the covariate effect, Clari is equal to 1 during the ", "from": "10824", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": " plus DE treatment period and 0 during the DE alone period, An external file tha"}, {"to": "11055", "prefix": "name is bcp0076-0107-mu5.jpgis the inter-patient variability in the absence of ", "from": "11042", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": ", and An external file that holds a picture, illustration, etc.\nObject name is b"}, {"to": "11233", "prefix": "6-0107-mu6.jpg is the increase in inter-patient variability in the presence of ", "from": "11220", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": ".\n\nThe covariates were added to the model in accordance with the procedure descr"}, {"to": "14500", "prefix": "he PK and PD model parameters.\n\nTesting the interaction\n\nThe administration of ", "from": "14487", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": " induced a significant change only in the bioavailability of DE. The population "}, {"to": "14701", "prefix": " in the presence of ", "from": "14688", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": ", the inter-individual variability of F increasing from 0.386 to 0.725 (CV%). Th"}, {"to": "14886", "prefix": "on of the absorption rate of dabigatran and its variability in the presence of ", "from": "14873", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": " is illustrated in Figure "}, {"to": "14952", "prefix": "Figure1.1. The impact of ", "from": "14939", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": " on peak concentration was an increase of 60.2% from (median, min"}, {"to": "15071", "prefix": " without ", "from": "15058", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": " to 279.4 "}, {"to": "15120", "prefix": " with ", "from": "15107", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": ". On AUC, an increase of 49.1% was observed from 1220.5 "}, {"to": "15222", "prefix": " without ", "from": "15209", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": " to 1820.4 "}, {"to": "15276", "prefix": " with ", "from": "15263", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": ".\n\nFigure 1\nFigure 1\nAbsorption rate of dabigatran with and without clarithromyc"}, {"to": "15358", "prefix": "rithromycin.\n\nFigure 1\nFigure 1\nAbsorption rate of dabigatran with and without ", "from": "15345", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": ". The solid black line represents the median absorption rate of dabigatran witho"}, {"to": "15455", "prefix": "e solid black line represents the median absorption rate of dabigatran without ", "from": "15442", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": " (A) and with clarithromycin (B). The dashed lines indicate the 5% and 95% perce"}, {"to": "15483", "prefix": " and with ", "from": "15470", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": " (B). The dashed lines indicate the 5% and 95% percentiles\nModel evaluation\n\nThe"}, {"to": "16122", "prefix": "ence interval of simulations. The grey circles represent data obtained without ", "from": "16109", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": ". The white circles represent data obtained with clarithromycin\nGo to:\nDiscussio"}, {"to": "16185", "prefix": "btained without clarithromycin. The white circles represent data obtained with ", "from": "16172", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": "\nGo to:\nDiscussion\nOur study showed that the best model to describe the pharmaco"}, {"to": "17794", "prefix": "effect on the absorption of digoxin, another P-gp substrate 12.\n\nIn our study, ", "from": "17781", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": " increased exposure to dabigatran (AUC) by more than 50%. This increase resulted"}, {"to": "18129", "prefix": "sult illustrates perfectly the mechanism involved in the inhibition of P-gp by ", "from": "18116", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": ".\n\nIn another study, evaluating the same interaction, the authors showed 19 and "}, {"to": "18396", "prefix": " interindividual variability in DE bioavailability observed in the presence of ", "from": "18383", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": " (38.6 vs. 72.5%) in our study, the effect of clarithromycin differing substanti"}, {"to": "18456", "prefix": " in our study, the effect of ", "from": "18443", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": " differing substantially from one volunteer to another (Figure "}, {"to": "19295", "prefix": " ", "from": "19282", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": ". Grey circles represent data obtained without clarithromycin. White circles rep"}, {"to": "19356", "prefix": " clarithromycin. Grey circles represent data obtained without ", "from": "19343", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": ". White circles represent data obtained with clarithromycin ...\nIn conclusion, t"}, {"to": "19415", "prefix": "ta obtained without clarithromycin. White circles represent data obtained with ", "from": "19402", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": " ...\nIn conclusion, the proposed model effectively describes the complex pharmac"}, {"to": "19714", "prefix": ", we showed that exposure to dabigatran is increased by 50% in the presence of ", "from": "19701", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC3703233", "exact": "clarithromycin", "suffix": " and is characterized by substantial variability. In contrast to non-compartment"}, {"to": "2773", "prefix": "y a serum esterase. It exerts its activity by direct competitive inhibition of ", "from": "2766", "name": "Thrombin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10528", "setId": "PMC3703233", "exact": "thrombin", "suffix": ". DE has a bioavailability of 6.5% due to a complex absorption process 3, necess"}, {"to": "3389", "prefix": "xed dose without monitoring.\n\nCompared with other anticoagulant drugs, such as ", "from": "3381", "name": "Vitamin K", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11258", "setId": "PMC3703233", "exact": "vitamin K", "suffix": " antagonists, dabigatran has a low potential for drug"}, {"to": "3804", "prefix": "nging from near 50% to over 200%, has been reported after co-administration of ", "from": "3795", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/MESH/D000638", "setId": "PMC3703233", "exact": "amiodarone", "suffix": ", ketoconazole, quinidine or verapamil 5. Some of these drug"}, {"to": "3818", "prefix": "ear 50% to over 200%, has been reported after co-administration of amiodarone, ", "from": "3807", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC3703233", "exact": "ketoconazole", "suffix": ", quinidine or verapamil 5. Some of these drug"}, {"to": "3829", "prefix": "r 200%, has been reported after co-administration of amiodarone, ketoconazole, ", "from": "3821", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "PMC3703233", "exact": "quinidine", "suffix": " or verapamil 5. Some of these drug"}, {"to": "3842", "prefix": "een reported after co-administration of amiodarone, ketoconazole, quinidine or ", "from": "3834", "name": "Verapamil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11170", "setId": "PMC3703233", "exact": "verapamil", "suffix": " 5. Some of these drug"}, {"to": "5124", "prefix": " and ", "from": "5115", "name": "Fibrinogen", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4385", "setId": "PMC3703233", "exact": "fibrinogen", "suffix": " level. Volunteers with renal insufficiency, hepatic insufficiency or a peptic u"}, {"to": "12644", "prefix": " s, median plasma ", "from": "12635", "name": "Fibrinogen", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4385", "setId": "PMC3703233", "exact": "fibrinogen", "suffix": " concentration 2.25 (1.6"}, {"to": "5992", "prefix": "two ", "from": "5986", "name": "Pradaxa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1037046", "setId": "PMC3703233", "exact": "Pradaxa", "suffix": ""}, {"to": "7045", "prefix": "venous blood samples collected by venipuncture, using whole blood collected in ", "from": "7039", "name": "Citrate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114200", "setId": "PMC3703233", "exact": "citrate", "suffix": " tubes for PD and heparinized tubes for PK analysis.\n\nDabigatran plasma concentr"}, {"to": "10087", "prefix": " 8.\n\nCovariate model\n\nBody mass index, weight, lean body weight, size, age and ", "from": "10078", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003404", "setId": "PMC3703233", "exact": "creatinine", "suffix": " clearance [calculated using the Modification of Diet in Renal Disease (MDRD) an"}, {"to": "12706", "prefix": "1 and median plasma ", "from": "12697", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003404", "setId": "PMC3703233", "exact": "creatinine", "suffix": " concentration 77 (72"}, {"to": "13828", "prefix": "weight, body mass index, body surface area, ", "from": "13819", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003404", "setId": "PMC3703233", "exact": "creatinine", "suffix": " clearance) was associated with a significant decrease in the objective function"}, {"to": "17736", "prefix": "successfully used to model P-gp inhibition and its effect on the absorption of ", "from": "17730", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "PMC3703233", "exact": "digoxin", "suffix": ", another P-gp substrate 12.\n\nIn our study, clarithromycin increased exposure to"}, {"to": "82", "prefix": "ABSTRACT\nIn clinical practice, antifungal therapy may be switched from ", "from": "72", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " to voriconazole; such sequential use poses the potential for drug interaction d"}, {"to": "350", "prefix": "el, randomized, two-way crossover study investigated the effect of concomitant ", "from": "340", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " on voriconazole pharmacokinetics in 10 subjects: 8 extensive metabolizers and 2"}, {"to": "547", "prefix": "19. The study consisted of 4-day voriconazole-only and 5-day voriconazole-plus-", "from": "537", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " treatments, separated by a 14-day washout. Voriconazole pharmacokinetics were d"}, {"to": "877", "prefix": "t the magnitude of drug interaction should antifungal therapy be switched from ", "from": "867", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " to voriconazole, following various simulated lag times for the switch. In CYP2C"}, {"to": "995", "prefix": "various simulated lag times for the switch. In CYP2C19 extensive metabolizers, ", "from": "985", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " increased the maximum plasma concentration and the area under the plasma concen"}, {"to": "1238", "prefix": "n poor metabolizers, however, voriconazole pharmacokinetics were unaffected by ", "from": "1228", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": ". The simulations based on pharmacokinetic modeling predicted that if voriconazo"}, {"to": "1386", "prefix": "ted that if voriconazole was started 6, 12, 24, or 36 h after the last dose of ", "from": "1376", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": ", the voriconazole AUC ratios (sequential therapy versus voriconazole only) afte"}, {"to": "1587", "prefix": " 1.41, 1.28, and 1.14, respectively. This suggests that the remaining systemic ", "from": "1577", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " would result in a marked drug interaction with voriconazole for "}, {"to": "1754", "prefix": "ugh no safety issues were observed during coadministration, concomitant use of ", "from": "1744", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " and voriconazole is not recommended. Frequent monitoring for voriconazole-relat"}, {"to": "1919", "prefix": "related adverse events is advisable if voriconazole is used sequentially after ", "from": "1909", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": ".\n\nGo to:\nINTRODUCTION\nThe pharmacokinetics of the triazole antifungal voriconaz"}, {"to": "2582", "prefix": ", including the structurally related antifungal agent ", "from": "2572", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " (12).\n\nVoriconazole and fluconazole have similar mechanisms of action, and use "}, {"to": "2618", "prefix": ".\n\nVoriconazole and ", "from": "2608", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " have similar mechanisms of action, and use of the combination of both drugs doe"}, {"to": "2924", "prefix": "r as combination therapy. However, voriconazole may be used sequentially after ", "from": "2914", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " in clinical practice. This situation is most likely to arise in hematology pati"}, {"to": "3038", "prefix": "his situation is most likely to arise in hematology patients who are receiving ", "from": "3028", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " prophylaxis for the prevention of invasive Candida infections and who subsequen"}, {"to": "3368", "prefix": "ho are treated for invasive Candida infections later confirmed to be caused by ", "from": "3358", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": "-resistant strains. The rationale for a therapeutic switch from fluconazole to v"}, {"to": "3443", "prefix": " by fluconazole-resistant strains. The rationale for a therapeutic switch from ", "from": "3433", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " to voriconazole is supported by in vitro and in vivo data showing good activity"}, {"to": "3564", "prefix": "y in vitro and in vivo data showing good activity of voriconazole against many ", "from": "3554", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": "-resistant Candida strains, even though there is some azole cross-resistance (14"}, {"to": "3736", "prefix": ". In Europe, voriconazole is specifically approved for the treatment of ", "from": "3726", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": "-resistant, serious invasive Candida infections (2).\n\nFluconazole is a potent CY"}, {"to": "3801", "prefix": ".\n\n", "from": "3791", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "Fluconazole", "suffix": " is a potent CYP2C19 inhibitor (27), and its systemic presence could inhibit vor"}, {"to": "4083", "prefix": "ment of serious and life-threatening fungal infections requiring a switch from ", "from": "4073", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " to voriconazole, it may not be feasible to delay voriconazole therapy to allow "}, {"to": "4194", "prefix": "may not be feasible to delay voriconazole therapy to allow sufficient time for ", "from": "4184", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " washout. The elimination half-life of fluconazole is approximately 30 h in adul"}, {"to": "4244", "prefix": "to allow sufficient time for fluconazole washout. The elimination half-life of ", "from": "4234", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " is approximately 30 h in adults (16), and fluconazole levels with the potential"}, {"to": "4298", "prefix": ", and ", "from": "4288", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " levels with the potential for inhibiting CYP2C19 activity may therefore be expe"}, {"to": "4428", "prefix": "g CYP2C19 activity may therefore be expected for some period of time following ", "from": "4418", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " discontinuation.\n\nTo examine these issues, we studied the pharmacokinetics of v"}, {"to": "4556", "prefix": "sues, we studied the pharmacokinetics of voriconazole when coadministered with ", "from": "4546", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " to assess the maximal impact of fluconazole-mediated CYP2C19 inhibition on vori"}, {"to": "4600", "prefix": "iconazole when coadministered with fluconazole to assess the maximal impact of ", "from": "4590", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": "-mediated CYP2C19 inhibition on voriconazole levels. A physiologically based pha"}, {"to": "4891", "prefix": "ions where voriconazole therapy is initiated after various lag times following ", "from": "4881", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " discontinuation.\n\nGo to:\nMATERIALS AND METHODS\nStudy design.\nThis was an open-l"}, {"to": "6000", "prefix": " period of voriconazole-only treatment and a 5-day period of voriconazole-plus-", "from": "5990", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " combination treatment, separated by a 14-day washout phase. The order in which "}, {"to": "6387", "prefix": "llowed by 200 mg every 12 h on days 2 and 3 and a single 200-mg dose on day 4. ", "from": "6377", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "Fluconazole", "suffix": " was administered as a single loading dose of 400 mg orally on day 1, followed b"}, {"to": "6633", "prefix": "for the administration of both agents. During the combination treatment phase, ", "from": "6623", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " was administered immediately after the voriconazole dose.\n\nA blood sample was t"}, {"to": "9194", "prefix": "conazole and was compared between voriconazole alone and the voriconazole-plus-", "from": "9184", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " combination. All statistical analyses were performed using SAS (version 8.02) s"}, {"to": "10143", "prefix": "e 1.\nSummary of input parameters for voriconazole used in the Simcyp model\nFor ", "from": "10133", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": ", standard inputs available within Simcyp were utilized. The inhibition constant"}, {"to": "10243", "prefix": " of ", "from": "10233", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " for the CYP2C19 enzyme used for simulating drug-drug interaction was 2.1 "}, {"to": "10374", "prefix": ". The literature reports Ki values for ", "from": "10364", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": "-mediated CYP3A4 inhibition ranging from 1.9 to 63 "}, {"to": "10794", "prefix": "both sexes. The dose, dosing interval, and dosing duration of voriconazole and ", "from": "10784", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " in the simulation were identical to those used in the clinical study. According"}, {"to": "11050", "prefix": ", or voriconazole was coadministered with ", "from": "11040", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " (first fluconazole dose of 400 mg and subsequent doses of 200 mg each every 24 "}, {"to": "11069", "prefix": "first ", "from": "11059", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " dose of 400 mg and subsequent doses of 200 mg each every 24 h). For simulating "}, {"to": "11179", "prefix": ". For simulating sequential dosing, ", "from": "11169", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " dosing remained the same, while voriconazole administration was initiated at ti"}, {"to": "11320", "prefix": "istration was initiated at times of 6, 12, and 24 h following the last dose of ", "from": "11310", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": ".\n\nGo to:\nRESULTS\nStudy population.\nFive subjects (mean age, 29 years; age range"}, {"to": "11487", "prefix": " received voriconazole alone followed by voriconazole plus ", "from": "11477", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": ", and five (mean age, 24 years; age range, 22 to 27 years) received voriconazole"}, {"to": "11584", "prefix": " received voriconazole plus ", "from": "11574", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " followed by voriconazole alone. The mean weights in the two groups were 70 kg ("}, {"to": "12488", "prefix": "d poor metabolizers given voriconazole alone and voriconazole with concomitant ", "from": "12478", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": ".\nTable 2.\nTable 2.\nPharmacokinetic parameters for voriconazole\nCoadministration"}, {"to": "12583", "prefix": "le 2.\nTable 2.\nPharmacokinetic parameters for voriconazole\nCoadministration of ", "from": "12573", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " had a different effect on voriconazole pharmacokinetics in EMs and PMs. In EMs,"}, {"to": "12753", "prefix": " plasma concentrations of voriconazole were increased when coadministered with ", "from": "12743", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " compared with voriconazole alone, while in PMs, the concentration-time profiles"}, {"to": "12950", "prefix": ". In EMs, Cmax and AUC12 values increased significantly when ", "from": "12940", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " was coadministered with voriconazole compared with when voriconazole was admini"}, {"to": "13173", "prefix": ".\n\nCoadministration of ", "from": "13163", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " reduced the intersubject variability of voriconazole Cmaxs and AUCs in EMs (Tab"}, {"to": "13407", "prefix": "ole pharmacokinetic parameters ranged from 18.7 to 34.9% for voriconazole plus ", "from": "13397", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": ", whereas they ranged from 37.8 to 62.0% for voriconazole alone.\n\nSimcyp modelin"}, {"to": "13853", "prefix": "voriconazole plus ", "from": "13843", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " versus fluconazole alone) of 2.65 (95% CI, 1.33 to 5.85) and 1.40 (95% CI, 1.14"}, {"to": "13872", "prefix": "voriconazole plus fluconazole versus ", "from": "13862", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " alone) of 2.65 (95% CI, 1.33 to 5.85) and 1.40 (95% CI, 1.14 to 2.20) for voric"}, {"to": "14273", "prefix": "ted mean plasma concentrations of voriconazole dosed alone or with concomitant ", "from": "14263", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " in extensive metabolizers (A) and poor metabolizers (B). Data points represent "}, {"to": "14565", "prefix": "luate the effect of sequential dosing of voriconazole following termination of ", "from": "14555", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " therapy. The doses of both drugs remained the same as in the clinical study, wi"}, {"to": "14789", "prefix": " after the last dose of ", "from": "14779", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": ". Accordingly, fluconazole was given at a dose of 400 mg on day 1, followed by 2"}, {"to": "14815", "prefix": " after the last dose of fluconazole. Accordingly, ", "from": "14805", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " was given at a dose of 400 mg on day 1, followed by 200 mg every 24 h on days 2"}, {"to": "15321", "prefix": "e dose of 200 mg and could result in higher voriconazole concentrations due to ", "from": "15311", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": "-mediated interaction. The predicted Cmax and AUC values for voriconazole and th"}, {"to": "15443", "prefix": "voriconazole after ", "from": "15433", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " versus voriconazole alone) are presented in Table 3. The predicted Cmaxs were c"}, {"to": "15678", "prefix": "for voriconazole were higher when this antifungal was given sequentially after ", "from": "15668", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " than when voriconazole was given alone. For instance, the voriconazole AUC rati"}, {"to": "15837", "prefix": "le AUC ratio was 1.51 when voriconazole was started 6 h after the last dose of ", "from": "15827", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": ", indicating a significant drug interaction. This effect diminished as the lag t"}, {"to": "16247", "prefix": "to 36 h. Overall, the simulation results suggest that the inhibitory effect of ", "from": "16237", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " on voriconazole metabolism would last for at least 24 h after the last dose of "}, {"to": "16338", "prefix": "on voriconazole metabolism would last for at least 24 h after the last dose of ", "from": "16328", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": ".\n\nTable 3.\nTable 3.\nModel-predicted pharmacokinetic parameters for the first do"}, {"to": "16479", "prefix": "c parameters for the first dose of voriconazole, when given sequentially after ", "from": "16469", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " at various lag times after the last fluconazole dose\nTolerability and safety.\nT"}, {"to": "16527", "prefix": " when given sequentially after fluconazole at various lag times after the last ", "from": "16517", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " dose\nTolerability and safety.\nThere were no serious adverse events or discontin"}, {"to": "17119", "prefix": "tly fewer adverse events were reported during treatment with voriconazole plus ", "from": "17109", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " (14 versus 11 treatment-related adverse events). No apparent clinically signifi"}, {"to": "17413", "prefix": "\nThe results of this clinical study suggest that concomitant administration of ", "from": "17403", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " and voriconazole significantly increases plasma voriconazole concentrations in "}, {"to": "17627", "prefix": "all for PMs, the pharmacokinetics of voriconazole appeared to be unaffected by ", "from": "17617", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " in that population. This observation is not surprising, since the innate metabo"}, {"to": "18415", "prefix": "this model. PBPK simulations of sequential use suggested that the influence of ", "from": "18405", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " on systemic levels of voriconazole would persist for at least 24 h after the la"}, {"to": "18517", "prefix": " levels of voriconazole would persist for at least 24 h after the last dose of ", "from": "18507", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": ".\n\nFluconazole is categorized as a potent inhibitor of CYP2C9 and CPY2C19, as we"}, {"to": "18531", "prefix": "iconazole would persist for at least 24 h after the last dose of fluconazole.\n\n", "from": "18521", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "Fluconazole", "suffix": " is categorized as a potent inhibitor of CYP2C9 and CPY2C19, as well as a modera"}, {"to": "18646", "prefix": "nt inhibitor of CYP2C9 and CPY2C19, as well as a moderate inhibitor of CYP3A4. ", "from": "18636", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "Fluconazole", "suffix": "'s effect on voriconazole pharmacokinetics is probably due to its inhibition of "}, {"to": "19271", "prefix": ". In contrast, ", "from": "19261", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " inhibits CYP2C19 and CYP3A4 with Kis of 2.1 "}, {"to": "19732", "prefix": "onazole pharmacokinetics was reduced when voriconazole was coadministered with ", "from": "19722", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " compared with the variability in pharmacokinetics when voriconazole was adminis"}, {"to": "19898", "prefix": "inistered alone. This presumably occurred because the inhibition of CYP2C19 by ", "from": "19888", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " caused EM subjects to behave in a similar fashion to PM subjects in this respec"}, {"to": "20066", "prefix": "ect. Nevertheless, the systemic exposure to voriconazole when given along with ", "from": "20056", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " observed in EMs did not exceed that observed in PMs. In clinical practice, vori"}, {"to": "20297", "prefix": "dose. On the basis of these results, it is tempting to deduce that concomitant ", "from": "20287", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " could be used as a booster to achieve therapeutic levels of voriconazole with d"}, {"to": "20683", "prefix": "eral factors that require additional consideration. First, the optimum dose of ", "from": "20673", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " needed to boost voriconazole levels is currently unknown. Second, fluconazole a"}, {"to": "20761", "prefix": " fluconazole needed to boost voriconazole levels is currently unknown. Second, ", "from": "20751", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " alters the shape of the concentration-time curve and markedly increases voricon"}, {"to": "21126", "prefix": ", especially if the patient has not responded to prior ", "from": "21116", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " therapy. Finally, there is also a greater likelihood that patients will experie"}, {"to": "21367", "prefix": " than with either agent alone. Concomitant administration of voriconazole with ", "from": "21357", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " is therefore not recommended at present until additional dose-finding studies a"}, {"to": "21537", "prefix": "re conducted to evaluate the efficacy and safety of specific voriconazole-plus-", "from": "21527", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " dosing regimens in the relevant therapeutic settings.\n\nNo clinically significan"}, {"to": "21701", "prefix": "ificant safety concerns were noted during coadministration of voriconazole and ", "from": "21691", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " in healthy volunteers in the present study. However, elevated voriconazole plas"}, {"to": "22089", "prefix": ". A ", "from": "22079", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": "-mediated increase in voriconazole levels would put patients at risk of exceedin"}, {"to": "22258", "prefix": "ng this threshold. The PBPK model predicted that in a sequential use scenario, ", "from": "22248", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " would continue to have a substantial effect on voriconazole pharmacokinetics fo"}, {"to": "22371", "prefix": " a substantial effect on voriconazole pharmacokinetics for at least 24 h after ", "from": "22361", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " discontinuation. However, it should be noted that voriconazole accumulates afte"}, {"to": "22549", "prefix": " and that the plasma voriconazole levels seen on the first day of ", "from": "22539", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": "-voriconazole sequential therapy are expected to be below those seen at steady s"}, {"to": "22702", "prefix": " seen at steady state. This would diminish some of the risks associated with a ", "from": "22692", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": "-mediated increase in voriconazole levels during sequential use in clinical prac"}, {"to": "22926", "prefix": "ents for voriconazole-associated adverse events during overlapping exposure to ", "from": "22916", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": ", especially if the affected patients receive additional concomitant drugs that "}, {"to": "23334", "prefix": "\nIn conclusion, the results of this study show that concomitantly administered ", "from": "23324", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " significantly increases plasma levels of voriconazole. Therefore, concomitant u"}, {"to": "23431", "prefix": "icantly increases plasma levels of voriconazole. Therefore, concomitant use of ", "from": "23421", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " and voriconazole is not recommended until it has been further evaluated in clin"}, {"to": "23651", "prefix": "related adverse events is advisable if voriconazole is used sequentially after ", "from": "23641", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": ", especially when voriconazole is initiated within 24 h of the last fluconazole "}, {"to": "23730", "prefix": "fluconazole, especially when voriconazole is initiated within 24 h of the last ", "from": "23720", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "PMC3195022", "exact": "fluconazole", "suffix": " dose.\n\nGo to:\nACKNOWLEDGMENTS\nThis study was sponsored by Pfizer Inc. Editorial"}, {"to": "98", "prefix": "T\nIn clinical practice, antifungal therapy may be switched from fluconazole to ", "from": "87", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": "; such sequential use poses the potential for drug interaction due to cytochrome"}, {"to": "234", "prefix": "-mediated inhibition of ", "from": "223", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " metabolism. This open-label, randomized, two-way crossover study investigated t"}, {"to": "366", "prefix": " two-way crossover study investigated the effect of concomitant fluconazole on ", "from": "355", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " pharmacokinetics in 10 subjects: 8 extensive metabolizers and 2 poor metabolize"}, {"to": "502", "prefix": " metabolizers and 2 poor metabolizers of CYP2C19. The study consisted of 4-day ", "from": "491", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": "-only and 5-day voriconazole-plus-fluconazole treatments, separated by a 14-day "}, {"to": "530", "prefix": "abolizers of CYP2C19. The study consisted of 4-day voriconazole-only and 5-day ", "from": "519", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": "-plus-fluconazole treatments, separated by a 14-day washout. Voriconazole pharma"}, {"to": "603", "prefix": "5-day voriconazole-plus-fluconazole treatments, separated by a 14-day washout. ", "from": "592", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "Voriconazole", "suffix": " pharmacokinetics were determined by noncompartmental analyses. A physiologicall"}, {"to": "893", "prefix": " of drug interaction should antifungal therapy be switched from fluconazole to ", "from": "882", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": ", following various simulated lag times for the switch. In CYP2C19 extensive met"}, {"to": "1115", "prefix": " of ", "from": "1104", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " by 57% and 178%, respectively. In poor metabolizers, however, voriconazole phar"}, {"to": "1190", "prefix": " of voriconazole by 57% and 178%, respectively. In poor metabolizers, however, ", "from": "1179", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " pharmacokinetics were unaffected by fluconazole. The simulations based on pharm"}, {"to": "1320", "prefix": "uconazole. The simulations based on pharmacokinetic modeling predicted that if ", "from": "1309", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " was started 6, 12, 24, or 36 h after the last dose of fluconazole, the voricona"}, {"to": "1404", "prefix": "onazole was started 6, 12, 24, or 36 h after the last dose of fluconazole, the ", "from": "1393", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " AUC ratios (sequential therapy versus voriconazole only) after the first dose w"}, {"to": "1455", "prefix": "sequential therapy versus ", "from": "1444", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " only) after the first dose would be 1.51, 1.41, 1.28, and 1.14, respectively. T"}, {"to": "1647", "prefix": " remaining systemic fluconazole would result in a marked drug interaction with ", "from": "1636", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " for "}, {"to": "1771", "prefix": "sues were observed during coadministration, concomitant use of fluconazole and ", "from": "1760", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " is not recommended. Frequent monitoring for voriconazole-related adverse events"}, {"to": "1828", "prefix": "se of fluconazole and voriconazole is not recommended. Frequent monitoring for ", "from": "1817", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": "-related adverse events is advisable if voriconazole is used sequentially after "}, {"to": "1880", "prefix": "d. Frequent monitoring for voriconazole-related adverse events is advisable if ", "from": "1869", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " is used sequentially after fluconazole.\n\nGo to:\nINTRODUCTION\nThe pharmacokineti"}, {"to": "2002", "prefix": "conazole.\n\nGo to:\nINTRODUCTION\nThe pharmacokinetics of the triazole antifungal ", "from": "1991", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " have been widely studied (7, 19, 20). The drug is primarily metabolized by hepa"}, {"to": "2351", "prefix": "19 probably accounts for a substantial part of the intersubject variability in ", "from": "2340", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " pharmacokinetics (22, 29, 30). Voriconazole metabolism may also be influenced b"}, {"to": "2395", "prefix": ". ", "from": "2384", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "Voriconazole", "suffix": " metabolism may also be influenced by the concomitant administration of other dr"}, {"to": "2602", "prefix": ".\n\n", "from": "2591", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "Voriconazole", "suffix": " and fluconazole have similar mechanisms of action, and use of the combination o"}, {"to": "2881", "prefix": "kely that they would be administered together as combination therapy. However, ", "from": "2870", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " may be used sequentially after fluconazole in clinical practice. This situation"}, {"to": "3176", "prefix": "dida infections and who subsequently develop invasive aspergillosis, for which ", "from": "3165", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " is regarded the treatment of choice (18, 26, 28). To a lesser extent, it may al"}, {"to": "3459", "prefix": "-resistant strains. The rationale for a therapeutic switch from fluconazole to ", "from": "3448", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " is supported by in vitro and in vivo data showing good activity of voriconazole"}, {"to": "3539", "prefix": "oriconazole is supported by in vitro and in vivo data showing good activity of ", "from": "3528", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " against many fluconazole-resistant Candida strains, even though there is some a"}, {"to": "3678", "prefix": ". In Europe, ", "from": "3667", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " is specifically approved for the treatment of fluconazole-resistant, serious in"}, {"to": "3890", "prefix": ", and its systemic presence could inhibit ", "from": "3879", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " metabolism and potentially increase the frequency of voriconazole-related adver"}, {"to": "3956", "prefix": "ould inhibit voriconazole metabolism and potentially increase the frequency of ", "from": "3945", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": "-related adverse events. In the treatment of serious and life-threatening fungal"}, {"to": "4099", "prefix": " and life-threatening fungal infections requiring a switch from fluconazole to ", "from": "4088", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": ", it may not be feasible to delay voriconazole therapy to allow sufficient time "}, {"to": "4145", "prefix": "ing a switch from fluconazole to voriconazole, it may not be feasible to delay ", "from": "4134", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " therapy to allow sufficient time for fluconazole washout. The elimination half-"}, {"to": "4519", "prefix": " discontinuation.\n\nTo examine these issues, we studied the pharmacokinetics of ", "from": "4508", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " when coadministered with fluconazole to assess the maximal impact of fluconazol"}, {"to": "4644", "prefix": "ole to assess the maximal impact of fluconazole-mediated CYP2C19 inhibition on ", "from": "4633", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " levels. A physiologically based pharmacokinetic (PBPK) modeling approach was th"}, {"to": "4824", "prefix": "magnitude of the drug interaction in situations where ", "from": "4813", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " therapy is initiated after various lag times following fluconazole discontinuat"}, {"to": "5933", "prefix": "r participation.\n\nThe study was divided into two treatments, a 4-day period of ", "from": "5922", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": "-only treatment and a 5-day period of voriconazole-plus-fluconazole combination "}, {"to": "5983", "prefix": "reatments, a 4-day period of voriconazole-only treatment and a 5-day period of ", "from": "5972", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": "-plus-fluconazole combination treatment, separated by a 14-day washout phase. Th"}, {"to": "6214", "prefix": " assigned randomly. All treatments were administered orally in a fasted state. ", "from": "6203", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "Voriconazole", "suffix": " was given as a loading dose of 400 mg orally twice daily (every 12 h) on day 1,"}, {"to": "6685", "prefix": "ombination treatment phase, fluconazole was administered immediately after the ", "from": "6674", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " dose.\n\nA blood sample was taken at the screening visit to determine the CYP2C19"}, {"to": "7165", "prefix": "gns, and 12-lead electrocardiogram measurements were used to evaluate safety.\n\n", "from": "7154", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "Voriconazole", "suffix": " pharmacokinetics.\nSerial plasma samples for voriconazole pharmacokinetics were "}, {"to": "7222", "prefix": " to evaluate safety.\n\nVoriconazole pharmacokinetics.\nSerial plasma samples for ", "from": "7211", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " pharmacokinetics were collected predosing and at 1, 2, 3, 4, 6, 8, 10, 12, 16, "}, {"to": "7386", "prefix": "2, 16, 24, 36, and 48 h after dosing on day 4. Plasma samples were assayed for ", "from": "7375", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " by a previously validated method using automated solid-phase extraction, follow"}, {"to": "7632", "prefix": "ml, respectively.\n\n", "from": "7621", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "Voriconazole", "suffix": " pharmacokinetic parameters were determined by noncompartmental analyses. Maximu"}, {"to": "8584", "prefix": ".\n\nStatistical analyses.\nPharmacokinetic parameters for ", "from": "8573", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " calculated on day 4 of each treatment period were used as endpoints for the sta"}, {"to": "9112", "prefix": " of ", "from": "9101", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " and was compared between voriconazole alone and the voriconazole-plus-fluconazo"}, {"to": "9150", "prefix": " of voriconazole and was compared between ", "from": "9139", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " alone and the voriconazole-plus-fluconazole combination. All statistical analys"}, {"to": "9177", "prefix": " of voriconazole and was compared between voriconazole alone and the ", "from": "9166", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": "-plus-fluconazole combination. All statistical analyses were performed using SAS"}, {"to": "9627", "prefix": ". A Simcyp model for ", "from": "9616", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " was developed using the physicochemical properties, in vitro data, and clinical"}, {"to": "10102", "prefix": ".\n\nTable 1.\nTable 1.\nSummary of input parameters for ", "from": "10091", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " used in the Simcyp model\nFor fluconazole, standard inputs available within Simc"}, {"to": "10778", "prefix": "rs, and included both sexes. The dose, dosing interval, and dosing duration of ", "from": "10767", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " and fluconazole in the simulation were identical to those used in the clinical "}, {"to": "10890", "prefix": "he simulation were identical to those used in the clinical study. Accordingly, ", "from": "10879", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " alone was dosed every 12 h for 4 days (first two doses of 400 mg and subsequent"}, {"to": "11014", "prefix": ", or ", "from": "11003", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " was coadministered with fluconazole (first fluconazole dose of 400 mg and subse"}, {"to": "11224", "prefix": " For simulating sequential dosing, fluconazole dosing remained the same, while ", "from": "11213", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " administration was initiated at times of 6, 12, and 24 h following the last dos"}, {"to": "11439", "prefix": " received ", "from": "11428", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " alone followed by voriconazole plus fluconazole, and five (mean age, 24 years; "}, {"to": "11470", "prefix": " received voriconazole alone followed by ", "from": "11459", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " plus fluconazole, and five (mean age, 24 years; age range, 22 to 27 years) rece"}, {"to": "11567", "prefix": " received ", "from": "11556", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " plus fluconazole followed by voriconazole alone. The mean weights in the two gr"}, {"to": "11609", "prefix": " received voriconazole plus fluconazole followed by ", "from": "11598", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " alone. The mean weights in the two groups were 70 kg (range, 63 to 77 kg) and 6"}, {"to": "12023", "prefix": ".\n\nPharmacokinetic data.\nFigure 1 shows the mean plasma ", "from": "12012", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " concentration-time profile by metabolizer type and by treatment group. As expec"}, {"to": "12120", "prefix": "ntration-time profile by metabolizer type and by treatment group. As expected, ", "from": "12109", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " concentrations in PMs were markedly higher than those in EMs. The Cmax and AUC1"}, {"to": "12217", "prefix": "ntrations in PMs were markedly higher than those in EMs. The Cmax and AUC12 of ", "from": "12206", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " in PMs were approximately 2.7- and 2.5-fold higher, respectively, than those in"}, {"to": "12372", "prefix": ".\n\nFig. 1.\nFig. 1.\nMean plasma concentrations of ", "from": "12361", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " over time in extensive and poor metabolizers given voriconazole alone and voric"}, {"to": "12436", "prefix": "centrations of voriconazole over time in extensive and poor metabolizers given ", "from": "12425", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " alone and voriconazole with concomitant fluconazole.\nTable 2.\nTable 2.\nPharmaco"}, {"to": "12459", "prefix": "zole over time in extensive and poor metabolizers given voriconazole alone and ", "from": "12448", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " with concomitant fluconazole.\nTable 2.\nTable 2.\nPharmacokinetic parameters for "}, {"to": "12551", "prefix": "with concomitant fluconazole.\nTable 2.\nTable 2.\nPharmacokinetic parameters for ", "from": "12540", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": "\nCoadministration of fluconazole had a different effect on voriconazole pharmaco"}, {"to": "12622", "prefix": "ers for voriconazole\nCoadministration of fluconazole had a different effect on ", "from": "12611", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " pharmacokinetics in EMs and PMs. In EMs, plasma concentrations of voriconazole "}, {"to": "12701", "prefix": "voriconazole pharmacokinetics in EMs and PMs. In EMs, plasma concentrations of ", "from": "12690", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " were increased when coadministered with fluconazole compared with voriconazole "}, {"to": "12780", "prefix": "voriconazole were increased when coadministered with fluconazole compared with ", "from": "12769", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " alone, while in PMs, the concentration-time profiles were similar during both t"}, {"to": "12987", "prefix": " AUC12 values increased significantly when fluconazole was coadministered with ", "from": "12976", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " compared with when voriconazole was administered alone (Table 2). In PMs, the p"}, {"to": "13019", "prefix": "antly when fluconazole was coadministered with voriconazole compared with when ", "from": "13008", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " was administered alone (Table 2). In PMs, the pharmacokinetic parameters were s"}, {"to": "13226", "prefix": ".\n\nCoadministration of fluconazole reduced the intersubject variability of ", "from": "13215", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " Cmaxs and AUCs in EMs (Table 2). In this group, the coefficient of variations i"}, {"to": "13320", "prefix": ". In this group, the coefficient of variations in ", "from": "13309", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " pharmacokinetic parameters ranged from 18.7 to 34.9% for voriconazole plus fluc"}, {"to": "13390", "prefix": "tions in voriconazole pharmacokinetic parameters ranged from 18.7 to 34.9% for ", "from": "13379", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " plus fluconazole, whereas they ranged from 37.8 to 62.0% for voriconazole alone"}, {"to": "13464", "prefix": " for voriconazole plus fluconazole, whereas they ranged from 37.8 to 62.0% for ", "from": "13453", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " alone.\n\nSimcyp modeling and simulations.\nThe in vitro data and clinical pharmac"}, {"to": "13612", "prefix": "ta and clinical pharmacokinetic parameters were used to build a PBPK model for ", "from": "13601", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " using Simcyp. Figure 2 shows the predicted plasma concentrations for voriconazo"}, {"to": "13694", "prefix": "iconazole using Simcyp. Figure 2 shows the predicted plasma concentrations for ", "from": "13683", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " in EMs and PMs using a dosing regimen identical to that used in the clinical st"}, {"to": "13836", "prefix": "", "from": "13825", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " plus fluconazole versus fluconazole alone) of 2.65 (95% CI, 1.33 to 5.85) and 1"}, {"to": "13959", "prefix": " for ", "from": "13948", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " AUCt and Cmax, respectively. However, no significant effect was found in PMs. T"}, {"to": "14229", "prefix": "alidity of the model.\n\nFig. 2.\nFig. 2.\nSimulated mean plasma concentrations of ", "from": "14218", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " dosed alone or with concomitant fluconazole in extensive metabolizers (A) and p"}, {"to": "14528", "prefix": "er simulations were carried out to evaluate the effect of sequential dosing of ", "from": "14517", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " following termination of fluconazole therapy. The doses of both drugs remained "}, {"to": "14679", "prefix": "both drugs remained the same as in the clinical study, with the exception that ", "from": "14668", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " was initiated sequentially at various time intervals (6, 12, 24, and 36 h) afte"}, {"to": "14918", "prefix": "t a dose of 400 mg on day 1, followed by 200 mg every 24 h on days 2 to 5, and ", "from": "14907", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " was initiated sequentially at doses of 400 mg every 12 h on day 5, followed by "}, {"to": "15147", "prefix": "parameters of interest from these simulations were the Cmax and AUC values for ", "from": "15136", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " after the first loading dose of 400 mg, since this represents double the mainte"}, {"to": "15287", "prefix": "is represents double the maintenance dose of 200 mg and could result in higher ", "from": "15276", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " concentrations due to fluconazole-mediated interaction. The predicted Cmax and "}, {"to": "15394", "prefix": "due to fluconazole-mediated interaction. The predicted Cmax and AUC values for ", "from": "15383", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " and their ratios (voriconazole after fluconazole versus voriconazole alone) are"}, {"to": "15425", "prefix": "", "from": "15414", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " after fluconazole versus voriconazole alone) are presented in Table 3. The pred"}, {"to": "15463", "prefix": "voriconazole after fluconazole versus ", "from": "15452", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " alone) are presented in Table 3. The predicted Cmaxs were comparable for both t"}, {"to": "15604", "prefix": "axs were comparable for both treatments; however, the predicted AUC values for ", "from": "15593", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " were higher when this antifungal was given sequentially after fluconazole than "}, {"to": "15701", "prefix": "higher when this antifungal was given sequentially after fluconazole than when ", "from": "15690", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " was given alone. For instance, the voriconazole AUC ratio was 1.51 when voricon"}, {"to": "15749", "prefix": "ly after fluconazole than when voriconazole was given alone. For instance, the ", "from": "15738", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " AUC ratio was 1.51 when voriconazole was started 6 h after the last dose of flu"}, {"to": "15786", "prefix": "nazole was given alone. For instance, the voriconazole AUC ratio was 1.51 when ", "from": "15775", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " was started 6 h after the last dose of fluconazole, indicating a significant dr"}, {"to": "16263", "prefix": "l, the simulation results suggest that the inhibitory effect of fluconazole on ", "from": "16252", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " metabolism would last for at least 24 h after the last dose of fluconazole.\n\nTa"}, {"to": "16436", "prefix": "e 3.\nTable 3.\nModel-predicted pharmacokinetic parameters for the first dose of ", "from": "16425", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": ", when given sequentially after fluconazole at various lag times after the last "}, {"to": "17102", "prefix": "ms, although slightly fewer adverse events were reported during treatment with ", "from": "17091", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " plus fluconazole (14 versus 11 treatment-related adverse events). No apparent c"}, {"to": "17430", "prefix": "this clinical study suggest that concomitant administration of fluconazole and ", "from": "17419", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " significantly increases plasma voriconazole concentrations in CYP2C19 EMs. Alth"}, {"to": "17474", "prefix": " administration of fluconazole and voriconazole significantly increases plasma ", "from": "17463", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " concentrations in CYP2C19 EMs. Although the sample size was small for PMs, the "}, {"to": "17586", "prefix": "P2C19 EMs. Although the sample size was small for PMs, the pharmacokinetics of ", "from": "17575", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " appeared to be unaffected by fluconazole in that population. This observation i"}, {"to": "18450", "prefix": "quential use suggested that the influence of fluconazole on systemic levels of ", "from": "18439", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " would persist for at least 24 h after the last dose of fluconazole.\n\nFluconazol"}, {"to": "18671", "prefix": "nd CPY2C19, as well as a moderate inhibitor of CYP3A4. Fluconazole's effect on ", "from": "18660", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " pharmacokinetics is probably due to its inhibition of CPY2C19, since voriconazo"}, {"to": "18753", "prefix": "iconazole pharmacokinetics is probably due to its inhibition of CPY2C19, since ", "from": "18742", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " metabolism is mainly mediated by CYP2C19, followed by CYP3A4, with CYP2C9 appea"}, {"to": "19091", "prefix": ". In a previous study, concomitant omeprazole increased the average AUC of ", "from": "19080", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " by about 40% (32); however, the magnitude of this increase does not require adj"}, {"to": "19199", "prefix": "; however, the magnitude of this increase does not require adjustments in the ", "from": "19188", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " dose when coadministered with omeprazole (17). In contrast, fluconazole inhibit"}, {"to": "19484", "prefix": ", and hence, it is not unexpected that its overall effect on ", "from": "19473", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " levels is greater than that of omeprazole.\n\nInterestingly, in this population o"}, {"to": "19649", "prefix": "tion of healthy Asian volunteers, the considerable intersubject variability in ", "from": "19638", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " pharmacokinetics was reduced when voriconazole was coadministered with fluconaz"}, {"to": "19696", "prefix": "ble intersubject variability in voriconazole pharmacokinetics was reduced when ", "from": "19685", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " was coadministered with fluconazole compared with the variability in pharmacoki"}, {"to": "19800", "prefix": "stered with fluconazole compared with the variability in pharmacokinetics when ", "from": "19789", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " was administered alone. This presumably occurred because the inhibition of CYP2"}, {"to": "20032", "prefix": "fashion to PM subjects in this respect. Nevertheless, the systemic exposure to ", "from": "20021", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " when given along with fluconazole observed in EMs did not exceed that observed "}, {"to": "20154", "prefix": "ole observed in EMs did not exceed that observed in PMs. In clinical practice, ", "from": "20143", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " is administered to both EMs and PMs at an identical dose. On the basis of these"}, {"to": "20370", "prefix": "mitant fluconazole could be used as a booster to achieve therapeutic levels of ", "from": "20359", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " with doses lower than those currently recommended, to allow once-daily voricona"}, {"to": "20454", "prefix": "onazole with doses lower than those currently recommended, to allow once-daily ", "from": "20443", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " dosing, or to reduce the intersubject variability in voriconazole pharmacokinet"}, {"to": "20520", "prefix": "w once-daily voriconazole dosing, or to reduce the intersubject variability in ", "from": "20509", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " pharmacokinetics. Although this approach seems attractive, there are several fa"}, {"to": "20712", "prefix": "ditional consideration. First, the optimum dose of fluconazole needed to boost ", "from": "20701", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " levels is currently unknown. Second, fluconazole alters the shape of the concen"}, {"to": "20846", "prefix": "nazole alters the shape of the concentration-time curve and markedly increases ", "from": "20835", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " trough concentrations, which have been linked to a higher incidence of voricona"}, {"to": "20930", "prefix": "onazole trough concentrations, which have been linked to a higher incidence of ", "from": "20919", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": "-associated toxicity (24). Third, an additional microbiologic benefit with the c"}, {"to": "21350", "prefix": "th agents combined than with either agent alone. Concomitant administration of ", "from": "21339", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " with fluconazole is therefore not recommended at present until additional dose-"}, {"to": "21520", "prefix": "-finding studies are conducted to evaluate the efficacy and safety of specific ", "from": "21509", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": "-plus-fluconazole dosing regimens in the relevant therapeutic settings.\n\nNo clin"}, {"to": "21685", "prefix": "o clinically significant safety concerns were noted during coadministration of ", "from": "21674", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " and fluconazole in healthy volunteers in the present study. However, elevated v"}, {"to": "21776", "prefix": " and fluconazole in healthy volunteers in the present study. However, elevated ", "from": "21765", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " plasma levels are associated with an increased likelihood of visual side effect"}, {"to": "21952", "prefix": ". Therapeutic drug monitoring of ", "from": "21941", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " suggests that trough concentrations greater than 6 "}, {"to": "22123", "prefix": ". A fluconazole-mediated increase in ", "from": "22112", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " levels would put patients at risk of exceeding this threshold. The PBPK model p"}, {"to": "22318", "prefix": "ntial use scenario, fluconazole would continue to have a substantial effect on ", "from": "22307", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " pharmacokinetics for at least 24 h after fluconazole discontinuation. However, "}, {"to": "22434", "prefix": "least 24 h after fluconazole discontinuation. However, it should be noted that ", "from": "22423", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " accumulates after multiple dosing (7) and that the plasma voriconazole levels s"}, {"to": "22505", "prefix": " and that the plasma ", "from": "22494", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " levels seen on the first day of fluconazole-voriconazole sequential therapy are"}, {"to": "22562", "prefix": " and that the plasma voriconazole levels seen on the first day of fluconazole-", "from": "22551", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " sequential therapy are expected to be below those seen at steady state. This wo"}, {"to": "22736", "prefix": " diminish some of the risks associated with a fluconazole-mediated increase in ", "from": "22725", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " levels during sequential use in clinical practice. However, it is prudent to re"}, {"to": "22857", "prefix": "in clinical practice. However, it is prudent to regularly monitor patients for ", "from": "22846", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": "-associated adverse events during overlapping exposure to fluconazole, especiall"}, {"to": "23051", "prefix": "nts receive additional concomitant drugs that inhibit CYP isozymes involved in ", "from": "23040", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " metabolism. This is not an unlikely scenario, given the often serious underlyin"}, {"to": "23388", "prefix": "oncomitantly administered fluconazole significantly increases plasma levels of ", "from": "23377", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": ". Therefore, concomitant use of fluconazole and voriconazole is not recommended "}, {"to": "23448", "prefix": "s plasma levels of voriconazole. Therefore, concomitant use of fluconazole and ", "from": "23437", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " is not recommended until it has been further evaluated in clinical trials. Freq"}, {"to": "23560", "prefix": "ntil it has been further evaluated in clinical trials. Frequent monitoring for ", "from": "23549", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": "-related adverse events is advisable if voriconazole is used sequentially after "}, {"to": "23612", "prefix": "s. Frequent monitoring for voriconazole-related adverse events is advisable if ", "from": "23601", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " is used sequentially after fluconazole, especially when voriconazole is initiat"}, {"to": "23681", "prefix": "isable if voriconazole is used sequentially after fluconazole, especially when ", "from": "23670", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "PMC3195022", "exact": "voriconazole", "suffix": " is initiated within 24 h of the last fluconazole dose.\n\nGo to:\nACKNOWLEDGMENTS\n"}, {"to": "2732", "prefix": "f action, and use of the combination of both drugs does not appear to offer an ", "from": "2724", "name": "imidacloprid", "fullId": "http://purl.bioontology.org/ontology/MESH/C082359", "setId": "PMC3195022", "exact": "advantage", "suffix": " over use of the single agents (23); therefore, it is unlikely that they would b"}, {"to": "5418", "prefix": "except ", "from": "5406", "name": "Acetaminophen", "fullId": "http://purl.bioontology.org/ontology/RXNORM/161", "setId": "PMC3195022", "exact": "acetaminophen", "suffix": ") within 3 weeks of starting the study; had received any experimental drug withi"}, {"to": "18884", "prefix": ". ", "from": "18875", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7646", "setId": "PMC3195022", "exact": "Omeprazole", "suffix": " is another potent competitive inhibitor of CYP2C19 (Ki, 3.1 "}, {"to": "19049", "prefix": ". In a previous study, concomitant ", "from": "19040", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7646", "setId": "PMC3195022", "exact": "omeprazole", "suffix": " increased the average AUC of voriconazole by about 40% (32); however, the magni"}, {"to": "19240", "prefix": "does not require adjustments in the voriconazole dose when coadministered with ", "from": "19231", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7646", "setId": "PMC3195022", "exact": "omeprazole", "suffix": " (17). In contrast, fluconazole inhibits CYP2C19 and CYP3A4 with Kis of 2.1 "}, {"to": "19526", "prefix": "xpected that its overall effect on voriconazole levels is greater than that of ", "from": "19517", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7646", "setId": "PMC3195022", "exact": "omeprazole", "suffix": ".\n\nInterestingly, in this population of healthy Asian volunteers, the considerab"}, {"to": "163", "prefix": "elimination of ", "from": "154", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/MESH/D000638", "setId": "PMC3900249", "exact": "amiodarone", "suffix": " resulted in a 6"}, {"to": "256", "prefix": "65% change in warfarin dose requirement. To evaluate the roles of ", "from": "247", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/MESH/D000638", "setId": "PMC3900249", "exact": "amiodarone", "suffix": " and its circulating metabolites in this highly variable inhibitory drug interac"}, {"to": "983", "prefix": "darone, to be a major contributor to the drug interaction between warfarin and ", "from": "974", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/MESH/D000638", "setId": "PMC3900249", "exact": "amiodarone", "suffix": ".\n\nKeywords: drug-drug interactions, plasma, in vitro, in vivo, pharmacokinetics"}, {"to": "1153", "prefix": " warfarin, inhibition, adverse drug reactions, metabolites\nGo to:\nIntroduction\n", "from": "1144", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/MESH/D000638", "setId": "PMC3900249", "exact": "Amiodarone", "suffix": " (AMIO) was originally introduced as an anti-anginal drug over 40 years ago (1),"}, {"to": "2357", "prefix": "40% depending on the ", "from": "2348", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/MESH/D000638", "setId": "PMC3900249", "exact": "amiodarone", "suffix": " maintenance dose (15, 16).\n\nEarly studies by Trager, O"}, {"to": "3809", "prefix": " and deaminated ", "from": "3800", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/MESH/D000638", "setId": "PMC3900249", "exact": "amiodarone", "suffix": " (DAA). Another potential product of AMIO metabolism is the O-desalkylated deriv"}, {"to": "4338", "prefix": ".\n\nFigure 1\nFigure 1\n", "from": "4329", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/MESH/D000638", "setId": "PMC3900249", "exact": "Amiodarone", "suffix": " metabolites in human plasma.\nThe aims of this research were threefold. Firstly,"}, {"to": "4564", "prefix": " 3.0 after ", "from": "4555", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/MESH/D000638", "setId": "PMC3900249", "exact": "amiodarone", "suffix": " was added or discontinued in a cohort of patients undergoing stable warfarin th"}, {"to": "6217", "prefix": " 3.0 after addition or discontinuation of ", "from": "6208", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/MESH/D000638", "setId": "PMC3900249", "exact": "amiodarone", "suffix": ".\nSynthesis of AMIO Metabolite Standards\n\nTo enable the most rigorous quantitati"}, {"to": "14230", "prefix": "measuring free drug fraction. The plasma free fractions for the metabolites of ", "from": "14221", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/MESH/D000638", "setId": "PMC3900249", "exact": "amiodarone", "suffix": " - MDEA, 3"}, {"to": "21311", "prefix": "l of 230 incidents in which an out-of-range INR was attributed to the warfarin-", "from": "21302", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/MESH/D000638", "setId": "PMC3900249", "exact": "amiodarone", "suffix": " drug interaction were identified. These incidents were associated with 163 epis"}, {"to": "21415", "prefix": "on were identified. These incidents were associated with 163 episodes in which ", "from": "21406", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/MESH/D000638", "setId": "PMC3900249", "exact": "amiodarone", "suffix": " was added or discontinued in patients taking warfarin, or in which the amiodaro"}, {"to": "21497", "prefix": "odarone was added or discontinued in patients taking warfarin, or in which the ", "from": "21488", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/MESH/D000638", "setId": "PMC3900249", "exact": "amiodarone", "suffix": " dose was changed. Of these 163 episodes, 90 were excluded from analysis due to "}, {"to": "21641", "prefix": "ded from analysis due to either unstable warfarin therapy prior to addition of ", "from": "21632", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/MESH/D000638", "setId": "PMC3900249", "exact": "amiodarone", "suffix": " (n"}, {"to": "21692", "prefix": ", an interaction due to change in ", "from": "21683", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/MESH/D000638", "setId": "PMC3900249", "exact": "amiodarone", "suffix": " dose (n"}, {"to": "21729", "prefix": "; warfarin and ", "from": "21720", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/MESH/D000638", "setId": "PMC3900249", "exact": "amiodarone", "suffix": " having been initiated concurrently (n"}, {"to": "21819", "prefix": "", "from": "21810", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/MESH/D000638", "setId": "PMC3900249", "exact": "amiodarone", "suffix": " therapy being less than 1 month (n"}, {"to": "22072", "prefix": "o represented in the cohort.\n\nRecruitment of Warfarin Patients for Analysis of ", "from": "22063", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/MESH/D000638", "setId": "PMC3900249", "exact": "Amiodarone", "suffix": " Plasma Metabolites\n\nThree patients stabilized on warfarin who were to be initia"}, {"to": "28523", "prefix": "", "from": "28514", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/MESH/D000638", "setId": "PMC3900249", "exact": "amiodarone", "suffix": " therapy. This work was supported by the National Institutes of Health [Project "}, {"to": "202", "prefix": "65% change in ", "from": "195", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " dose requirement. To evaluate the roles of amiodarone and its circulating metab"}, {"to": "583", "prefix": "-", "from": "576", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " 7-hydroxylation in human liver microsomes, by parent drug and metabolites, and "}, {"to": "968", "prefix": "idesethylamiodarone, to be a major contributor to the drug interaction between ", "from": "961", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " and amiodarone.\n\nKeywords: drug-drug interactions, plasma, in vitro, in vivo, p"}, {"to": "1073", "prefix": "Keywords: drug-drug interactions, plasma, in vitro, in vivo, pharmacokinetics, ", "from": "1066", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": ", inhibition, adverse drug reactions, metabolites\nGo to:\nIntroduction\nAmiodarone"}, {"to": "1871", "prefix": "eraction that AMIO exhibits is its potentiation of the anticoagulant effect of ", "from": "1864", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": ", which greatly increases the patient"}, {"to": "2090", "prefix": ". Stroke is a major concern in patients with AF and since ", "from": "2083", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " is the preferred treatment for stroke prevention, AMIO is therefore often co-ad"}, {"to": "2194", "prefix": " treatment for stroke prevention, AMIO is therefore often co-administered with ", "from": "2187", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " (14). An interaction always occurs between these two drugs (15, 16) that typica"}, {"to": "2319", "prefix": " that typically necessitates a dose reduction in ", "from": "2312", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " of 25"}, {"to": "2510", "prefix": "-", "from": "2503", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " (17) and decreases the formation clearances of (S)-warfarin metabolites to a gr"}, {"to": "2570", "prefix": "-", "from": "2563", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " metabolites to a greater extent than (R)-warfarin metabolites (18). However, AM"}, {"to": "2620", "prefix": "-", "from": "2613", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " metabolites (18). However, AMIO proved to be a relatively weak inhibitor of (S)"}, {"to": "2709", "prefix": "-", "from": "2702", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " metabolism in human liver microsomes (HLM) (18) and AMIO"}, {"to": "3031", "prefix": "cause CYP2C9 is the major P450 that terminates the pharmacological activity of ", "from": "3024", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " (21). Moreover, MDEA is present in human plasma at a concentration approximatel"}, {"to": "3437", "prefix": ". These observations prompt the hypothesis that a major mechanism of the ", "from": "3430", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": "-AMIO interaction is inhibition of CYP2C9-mediated (S)-warfarin metabolism by MD"}, {"to": "3500", "prefix": "-", "from": "3493", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " metabolism by MDEA.\n\nAlthough MDEA is the major metabolite of AMIO in humans, a"}, {"to": "4004", "prefix": "sible that one or more of these minor AMIO metabolites could contribute to the ", "from": "3997", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " drug interaction and, in fact, several close analogs of ODAA have been shown to"}, {"to": "4494", "prefix": "d. Firstly, a retrospective study was performed to determine mean and range of ", "from": "4487", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " dose change required to maintain an INR of 2.0 "}, {"to": "4641", "prefix": "amiodarone was added or discontinued in a cohort of patients undergoing stable ", "from": "4634", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " therapy. Next, stabilized plasma concentrations, [I], of AMIO and five of its c"}, {"to": "4779", "prefix": "I], of AMIO and five of its circulating metabolites were determined in several ", "from": "4772", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " patients undergoing combination therapy. In order to measure low metabolite con"}, {"to": "5165", "prefix": "-", "from": "5158", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " 7-hydroxylation in HLM. To best assess the likelihood of an in vivo drug intera"}, {"to": "5488", "prefix": "nt drug and circulating metabolites.\n\nGo to:\nResults\nIn vivo Effect of AMIO on ", "from": "5481", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "Warfarin", "suffix": " Dose Requirement\n\nOver the six year period of the retrospective clinical evalua"}, {"to": "5693", "prefix": "fitting the parameters of our analysis for an out of range INR attributed to a ", "from": "5686", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": "-AMIO drug interaction which occurred upon either addition or elimination of AMI"}, {"to": "5821", "prefix": "n either addition or elimination of AMIO therapy to patients undergoing stable ", "from": "5814", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " treatment. Results of the analysis are described in Table 1. The mean change in"}, {"to": "5910", "prefix": "reatment. Results of the analysis are described in Table 1. The mean change in ", "from": "5903", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " dose required to maintain an INR of 2"}, {"to": "5970", "prefix": "3 was 25.6%. ", "from": "5963", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "Warfarin", "suffix": " dosing change requirements were highly variable, with a range of 5.9% to 65%.\n\n"}, {"to": "6129", "prefix": "o 65%.\n\nTable 1\nTable 1\nDemographic characteristics of patients, and change in ", "from": "6122", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " dose required to maintain INR 2.0 "}, {"to": "7656", "prefix": "n of these compounds in the plasma of clinical patients undergoing concomitant ", "from": "7649", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " and AMIO therapy (Figure 2). Blood was drawn from three patients at various tim"}, {"to": "7939", "prefix": "en to plateau at around 8 weeks after addition of AMIO therapy to a stabilized ", "from": "7932", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " regime (Figure 3), therefore, average drug and metabolite plasma concentrations"}, {"to": "8997", "prefix": ", already undergoing ", "from": "8990", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " treatment, who were started on AMIO therapy. Error bars denote standard error m"}, {"to": "9212", "prefix": "-", "from": "9205", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " 7-hydroxylation by AMIO and its circulating human metabolites.\nInhibition of (S"}, {"to": "9302", "prefix": "-", "from": "9295", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "Warfarin", "suffix": " 7-Hydroxylation in HLM\n\nKinetic studies were carried out to determine the enzym"}, {"to": "9474", "prefix": "-", "from": "9467", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " metabolism by AMIO and its metabolites, in pooled HLM. Both ODAA (Figure 4A) an"}, {"to": "9634", "prefix": "-", "from": "9627", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " 7-hydroxylation, with KI"}, {"to": "9795", "prefix": "-OHMDEA all appeared to be mixed inhibitors of ", "from": "9788", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " metabolism in HLM (Figure 4C"}, {"to": "10548", "prefix": "-", "from": "10541", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " concentration (1, 4 and 16 "}, {"to": "11740", "prefix": "-", "from": "11733", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": ", for studies in HLM, or 2 "}, {"to": "11785", "prefix": "mL rac-", "from": "11778", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " (approximate physiological concentration), for studies in human plasma. Warfari"}, {"to": "11866", "prefix": ", for studies in human plasma. ", "from": "11859", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "Warfarin", "suffix": " was found not to affect metabolite protein binding in either HLM or plasma as t"}, {"to": "12434", "prefix": "-", "from": "12427", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " 7-hydroxylation in HLM, was calculated to be 0.028, 0.20, 1.1, 3.4, 0.0076 and "}, {"to": "12957", "prefix": ".\n\nGo to:\nDiscussion\nThe ", "from": "12950", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": "-AMIO interaction is known to be due to metabolic inhibition of the P450 enzymes"}, {"to": "13079", "prefix": "e to metabolic inhibition of the P450 enzymes responsible for the clearance of ", "from": "13072", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": ", mainly CYP2C9 (18). In patient studies, we confirmed (i) the wide inter-indivi"}, {"to": "13208", "prefix": " the wide inter-individual variability in the magnitude of the ", "from": "13201", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": "-AMIO interaction reported initially by Kerin et al., (15), and (ii) the plasma "}, {"to": "14512", "prefix": "-", "from": "14505", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " 7-hydroxylation by AMIO, MDEA, 3"}, {"to": "14663", "prefix": "-", "from": "14656", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " metabolism in HLM while the amine compounds AMIO, MDEA, 3"}, {"to": "14776", "prefix": "-", "from": "14769", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " 7-hydroxylation (Figure 4). Ohyama, et al., previously reported AMIO to be a no"}, {"to": "14927", "prefix": "-", "from": "14920", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " metabolism in microsomes derived from human B-lymphoblastoid cells co-expressin"}, {"to": "15713", "prefix": "asure, our data suggest that both DDEA and ODAA are likely to cause a DDI with ", "from": "15706", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": ", while MDEA is a possible contributor.\n\nThere are, however, potential problems "}, {"to": "16665", "prefix": "-OHMDEA would be judged as unlikely to contribute to the potentiation of the ", "from": "16658", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " anticoagulant effect. Also, though warfarin binds very strongly to plasma (fu(s"}, {"to": "16709", "prefix": "tribute to the potentiation of the warfarin anticoagulant effect. Also, though ", "from": "16702", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " binds very strongly to plasma (fu(serum) "}, {"to": "17027", "prefix": "-", "from": "17020", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " caused by the drug interaction with AMIO can be predicted according to equation"}, {"to": "17290", "prefix": "-", "from": "17283", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " clearance based on the sum of the [I]"}, {"to": "17718", "prefix": "-", "from": "17711", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " caused by the drug interaction with AMIO has been reported to range from 27 to "}, {"to": "17821", "prefix": "rug interaction with AMIO has been reported to range from 27 to 110% in single ", "from": "17814", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " dose studies carried out in small groups (n "}, {"to": "18057", "prefix": " 65% change in ", "from": "18050", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " dose requirement is in good agreement with this clearance data. However, it is "}, {"to": "20180", "prefix": "he most likely metabolite to potentiate the anticoagulant effect when AMIO and ", "from": "20173", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " are given in combination, even though AMIO plasma concentrations were roughly 2"}, {"to": "20933", "prefix": "explains inter-individual variability in the drug interaction between AMIO and ", "from": "20926", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": ".\n\nGo to:\nMethods\nRetrospective Clinical Evaluation of the AMIO"}, {"to": "21005", "prefix": "", "from": "20998", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "Warfarin", "suffix": " Drug-Interaction\n\nFrom 7"}, {"to": "21187", "prefix": "rovided routine outpatient anticoagulation management for 3129 patients taking ", "from": "21180", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": ". During this 6 year period, a total of 230 incidents in which an out-of-range I"}, {"to": "21300", "prefix": "d, a total of 230 incidents in which an out-of-range INR was attributed to the ", "from": "21293", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": "-amiodarone drug interaction were identified. These incidents were associated wi"}, {"to": "21469", "prefix": " 163 episodes in which amiodarone was added or discontinued in patients taking ", "from": "21462", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": ", or in which the amiodarone dose was changed. Of these 163 episodes, 90 were ex"}, {"to": "21601", "prefix": ". Of these 163 episodes, 90 were excluded from analysis due to either unstable ", "from": "21594", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " therapy prior to addition of amiodarone (n"}, {"to": "21714", "prefix": "; ", "from": "21707", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " and amiodarone having been initiated concurrently (n"}, {"to": "21808", "prefix": ", the duration of concurrent ", "from": "21801", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": ""}, {"to": "22036", "prefix": " also represented in the cohort.\n\nRecruitment of ", "from": "22029", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "Warfarin", "suffix": " Patients for Analysis of Amiodarone Plasma Metabolites\n\nThree patients stabiliz"}, {"to": "22130", "prefix": "ts for Analysis of Amiodarone Plasma Metabolites\n\nThree patients stabilized on ", "from": "22123", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " who were to be initiated on concomitant AMIO therapy were recruited through Car"}, {"to": "22569", "prefix": "f AMIO in the three patients resulted in a 33, 40 or 71% reduction in required ", "from": "22562", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": " dose. All patients gave informed consent for the study which was approved by th"}, {"to": "24503", "prefix": "v of a 100x concentrated methanolic inhibitor stock and S-", "from": "24496", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": ", added as substrate (at 1, 4 or 16 "}, {"to": "24824", "prefix": "-", "from": "24817", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": ", inhibitor and buffer at 37"}, {"to": "28512", "prefix": "logy, for her help in providing us with blood samples from patients undergoing ", "from": "28505", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3900249", "exact": "warfarin", "suffix": ""}, {"to": "1635", "prefix": " administered together with a wide range of other therapeutic agents including ", "from": "1624", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "PMC3900249", "exact": "theophylline", "suffix": " (8), flecainide (9), cyclosporine A (10, 11) and dextromethorphan (12). However"}, {"to": "1651", "prefix": ", ", "from": "1642", "name": "Flecainide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4441", "setId": "PMC3900249", "exact": "flecainide", "suffix": " (9), cyclosporine A (10, 11) and dextromethorphan (12). However, the most commo"}, {"to": "1671", "prefix": ", ", "from": "1658", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "PMC3900249", "exact": "cyclosporine A", "suffix": " (10, 11) and dextromethorphan (12). However, the most common, as well as potent"}, {"to": "1701", "prefix": " and ", "from": "1686", "name": "Dextromethorphan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3289", "setId": "PMC3900249", "exact": "dextromethorphan", "suffix": " (12). However, the most common, as well as potentially the most dangerous drug "}, {"to": "7053", "prefix": "9 and 11, which were both derived from unlabeled ODAA utilizing 1,2-dibromo-d4-", "from": "7048", "name": "Ethane", "fullId": "http://purl.bioontology.org/ontology/MESH/D004980", "setId": "PMC3900249", "exact": "ethane", "suffix": " as the deuterium source (Scheme 1B). These procedures provided the required sta"}, {"to": "14590", "prefix": "-OHMDEA, DDEA, ODAA and DAA. Both the ", "from": "14585", "name": "Phenol", "fullId": "http://purl.bioontology.org/ontology/MESH/D019800", "setId": "PMC3900249", "exact": "phenol", "suffix": ", ODAA, and the alcohol, DAA, were competitive inhibitors of (S)-warfarin metabo"}, {"to": "18722", "prefix": " MBIs of CYP2C9-mediated ", "from": "18713", "name": "Diclofenac", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3355", "setId": "PMC3900249", "exact": "diclofenac", "suffix": " 4"}, {"to": "24626", "prefix": "L total volume with 100 mM ", "from": "24608", "name": "potassium phosphate", "fullId": "http://purl.bioontology.org/ontology/MESH/C013216", "setId": "PMC3900249", "exact": "potassium phosphate", "suffix": " buffer, pH 7.4. The concentrations of inhibitor used in the KI studies varied w"}, {"to": "31", "prefix": "Abstract\nBackground: ", "from": "22", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC1459289", "exact": "Nelfinavir", "suffix": ", an HIV protease inhibitor with numerous drug"}, {"to": "257", "prefix": "escribed for HIV-associated dyslipidemia.\n\nObjective: To examine the effect of ", "from": "248", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC1459289", "exact": "nelfinavir", "suffix": " on pravastatin pharmacokinetics.\n\nDesign: Open-label study in healthy HIV-seron"}, {"to": "569", "prefix": "underwent intensive sampling for pharmacokinetics on day 3. Subjects took only ", "from": "560", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC1459289", "exact": "nelfinavir", "suffix": " 1250 mg twice daily on days 4"}, {"to": "648", "prefix": "15, subjects continued ", "from": "639", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC1459289", "exact": "nelfinavir", "suffix": " and reinitiated pravastatin. Plasma samples were collected over 24 h for the ca"}, {"to": "1116", "prefix": "m plasma concentrations were also lower when pravastatin was administered with ", "from": "1107", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC1459289", "exact": "nelfinavir", "suffix": ". Median values for the maximum plasma concentrations were 27.9 and 12.4 ng"}, {"to": "1338", "prefix": "-subject decrease was 40.1%.\n\nConclusions: Coadministration of pravastatin and ", "from": "1329", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC1459289", "exact": "nelfinavir", "suffix": " led to a substantial reduction in pravastatin plasma concentrations. Higher dos"}, {"to": "1573", "prefix": "timal lipid-lowering activity.\n\nKeywords: HIV infection, statins, pravastatin, ", "from": "1564", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC1459289", "exact": "nelfinavir", "suffix": ", drug interactions\nGo to:\nIntroduction\nNelfinavir (NFV) is an HIV protease inhi"}, {"to": "1623", "prefix": "ction, statins, pravastatin, nelfinavir, drug interactions\nGo to:\nIntroduction\n", "from": "1614", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC1459289", "exact": "Nelfinavir", "suffix": " (NFV) is an HIV protease inhibitor (PI) that has demonstrated numerous drug"}, {"to": "8727", "prefix": " coadminstration of ", "from": "8718", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC1459289", "exact": "nelfinavir", "suffix": ". The 95% confidence intervals around the geometric means are ...\nTable 1\nTable "}, {"to": "8866", "prefix": "c means are ...\nTable 1\nTable 1\nPravastatin pharmacokinetics parameters in the ", "from": "8857", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC1459289", "exact": "nelfinavir", "suffix": " arm (n "}, {"to": "10264", "prefix": "therapy. Interestingly, even in this study, the short-course administration of ", "from": "10255", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC1459289", "exact": "nelfinavir", "suffix": " in healthy HIV-seronegative subjects was associated with a 105 mg"}, {"to": "141", "prefix": "drug interactions, is associated with dyslipidemia. ", "from": "131", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "Pravastatin", "suffix": " is the preferred statin prescribed for HIV-associated dyslipidemia.\n\nObjective:"}, {"to": "272", "prefix": "IV-associated dyslipidemia.\n\nObjective: To examine the effect of nelfinavir on ", "from": "262", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " pharmacokinetics.\n\nDesign: Open-label study in healthy HIV-seronegative adults "}, {"to": "463", "prefix": " Clinical Trials Group sites in the United States.\n\nMethods: Subjects received ", "from": "453", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " 40 mg daily and underwent intensive sampling for pharmacokinetics on day 3. Sub"}, {"to": "676", "prefix": "15, subjects continued nelfinavir and reinitiated ", "from": "666", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": ". Plasma samples were collected over 24 h for the calculation of pravastatin are"}, {"to": "752", "prefix": "ed pravastatin. Plasma samples were collected over 24 h for the calculation of ", "from": "742", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " area under the concentration"}, {"to": "979", "prefix": "es were available for analysis. The median within-subject percentage change in ", "from": "969", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " AUC was a decrease of 46.5%. Pravastatin maximum plasma concentrations were als"}, {"to": "1020", "prefix": "n within-subject percentage change in pravastatin AUC was a decrease of 46.5%. ", "from": "1010", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "Pravastatin", "suffix": " maximum plasma concentrations were also lower when pravastatin was administered"}, {"to": "1083", "prefix": "rease of 46.5%. Pravastatin maximum plasma concentrations were also lower when ", "from": "1073", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " was administered with nelfinavir. Median values for the maximum plasma concentr"}, {"to": "1323", "prefix": "he median within-subject decrease was 40.1%.\n\nConclusions: Coadministration of ", "from": "1313", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " and nelfinavir led to a substantial reduction in pravastatin plasma concentrati"}, {"to": "1384", "prefix": "administration of pravastatin and nelfinavir led to a substantial reduction in ", "from": "1374", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " plasma concentrations. Higher doses of pravastatin may need to be prescribed in"}, {"to": "1435", "prefix": " a substantial reduction in pravastatin plasma concentrations. Higher doses of ", "from": "1425", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " may need to be prescribed in order to achieve optimal lipid-lowering activity.\n"}, {"to": "1561", "prefix": "to achieve optimal lipid-lowering activity.\n\nKeywords: HIV infection, statins, ", "from": "1551", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": ", nelfinavir, drug interactions\nGo to:\nIntroduction\nNelfinavir (NFV) is an HIV p"}, {"to": "2189", "prefix": "imilarly, atorvastatin exposure was also increased by CYP3A4 inhibitors [2,3]. ", "from": "2179", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "Pravastatin", "suffix": " was likely to be safe when coadministered with ritonavir"}, {"to": "2332", "prefix": "saquinavir because, instead of an increase, we observed a 50% decrease in ", "from": "2322", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " area under the concentration"}, {"to": "2420", "prefix": ". Although we also showed that ", "from": "2410", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " did not alter NFV pharmacokinetics, we did not examine the effect of NFV on pra"}, {"to": "2508", "prefix": "in did not alter NFV pharmacokinetics, we did not examine the effect of NFV on ", "from": "2498", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " pharmacokinetics. More recently, we have demonstrated that a non-nucleoside rev"}, {"to": "2702", "prefix": "itor efavirenz, which is a CYP3A4 inducer, also reduced the plasma exposure of ", "from": "2692", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " [4].\n\nThe mechanism by which these drugs reduce plasma exposure to pravastatin "}, {"to": "2781", "prefix": "pravastatin [4].\n\nThe mechanism by which these drugs reduce plasma exposure to ", "from": "2771", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " is unknown, but this drug"}, {"to": "2873", "prefix": "drug interaction is of concern because a reduction in ", "from": "2863", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " plasma concentration may adversely affect the drug's ability to lower serum cho"}, {"to": "3214", "prefix": "vir in that it is an inhibitor of CYP3A4 but an inducer of other CYP isoforms. ", "from": "3204", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "Pravastatin", "suffix": " metabolism is complex, utilizing both oxidative and conjugative enzymes for eli"}, {"to": "3448", "prefix": "sm. This study examines the hypothesis that NFV would have a similar effect on ", "from": "3438", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " pharmacokinetics as ritonavir"}, {"to": "3740", "prefix": " objectives were to examine the effect of efavirenz on the pharmacokinetics of ", "from": "3730", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": ", atorvastatin, and simvastatin and the effect of NFV on the pharmacokinetics of"}, {"to": "3832", "prefix": "atorvastatin, and simvastatin and the effect of NFV on the pharmacokinetics of ", "from": "3822", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": ". The efavirenz"}, {"to": "3984", "prefix": "]. The data presented here address the effect of NFVon the pharmacokinetics of ", "from": "3974", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": ". At the time of this study design, NFV was the most commonly prescribed PI in a"}, {"to": "4402", "prefix": "m from August through December 2001.\n\nStudy design\n\nSubjects self-administered ", "from": "4392", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " 40 mg daily in the morning for the first 3 days and on the fourth day pravastat"}, {"to": "4484", "prefix": "vastatin 40 mg daily in the morning for the first 3 days and on the fourth day ", "from": "4474", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " was administered under observation. Blood samples were obtained before drug adm"}, {"to": "4660", "prefix": "ation as well as 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 h after administration, for ", "from": "4650", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " pharmacokinetics. On days 4 through 12, subjects took NFV 1250 mg twice daily w"}, {"to": "4822", "prefix": " daily with meals. On days 13 through 15, subjects continued NFV and restarted ", "from": "4812", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " with the morning dose of NFV. On day 16, pravastatin and NFV doses were adminis"}, {"to": "4875", "prefix": "ntinued NFV and restarted pravastatin with the morning dose of NFV. On day 16, ", "from": "4865", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " and NFV doses were administered under observation and samples were collected ov"}, {"to": "4978", "prefix": "s were administered under observation and samples were collected over 24 h for ", "from": "4968", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " pharmacokinetics. Fasting serum total cholesterol, triglycerides, and high dens"}, {"to": "5563", "prefix": "ses, approved this study and informed consent was obtained from all subjects.\n\n", "from": "5553", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "Pravastatin", "suffix": " assay\n\nSamples for pravastatin plasma concentrations were analyzed by Advion Bi"}, {"to": "5594", "prefix": "formed consent was obtained from all subjects.\n\nPravastatin assay\n\nSamples for ", "from": "5584", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " plasma concentrations were analyzed by Advion Biosciences Inc. (Ithaca, New Yor"}, {"to": "5776", "prefix": "reviously published [2,4].\n\nStatistical analyses\n\nThe primary endpoint was the ", "from": "5766", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " AUC from 0 to 24 h before and after coadministration of NFV. Values for AUC wer"}, {"to": "6539", "prefix": "C and in Cmax values, was used to test the null hypothesis of no difference in ", "from": "6529", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " exposure before initiation of NFV versus after dosing to steady state. Values o"}, {"to": "6737", "prefix": "use high plasma concentrations of statins may be associated with toxicity [7]. ", "from": "6727", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "Pravastatin", "suffix": " exposure when taken with NFV relative to when taken alone, median within-subjec"}, {"to": "7950", "prefix": "Pacific Islanders.\n\nPlots of time-specific geometric mean concentrations of ", "from": "7940", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " with and without NFV are shown in Fig. 1. Median pravastatin AUC values on days"}, {"to": "8011", "prefix": "concentrations of pravastatin with and without NFV are shown in Fig. 1. Median ", "from": "8001", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " AUC values on days 3 and 16 were 86.5 and 46.8 ng"}, {"to": "8318", "prefix": "0.65. ", "from": "8308", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "Pravastatin", "suffix": " Cmax values were also lower when pravastatin was administered with NFV. Median "}, {"to": "8363", "prefix": "0.65. Pravastatin Cmax values were also lower when ", "from": "8353", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " was administered with NFV. Median Cmax values were 27.9 and 12.4 ng"}, {"to": "8586", "prefix": ".\n\nFig. 1\nFig. 1\nGeometric mean concentration of ", "from": "8576", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " at each scheduled sample time and under the two dosing conditions, without (day"}, {"to": "8820", "prefix": "he 95% confidence intervals around the geometric means are ...\nTable 1\nTable 1\n", "from": "8810", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "Pravastatin", "suffix": " pharmacokinetics parameters in the nelfinavir arm (n "}, {"to": "9180", "prefix": " changes after 3 days of ", "from": "9170", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " administration were "}, {"to": "9360", "prefix": " from day 13 to day 16, for a median difference in within-subject response to ", "from": "9350", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " of 28 mg"}, {"to": "9553", "prefix": "also calculated because the baseline LDL was increased by NFV. After 3 days of ", "from": "9543", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " administration, the median changes were "}, {"to": "9749", "prefix": " from day 13 to day 16, for a median difference in within-subject response to ", "from": "9739", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " of 6.7% (mean, 5.5). This difference was not statistically significant (P "}, {"to": "10369", "prefix": "l median increase in LDL.\n\n", "from": "10359", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "Pravastatin", "suffix": " has become the preferred statin because of its lack of significant metabolism b"}, {"to": "10511", "prefix": " of significant metabolism by P4503A4 and results from studies suggesting that ", "from": "10501", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " is safe and tolerable in patients taking potent antiretroviral therapy [10]. In"}, {"to": "10679", "prefix": "saquinavir decreased the ", "from": "10669", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " median AUC by 50% [2]. In this study, NFV administration to steady state reduce"}, {"to": "10788", "prefix": "[2]. In this study, NFV administration to steady state reduced the exposure to ", "from": "10778", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " by a median of 46.5%. Similarly, we have also demonstrated that efavirenz reduc"}, {"to": "10893", "prefix": " 46.5%. Similarly, we have also demonstrated that efavirenz reduces the AUC of ", "from": "10883", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " [4].This reduction in exposure may compromise the effectiveness of pravastatin "}, {"to": "10972", "prefix": "pravastatin [4].This reduction in exposure may compromise the effectiveness of ", "from": "10962", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " in patients taking certain PI drugs or efavirenz. Although our study was not ad"}, {"to": "11105", "prefix": "virenz. Although our study was not adequately powered nor designed to evaluate ", "from": "11095", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": "'s effectiveness in lowering LDL, we did note a trend suggesting that its effect"}, {"to": "11241", "prefix": "a trend suggesting that its effectiveness was reduced.\n\nThe mechanism by which ", "from": "11231", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " concentrations are reduced is not known. The metabolism of pravastatin is compl"}, {"to": "11312", "prefix": "y which pravastatin concentrations are reduced is not known. The metabolism of ", "from": "11302", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " is complex. Induction of non-CYP3A4 oxidation or glucuronidation may result in "}, {"to": "11427", "prefix": " non-CYP3A4 oxidation or glucuronidation may result in more rapid clearance of ", "from": "11417", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": ". In addition, hepatic transporter OATP1B1 may participate in increased drug eli"}, {"to": "11616", "prefix": "ifampin, which induces both CYP isoforms as well as some transporters, reduced ", "from": "11606", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " exposure by a mean of 30% without affecting Cmax [14]. However, the CYP3A4 inhi"}, {"to": "11771", "prefix": "the CYP3A4 inhibitors itraconazole and mibefradil had no significant effect on ", "from": "11761", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " AUC [15]. Gemfibrozil as well as ciclosporin have been shown to increase pravas"}, {"to": "11856", "prefix": "tatin AUC [15]. Gemfibrozil as well as ciclosporin have been shown to increase ", "from": "11846", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " exposure during concomitant administration, pointing to probable involvement of"}, {"to": "12078", "prefix": "[16,17]. Regardless of the mechanism, the implication is that effectiveness of ", "from": "12068", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " may be reduced.\n\nClinical studies of pravastatin for the treatment of HIV-assoc"}, {"to": "12127", "prefix": "tion is that effectiveness of pravastatin may be reduced.\n\nClinical studies of ", "from": "12117", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " for the treatment of HIV-associated dyslipidemia have shown mixed results. For "}, {"to": "12252", "prefix": "d dyslipidemia have shown mixed results. For example, in a randomized trial of ", "from": "12242", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " versus fenofibrate for combined HIV-associated dyslipidemia, only 36% of subjec"}, {"to": "12362", "prefix": "for combined HIV-associated dyslipidemia, only 36% of subjects receiving 40 mg ", "from": "12352", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " daily met the LDL goal (median 20% decrease) and 18% met the triglyceride goal "}, {"to": "12573", "prefix": "", "from": "12563", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " or bezafibrate) with a switch from PI drug to non-nucleoside reverse transcript"}, {"to": "12825", "prefix": ", LDL, and triglycerides of 45.8%, 39.5%, and 41.2%, respectively, after 20 mg ", "from": "12815", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " daily for 12 months. Interestingly, 55% of subjects receiving pravastatin had n"}, {"to": "12899", "prefix": "0 mg pravastatin daily for 12 months. Interestingly, 55% of subjects receiving ", "from": "12889", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " had normal total cholesterol at 12 months. Benesic and colleagues [20] reported"}, {"to": "13025", "prefix": "months. Benesic and colleagues [20] reported results for patients treated with ", "from": "13015", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " or fluvastatin. In 13 pravastatin-treated subjects (11 taking 10 mg pravastatin"}, {"to": "13059", "prefix": "] reported results for patients treated with pravastatin or fluvastatin. In 13 ", "from": "13049", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": "-treated subjects (11 taking 10 mg pravastatin), a decrease in total cholesterol"}, {"to": "13105", "prefix": "11 taking 10 mg ", "from": "13095", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": "), a decrease in total cholesterol levels (from 7.12 to 6.29 mmol"}, {"to": "13274", "prefix": "eeks of therapy was reported. The reduction of LDL level was only 14.4% in the ", "from": "13264", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " group, without a significant reduction in triglycerides. None of these studies "}, {"to": "13603", "prefix": "or other factors may account for variations in efficacy reported.\n\nIn summary, ", "from": "13593", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " remains the statin of choice in HIV-infected persons taking antiretroviral ther"}, {"to": "13807", "prefix": "ared with simvastatin and atorvastatin. The observed near 50% reduction in the ", "from": "13797", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " median AUC and a trend toward less reduction in LDL when coadministered with NF"}, {"to": "13929", "prefix": "ess reduction in LDL when coadministered with NFV suggest that higher doses of ", "from": "13919", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " may need to be prescribed to achieve optimal lipid-lowering activity. It remain"}, {"to": "14055", "prefix": "e optimal lipid-lowering activity. It remains unclear what the optimal dose of ", "from": "14045", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " is to achieve maximal lipid-lowering activity safely in HIV-infected individual"}, {"to": "14260", "prefix": " is also possible that greater improvements in lipid levels may be observed if ", "from": "14250", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " doses are adjusted in the setting of agents that are known to induce reductions"}, {"to": "14455", "prefix": "er studies exploring the safety, tolerability, and efficacy of higher doses of ", "from": "14445", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " are warranted.\n\nGo to:\nAcknowledgements\nThe ACTG A5108 team would like to thank"}, {"to": "1954", "prefix": "ductase inhibitors known as statins. In a previous study, we demonstrated that ", "from": "1944", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC1459289", "exact": "simvastatin", "suffix": " should not be used with ritonavir"}, {"to": "3771", "prefix": " effect of efavirenz on the pharmacokinetics of pravastatin, atorvastatin, and ", "from": "3761", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC1459289", "exact": "simvastatin", "suffix": " and the effect of NFV on the pharmacokinetics of pravastatin. The efavirenz"}, {"to": "13738", "prefix": " persons taking antiretroviral therapy, given its safety profile compared with ", "from": "13728", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC1459289", "exact": "simvastatin", "suffix": " and atorvastatin. The observed near 50% reduction in the pravastatin median AUC"}, {"to": "1988", "prefix": " In a previous study, we demonstrated that simvastatin should not be used with ", "from": "1980", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC1459289", "exact": "ritonavir", "suffix": ""}, {"to": "2246", "prefix": "4 inhibitors [2,3]. Pravastatin was likely to be safe when coadministered with ", "from": "2238", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC1459289", "exact": "ritonavir", "suffix": ""}, {"to": "3065", "prefix": "V is one of the few PI drugs in clinical use that is not usually combined with ", "from": "3057", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC1459289", "exact": "ritonavir", "suffix": ", but NFV has a similar effect on the CYP enzymes as ritonavir in that it is an "}, {"to": "3127", "prefix": "ly combined with ritonavir, but NFV has a similar effect on the CYP enzymes as ", "from": "3119", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC1459289", "exact": "ritonavir", "suffix": " in that it is an inhibitor of CYP3A4 but an inducer of other CYP isoforms. Prav"}, {"to": "3478", "prefix": "thesis that NFV would have a similar effect on pravastatin pharmacokinetics as ", "from": "3470", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC1459289", "exact": "ritonavir", "suffix": ""}, {"to": "10642", "prefix": "otent antiretroviral therapy [10]. In our previous study, we demonstrated that ", "from": "10634", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC1459289", "exact": "ritonavir", "suffix": ""}, {"to": "1999", "prefix": "", "from": "1990", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83395", "setId": "PMC1459289", "exact": "saquinavir", "suffix": " because of the large increases in plasma concentrations from inhibition of CYP3"}, {"to": "2257", "prefix": "", "from": "2248", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83395", "setId": "PMC1459289", "exact": "saquinavir", "suffix": " because, instead of an increase, we observed a 50% decrease in pravastatin area"}, {"to": "3489", "prefix": "", "from": "3480", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83395", "setId": "PMC1459289", "exact": "saquinavir", "suffix": ".\n\nGo to:\nMethods\nThe AIDS Clinical Trials Group (ACTG) study A5108 was a phase "}, {"to": "10653", "prefix": "", "from": "10644", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83395", "setId": "PMC1459289", "exact": "saquinavir", "suffix": " decreased the pravastatin median AUC by 50% [2]. In this study, NFV administrat"}, {"to": "2121", "prefix": " in plasma concentrations from inhibition of CYP3A4 metabolism [2]. Similarly, ", "from": "2110", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC1459289", "exact": "atorvastatin", "suffix": " exposure was also increased by CYP3A4 inhibitors [2,3]. Pravastatin was likely "}, {"to": "3754", "prefix": "ere to examine the effect of efavirenz on the pharmacokinetics of pravastatin, ", "from": "3743", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC1459289", "exact": "atorvastatin", "suffix": ", and simvastatin and the effect of NFV on the pharmacokinetics of pravastatin. "}, {"to": "13755", "prefix": "antiretroviral therapy, given its safety profile compared with simvastatin and ", "from": "13744", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC1459289", "exact": "atorvastatin", "suffix": ". The observed near 50% reduction in the pravastatin median AUC and a trend towa"}, {"to": "2626", "prefix": "ly, we have demonstrated that a non-nucleoside reverse transcriptase inhibitor ", "from": "2618", "name": "efavirenz", "fullId": "http://purl.bioontology.org/ontology/RXNORM/195085", "setId": "PMC1459289", "exact": "efavirenz", "suffix": ", which is a CYP3A4 inducer, also reduced the plasma exposure of pravastatin [4]"}, {"to": "3701", "prefix": "c drug interaction study. The primary objectives were to examine the effect of ", "from": "3693", "name": "efavirenz", "fullId": "http://purl.bioontology.org/ontology/RXNORM/195085", "setId": "PMC1459289", "exact": "efavirenz", "suffix": " on the pharmacokinetics of pravastatin, atorvastatin, and simvastatin and the e"}, {"to": "10862", "prefix": "to pravastatin by a median of 46.5%. Similarly, we have also demonstrated that ", "from": "10854", "name": "efavirenz", "fullId": "http://purl.bioontology.org/ontology/RXNORM/195085", "setId": "PMC1459289", "exact": "efavirenz", "suffix": " reduces the AUC of pravastatin [4].This reduction in exposure may compromise th"}, {"to": "11021", "prefix": "romise the effectiveness of pravastatin in patients taking certain PI drugs or ", "from": "11013", "name": "efavirenz", "fullId": "http://purl.bioontology.org/ontology/RXNORM/195085", "setId": "PMC1459289", "exact": "efavirenz", "suffix": ". Although our study was not adequately powered nor designed to evaluate pravast"}, {"to": "2961", "prefix": "in plasma concentration may adversely affect the drug's ability to lower serum ", "from": "2951", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC1459289", "exact": "cholesterol", "suffix": " effectively. NFV is one of the few PI drugs in clinical use that is not usually"}, {"to": "5028", "prefix": "were collected over 24 h for pravastatin pharmacokinetics. Fasting serum total ", "from": "5018", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC1459289", "exact": "cholesterol", "suffix": ", triglycerides, and high density lipoprotein concentrations were measured at ba"}, {"to": "12735", "prefix": "anscriptase inhibitors, Calza and colleagues [19] reported reductions in total ", "from": "12725", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC1459289", "exact": "cholesterol", "suffix": ", LDL, and triglycerides of 45.8%, 39.5%, and 41.2%, respectively, after 20 mg p"}, {"to": "12928", "prefix": " months. Interestingly, 55% of subjects receiving pravastatin had normal total ", "from": "12918", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC1459289", "exact": "cholesterol", "suffix": " at 12 months. Benesic and colleagues [20] reported results for patients treated"}, {"to": "13139", "prefix": ", a decrease in total ", "from": "13129", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC1459289", "exact": "cholesterol", "suffix": " levels (from 7.12 to 6.29 mmol"}, {"to": "7535", "prefix": " the 14 subjects, two had grade 2 gastrointestinal complaints, one had grade 3 ", "from": "7529", "name": "Alanine", "fullId": "http://purl.bioontology.org/ontology/MESH/D000409", "setId": "PMC1459289", "exact": "alanine", "suffix": " aminotransferase and grade 2 aspartate aminotransferase on day 16, one had grad"}, {"to": "11533", "prefix": "13]. ", "from": "11526", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1459289", "exact": "Rifampin", "suffix": ", which induces both CYP isoforms as well as some transporters, reduced pravasta"}, {"to": "11715", "prefix": "e by a mean of 30% without affecting Cmax [14]. However, the CYP3A4 inhibitors ", "from": "11704", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1459289", "exact": "itraconazole", "suffix": " and mibefradil had no significant effect on pravastatin AUC [15]. Gemfibrozil a"}, {"to": "11730", "prefix": "% without affecting Cmax [14]. However, the CYP3A4 inhibitors itraconazole and ", "from": "11721", "name": "Mibefradil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83213", "setId": "PMC1459289", "exact": "mibefradil", "suffix": " had no significant effect on pravastatin AUC [15]. Gemfibrozil as well as ciclo"}, {"to": "11793", "prefix": "itraconazole and mibefradil had no significant effect on pravastatin AUC [15]. ", "from": "11783", "name": "Gemfibrozil", "fullId": "http://purl.bioontology.org/ontology/MESH/D015248", "setId": "PMC1459289", "exact": "Gemfibrozil", "suffix": " as well as ciclosporin have been shown to increase pravastatin exposure during "}, {"to": "11816", "prefix": "adil had no significant effect on pravastatin AUC [15]. Gemfibrozil as well as ", "from": "11806", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "PMC1459289", "exact": "ciclosporin", "suffix": " have been shown to increase pravastatin exposure during concomitant administrat"}, {"to": "12271", "prefix": " shown mixed results. For example, in a randomized trial of pravastatin versus ", "from": "12261", "name": "Fenofibrate", "fullId": "http://purl.bioontology.org/ontology/MESH/D011345", "setId": "PMC1459289", "exact": "fenofibrate", "suffix": " for combined HIV-associated dyslipidemia, only 36% of subjects receiving 40 mg "}, {"to": "12588", "prefix": "pravastatin or ", "from": "12578", "name": "Bezafibrate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1525", "setId": "PMC1459289", "exact": "bezafibrate", "suffix": ") with a switch from PI drug to non-nucleoside reverse transcriptase inhibitors,"}, {"to": "13040", "prefix": " and colleagues [20] reported results for patients treated with pravastatin or ", "from": "13030", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1459289", "exact": "fluvastatin", "suffix": ". In 13 pravastatin-treated subjects (11 taking 10 mg pravastatin), a decrease i"}, {"to": "301", "prefix": "luences the dose needed for achieving optimal lipid control for atorva statin, ", "from": "291", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3681953", "exact": "simvastatin", "suffix": ", and lovastatin. CYP3A4"}, {"to": "1362", "prefix": "nged from 0.129 to 0.166, 0.036 to 0.185, and 0.014 to 0.044 for atorvastatin, ", "from": "1352", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3681953", "exact": "simvastatin", "suffix": ", and the combined statin analysis, respectively.\n\nConclusions\n\nThe previously-r"}, {"to": "2326", "prefix": " and CYP3A5 in the gut and liver, and ", "from": "2316", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3681953", "exact": "simvastatin", "suffix": " is mainly metabolized by CYP3A4 and CYP3A5 but also by CYP2C8 [4]. The extent t"}, {"to": "3480", "prefix": "equired by homozygotic wild-type patients taking stable doses of atorvastatin, ", "from": "3470", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3681953", "exact": "simvastatin", "suffix": ", or lovastatin for optimal lipid control [6]. Another study reported a signific"}, {"to": "3646", "prefix": "22 and increased lipid-lowering response to ", "from": "3636", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3681953", "exact": "simvastatin", "suffix": " [7].\n\nOther studies have recently reported similar influence of CYP3A4"}, {"to": "5214", "prefix": "indings of a few recent clinical studies suggest a more significant role [11]. ", "from": "5204", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3681953", "exact": "Simvastatin", "suffix": " exposure was higher for CYP3A5"}, {"to": "5669", "prefix": "3 and efficacy or tolerability of ", "from": "5659", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3681953", "exact": "simvastatin", "suffix": " in another reported study [16].\n\nThe findings reported in the current literatur"}, {"to": "5867", "prefix": ", CYP3A5 likely plays only a secondary role in the metabolism of atorvastatin, ", "from": "5857", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3681953", "exact": "simvastatin", "suffix": ", and lovastatin. Nonetheless, our current investigation intends to use the CYP3"}, {"to": "7297", "prefix": "ed genotype group. Median, first quartile, and third quartile of atorvastatin, ", "from": "7287", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3681953", "exact": "simvastatin", "suffix": ", and lovastatin dose were determined for each combined genotype group. As utili"}, {"to": "7587", "prefix": "g the three statins. Potency differences were accounted for by normalizing the ", "from": "7577", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3681953", "exact": "simvastatin", "suffix": " and lovastatin doses to atorvastatin-equivalent doses (i.e., simvastatin and lo"}, {"to": "7660", "prefix": "i.e., ", "from": "7650", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3681953", "exact": "simvastatin", "suffix": " and lovastatin have 83% and 58% the potency, respectively, of atorvastatin [5])"}, {"to": "9906", "prefix": "enotype groups for each dose level are listed in Table 2. For atorvastatin and ", "from": "9896", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3681953", "exact": "simvastatin", "suffix": ", the highest percentages of individuals in the PM group appear to occupy the lo"}, {"to": "10260", "prefix": " for both atorvastatin and ", "from": "10250", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3681953", "exact": "simvastatin", "suffix": ", p "}, {"to": "10384", "prefix": "tively. The proportions for EMs were significantly different from expected for ", "from": "10374", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3681953", "exact": "simvastatin", "suffix": " only, p "}, {"to": "10763", "prefix": "5 approach was inferior to the single-gene approach for atorvastatin, ", "from": "10753", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3681953", "exact": "simvastatin", "suffix": ", and for the combined statin analysis: the p-values for the ordered logistic re"}, {"to": "10987", "prefix": " and 0.166, respectively, for atorvastatin; 0.036 and 0.185, respectively, for ", "from": "10977", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3681953", "exact": "simvastatin", "suffix": "; and 0.014 and 0.044, respectively, for the combined statin analysis.\n\nTable 3\n"}, {"to": "317", "prefix": "needed for achieving optimal lipid control for atorva statin, simvastatin, and ", "from": "308", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC3681953", "exact": "lovastatin", "suffix": ". CYP3A4"}, {"to": "2219", "prefix": "and gene-gene interaction studies are largely lacking [2, 3]. Atorvastatin and ", "from": "2210", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC3681953", "exact": "lovastatin", "suffix": " are primarily metabolized by cytochrome P450 3A4 (CYP3A4) and CYP3A5 in the gut"}, {"to": "3495", "prefix": "ygotic wild-type patients taking stable doses of atorvastatin, simvastatin, or ", "from": "3486", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC3681953", "exact": "lovastatin", "suffix": " for optimal lipid control [6]. Another study reported a significant association"}, {"to": "5883", "prefix": "lays only a secondary role in the metabolism of atorvastatin, simvastatin, and ", "from": "5874", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC3681953", "exact": "lovastatin", "suffix": ". Nonetheless, our current investigation intends to use the CYP3A4"}, {"to": "7313", "prefix": ". Median, first quartile, and third quartile of atorvastatin, simvastatin, and ", "from": "7304", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC3681953", "exact": "lovastatin", "suffix": " dose were determined for each combined genotype group. As utilized in our previ"}, {"to": "7602", "prefix": "ins. Potency differences were accounted for by normalizing the simvastatin and ", "from": "7593", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC3681953", "exact": "lovastatin", "suffix": " doses to atorvastatin-equivalent doses (i.e., simvastatin and lovastatin have 8"}, {"to": "7675", "prefix": "i.e., simvastatin and ", "from": "7666", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC3681953", "exact": "lovastatin", "suffix": " have 83% and 58% the potency, respectively, of atorvastatin [5]).\n\nNumbers and "}, {"to": "1349", "prefix": "is; values changed from 0.129 to 0.166, 0.036 to 0.185, and 0.014 to 0.044 for ", "from": "1338", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3681953", "exact": "atorvastatin", "suffix": ", simvastatin, and the combined statin analysis, respectively.\n\nConclusions\n\nThe"}, {"to": "2204", "prefix": "o guide therapy, and gene-gene interaction studies are largely lacking [2, 3]. ", "from": "2193", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3681953", "exact": "Atorvastatin", "suffix": " and lovastatin are primarily metabolized by cytochrome P450 3A4 (CYP3A4) and CY"}, {"to": "2785", "prefix": "xample, CYP3A4 and CYP3A5 were determined to be responsible for 85% and 15% of ", "from": "2774", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3681953", "exact": "atorvastatin", "suffix": " metabolism, respectively, in a reported in vitro study. Nonetheless, inter-indi"}, {"to": "3467", "prefix": " statin dose required by homozygotic wild-type patients taking stable doses of ", "from": "3456", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3681953", "exact": "atorvastatin", "suffix": ", simvastatin, or lovastatin for optimal lipid control [6]. Another study report"}, {"to": "5492", "prefix": "ersely, another study determined that drug exposure of the biologically active ", "from": "5481", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3681953", "exact": "atorvastatin", "suffix": " acid metabolite was not significantly influenced by CYP3A5 status [15], and no "}, {"to": "5854", "prefix": "ctory; however, CYP3A5 likely plays only a secondary role in the metabolism of ", "from": "5843", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3681953", "exact": "atorvastatin", "suffix": ", simvastatin, and lovastatin. Nonetheless, our current investigation intends to"}, {"to": "7284", "prefix": "or each combined genotype group. Median, first quartile, and third quartile of ", "from": "7273", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3681953", "exact": "atorvastatin", "suffix": ", simvastatin, and lovastatin dose were determined for each combined genotype gr"}, {"to": "7624", "prefix": "nces were accounted for by normalizing the simvastatin and lovastatin doses to ", "from": "7613", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3681953", "exact": "atorvastatin", "suffix": "-equivalent doses (i.e., simvastatin and lovastatin have 83% and 58% the potency"}, {"to": "7735", "prefix": ".e., simvastatin and lovastatin have 83% and 58% the potency, respectively, of ", "from": "7724", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3681953", "exact": "atorvastatin", "suffix": " [5]).\n\nNumbers and percentages of individuals receiving statin doses within spe"}, {"to": "9890", "prefix": "5 combined-genotype groups for each dose level are listed in Table 2. For ", "from": "9879", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3681953", "exact": "atorvastatin", "suffix": " and simvastatin, the highest percentages of individuals in the PM group appear "}, {"to": "10244", "prefix": " for both ", "from": "10233", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3681953", "exact": "atorvastatin", "suffix": " and simvastatin, p "}, {"to": "10750", "prefix": "5 approach was inferior to the single-gene approach for ", "from": "10739", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3681953", "exact": "atorvastatin", "suffix": ", simvastatin, and for the combined statin analysis: the p-values for the ordere"}, {"to": "10939", "prefix": "ion model and the Kruskal-Wallis model were 0.129 and 0.166, respectively, for ", "from": "10928", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3681953", "exact": "atorvastatin", "suffix": "; 0.036 and 0.185, respectively, for simvastatin; and 0.014 and 0.044, respectiv"}, {"to": "3942", "prefix": "ng dose selection or predicting response to certain CYP3A substrates including ", "from": "3933", "name": "Tacrolimus", "fullId": "http://purl.bioontology.org/ontology/MESH/D016559", "setId": "PMC3681953", "exact": "tacrolimus", "suffix": " and cyclosporine [8 "}, {"to": "12053", "prefix": "olism. For CYP3A substrates relying more heavily on CYP3A5 metabolism, such as ", "from": "12044", "name": "Tacrolimus", "fullId": "http://purl.bioontology.org/ontology/MESH/D016559", "setId": "PMC3681953", "exact": "tacrolimus", "suffix": ", the combined-genotype approach has proven worthwhile [9].\n\nDespite the finding"}, {"to": "3959", "prefix": "on or predicting response to certain CYP3A substrates including tacrolimus and ", "from": "3948", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "PMC3681953", "exact": "cyclosporine", "suffix": " [8 "}, {"to": "115", "prefix": " variability among patients plays an important role in determining the dose of ", "from": "108", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": " that should be used when oral anticoagulation is initiated, but practical metho"}, {"to": "360", "prefix": " population. We developed and used an algorithm for estimating the appropriate ", "from": "353", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": " dose that is based on both clinical and genetic data from a broad population ba"}, {"to": "836", "prefix": "ch algorithm by calculating the percentage of patients whose predicted dose of ", "from": "829", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": " was within 20% of the actual stable therapeutic dose; we also evaluated other c"}, {"to": "1096", "prefix": "thm accurately identified larger proportions of patients who required 21 mg of ", "from": "1089", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": " or less per week and of those who required 49 mg or more per week to achieve th"}, {"to": "1494", "prefix": " of a pharmacogenetic algorithm for estimating the appropriate initial dose of ", "from": "1487", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": " produces recommendations that are significantly closer to the required stable t"}, {"to": "1767", "prefix": "ts were observed in the 46.2% of the population that required 21 mg or less of ", "from": "1760", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": " per week or 49 mg or more per week for therapeutic anticoagulation.\n\nWarfarin i"}, {"to": "1845", "prefix": " warfarin per week or 49 mg or more per week for therapeutic anticoagulation.\n\n", "from": "1838", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "Warfarin", "suffix": " is the most widely used oral anticoagulant agent worldwide; more than 30 millio"}, {"to": "2031", "prefix": "e written for this drug in the United States in 2004.1 The appropriate dose of ", "from": "2024", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": " is difficult to establish because it can vary by a factor of 10 among patients,"}, {"to": "2633", "prefix": "ibute significantly to the variability among patients in dose requirements for ", "from": "2626", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": ".3-18 In 2007, the Food and Drug Administration added pharmacogenetic informatio"}, {"to": "2730", "prefix": "007, the Food and Drug Administration added pharmacogenetic information to the ", "from": "2723", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": " product label19 but did not propose a specific method for using genetic informa"}, {"to": "3236", "prefix": "ng or planned in the United States23 and Europe to test whether algorithms for ", "from": "3229", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": " dosage that use genetic information improve the outcomes for patients (e.g., be"}, {"to": "3451", "prefix": ". We developed a pharmacogenetic dose algorithm for ", "from": "3444", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": " with the use of a large and diverse data set that included data from patients a"}, {"to": "3899", "prefix": "strategy.\n\nGo to:\nMETHODS\nDATA COLLECTION AND STUDY COHORTS\n\nThe International ", "from": "3892", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "Warfarin", "suffix": " Pharmacogenetics Consortium comprises 21 research groups from 9 countries and 4"}, {"to": "4109", "prefix": "d clinical and genetic data for a total of 5700 patients who were treated with ", "from": "4102", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": ". These data were curated (i.e., collected, formatted, and subjected to quality "}, {"to": "4749", "prefix": "e collected data on clinical factors that have previously been associated with ", "from": "4742", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": " therapy and that were available from the information received from all or most "}, {"to": "4935", "prefix": "ncluded information on demographic characteristics, the primary indication for ", "from": "4928", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": " treatment, the stable therapeutic dose of warfarin, the treatment INR (the INR "}, {"to": "4986", "prefix": " the primary indication for warfarin treatment, the stable therapeutic dose of ", "from": "4979", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": ", the treatment INR (the INR achieved with a stable warfarin dose), the target I"}, {"to": "5046", "prefix": "the INR achieved with a stable ", "from": "5039", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": " dose), the target INR (the desired INR), the use of concomitant medications (gr"}, {"to": "5974", "prefix": "ilable for this study. The outcome variable was the stable therapeutic dose of ", "from": "5967", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": ", defined as the steady-state dose that led to stable anticoagulation levels. Al"}, {"to": "6237", "prefix": " over a period during which the dose of ", "from": "6230", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": " was stable (Section 2 in Supplementary Appendix 1).\n\nGENOTYPE QUALITY CONTROL\n\n"}, {"to": "7734", "prefix": "ified according to site, for a total of 4043 patients who had a stable dose of ", "from": "7727", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": " and a target INR of 2 to 3) as the "}, {"to": "9912", "prefix": " that did not include genetic factors and a model with a fixed dose of 5 mg of ", "from": "9905", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": " per day. The clinical model was built with the use of the same methods as the p"}, {"to": "10614", "prefix": "ch algorithm by calculating the percentage of patients whose predicted dose of ", "from": "10607", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": " was within 20% of the actual stable therapeutic dose. In addition, we calculate"}, {"to": "15940", "prefix": "s are shown in Section 7 in Supplementary Appendix 1; a graph of the predicted ", "from": "15933", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": " dose based on the pharmacogenetic algorithm as compared with the observed dose "}, {"to": "16138", "prefix": "wn in Section 8 in Supplementary Appendix 1.\n\nFigure 1\nFigure 1\nComparisons of ", "from": "16131", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "Warfarin", "suffix": " Doses Predicted According to the Clinical Algorithm and the Pharmacogenetic Alg"}, {"to": "16259", "prefix": "Clinical Algorithm and the Pharmacogenetic Algorithm\nTable 2\nTable 2\nPredicted ", "from": "16252", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "Warfarin", "suffix": " Doses with the Pharmacogenetic Algorithm, Clinical Algorithm, and Fixed-Dose Ap"}, {"to": "17391", "prefix": " are shown in Figure 2 and Table 3. For patients who required 21 mg or less of ", "from": "17384", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": " per week (33.9% of the total cohort), the pharmacogenetic algorithm provided a "}, {"to": "19599", "prefix": "oved the dose prediction for patients who required either high or low doses of ", "from": "19592", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": ", a group that accounted for 46% of the entire cohort.\n\nFigure 2\nFigure 2\nPercen"}, {"to": "20024", "prefix": "plus-Validation Cohort with an Ideal, Underestimated, or Overestimated Dose of ", "from": "20017", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "Warfarin", "suffix": ", as Estimated with the Pharmacogenetic Algorithm, Clinical Algorithm, and Fixed"}, {"to": "20264", "prefix": "nical Algorithms to Correctly Identify Patients Requiring Low or High Doses of ", "from": "20257", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "Warfarin", "suffix": ".\nOverall, estimates of dose derived with the use of the pharmacogenetic algorit"}, {"to": "21264", "prefix": "developed provided significantly better predictions of the appropriate dose of ", "from": "21257", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": " than either the clinical algorithm or a fixed-dose approach. The greatest diffe"}, {"to": "21447", "prefix": " dose-prediction approaches were noted among patients whose stable therapeutic ", "from": "21440", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": " doses were 21 mg or less per week and among those whose stable doses were 49 mg"}, {"to": "21887", "prefix": "\n\nOur analysis does not address the issue of whether a precise initial dose of ", "from": "21880", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": " translates into improved clinical end points, such as a reduction in the time n"}, {"to": "22617", "prefix": "ection of the graph of pharmacogenetic dose prediction as compared with actual ", "from": "22610", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": " dose (Section 8 in Supplementary Appendix 1) suggests that the pharmacogenetic "}, {"to": "22789", "prefix": "ithm performed less predictably among patients who required very high doses of ", "from": "22782", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": " ("}, {"to": "22909", "prefix": "netic markers explored in our study primarily explain increased sensitivity to ", "from": "22902", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": ", not increased resistance. Mutations of VKORC1 have been associated with resist"}, {"to": "23005", "prefix": "reased resistance. Mutations of VKORC1 have been associated with resistance to ", "from": "22998", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": ", but these mutations are rare except in Ethiopian and certain Jewish population"}, {"to": "23296", "prefix": "variants that can improve predictability in patients who require high doses of ", "from": "23289", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": ".\n\nOur study has other limitations. First, we did not have sufficient data acros"}, {"to": "23780", "prefix": "environmental factors32 that could help predict the stable therapeutic dose of ", "from": "23773", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": ". However, the percentage of dose variability among patients that is explained b"}, {"to": "24849", "prefix": " included in this study represents the typical population that is treated with ", "from": "24842", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": " "}, {"to": "25176", "prefix": " diverse cohort of patients, we developed a pharmacogenetic dose algorithm for ", "from": "25169", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": " that uses genotypes from two genes (VKORC1 and CYP2C9) and clinical variables t"}, {"to": "25374", "prefix": "c dose. This pharmacogenetic algorithm predicts the stable therapeutic dose of ", "from": "25367", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": " better than a fixed-dose approach and better than a clinical algorithm built fr"}, {"to": "25788", "prefix": "th the greatest benefit seen in patients ultimately requiring 21 mg or less of ", "from": "25781", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": " per week and in those requiring 49 mg or more per week. The pharmacogenetic alg"}, {"to": "26026", "prefix": " the efficacy of genetically informed dose estimation for patients who require ", "from": "26019", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": ".\n\nGo to:\nSupplementary Material\nSupplementary appendix 1\n\nClick here to view.(4"}, {"to": "28785", "prefix": "the association of polymorphisms in CYP4F2 with the stable therapeutic dose of ", "from": "28778", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC2722908", "exact": "warfarin", "suffix": " (a patent that has been licensed by the Marshfield Clinic to Osmetech Molecular"}, {"to": "5639", "prefix": "e.g., ", "from": "5631", "name": "Vitamin K", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11258", "setId": "PMC2722908", "exact": "vitamin K", "suffix": " intake and smoking status) were not consistently available and thus were not in"}, {"to": "23475", "prefix": "search groups to include potentially important factors such as smoking status, ", "from": "23467", "name": "Vitamin K", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11258", "setId": "PMC2722908", "exact": "vitamin K", "suffix": " intake, or alcohol consumption, as well as other genetic factors (e.g., cytochr"}, {"to": "8395", "prefix": "l trees, multivariate adaptive regression splines, least-angle regression, and ", "from": "8391", "name": "alachlor", "fullId": "http://purl.bioontology.org/ontology/MESH/C000188", "setId": "PMC2722908", "exact": "Lasso", "suffix": ", in addition to ordinary linear regression. Logarithmic and square-root transfo"}, {"to": "15371", "prefix": "demographic characteristics, genotype combinations, race, and use or nonuse of ", "from": "15362", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/MESH/D000638", "setId": "PMC2722908", "exact": "amiodarone", "suffix": " (an important interacting drug). These data show the way in which the addition "}, {"to": "755", "prefix": " who were initiated during the study on ", "from": "746", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "PMC1156914", "exact": "olanzapine", "suffix": " (N "}, {"to": "1577", "prefix": "rapy, 155.7 days on polypharmacy, and 13.9 days without antipsychotic therapy. ", "from": "1568", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "PMC1156914", "exact": "Olanzapine", "suffix": "-initiated patients were significantly more likely to be on monotherapy with the"}, {"to": "1849", "prefix": ". The number of monotherapy days was significantly greater for ", "from": "1840", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "PMC1156914", "exact": "olanzapine", "suffix": " than quetiapine (p "}, {"to": "1900", "prefix": ", but not for ", "from": "1891", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "PMC1156914", "exact": "olanzapine", "suffix": " versus risperidone, or for risperidone versus quetiapine-initiated patients.\n\nC"}, {"to": "5892", "prefix": "t previous studies reported higher monotherapy or lower polypharmacy rates for ", "from": "5883", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "PMC1156914", "exact": "olanzapine", "suffix": " compared to risperidone [18,19,28,29], and compared to quetiapine-treated patie"}, {"to": "6006", "prefix": "[18,19,28,29], and compared to quetiapine-treated patients [25,27,30], whereas ", "from": "5997", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "PMC1156914", "exact": "olanzapine", "suffix": " and risperidone-treated patients were not found to significantly differ on poly"}, {"to": "6950", "prefix": " ", "from": "6941", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "PMC1156914", "exact": "olanzapine", "suffix": ", quetiapine, or risperidone "}, {"to": "9462", "prefix": " ", "from": "9453", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "PMC1156914", "exact": "olanzapine", "suffix": ", quetiapine, or risperidone, in regular oral formulation. Participants were def"}, {"to": "11712", "prefix": "", "from": "11703", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "PMC1156914", "exact": "olanzapine", "suffix": ", quetiapine, or risperidone): (a) the percentage of patients on antipsychotic m"}, {"to": "15442", "prefix": " included patients who were initiated during the study on ", "from": "15433", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "PMC1156914", "exact": "olanzapine", "suffix": " (N "}, {"to": "15995", "prefix": "ted with atypical antipsychotics and mood stabilizers; a greater percentage of ", "from": "15986", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "PMC1156914", "exact": "olanzapine", "suffix": "-treated patients were treated with typical antipsychotics in both oral and depo"}, {"to": "16367", "prefix": " disorders.\n\nTable 1\nTable 1\nBaseline characteristics of patients initiated on ", "from": "16358", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "PMC1156914", "exact": "olanzapine", "suffix": ", risperidone, and quetiapine\nMedication dose\n\nThe dosing of each antipsychotic "}, {"to": "19162", "prefix": "polypharmacy\n\nA significantly greater percentage of ", "from": "19153", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "PMC1156914", "exact": "olanzapine", "suffix": "-treated patients were on antipsychotic monotherapy during the 1-year period com"}, {"to": "19292", "prefix": "onotherapy during the 1-year period compared to risperidone and to quetiapine. ", "from": "19283", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "PMC1156914", "exact": "Olanzapine", "suffix": "-treated patients were 2.08 times more likely to be on monotherapy than quetiapi"}, {"to": "20549", "prefix": "n antipsychotic polypharmacy or antipsychotic monotherapy. Abbreviations: OLZ, ", "from": "20540", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "PMC1156914", "exact": "olanzapine", "suffix": "; Poly, polypharmacy at initiation; QUE, quetiapine; RIS, risperidone; Mono, mon"}, {"to": "20743", "prefix": "e observed mean number of monotherapy days on the initiating antipsychotic for ", "from": "20734", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "PMC1156914", "exact": "olanzapine", "suffix": ", quetiapine, and risperidone are presented in Table "}, {"to": "20955", "prefix": "ating on polypharmacy. For monotherapy or polypharmacy initiators, patients on ", "from": "20946", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "PMC1156914", "exact": "olanzapine", "suffix": " had a greater number of days of monotherapy on the initiating medication while "}, {"to": "21207", "prefix": "pair-wise comparisons found a significantly longer duration on monotherapy for ", "from": "21198", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "PMC1156914", "exact": "olanzapine", "suffix": " compared to quetiapine (p "}, {"to": "21375", "prefix": ". The difference between ", "from": "21366", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "PMC1156914", "exact": "olanzapine", "suffix": " and risperidone was not statistically significant.\n\nTable 3\nTable 3\nNumber of m"}, {"to": "22730", "prefix": "", "from": "22721", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "PMC1156914", "exact": "olanzapine", "suffix": ", quetiapine, and risperidone). These monotherapy-initiated patients continued o"}, {"to": "26209", "prefix": " commonly prescribed atypical antipsychotic medications. Patients initiated on ", "from": "26200", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "PMC1156914", "exact": "olanzapine", "suffix": " were significantly more likely to be on monotherapy compared to quetiapine (rat"}, {"to": "26484", "prefix": " The current findings appear consistent with several previous studies in which ", "from": "26475", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "PMC1156914", "exact": "olanzapine", "suffix": "-treated patients were found to have significantly higher rate of monotherapy co"}, {"to": "26953", "prefix": " database [28], in which the proportion of schizophrenia patients treated with ", "from": "26944", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "PMC1156914", "exact": "olanzapine", "suffix": " monotherapy remained relatively steady over the first 3 months of treatment whi"}, {"to": "30666", "prefix": "in this case, ", "from": "30657", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "PMC1156914", "exact": "olanzapine", "suffix": "). Although we cannot completely rule out this possibility, sponsor bias is unli"}, {"to": "777", "prefix": ", ", "from": "768", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": " (N "}, {"to": "1765", "prefix": " or ", "from": "1756", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": " (p "}, {"to": "1865", "prefix": ". The number of monotherapy days was significantly greater for olanzapine than ", "from": "1856", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": " (p "}, {"to": "1957", "prefix": ", but not for olanzapine versus risperidone, or for risperidone versus ", "from": "1948", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": "-initiated patients.\n\nConclusion\n\nDespite guidelines recommending the use of pol"}, {"to": "5748", "prefix": "cy among atypical agents is sparse [8,26-30]. It is unclear if risperidone and ", "from": "5739", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": "-treated patients differ on monotherapy parameters. Most previous studies report"}, {"to": "5958", "prefix": "cy rates for olanzapine compared to risperidone [18,19,28,29], and compared to ", "from": "5949", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": "-treated patients [25,27,30], whereas olanzapine and risperidone-treated patient"}, {"to": "6962", "prefix": " olanzapine, ", "from": "6953", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": ", or risperidone "}, {"to": "9474", "prefix": " olanzapine, ", "from": "9465", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": ", or risperidone, in regular oral formulation. Participants were defined as init"}, {"to": "11724", "prefix": "olanzapine, ", "from": "11715", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": ", or risperidone): (a) the percentage of patients on antipsychotic monotherapy w"}, {"to": "15464", "prefix": ", ", "from": "15455", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": " (N "}, {"to": "15711", "prefix": " patients on antipsychotic polypharmacy at initiation, which was highest among ", "from": "15702", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": "-treated patients and lowest for the risperidone treatment group. During the 2 m"}, {"to": "15879", "prefix": "months prior to initiation on the index antipsychotic, a greater percentage of ", "from": "15870", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": "-treated patients were treated with atypical antipsychotics and mood stabilizers"}, {"to": "16177", "prefix": "s; risperidone patients had fewer antipsychotic monotherapy days. Further, the ", "from": "16168", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": " treatment group had least males, the lowest illness duration, and fewest patien"}, {"to": "16396", "prefix": "Baseline characteristics of patients initiated on olanzapine, risperidone, and ", "from": "16387", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": "\nMedication dose\n\nThe dosing of each antipsychotic during the year post initiati"}, {"to": "19280", "prefix": "ipsychotic monotherapy during the 1-year period compared to risperidone and to ", "from": "19271", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": ". Olanzapine-treated patients were 2.08 times more likely to be on monotherapy t"}, {"to": "19374", "prefix": "nzapine-treated patients were 2.08 times more likely to be on monotherapy than ", "from": "19365", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": " (Odds Ratio (OR) "}, {"to": "19604", "prefix": ". Differences between risperidone and ", "from": "19595", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": " initiators showed a trend toward significance (OR "}, {"to": "20600", "prefix": "herapy. Abbreviations: OLZ, olanzapine; Poly, polypharmacy at initiation; QUE, ", "from": "20591", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": "; RIS, risperidone; Mono, monotherapy at initiation\nThe observed mean number of "}, {"to": "20755", "prefix": "ean number of monotherapy days on the initiating antipsychotic for olanzapine, ", "from": "20746", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": ", and risperidone are presented in Table "}, {"to": "21045", "prefix": "had a greater number of days of monotherapy on the initiating medication while ", "from": "21036", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": " initiators had the fewest. Using a propensity score bootstrap analysis, pair-wi"}, {"to": "21230", "prefix": "ound a significantly longer duration on monotherapy for olanzapine compared to ", "from": "21221", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": " (p "}, {"to": "21329", "prefix": " and a trend toward longer duration for risperidone initiators as compared to ", "from": "21320", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": " (p "}, {"to": "22742", "prefix": "olanzapine, ", "from": "22733", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": ", and risperidone). These monotherapy-initiated patients continued on monotherap"}, {"to": "26284", "prefix": " on olanzapine were significantly more likely to be on monotherapy compared to ", "from": "26275", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": " (rate and duration) or risperidone-initiated patients (rate only) during the 1-"}, {"to": "26627", "prefix": "her rate of monotherapy compared to risperidone [18,19,28,29], and compared to ", "from": "26618", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": "-treated patients [25,27,30], with the quetiapine treatment group being the leas"}, {"to": "26676", "prefix": "18,19,28,29], and compared to quetiapine-treated patients [25,27,30], with the ", "from": "26667", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": " treatment group being the least likely to be treated monotherapy [8,27]. Findin"}, {"to": "29747", "prefix": "eatment indication is also important because some antipsychotics, particularly ", "from": "29738", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": " in low doses, may have been used to treat insomnia rather than core symptoms of"}, {"to": "29904", "prefix": " symptoms of schizophrenia. Although some have speculated that higher doses of ", "from": "29895", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": " produce better outcome, the available data [35] do not support this. Davis and "}, {"to": "30039", "prefix": "5] do not support this. Davis and Chen [35] observed, however, \"the sponsor of ", "from": "30030", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": " has 2 studies of dose response, one nearing completion, and the other just begi"}, {"to": "31216", "prefix": "study conducted by the sponsors of risperidone [35], comparing risperidone and ", "from": "31207", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": " on the rate of antipsychotic polypharmacy. That short term trial found the rela"}, {"to": "31317", "prefix": "", "from": "31308", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": " vs. risperidone) of using antipsychotic polypharmacy to be higher for quetiapin"}, {"to": "31398", "prefix": " of using antipsychotic polypharmacy to be higher for ", "from": "31389", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": " compared to risperidone (odds ratio 1.90, 95% CI, 1.29"}, {"to": "31594", "prefix": "observational study, in which the odds ratio for antipsychotic polypharmacy of ", "from": "31585", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/51272", "setId": "PMC1156914", "exact": "quetiapine", "suffix": " vs. risperidone was 1.53 (95% CI 0.94"}, {"to": "803", "prefix": ", or ", "from": "793", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "PMC1156914", "exact": "risperidone", "suffix": " (N "}, {"to": "1740", "prefix": "ith the initiating antipsychotic during the 1-year post initiation compared to ", "from": "1730", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "PMC1156914", "exact": "risperidone", "suffix": " (p "}, {"to": "1919", "prefix": ", but not for olanzapine versus ", "from": "1909", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "PMC1156914", "exact": "risperidone", "suffix": ", or for risperidone versus quetiapine-initiated patients.\n\nConclusion\n\nDespite "}, {"to": "1939", "prefix": ", but not for olanzapine versus risperidone, or for ", "from": "1929", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "PMC1156914", "exact": "risperidone", "suffix": " versus quetiapine-initiated patients.\n\nConclusion\n\nDespite guidelines recommend"}, {"to": "5733", "prefix": "py or polypharmacy among atypical agents is sparse [8,26-30]. It is unclear if ", "from": "5723", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "PMC1156914", "exact": "risperidone", "suffix": " and quetiapine-treated patients differ on monotherapy parameters. Most previous"}, {"to": "5916", "prefix": "rted higher monotherapy or lower polypharmacy rates for olanzapine compared to ", "from": "5906", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "PMC1156914", "exact": "risperidone", "suffix": " [18,19,28,29], and compared to quetiapine-treated patients [25,27,30], whereas "}, {"to": "6022", "prefix": "and compared to quetiapine-treated patients [25,27,30], whereas olanzapine and ", "from": "6012", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "PMC1156914", "exact": "risperidone", "suffix": "-treated patients were not found to significantly differ on polypharmacy rates i"}, {"to": "6978", "prefix": " olanzapine, quetiapine, or ", "from": "6968", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "PMC1156914", "exact": "risperidone", "suffix": " "}, {"to": "9490", "prefix": " olanzapine, quetiapine, or ", "from": "9480", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "PMC1156914", "exact": "risperidone", "suffix": ", in regular oral formulation. Participants were defined as initiators if they w"}, {"to": "11740", "prefix": "olanzapine, quetiapine, or ", "from": "11730", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "PMC1156914", "exact": "risperidone", "suffix": "): (a) the percentage of patients on antipsychotic monotherapy with the index at"}, {"to": "15490", "prefix": ", or ", "from": "15480", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "PMC1156914", "exact": "risperidone", "suffix": " (N "}, {"to": "15759", "prefix": "iation, which was highest among quetiapine-treated patients and lowest for the ", "from": "15749", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "PMC1156914", "exact": "risperidone", "suffix": " treatment group. During the 2 months prior to initiation on the index antipsych"}, {"to": "16102", "prefix": " were treated with typical antipsychotics in both oral and depot formulations; ", "from": "16092", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "PMC1156914", "exact": "risperidone", "suffix": " patients had fewer antipsychotic monotherapy days. Further, the quetiapine trea"}, {"to": "16380", "prefix": "\nTable 1\nTable 1\nBaseline characteristics of patients initiated on olanzapine, ", "from": "16370", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "PMC1156914", "exact": "risperidone", "suffix": ", and quetiapine\nMedication dose\n\nThe dosing of each antipsychotic during the ye"}, {"to": "19262", "prefix": "atients were on antipsychotic monotherapy during the 1-year period compared to ", "from": "19252", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "PMC1156914", "exact": "risperidone", "suffix": " and to quetiapine. Olanzapine-treated patients were 2.08 times more likely to b"}, {"to": "19516", "prefix": ", and 1.36 times more likely to be on monotherapy than ", "from": "19506", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "PMC1156914", "exact": "risperidone", "suffix": " (OR "}, {"to": "19589", "prefix": ". Differences between ", "from": "19579", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "PMC1156914", "exact": "risperidone", "suffix": " and quetiapine initiators showed a trend toward significance (OR "}, {"to": "20618", "prefix": "ions: OLZ, olanzapine; Poly, polypharmacy at initiation; QUE, quetiapine; RIS, ", "from": "20608", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "PMC1156914", "exact": "risperidone", "suffix": "; Mono, monotherapy at initiation\nThe observed mean number of monotherapy days o"}, {"to": "20772", "prefix": "notherapy days on the initiating antipsychotic for olanzapine, quetiapine, and ", "from": "20762", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "PMC1156914", "exact": "risperidone", "suffix": " are presented in Table "}, {"to": "21292", "prefix": " and a trend toward longer duration for ", "from": "21282", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "PMC1156914", "exact": "risperidone", "suffix": " initiators as compared to quetiapine (p "}, {"to": "21391", "prefix": ". The difference between olanzapine and ", "from": "21381", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "PMC1156914", "exact": "risperidone", "suffix": " was not statistically significant.\n\nTable 3\nTable 3\nNumber of monotherapy days "}, {"to": "22759", "prefix": "olanzapine, quetiapine, and ", "from": "22749", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "PMC1156914", "exact": "risperidone", "suffix": "). These monotherapy-initiated patients continued on monotherapy for only about "}, {"to": "26319", "prefix": " or ", "from": "26309", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "PMC1156914", "exact": "risperidone", "suffix": "-initiated patients (rate only) during the 1-year post treatment initiation. The"}, {"to": "26585", "prefix": "tients were found to have significantly higher rate of monotherapy compared to ", "from": "26575", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "PMC1156914", "exact": "risperidone", "suffix": " [18,19,28,29], and compared to quetiapine-treated patients [25,27,30], with the"}, {"to": "27084", "prefix": "ver the first 3 months of treatment while the proportion of patients receiving ", "from": "27074", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "PMC1156914", "exact": "risperidone", "suffix": " monotherapy decreased over time.\n\nThe present study helps demonstrate the dynam"}, {"to": "31173", "prefix": "comes from a recent double-blind randomized study conducted by the sponsors of ", "from": "31163", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "PMC1156914", "exact": "risperidone", "suffix": " [35], comparing risperidone and quetiapine on the rate of antipsychotic polypha"}, {"to": "31201", "prefix": "lind randomized study conducted by the sponsors of risperidone [35], comparing ", "from": "31191", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "PMC1156914", "exact": "risperidone", "suffix": " and quetiapine on the rate of antipsychotic polypharmacy. That short term trial"}, {"to": "31333", "prefix": "quetiapine vs. ", "from": "31323", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "PMC1156914", "exact": "risperidone", "suffix": ") of using antipsychotic polypharmacy to be higher for quetiapine compared to ri"}, {"to": "31422", "prefix": " of using antipsychotic polypharmacy to be higher for quetiapine compared to ", "from": "31412", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "PMC1156914", "exact": "risperidone", "suffix": " (odds ratio 1.90, 95% CI, 1.29"}, {"to": "31610", "prefix": "tudy, in which the odds ratio for antipsychotic polypharmacy of quetiapine vs. ", "from": "31600", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "PMC1156914", "exact": "risperidone", "suffix": " was 1.53 (95% CI 0.94"}, {"to": "25", "prefix": "Abstract\nAIM\n\n", "from": "15", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "Eltrombopag", "suffix": ", an oral, nonpeptide thrombopoietin receptor agonist, inhibits the organic anio"}, {"to": "630", "prefix": "lting in increased efficacy and toxicity. To determine if co-administration of ", "from": "620", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " with rosuvastatin alters plasma rosuvastatin exposure, an open-label study was "}, {"to": "806", "prefix": "ted in 42 healthy adult subjects.\n\nMETHODS\n\nSubjects received rosuvastatin and ", "from": "796", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " orally: day 1, rosuvastatin 10 mg single dose; days 6 to 9, eltrombopag 75 mg o"}, {"to": "878", "prefix": "in and eltrombopag orally: day 1, rosuvastatin 10 mg single dose; days 6 to 9, ", "from": "868", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " 75 mg once daily; day 10, eltrombopag 75 mg once daily and rosuvastatin 10 mg s"}, {"to": "916", "prefix": "vastatin 10 mg single dose; days 6 to 9, eltrombopag 75 mg once daily; day 10, ", "from": "906", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " 75 mg once daily and rosuvastatin 10 mg single dose. Adverse event assessments "}, {"to": "1177", "prefix": "s were collected days 1 to 5 and days 10 to 14.\n\nRESULTS\n\nCo-administration of ", "from": "1167", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " with rosuvastatin increased geometric mean (90% confidence interval) plasma ros"}, {"to": "1484", "prefix": "sian compared with Asian subjects.\n\nCONCLUSIONS\n\nConcomitant administration of ", "from": "1474", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " with rosuvastatin was associated with increased rosuvastatin exposure. The ther"}, {"to": "1663", "prefix": "ndex of HMG Co-A reductase inhibitors may be reduced by the concomitant use of ", "from": "1653", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": ". In subjects taking eltrombopag, a reduced dose of HMG Co-A reductase inhibitor"}, {"to": "1695", "prefix": "itors may be reduced by the concomitant use of eltrombopag. In subjects taking ", "from": "1685", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": ", a reduced dose of HMG Co-A reductase inhibitors may be needed.\n\nKeywords: BCRP"}, {"to": "1806", "prefix": "MG Co-A reductase inhibitors may be needed.\n\nKeywords: BCRP, drug interaction, ", "from": "1796", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": ", OATP1B1, rosuvastatin\nWHAT IS ALREADY KNOWN ABOUT THIS SUBJECT\n\nOATP1B1 is imp"}, {"to": "2006", "prefix": "osuvastatin and BCRP is important for rosuvastatin absorption and elimination. ", "from": "1996", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "Eltrombopag", "suffix": " inhibits OATP1B1 and BCRP in vitro at clinically relevant concentrations. Inhib"}, {"to": "2261", "prefix": "he risk of exposure-dependent toxicities. To determine if co-administration of ", "from": "2251", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " with rosuvastatin alters plasma rosuvastatin exposure, an open-label study was "}, {"to": "2444", "prefix": "42 healthy adult subjects.\nWHAT THIS STUDY ADDS\n\nConcomitant administration of ", "from": "2434", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " with rosuvastatin was associated with increased rosuvastatin exposure via inhib"}, {"to": "2659", "prefix": "ndex of HMG Co-A reductase inhibitors may be reduced by the concomitant use of ", "from": "2649", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": ". In subjects taking eltrombopag, a reduced dose of HMG Co-A reductase inhibitor"}, {"to": "2691", "prefix": "itors may be reduced by the concomitant use of eltrombopag. In subjects taking ", "from": "2681", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": ", a reduced dose of HMG Co-A reductase inhibitors may be needed.\nGo to:\nIntroduc"}, {"to": "2787", "prefix": "duced dose of HMG Co-A reductase inhibitors may be needed.\nGo to:\nIntroduction\n", "from": "2777", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "Eltrombopag", "suffix": " (GlaxoSmithKline) is an oral, nonpeptide thrombopoietin receptor agonist approv"}, {"to": "3095", "prefix": "3]. ", "from": "3085", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "Eltrombopag", "suffix": " binds to the transmembrane domain of the thrombopoietin receptor and increases "}, {"to": "3299", "prefix": "liferation and differentiation of megakaryocytes [4].\n\nIn preclinical studies, ", "from": "3289", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " inhibited the organic anion transporting polypeptide 1B1 (OATP1B1) and breast c"}, {"to": "3423", "prefix": ". ", "from": "3413", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "Eltrombopag", "suffix": " was also identified as a BCRP substrate in vitro. OATP1B1 is highly expressed i"}, {"to": "4848", "prefix": "yclosporin [11, 12]. The objective of this study was to evaluate the impact of ", "from": "4838", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " on plasma rosuvastatin exposure.\n\nGo to:\nMethods\nStudy design\n\nAn open-label, s"}, {"to": "5155", "prefix": "ubjects provided written, informed consent. Subjects received rosuvastatin and ", "from": "5145", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " orally in the following sequence: day 1, rosuvastatin 10 mg single dose; day 6 "}, {"to": "5261", "prefix": "ollowing sequence: day 1, rosuvastatin 10 mg single dose; day 6 through day 9, ", "from": "5251", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " 75 mg once daily; day 10, eltrombopag 75 mg once daily and rosuvastatin 10 mg s"}, {"to": "5299", "prefix": " 10 mg single dose; day 6 through day 9, eltrombopag 75 mg once daily; day 10, ", "from": "5289", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " 75 mg once daily and rosuvastatin 10 mg single dose. This study was designed an"}, {"to": "9880", "prefix": " actual concentrations. Plasma PK samples collected on day 10 were assayed for ", "from": "9870", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " using a validated analytical method based on protein precipitation, followed by"}, {"to": "10068", "prefix": "l aliquot of plasma, the lower limit of quantification for the ", "from": "10058", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " assay was 100 ng ml"}, {"to": "10762", "prefix": " of rosuvastatin when administered alone or co-administered with ", "from": "10752", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": ". Cmax and the first time to reach Cmax (tmax) were the actual observed values. "}, {"to": "11294", "prefix": "here Ct was the last observed quantifiable concentration.\n\nSteady-state plasma ", "from": "11284", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " Cmax and AUC over a dosing interval (AUC(0,"}, {"to": "11422", "prefix": " were estimated for the combination regimen only. In addition, plasma ", "from": "11412", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " trough concentrations collected on day 10 prior to administration of rosuvastat"}, {"to": "11603", "prefix": " after rosuvastatin co-administration were measured.\n\nTo assess the effects of ", "from": "11593", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " on rosuvastatin PK, log transformed plasma rosuvastatin AUC(0,"}, {"to": "12056", "prefix": "n back-transformed to give point and interval estimates for the ratios. Plasma ", "from": "12046", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " and rosuvastatin PK parameters were summarized by treatment and by race and gen"}, {"to": "15556", "prefix": "a rosuvastatin pharmacokinetics and treatment comparisons\nCo-administration of ", "from": "15546", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " with rosuvastatin increased plasma rosuvastatin AUC(0,"}, {"to": "15757", "prefix": ". The impact of ", "from": "15747", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " on plasma rosuvastatin exposure differed by race. Plasma rosuvastatin AUC(0,"}, {"to": "16152", "prefix": "e overall population and by race for each treatment in Figure 1. The impact of ", "from": "16142", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " on plasma rosuvastatin exposure appeared to differ by gender within the non-Asi"}, {"to": "16388", "prefix": " ", "from": "16378", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": ") ("}, {"to": "17597", "prefix": "\nFor the overall population, the geometric mean of plasma ", "from": "17587", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " Cmax was 8.00 "}, {"to": "17674", "prefix": "1 h, and plasma ", "from": "17664", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " exposures were similar between Asian and non-Asian subjects and between the BCR"}, {"to": "17894", "prefix": " with the c.421AA genotype had the highest plasma ", "from": "17884", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " AUC(0,"}, {"to": "18096", "prefix": "Asian male subject with the c.421CC genotype. When races were combined, plasma ", "from": "18086", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " exposure was similar between males and females (Table 5), but within the non-As"}, {"to": "18240", "prefix": ", but within the non-Asian group, women had approximately 46% higher plasma ", "from": "18230", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " AUC(0,"}, {"to": "18344", "prefix": " ", "from": "18334", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " trough concentrations of 2.98 "}, {"to": "18659", "prefix": "istration of a single dose of rosuvastatin.\n\nTable 5\nTable 5\nSummary of plasma ", "from": "18649", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " pharmacokinetics\nSafety\n\nAEs were reported by 10% to 21% of subjects per treatm"}, {"to": "19132", "prefix": " platelet counts were observed in several subjects following administration of ", "from": "19122", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": ". At the follow-up visit, 16 subjects (38%) had platelet counts "}, {"to": "19718", "prefix": ".\n\nGo to:\nDiscussion\nThis study was conducted because in vitro data identified ", "from": "19708", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " as an inhibitor of both OATP1B1 and BCRP with IC50s of 2.7 "}, {"to": "19808", "prefix": ". ", "from": "19798", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "Eltrombopag", "suffix": " concentrations achieved clinically are higher than this IC50 value (Table 5), a"}, {"to": "20528", "prefix": "y and efficacy. The central finding of the study was that co-administration of ", "from": "20518", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " 75 mg once daily with a single dose of rosuvastatin 10 mg increased plasma rosu"}, {"to": "21596", "prefix": "tabolizing transporters [14]. It was anticipated that inhibition of OATP1B1 by ", "from": "21586", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " would have a lesser effect on plasma rosuvastatin exposure in Asian subjects co"}, {"to": "23491", "prefix": "se female healthy volunteers [15].\n\nBecause the in vitro inhibition potency of ", "from": "23481", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " is similar for OATP1B1 and BCRP and because genetic polymorphisms in both trans"}, {"to": "23715", "prefix": "xposure, it is probable that the increased rosuvastatin exposure observed with ", "from": "23705", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " co-administration is due to inhibition of both transporters. Inhibition of OATP"}, {"to": "24439", "prefix": "a substrate for the bile acid uptake transporter NTCP [13]. It is not known if ", "from": "24429", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " has an impact on these other transporters.\n\nOATP1B1 is highly expressed on the "}, {"to": "25760", "prefix": " polymorphisms, the results of the ", "from": "25750", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": "-rosuvastatin interaction study may be extended to other statins. In subjects wh"}, {"to": "25874", "prefix": "n study may be extended to other statins. In subjects who were co-administered ", "from": "25864", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " and rosuvastatin, increased rosuvastatin Cmax (mean 103% increase) and AUC(0,"}, {"to": "26109", "prefix": " should consider reducing a subject's dose of statin when co-administered with ", "from": "26099", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": ". Monitoring side effects, clinical chemistry, and lipid concentrations is warra"}, {"to": "26232", "prefix": "al chemistry, and lipid concentrations is warranted in subjects receiving both ", "from": "26222", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " and a statin. As noted by other investigators, most clinically significant drug"}, {"to": "26472", "prefix": "propriate drug selection and dosing [5].\n\nThe impact of rosuvastatin on plasma ", "from": "26462", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " PK was not formally assessed. However, eltrombopag trough concentrations collec"}, {"to": "26523", "prefix": "t of rosuvastatin on plasma eltrombopag PK was not formally assessed. However, ", "from": "26513", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " trough concentrations collected prior to co-administration of rosuvastatin were"}, {"to": "26741", "prefix": " after co-administration of a single dose of rosuvastatin. In addition, plasma ", "from": "26731", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " exposure for the 75 mg once daily regimen (in combination with a single dose of"}, {"to": "26889", "prefix": " was generally as expected based on plasma ", "from": "26879", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " exposures observed in other eltrombopag studies [20"}, {"to": "26929", "prefix": " generally as expected based on plasma eltrombopag exposures observed in other ", "from": "26919", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " studies [20"}, {"to": "27044", "prefix": "re, there does not appear to be a significant impact of rosuvastatin on plasma ", "from": "27034", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " PK.\n\nPlasma eltrombopag exposures collected in the presence of rosuvastatin wer"}, {"to": "27068", "prefix": "r to be a significant impact of rosuvastatin on plasma eltrombopag PK.\n\nPlasma ", "from": "27058", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " exposures collected in the presence of rosuvastatin were similar between Asian "}, {"to": "27279", "prefix": "ent with previous studies that have shown approximately two-fold higher plasma ", "from": "27269", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " exposures in Asian vs. non-Asian subjects [21, 22]. In these prior studies, the"}, {"to": "27601", "prefix": " Americans. Within the non-Asian population, female subjects had higher plasma ", "from": "27591", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " exposure, which is consistent with previous reports [22]. Eltrombopag is a BCRP"}, {"to": "27671", "prefix": "r plasma eltrombopag exposure, which is consistent with previous reports [22]. ", "from": "27661", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "Eltrombopag", "suffix": " is a BCRP substrate and plasma eltrombopag exposure was similar between c.421CC"}, {"to": "27714", "prefix": "sistent with previous reports [22]. Eltrombopag is a BCRP substrate and plasma ", "from": "27704", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " exposure was similar between c.421CC and c.421CA genotypes. Although the one su"}, {"to": "27873", "prefix": " with the c.421AA genotype had the highest plasma ", "from": "27863", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " AUC(0,"}, {"to": "28169", "prefix": "conclusions can be drawn as to whether this genotype is associated with plasma ", "from": "28159", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " exposure.\n\nIn conclusion, concomitant administration of eltrombopag with rosuva"}, {"to": "28237", "prefix": "ith plasma eltrombopag exposure.\n\nIn conclusion, concomitant administration of ", "from": "28227", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " with rosuvastatin was associated with increased rosuvastatin exposure. The ther"}, {"to": "28416", "prefix": "ndex of HMG Co-A reductase inhibitors may be reduced by the concomitant use of ", "from": "28406", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": ". In subjects taking eltrombopag, a reduced dose of HMG Co-A reductase inhibitor"}, {"to": "28448", "prefix": "itors may be reduced by the concomitant use of eltrombopag. In subjects taking ", "from": "28438", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": ", a reduced dose of HMG Co-A reductase inhibitors may be needed.\n\nGo to:\nAcknowl"}, {"to": "255", "prefix": " in vitro. OATP1B1 is important for hepatic uptake of ", "from": "244", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " and inhibition of this transporter could reduce cholesterol-lowering efficacy a"}, {"to": "519", "prefix": "rter and inhibition of this transporter could increase both hepatic and plasma ", "from": "508", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " concentrations, resulting in increased efficacy and toxicity. To determine if c"}, {"to": "648", "prefix": "d efficacy and toxicity. To determine if co-administration of eltrombopag with ", "from": "637", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " alters plasma rosuvastatin exposure, an open-label study was conducted in 42 he"}, {"to": "675", "prefix": " determine if co-administration of eltrombopag with rosuvastatin alters plasma ", "from": "664", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure, an open-label study was conducted in 42 healthy adult subjects.\n\nMETH"}, {"to": "790", "prefix": " study was conducted in 42 healthy adult subjects.\n\nMETHODS\n\nSubjects received ", "from": "779", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " and eltrombopag orally: day 1, rosuvastatin 10 mg single dose; days 6 to 9, elt"}, {"to": "834", "prefix": "jects.\n\nMETHODS\n\nSubjects received rosuvastatin and eltrombopag orally: day 1, ", "from": "823", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " 10 mg single dose; days 6 to 9, eltrombopag 75 mg once daily; day 10, eltrombop"}, {"to": "950", "prefix": "6 to 9, eltrombopag 75 mg once daily; day 10, eltrombopag 75 mg once daily and ", "from": "939", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " 10 mg single dose. Adverse event assessments were performed daily and at the fo"}, {"to": "1195", "prefix": "days 1 to 5 and days 10 to 14.\n\nRESULTS\n\nCo-administration of eltrombopag with ", "from": "1184", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " increased geometric mean (90% confidence interval) plasma rosuvastatin AUC(0,"}, {"to": "1266", "prefix": " plasma ", "from": "1255", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " AUC(0,"}, {"to": "1502", "prefix": "h Asian subjects.\n\nCONCLUSIONS\n\nConcomitant administration of eltrombopag with ", "from": "1491", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " was associated with increased rosuvastatin exposure. The therapeutic index of H"}, {"to": "1545", "prefix": " administration of eltrombopag with rosuvastatin was associated with increased ", "from": "1534", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure. The therapeutic index of HMG Co-A reductase inhibitors may be reduced"}, {"to": "1829", "prefix": "bitors may be needed.\n\nKeywords: BCRP, drug interaction, eltrombopag, OATP1B1, ", "from": "1818", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": "\nWHAT IS ALREADY KNOWN ABOUT THIS SUBJECT\n\nOATP1B1 is important for hepatic upta"}, {"to": "1927", "prefix": "S ALREADY KNOWN ABOUT THIS SUBJECT\n\nOATP1B1 is important for hepatic uptake of ", "from": "1916", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " and BCRP is important for rosuvastatin absorption and elimination. Eltrombopag "}, {"to": "1966", "prefix": "P1B1 is important for hepatic uptake of rosuvastatin and BCRP is important for ", "from": "1955", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " absorption and elimination. Eltrombopag inhibits OATP1B1 and BCRP in vitro at c"}, {"to": "2279", "prefix": "re-dependent toxicities. To determine if co-administration of eltrombopag with ", "from": "2268", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " alters plasma rosuvastatin exposure, an open-label study was conducted in 42 he"}, {"to": "2306", "prefix": " determine if co-administration of eltrombopag with rosuvastatin alters plasma ", "from": "2295", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure, an open-label study was conducted in 42 healthy adult subjects.\nWHAT "}, {"to": "2462", "prefix": "subjects.\nWHAT THIS STUDY ADDS\n\nConcomitant administration of eltrombopag with ", "from": "2451", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " was associated with increased rosuvastatin exposure via inhibition of drug tran"}, {"to": "2505", "prefix": " administration of eltrombopag with rosuvastatin was associated with increased ", "from": "2494", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure via inhibition of drug transporters. The therapeutic index of HMG Co-A"}, {"to": "3638", "prefix": " [5]. OATP1B1 is important for ", "from": "3627", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " disposition as demonstrated by genetic polymorphism, where subjects with the ho"}, {"to": "3789", "prefix": " c.521CC genotype had 65% higher ", "from": "3778", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " mean area under the curve (AUC(0,48 h)) than those with the homozygous c.521TT "}, {"to": "4046", "prefix": " has also been associated with higher plasma ", "from": "4035", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure [7]. BCRP is an efflux transporter that transports drugs from the live"}, {"to": "4216", "prefix": "er into bile and also limits intestinal drug absorption. BCRP is important for ", "from": "4205", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " disposition as demonstrated by genetic polymorphism, where subjects with the he"}, {"to": "4403", "prefix": " c.421CA or homozygous c.421AA genotypes had approximately two-fold the ", "from": "4392", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " AUC(0,"}, {"to": "4633", "prefix": " cholesterol in subjects receiving ", "from": "4622", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " therapy [10].\n\nRosuvastatin has known transporter-mediated drug interactions, s"}, {"to": "4661", "prefix": " cholesterol in subjects receiving rosuvastatin therapy [10].\n\n", "from": "4650", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "Rosuvastatin", "suffix": " has known transporter-mediated drug interactions, such as its interaction with "}, {"to": "4871", "prefix": "he objective of this study was to evaluate the impact of eltrombopag on plasma ", "from": "4860", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure.\n\nGo to:\nMethods\nStudy design\n\nAn open-label, single sequence study wa"}, {"to": "5139", "prefix": " and women. All subjects provided written, informed consent. Subjects received ", "from": "5128", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " and eltrombopag orally in the following sequence: day 1, rosuvastatin 10 mg sin"}, {"to": "5209", "prefix": "received rosuvastatin and eltrombopag orally in the following sequence: day 1, ", "from": "5198", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " 10 mg single dose; day 6 through day 9, eltrombopag 75 mg once daily; day 10, e"}, {"to": "5333", "prefix": " day 9, eltrombopag 75 mg once daily; day 10, eltrombopag 75 mg once daily and ", "from": "5322", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " 10 mg single dose. This study was designed and monitored in accordance with Goo"}, {"to": "7204", "prefix": ", 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 60, 72, 84 and 96 h after single dose ", "from": "7193", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " administration on days 1 and 10. A blood sample was obtained on day "}, {"to": "9103", "prefix": ".\n\nPlasma PK samples collected on days 1 and 10 were assayed for ", "from": "9092", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " using a validated analytical method based on solid phase extraction, followed b"}, {"to": "9371", "prefix": "l aliquot of plasma, the lower limit of quantification for the ", "from": "9360", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " assay was 0.2 ng ml"}, {"to": "10702", "prefix": " of ", "from": "10691", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " when administered alone or co-administered with eltrombopag. Cmax and the first"}, {"to": "11504", "prefix": "trombopag trough concentrations collected on day 10 prior to administration of ", "from": "11493", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " and 24 h after rosuvastatin co-administration were measured.\n\nTo assess the eff"}, {"to": "11532", "prefix": "ons collected on day 10 prior to administration of rosuvastatin and 24 h after ", "from": "11521", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " co-administration were measured.\n\nTo assess the effects of eltrombopag on rosuv"}, {"to": "11619", "prefix": "atin co-administration were measured.\n\nTo assess the effects of eltrombopag on ", "from": "11608", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " PK, log transformed plasma rosuvastatin AUC(0,"}, {"to": "11659", "prefix": "o assess the effects of eltrombopag on rosuvastatin PK, log transformed plasma ", "from": "11648", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " AUC(0,"}, {"to": "12073", "prefix": "ed to give point and interval estimates for the ratios. Plasma eltrombopag and ", "from": "12062", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " PK parameters were summarized by treatment and by race and gender within treatm"}, {"to": "12177", "prefix": "s were summarized by treatment and by race and gender within treatment. Plasma ", "from": "12166", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " concentration"}, {"to": "12269", "prefix": "time profiles were plotted by treatment, race and gender. Plasma ", "from": "12258", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " AUC(0,"}, {"to": "12489", "prefix": "ted as secondary analyses. Similar to the primary statistical analysis, plasma ", "from": "12478", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " PK values were compared between treatments for subgroups based on race (Asian v"}, {"to": "12671", "prefix": " and gender.\n\nMultivariate analyses of the relationship between day 1 plasma ", "from": "12660", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " AUC(0,"}, {"to": "14553", "prefix": " were retained as significant predictors of plasma ", "from": "14542", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " AUC(0,"}, {"to": "14803", "prefix": " were retained in the final model as significant predictors of plasma ", "from": "14792", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " AUC(0,"}, {"to": "15135", "prefix": ". Asian participants had a 109% higher ", "from": "15124", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " AUC(0,"}, {"to": "15218", "prefix": " and a 139% higher Cmax compared with non-Asian subjects when ", "from": "15207", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " was administered alone (Table 4). Within the non-Asian population, female parti"}, {"to": "15333", "prefix": ". Within the non-Asian population, female participants had 50% higher ", "from": "15322", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " AUC(0,"}, {"to": "15408", "prefix": " and 84% higher Cmax compared with male subjects when ", "from": "15397", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " was administered alone.\n\nTable 4\nTable 4\nSummary of plasma rosuvastatin pharmac"}, {"to": "15480", "prefix": "s when rosuvastatin was administered alone.\n\nTable 4\nTable 4\nSummary of plasma ", "from": "15469", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " pharmacokinetics and treatment comparisons\nCo-administration of eltrombopag wit"}, {"to": "15574", "prefix": "armacokinetics and treatment comparisons\nCo-administration of eltrombopag with ", "from": "15563", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " increased plasma rosuvastatin AUC(0,"}, {"to": "15604", "prefix": "omparisons\nCo-administration of eltrombopag with rosuvastatin increased plasma ", "from": "15593", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " AUC(0,"}, {"to": "15714", "prefix": "d Cmax by 103% in the overall study population compared with administration of ", "from": "15703", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " alone (Table 4). The impact of eltrombopag on plasma rosuvastatin exposure diff"}, {"to": "15780", "prefix": ". The impact of eltrombopag on plasma ", "from": "15769", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure differed by race. Plasma rosuvastatin AUC(0,"}, {"to": "15827", "prefix": "impact of eltrombopag on plasma rosuvastatin exposure differed by race. Plasma ", "from": "15816", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " AUC(0,"}, {"to": "16013", "prefix": ". Median plasma ", "from": "16002", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " concentration"}, {"to": "16175", "prefix": "nd by race for each treatment in Figure 1. The impact of eltrombopag on plasma ", "from": "16164", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure appeared to differ by gender within the non-Asian population (Table 4)"}, {"to": "16302", "prefix": ".\n\nFigure 1\nFigure 1\nMedian plasma ", "from": "16291", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " concentration"}, {"to": "16809", "prefix": "3 had higher plasma ", "from": "16798", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposures than subjects with scores of 0"}, {"to": "16911", "prefix": "1, and there was also a trend for higher plasma ", "from": "16900", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposures for subjects in category 4 (approach 2). However, given the small sam"}, {"to": "17109", "prefix": "o draw firm conclusions regarding the relationship between genotype and plasma ", "from": "17098", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure. Plasma rosuvastatin AUC(0,"}, {"to": "17139", "prefix": "ing the relationship between genotype and plasma rosuvastatin exposure. Plasma ", "from": "17128", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " AUC(0,"}, {"to": "17288", "prefix": "yed in Figure 2, along with race and gender details.\n\nFigure 2\nFigure 2\nPlasma ", "from": "17277", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " AUC(0,"}, {"to": "18465", "prefix": " collected on day 10 prior to co-administration of ", "from": "18454", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " were similar to trough concentrations of 3.22 "}, {"to": "18611", "prefix": " collected 24 h after co-administration of a single dose of ", "from": "18600", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": ".\n\nTable 5\nTable 5\nSummary of plasma eltrombopag pharmacokinetics\nSafety\n\nAEs we"}, {"to": "19938", "prefix": ", and OATP1B1 and BCRP are important for ", "from": "19927", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " disposition. Statins are widely used cholesterol-lowering agents [13] and are g"}, {"to": "20580", "prefix": "s that co-administration of eltrombopag 75 mg once daily with a single dose of ", "from": "20569", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " 10 mg increased plasma rosuvastatin Cmax by 103% and AUC(0,"}, {"to": "20616", "prefix": "pag 75 mg once daily with a single dose of rosuvastatin 10 mg increased plasma ", "from": "20605", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " Cmax by 103% and AUC(0,"}, {"to": "20708", "prefix": " by 55% in the overall study population compared with ", "from": "20697", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " alone (Table 4).\n\nBecause it was known that Asian subjects have higher rosuvast"}, {"to": "20792", "prefix": ".\n\nBecause it was known that Asian subjects have higher ", "from": "20781", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposures than non-Asian subjects [7], this study enrolled subjects at one site"}, {"to": "21009", "prefix": "s. Consistent with previous data, Asian race was associated with higher plasma ", "from": "20998", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure, with Asian subjects having approximately twice the exposure as non-As"}, {"to": "21149", "prefix": "ly twice the exposure as non-Asian subjects enrolled in the current study when ", "from": "21138", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " was given alone. Interestingly, the non-Asian group studied by Lee et al. [7] w"}, {"to": "21429", "prefix": " African American subjects. The observed interindividual variability in plasma ", "from": "21418", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure could be due to different genetic polymorphisms that encode drug-metab"}, {"to": "21646", "prefix": "that inhibition of OATP1B1 by eltrombopag would have a lesser effect on plasma ", "from": "21635", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure in Asian subjects compared with non-Asian subjects, whose transporter "}, {"to": "22031", "prefix": " have not been associated with racial differences in ", "from": "22020", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " PK, but have been associated with rosuvastatin PK variability in White subjects"}, {"to": "22078", "prefix": "ated with racial differences in rosuvastatin PK, but have been associated with ", "from": "22067", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " PK variability in White subjects [7]. BCRP C421A polymorphisms have been associ"}, {"to": "22180", "prefix": "lity in White subjects [7]. BCRP C421A polymorphisms have been associated with ", "from": "22169", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " PK variability as well [8]. The study was not designed to stratify enrolment by"}, {"to": "22530", "prefix": "O1B1 A388G genotypes, which have not been independently associated with plasma ", "from": "22519", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure, were relatively evenly distributed across the enrolled population. In"}, {"to": "22750", "prefix": "was included separately, genotype was not significantly associated with plasma ", "from": "22739", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure when race, gender and body weight were included in the model. In multi"}, {"to": "23002", "prefix": "re was some association between haplotype and genotype combinations and plasma ", "from": "22991", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure when race, gender and body weight were included in the model, but give"}, {"to": "23247", "prefix": ".\n\nThe finding of statistically significant higher plasma ", "from": "23236", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposures in female subjects has not been reported in the literature to our kno"}, {"to": "23623", "prefix": "use genetic polymorphisms in both transporters are known to be associated with ", "from": "23612", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure, it is probable that the increased rosuvastatin exposure observed with"}, {"to": "23680", "prefix": "to be associated with rosuvastatin exposure, it is probable that the increased ", "from": "23669", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure observed with eltrombopag co-administration is due to inhibition of bo"}, {"to": "23828", "prefix": "due to inhibition of both transporters. Inhibition of OATP1B1 increases plasma ", "from": "23817", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure by reducing the hepatic uptake; in this scenario, rosuvastatin efficac"}, {"to": "23900", "prefix": "plasma rosuvastatin exposure by reducing the hepatic uptake; in this scenario, ", "from": "23889", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " efficacy may be reduced and toxicity may be increased. In contrast, inhibition "}, {"to": "24017", "prefix": "nd toxicity may be increased. In contrast, inhibition of BCRP increases plasma ", "from": "24006", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure by enhancing rosuvastatin absorption and"}, {"to": "24052", "prefix": "ntrast, inhibition of BCRP increases plasma rosuvastatin exposure by enhancing ", "from": "24041", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " absorption and"}, {"to": "24097", "prefix": "or by inhibiting ", "from": "24086", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " elimination in the bile; in this scenario rosuvastatin efficacy and toxicity ma"}, {"to": "24152", "prefix": "or by inhibiting rosuvastatin elimination in the bile; in this scenario ", "from": "24141", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " efficacy and toxicity may both be increased. In vitro evidence also suggests th"}, {"to": "24247", "prefix": "icacy and toxicity may both be increased. In vitro evidence also suggests that ", "from": "24236", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " is a substrate for other hepatic uptake transporters including OATP1B3, OATP2B1"}, {"to": "24910", "prefix": " 521CC genotype had 1.65- to 3.21-fold higher exposures of ", "from": "24899", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": ", pravastatin, simvastatin, lovastatin and atorvastatin than those with the homo"}, {"to": "25475", "prefix": " the intestine and into the bile. BCRP polymorphisms have been associated with ", "from": "25464", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": ", atorvastatin, fluvastatin and simvastatin lactone (but not acid), but not prav"}, {"to": "25773", "prefix": " polymorphisms, the results of the eltrombopag-", "from": "25762", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " interaction study may be extended to other statins. In subjects who were co-adm"}, {"to": "25891", "prefix": "xtended to other statins. In subjects who were co-administered eltrombopag and ", "from": "25880", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": ", increased rosuvastatin Cmax (mean 103% increase) and AUC(0,"}, {"to": "25915", "prefix": ". In subjects who were co-administered eltrombopag and rosuvastatin, increased ", "from": "25904", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " Cmax (mean 103% increase) and AUC(0,"}, {"to": "26450", "prefix": "gs can be avoided by appropriate drug selection and dosing [5].\n\nThe impact of ", "from": "26439", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " on plasma eltrombopag PK was not formally assessed. However, eltrombopag trough"}, {"to": "26598", "prefix": "ver, eltrombopag trough concentrations collected prior to co-administration of ", "from": "26587", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " were similar to trough concentrations collected 24 h after co-administration of"}, {"to": "26708", "prefix": "ough concentrations collected 24 h after co-administration of a single dose of ", "from": "26697", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": ". In addition, plasma eltrombopag exposure for the 75 mg once daily regimen (in "}, {"to": "26834", "prefix": "in combination with a single dose of ", "from": "26823", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": ") was generally as expected based on plasma eltrombopag exposures observed in ot"}, {"to": "27022", "prefix": "22]. Therefore, there does not appear to be a significant impact of ", "from": "27011", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " on plasma eltrombopag PK.\n\nPlasma eltrombopag exposures collected in the presen"}, {"to": "27120", "prefix": "sma eltrombopag PK.\n\nPlasma eltrombopag exposures collected in the presence of ", "from": "27109", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " were similar between Asian and non-Asian subjects. This is inconsistent with pr"}, {"to": "28255", "prefix": "bopag exposure.\n\nIn conclusion, concomitant administration of eltrombopag with ", "from": "28244", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " was associated with increased rosuvastatin exposure. The therapeutic index of H"}, {"to": "28298", "prefix": " administration of eltrombopag with rosuvastatin was associated with increased ", "from": "28287", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure. The therapeutic index of HMG Co-A reductase inhibitors may be reduced"}, {"to": "315", "prefix": "hepatic uptake of rosuvastatin and inhibition of this transporter could reduce ", "from": "305", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3162661", "exact": "cholesterol", "suffix": "-lowering efficacy and increase the risk of exposure-dependent toxicities. In co"}, {"to": "2138", "prefix": "nically relevant concentrations. Inhibition of these transporters could change ", "from": "2128", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3162661", "exact": "cholesterol", "suffix": "-lowering efficacy and increase the risk of exposure-dependent toxicities. To de"}, {"to": "4598", "prefix": " ", "from": "4588", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3162661", "exact": "cholesterol", "suffix": " in subjects receiving rosuvastatin therapy [10].\n\nRosuvastatin has known transp"}, {"to": "19987", "prefix": "1 and BCRP are important for rosuvastatin disposition. Statins are widely used ", "from": "19977", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3162661", "exact": "cholesterol", "suffix": "-lowering agents [13] and are generally used as chronic therapy, but they are as"}, {"to": "4752", "prefix": "has known transporter-mediated drug interactions, such as its interaction with ", "from": "4742", "name": "Gemfibrozil", "fullId": "http://purl.bioontology.org/ontology/MESH/D015248", "setId": "PMC3162661", "exact": "gemfibrozil", "suffix": " and cyclosporin [11, 12]. The objective of this study was to evaluate the impac"}, {"to": "4768", "prefix": "orter-mediated drug interactions, such as its interaction with gemfibrozil and ", "from": "4758", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "PMC3162661", "exact": "cyclosporin", "suffix": " [11, 12]. The objective of this study was to evaluate the impact of eltrombopag"}, {"to": "24923", "prefix": " 521CC genotype had 1.65- to 3.21-fold higher exposures of rosuvastatin, ", "from": "24913", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC3162661", "exact": "pravastatin", "suffix": ", simvastatin, lovastatin and atorvastatin than those with the homozygous 521TT "}, {"to": "25562", "prefix": ", but not ", "from": "25552", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC3162661", "exact": "pravastatin", "suffix": " or pitavastatin [8, 9, 18, 19].\n\nGiven that exposures to several HMG-CoA reduct"}, {"to": "24936", "prefix": "genotype had 1.65- to 3.21-fold higher exposures of rosuvastatin, pravastatin, ", "from": "24926", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3162661", "exact": "simvastatin", "suffix": ", lovastatin and atorvastatin than those with the homozygous 521TT (control) gen"}, {"to": "25518", "prefix": "orphisms have been associated with rosuvastatin, atorvastatin, fluvastatin and ", "from": "25508", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3162661", "exact": "simvastatin", "suffix": " lactone (but not acid), but not pravastatin or pitavastatin [8, 9, 18, 19].\n\nGi"}, {"to": "24948", "prefix": "1.65- to 3.21-fold higher exposures of rosuvastatin, pravastatin, simvastatin, ", "from": "24939", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC3162661", "exact": "lovastatin", "suffix": " and atorvastatin than those with the homozygous 521TT (control) genotypes [6, 1"}, {"to": "24965", "prefix": "old higher exposures of rosuvastatin, pravastatin, simvastatin, lovastatin and ", "from": "24954", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3162661", "exact": "atorvastatin", "suffix": " than those with the homozygous 521TT (control) genotypes [6, 16, 17]. In contra"}, {"to": "25489", "prefix": " and into the bile. BCRP polymorphisms have been associated with rosuvastatin, ", "from": "25478", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3162661", "exact": "atorvastatin", "suffix": ", fluvastatin and simvastatin lactone (but not acid), but not pravastatin or pit"}, {"to": "25060", "prefix": " genotypes [6, 16, 17]. In contrast, ", "from": "25050", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC3162661", "exact": "fluvastatin", "suffix": " exposure was not different among the T521C genotypes, further suggesting that O"}, {"to": "25183", "prefix": " the T521C genotypes, further suggesting that OATP1B1 may not be important for ", "from": "25173", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC3162661", "exact": "fluvastatin", "suffix": " disposition. BCRP is highly expressed on the apical membrane of enterocytes of "}, {"to": "25502", "prefix": "bile. BCRP polymorphisms have been associated with rosuvastatin, atorvastatin, ", "from": "25492", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC3162661", "exact": "fluvastatin", "suffix": " and simvastatin lactone (but not acid), but not pravastatin or pitavastatin [8,"}, {"to": "25578", "prefix": ", but not pravastatin or ", "from": "25567", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "PMC3162661", "exact": "pitavastatin", "suffix": " [8, 9, 18, 19].\n\nGiven that exposures to several HMG-CoA reductase inhibitors a"}, {"to": "116", "prefix": "on interactions account for a significant proportion of overanticoagulation in ", "from": "109", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC1490169", "exact": "warfarin", "suffix": " users. However, little is known about the incidence or degree of interaction wi"}, {"to": "416", "prefix": "y used oral antibiotics.\n\nDESIGN\n\nRetrospective cohort study of patients using ", "from": "409", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC1490169", "exact": "warfarin", "suffix": " who initiated an antibiotic (azithromycin, levofloxacin, or trimethoprim"}, {"to": "1505", "prefix": " increase the incidence and degree of overanticoagulation.\n\nKeywords: ", "from": "1498", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC1490169", "exact": "warfarin", "suffix": ", overanticoagulation, drug interaction, azithromycin, levofloxacin, trimethopri"}, {"to": "1628", "prefix": "sulfamethoxazole\nThe benefits of ", "from": "1621", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC1490169", "exact": "warfarin", "suffix": " are well established but offset by the risk of major hemorrhage, which occurs a"}, {"to": "2418", "prefix": " to:\nMETHODS\nWe conducted a retrospective cohort study of patients with stable ", "from": "2411", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC1490169", "exact": "warfarin", "suffix": " doses and INRs who received a prescription for terazosin, azithromycin, levoflo"}, {"to": "2725", "prefix": "r. Terazosin was chosen as our control because of its lack of interaction with ", "from": "2718", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC1490169", "exact": "warfarin", "suffix": ".9 Participants were included if 2 inclusion INRs (the last occurring within 30 "}, {"to": "3216", "prefix": "as closely after commencing it. Subjects were excluded if they had a change in ", "from": "3209", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC1490169", "exact": "warfarin", "suffix": " dosing or initiated or changed a scheduled medication that is known to interact"}, {"to": "3310", "prefix": " or initiated or changed a scheduled medication that is known to interact with ", "from": "3303", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC1490169", "exact": "warfarin", "suffix": " during or after collection of their inclusion INRs. As needed medications were "}, {"to": "3463", "prefix": "ications were allowed if the medication was not commonly felt to interact with ", "from": "3456", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC1490169", "exact": "warfarin", "suffix": " based on an accepted text of drug interactions.10 Patients were included twice "}, {"to": "5662", "prefix": " all groups was 70 years old. There were no differences in the indications for ", "from": "5655", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC1490169", "exact": "warfarin", "suffix": " use (P"}, {"to": "6182", "prefix": "SMX.\n\nA graded increase in both the incidence and degree of ", "from": "6175", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC1490169", "exact": "warfarin", "suffix": " interaction from terazosin to azithromycin to levofloxacin to TMP"}, {"to": "7633", "prefix": "SMX was added to chronic ", "from": "7626", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC1490169", "exact": "warfarin", "suffix": " therapy in patients who were acutely ill. Prior studies are limited because the"}, {"to": "8891", "prefix": " and lack proper randomization. Yamreudeewong et al.16 completed a study of 18 ", "from": "8884", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC1490169", "exact": "warfarin", "suffix": " users who required levofloxacin daily for 5 to 10 days for infectious indicatio"}, {"to": "9664", "prefix": "ith our findings.\n\nIt is well known that sulfa-based antibiotics interact with ", "from": "9657", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC1490169", "exact": "warfarin", "suffix": ", but the incidence has not been adequately studied.5 Comparing 300 outpatients "}, {"to": "10054", "prefix": "d colleagues evaluated 11 subjects who were neither acutely ill nor on chronic ", "from": "10047", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC1490169", "exact": "warfarin", "suffix": " and concluded that TMP"}, {"to": "10128", "prefix": "SMX potentiates the prothrombin effect of ", "from": "10121", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC1490169", "exact": "warfarin", "suffix": ".18\n\nOur study has several strengths. We eliminated patients who did not have bo"}, {"to": "10228", "prefix": "y has several strengths. We eliminated patients who did not have both a stable ", "from": "10221", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC1490169", "exact": "warfarin", "suffix": " dose and a stable level of anticoagulant intensity and limited the follow-up pe"}, {"to": "11098", "prefix": "ol to confer validity to our findings. Terazosin is known not to interact with ", "from": "11091", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC1490169", "exact": "warfarin", "suffix": ", while TMP"}, {"to": "11312", "prefix": " conclusions regarding the interaction between azithromycin, levofloxacin, and ", "from": "11305", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC1490169", "exact": "warfarin", "suffix": ".\n\nOur study also has several significant limitations. We could not control for "}, {"to": "458", "prefix": "", "from": "447", "name": "Azithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/18631", "setId": "PMC1490169", "exact": "azithromycin", "suffix": ", levofloxacin, or trimethoprim"}, {"to": "923", "prefix": "0.15 for terazosin, 0.51 for ", "from": "912", "name": "Azithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/18631", "setId": "PMC1490169", "exact": "azithromycin", "suffix": ", 0.85 for levofloxacin, and 1.76 for TMP"}, {"to": "1157", "prefix": "sin group. The incidence of supratherapeutic INR was 5% for terazosin, 31% for ", "from": "1146", "name": "Azithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/18631", "setId": "PMC1490169", "exact": "azithromycin", "suffix": ", 33% for levofloxacin, and 69% for TMP"}, {"to": "1279", "prefix": "4.0 was 0% for terazosin, 16% for ", "from": "1268", "name": "Azithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/18631", "setId": "PMC1490169", "exact": "azithromycin", "suffix": ", 19% for levofloxacin, and 44% for TMP"}, {"to": "1399", "prefix": "", "from": "1388", "name": "Azithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/18631", "setId": "PMC1490169", "exact": "azithromycin", "suffix": ", levofloxacin, and TMP"}, {"to": "1558", "prefix": "eranticoagulation.\n\nKeywords: warfarin, overanticoagulation, drug interaction, ", "from": "1547", "name": "Azithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/18631", "setId": "PMC1490169", "exact": "azithromycin", "suffix": ", levofloxacin, trimethoprim"}, {"to": "2489", "prefix": "with stable warfarin doses and INRs who received a prescription for terazosin, ", "from": "2478", "name": "Azithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/18631", "setId": "PMC1490169", "exact": "azithromycin", "suffix": ", levofloxacin, or TMP"}, {"to": "4548", "prefix": "ntified 333 prescriptions for terazosin in 333 patients, 273 prescriptions for ", "from": "4537", "name": "Azithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/18631", "setId": "PMC1490169", "exact": "azithromycin", "suffix": " in 158 patients, 370 prescriptions for levofloxacin in 258 patients, and 151 pr"}, {"to": "4721", "prefix": "SMX in 120 patients. Initially 43, 35, 41, and 24 terazosin, ", "from": "4710", "name": "Azithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/18631", "setId": "PMC1490169", "exact": "azithromycin", "suffix": ", levofloxacin, and TMP"}, {"to": "5128", "prefix": "nd an additional 11 patients had INRs drawn between days 15 and 30. Thirty-two ", "from": "5117", "name": "Azithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/18631", "setId": "PMC1490169", "exact": "azithromycin", "suffix": ", 27 levofloxacin, and 16 TMP"}, {"to": "5476", "prefix": "", "from": "5465", "name": "Azithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/18631", "setId": "PMC1490169", "exact": "azithromycin", "suffix": "), 6 (levofloxacin), and 6 (TMP"}, {"to": "5689", "prefix": ". ", "from": "5678", "name": "Azithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/18631", "setId": "PMC1490169", "exact": "Azithromycin", "suffix": " and TMP"}, {"to": "6062", "prefix": "dL for ", "from": "6051", "name": "Azithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/18631", "setId": "PMC1490169", "exact": "azithromycin", "suffix": ", 2.0 mg"}, {"to": "6225", "prefix": "ase in both the incidence and degree of warfarin interaction from terazosin to ", "from": "6214", "name": "Azithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/18631", "setId": "PMC1490169", "exact": "azithromycin", "suffix": " to levofloxacin to TMP"}, {"to": "6498", "prefix": ", mean increases in INR of 0.51, 0.85, and 1.76 were seen in the ", "from": "6487", "name": "Azithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/18631", "setId": "PMC1490169", "exact": "azithromycin", "suffix": ", levofloxacin, and TMP"}, {"to": "6624", "prefix": "", "from": "6613", "name": "Azithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/18631", "setId": "PMC1490169", "exact": "azithromycin", "suffix": "), 33% (levofloxacin), and 69% (TMP"}, {"to": "6864", "prefix": "", "from": "6853", "name": "Azithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/18631", "setId": "PMC1490169", "exact": "azithromycin", "suffix": "), 19% (levofloxacin), and 44% (TMP"}, {"to": "7017", "prefix": "SMX versus terazosin, with a nonsignificant trend between both ", "from": "7006", "name": "Azithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/18631", "setId": "PMC1490169", "exact": "azithromycin", "suffix": " and levofloxacin versus terazosin. Even more significant rises in INR were cons"}, {"to": "7577", "prefix": " data show a significant increase in the incidence of overanticoagulation when ", "from": "7566", "name": "Azithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/18631", "setId": "PMC1490169", "exact": "azithromycin", "suffix": ", levofloxacin, or TMP"}, {"to": "8274", "prefix": "ective studies found no significant differences in INR after the initiation of ", "from": "8263", "name": "Azithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/18631", "setId": "PMC1490169", "exact": "azithromycin", "suffix": " for clinical indications compared with terazosin9 or felodipine.11 However, onl"}, {"to": "8377", "prefix": "l indications compared with terazosin9 or felodipine.11 However, only 19 of 43 ", "from": "8366", "name": "Azithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/18631", "setId": "PMC1490169", "exact": "azithromycin", "suffix": " subjects had a follow-up INR within 15 days, with the remaining 24 patients pos"}, {"to": "10801", "prefix": "r chronic liver disease. Chronic renal disease was seen more frequently in the ", "from": "10790", "name": "Azithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/18631", "setId": "PMC1490169", "exact": "azithromycin", "suffix": " and levofloxacin groups than the TMP"}, {"to": "11284", "prefix": "nd positive ends strengthens our conclusions regarding the interaction between ", "from": "11273", "name": "Azithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/18631", "setId": "PMC1490169", "exact": "azithromycin", "suffix": ", levofloxacin, and warfarin.\n\nOur study also has several significant limitation"}, {"to": "11875", "prefix": " to:\nCONCLUSION\nAmong acutely ill outpatients, the use of the oral antibiotics ", "from": "11864", "name": "Azithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/18631", "setId": "PMC1490169", "exact": "azithromycin", "suffix": ", levofloxacin, and TMP"}, {"to": "472", "prefix": "azithromycin, ", "from": "461", "name": "Levofloxacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D064704", "setId": "PMC1490169", "exact": "levofloxacin", "suffix": ", or trimethoprim"}, {"to": "946", "prefix": "0.15 for terazosin, 0.51 for azithromycin, 0.85 for ", "from": "935", "name": "Levofloxacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D064704", "setId": "PMC1490169", "exact": "levofloxacin", "suffix": ", and 1.76 for TMP"}, {"to": "1179", "prefix": "ce of supratherapeutic INR was 5% for terazosin, 31% for azithromycin, 33% for ", "from": "1168", "name": "Levofloxacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D064704", "setId": "PMC1490169", "exact": "levofloxacin", "suffix": ", and 69% for TMP"}, {"to": "1301", "prefix": "4.0 was 0% for terazosin, 16% for azithromycin, 19% for ", "from": "1290", "name": "Levofloxacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D064704", "setId": "PMC1490169", "exact": "levofloxacin", "suffix": ", and 44% for TMP"}, {"to": "1413", "prefix": "azithromycin, ", "from": "1402", "name": "Levofloxacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D064704", "setId": "PMC1490169", "exact": "levofloxacin", "suffix": ", and TMP"}, {"to": "1572", "prefix": "ion.\n\nKeywords: warfarin, overanticoagulation, drug interaction, azithromycin, ", "from": "1561", "name": "Levofloxacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D064704", "setId": "PMC1490169", "exact": "levofloxacin", "suffix": ", trimethoprim"}, {"to": "2281", "prefix": "azithromycin, ", "from": "2270", "name": "Levofloxacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D064704", "setId": "PMC1490169", "exact": "levofloxacin", "suffix": ", and trimethoprim"}, {"to": "2503", "prefix": "rfarin doses and INRs who received a prescription for terazosin, azithromycin, ", "from": "2492", "name": "Levofloxacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D064704", "setId": "PMC1490169", "exact": "levofloxacin", "suffix": ", or TMP"}, {"to": "4600", "prefix": "nts, 273 prescriptions for azithromycin in 158 patients, 370 prescriptions for ", "from": "4589", "name": "Levofloxacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D064704", "setId": "PMC1490169", "exact": "levofloxacin", "suffix": " in 258 patients, and 151 prescriptions for TMP"}, {"to": "4735", "prefix": "SMX in 120 patients. Initially 43, 35, 41, and 24 terazosin, azithromycin, ", "from": "4724", "name": "Levofloxacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D064704", "setId": "PMC1490169", "exact": "levofloxacin", "suffix": ", and TMP"}, {"to": "5145", "prefix": "11 patients had INRs drawn between days 15 and 30. Thirty-two azithromycin, 27 ", "from": "5134", "name": "Levofloxacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D064704", "setId": "PMC1490169", "exact": "levofloxacin", "suffix": ", and 16 TMP"}, {"to": "5494", "prefix": "", "from": "5483", "name": "Levofloxacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D064704", "setId": "PMC1490169", "exact": "levofloxacin", "suffix": "), and 6 (TMP"}, {"to": "5771", "prefix": "SMX were prescribed primarily for pulmonary infections while ", "from": "5760", "name": "Levofloxacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D064704", "setId": "PMC1490169", "exact": "levofloxacin", "suffix": " was used most often for urinary tract infections. Terazosin was nearly always p"}, {"to": "6090", "prefix": "dL for ", "from": "6079", "name": "Levofloxacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D064704", "setId": "PMC1490169", "exact": "levofloxacin", "suffix": ", and 2.5 mg"}, {"to": "6241", "prefix": "incidence and degree of warfarin interaction from terazosin to azithromycin to ", "from": "6230", "name": "Levofloxacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D064704", "setId": "PMC1490169", "exact": "levofloxacin", "suffix": " to TMP"}, {"to": "6512", "prefix": ", mean increases in INR of 0.51, 0.85, and 1.76 were seen in the azithromycin, ", "from": "6501", "name": "Levofloxacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D064704", "setId": "PMC1490169", "exact": "levofloxacin", "suffix": ", and TMP"}, {"to": "6644", "prefix": "", "from": "6633", "name": "Levofloxacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D064704", "setId": "PMC1490169", "exact": "levofloxacin", "suffix": "), and 69% (TMP"}, {"to": "6884", "prefix": "", "from": "6873", "name": "Levofloxacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D064704", "setId": "PMC1490169", "exact": "levofloxacin", "suffix": "), and 44% (TMP"}, {"to": "7034", "prefix": "MX versus terazosin, with a nonsignificant trend between both azithromycin and ", "from": "7023", "name": "Levofloxacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D064704", "setId": "PMC1490169", "exact": "levofloxacin", "suffix": " versus terazosin. Even more significant rises in INR were consistently seen wit"}, {"to": "7591", "prefix": "ignificant increase in the incidence of overanticoagulation when azithromycin, ", "from": "7580", "name": "Levofloxacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D064704", "setId": "PMC1490169", "exact": "levofloxacin", "suffix": ", or TMP"}, {"to": "8923", "prefix": "on. Yamreudeewong et al.16 completed a study of 18 warfarin users who required ", "from": "8912", "name": "Levofloxacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D064704", "setId": "PMC1490169", "exact": "levofloxacin", "suffix": " daily for 5 to 10 days for infectious indications. No difference was found in t"}, {"to": "10818", "prefix": "isease. Chronic renal disease was seen more frequently in the azithromycin and ", "from": "10807", "name": "Levofloxacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D064704", "setId": "PMC1490169", "exact": "levofloxacin", "suffix": " groups than the TMP"}, {"to": "11298", "prefix": "ds strengthens our conclusions regarding the interaction between azithromycin, ", "from": "11287", "name": "Levofloxacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D064704", "setId": "PMC1490169", "exact": "levofloxacin", "suffix": ", and warfarin.\n\nOur study also has several significant limitations. We could no"}, {"to": "11889", "prefix": "N\nAmong acutely ill outpatients, the use of the oral antibiotics azithromycin, ", "from": "11878", "name": "Levofloxacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D064704", "setId": "PMC1490169", "exact": "levofloxacin", "suffix": ", and TMP"}, {"to": "489", "prefix": "azithromycin, levofloxacin, or ", "from": "478", "name": "Trimethoprim", "fullId": "http://purl.bioontology.org/ontology/MESH/D014295", "setId": "PMC1490169", "exact": "trimethoprim", "suffix": ""}, {"to": "1586", "prefix": ": warfarin, overanticoagulation, drug interaction, azithromycin, levofloxacin, ", "from": "1575", "name": "Trimethoprim", "fullId": "http://purl.bioontology.org/ontology/MESH/D014295", "setId": "PMC1490169", "exact": "trimethoprim", "suffix": ""}, {"to": "2299", "prefix": "azithromycin, levofloxacin, and ", "from": "2288", "name": "Trimethoprim", "fullId": "http://purl.bioontology.org/ontology/MESH/D014295", "setId": "PMC1490169", "exact": "trimethoprim", "suffix": ""}, {"to": "506", "prefix": "", "from": "491", "name": "Sulfamethoxazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10180", "setId": "PMC1490169", "exact": "sulfamethoxazole", "suffix": " (TMP"}, {"to": "1603", "prefix": "", "from": "1588", "name": "Sulfamethoxazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10180", "setId": "PMC1490169", "exact": "sulfamethoxazole", "suffix": "\nThe benefits of warfarin are well established but offset by the risk of major h"}, {"to": "2316", "prefix": "", "from": "2301", "name": "Sulfamethoxazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10180", "setId": "PMC1490169", "exact": "sulfamethoxazole", "suffix": " (TMP"}, {"to": "530", "prefix": " or ", "from": "522", "name": "Terazosin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37798", "setId": "PMC1490169", "exact": "terazosin", "suffix": " for clinical indications between January 1998 and December 2002. The incidence "}, {"to": "900", "prefix": "0.15 for ", "from": "892", "name": "Terazosin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37798", "setId": "PMC1490169", "exact": "terazosin", "suffix": ", 0.51 for azithromycin, 0.85 for levofloxacin, and 1.76 for TMP"}, {"to": "1069", "prefix": "INR changes in the antibiotic groups were all statistically different from the ", "from": "1061", "name": "Terazosin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37798", "setId": "PMC1490169", "exact": "terazosin", "suffix": " group. The incidence of supratherapeutic INR was 5% for terazosin, 31% for azit"}, {"to": "1135", "prefix": "ent from the terazosin group. The incidence of supratherapeutic INR was 5% for ", "from": "1127", "name": "Terazosin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37798", "setId": "PMC1490169", "exact": "terazosin", "suffix": ", 31% for azithromycin, 33% for levofloxacin, and 69% for TMP"}, {"to": "1257", "prefix": "4.0 was 0% for ", "from": "1249", "name": "Terazosin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37798", "setId": "PMC1490169", "exact": "terazosin", "suffix": ", 16% for azithromycin, 19% for levofloxacin, and 44% for TMP"}, {"to": "2475", "prefix": "f patients with stable warfarin doses and INRs who received a prescription for ", "from": "2467", "name": "Terazosin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37798", "setId": "PMC1490169", "exact": "terazosin", "suffix": ", azithromycin, levofloxacin, or TMP"}, {"to": "2650", "prefix": "and December 2002 at a university-affiliated Veteran's Affairs Medical Center. ", "from": "2642", "name": "Terazosin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37798", "setId": "PMC1490169", "exact": "Terazosin", "suffix": " was chosen as our control because of its lack of interaction with warfarin.9 Pa"}, {"to": "2863", "prefix": "", "from": "2855", "name": "Terazosin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37798", "setId": "PMC1490169", "exact": "terazosin", "suffix": ") were within"}, {"to": "3092", "prefix": " any of the antibiotic medications. The time frame was extended to 30 days for ", "from": "3084", "name": "Terazosin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37798", "setId": "PMC1490169", "exact": "terazosin", "suffix": ", as INRs are generally not followed as closely after commencing it. Subjects we"}, {"to": "4496", "prefix": ".\n\nGo to:\nRESULTS\nWe identified 333 prescriptions for ", "from": "4488", "name": "Terazosin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37798", "setId": "PMC1490169", "exact": "terazosin", "suffix": " in 333 patients, 273 prescriptions for azithromycin in 158 patients, 370 prescr"}, {"to": "4707", "prefix": "SMX in 120 patients. Initially 43, 35, 41, and 24 ", "from": "4699", "name": "Terazosin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37798", "setId": "PMC1490169", "exact": "terazosin", "suffix": ", azithromycin, levofloxacin, and TMP"}, {"to": "4990", "prefix": "where needed until all exclusions were made as indicated. Nine patients in the ", "from": "4982", "name": "Terazosin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37798", "setId": "PMC1490169", "exact": "terazosin", "suffix": " group had follow-up INRs on or before day 15 and an additional 11 patients had "}, {"to": "5330", "prefix": "acteristics and Clinical Features\nThere were no differences in outcomes in the ", "from": "5322", "name": "Terazosin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37798", "setId": "PMC1490169", "exact": "terazosin", "suffix": " data analyzed at day 15 or 30, so the latter was used in all further analysis. "}, {"to": "5458", "prefix": "", "from": "5450", "name": "Terazosin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37798", "setId": "PMC1490169", "exact": "terazosin", "suffix": "), 7 (azithromycin), 6 (levofloxacin), and 6 (TMP"}, {"to": "5831", "prefix": "nfections while levofloxacin was used most often for urinary tract infections. ", "from": "5823", "name": "Terazosin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37798", "setId": "PMC1490169", "exact": "Terazosin", "suffix": " was nearly always prescribed for symptomatic benign prostatic hypertrophy. Chro"}, {"to": "6209", "prefix": " graded increase in both the incidence and degree of warfarin interaction from ", "from": "6201", "name": "Terazosin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37798", "setId": "PMC1490169", "exact": "terazosin", "suffix": " to azithromycin to levofloxacin to TMP"}, {"to": "6365", "prefix": "rall, the mean INR increased significantly for all 3 antibiotics compared with ", "from": "6357", "name": "Terazosin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37798", "setId": "PMC1490169", "exact": "terazosin", "suffix": ". While the INR decreased slightly for terazosin ("}, {"to": "6413", "prefix": "ll 3 antibiotics compared with terazosin. While the INR decreased slightly for ", "from": "6405", "name": "Terazosin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37798", "setId": "PMC1490169", "exact": "terazosin", "suffix": " ("}, {"to": "6604", "prefix": "", "from": "6596", "name": "Terazosin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37798", "setId": "PMC1490169", "exact": "terazosin", "suffix": "), 31% (azithromycin), 33% (levofloxacin), and 69% (TMP"}, {"to": "6728", "prefix": " of patients. The P-value for all 3 antibiotics versus ", "from": "6720", "name": "Terazosin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37798", "setId": "PMC1490169", "exact": "terazosin", "suffix": " was "}, {"to": "6844", "prefix": "", "from": "6836", "name": "Terazosin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37798", "setId": "PMC1490169", "exact": "terazosin", "suffix": "), 16% (azithromycin), 19% (levofloxacin), and 44% (TMP"}, {"to": "6962", "prefix": "SMX versus ", "from": "6954", "name": "Terazosin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37798", "setId": "PMC1490169", "exact": "terazosin", "suffix": ", with a nonsignificant trend between both azithromycin and levofloxacin versus "}, {"to": "7051", "prefix": " with a nonsignificant trend between both azithromycin and levofloxacin versus ", "from": "7043", "name": "Terazosin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37798", "setId": "PMC1490169", "exact": "terazosin", "suffix": ". Even more significant rises in INR were consistently seen with TMP"}, {"to": "10856", "prefix": "SMX and ", "from": "10848", "name": "Terazosin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37798", "setId": "PMC1490169", "exact": "terazosin", "suffix": " groups; however, the significance of this is unknown but is likely to be minima"}, {"to": "10981", "prefix": "", "from": "10973", "name": "Terazosin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37798", "setId": "PMC1490169", "exact": "terazosin", "suffix": ") and positive (TMP"}, {"to": "11059", "prefix": " control to confer validity to our findings. ", "from": "11051", "name": "Terazosin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37798", "setId": "PMC1490169", "exact": "Terazosin", "suffix": " is known not to interact with warfarin, while TMP"}, {"to": "5996", "prefix": "Chronic renal disease was common while chronic liver disease was not. The mean ", "from": "5987", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003404", "setId": "PMC1490169", "exact": "creatinine", "suffix": " in the patients with renal failure was 2.3 mg"}, {"to": "8338", "prefix": "nitiation of azithromycin for clinical indications compared with terazosin9 or ", "from": "8329", "name": "Felodipine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4316", "setId": "PMC1490169", "exact": "felodipine", "suffix": ".11 However, only 19 of 43 azithromycin subjects had a follow-up INR within 15 d"}, {"to": "10109", "prefix": "SMX potentiates the ", "from": "10099", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "PMC1490169", "exact": "prothrombin", "suffix": " effect of warfarin.18\n\nOur study has several strengths. We eliminated patients "}, {"to": "122", "prefix": " reductase inhibitors are effective agents in lowering ", "from": "112", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC90851", "exact": "cholesterol", "suffix": " and triglycerides and are being used by human immunodeficiency virus-positive p"}, {"to": "2715", "prefix": ", are being used to reduce ", "from": "2705", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC90851", "exact": "cholesterol", "suffix": " and triglycerides in HIV-positive patients.\n\nMany HMG-CoA reductase inhibitors "}, {"to": "10318", "prefix": "were monitored and evaluated. Metabolic laboratory parameters, including total ", "from": "10308", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC90851", "exact": "cholesterol", "suffix": ", low-density lipoproteins (LDL), triglycerides, glucose, insulin, and C-peptide"}, {"to": "11643", "prefix": " for at least 10 days. Mean baseline values and percent changes in total ", "from": "11633", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC90851", "exact": "cholesterol", "suffix": ", LDL, and triglycerides on days 14 and 28 were calculated for each group.\n\nGo t"}, {"to": "16795", "prefix": "cations were expected to have drug interactions with the study drugs.\n\nFasting ", "from": "16785", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC90851", "exact": "cholesterol", "suffix": " and LDL levels were significantly reduced in both arms on days 14 and 28 (Table"}, {"to": "23411", "prefix": "nge in drug concentrations in the liver. It was interesting to observe similar ", "from": "23401", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC90851", "exact": "cholesterol", "suffix": "-lowering effects of atorvastatin and simvastatin in the presence and absence of"}, {"to": "683", "prefix": "label, multiple-dose study was performed to determine the interactions between ", "from": "674", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": ", a protease inhibitor, and two HMG-CoA reductase inhibitors, atorvastatin and s"}, {"to": "962", "prefix": " for the first 14 days of the study. ", "from": "953", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "Nelfinavir", "suffix": " (1,250 mg twice a day) was added on days 15 to 28. Pharmacokinetic assessment w"}, {"to": "1121", "prefix": "sessment was performed on days 14 and 28. The study drugs were well tolerated. ", "from": "1112", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "Nelfinavir", "suffix": " increased the steady-state area under the plasma concentration-time curve durin"}, {"to": "1472", "prefix": "Neither atorvastatin nor simvastatin appeared to alter the pharmacokinetics of ", "from": "1463", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": ". It is recommended that coadministration of simvastatin with nelfinavir should "}, {"to": "1544", "prefix": "ics of nelfinavir. It is recommended that coadministration of simvastatin with ", "from": "1535", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " should be avoided, whereas atorvastatin should be used with nelfinavir with cau"}, {"to": "1615", "prefix": "in with nelfinavir should be avoided, whereas atorvastatin should be used with ", "from": "1606", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " with caution.\n\nThe combination of a human immunodeficiency virus (HIV) protease"}, {"to": "4011", "prefix": ". ", "from": "4002", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "Nelfinavir", "suffix": ", like the other protease inhibitors, is an inhibitor of CYP3A4, although it is "}, {"to": "4148", "prefix": "bitor of CYP3A4, although it is not as strong a CYP3A4 inhibitor as ritonavir. ", "from": "4139", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "Nelfinavir", "suffix": " is a widely prescribed protease inhibitor. It is therefore important to study t"}, {"to": "4256", "prefix": "ibed protease inhibitor. It is therefore important to study the interaction of ", "from": "4247", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " and HMG-CoA reductase inhibitors. Two HMG-CoA reductase inhibitors were chosen "}, {"to": "4707", "prefix": "dose, single-center study to determine the pharmacokinetic interaction between ", "from": "4698", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " and atorvastatin or nelfinavir and simvastatin in healthy volunteers. Thirty-tw"}, {"to": "4738", "prefix": "termine the pharmacokinetic interaction between nelfinavir and atorvastatin or ", "from": "4729", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " and simvastatin in healthy volunteers. Thirty-two subjects were enrolled in the"}, {"to": "5702", "prefix": " plus ", "from": "5693", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " (Viracept; 1,250 mg twice a day [BID]) for an additional 14 days (days 15 to 28"}, {"to": "5816", "prefix": ". All atorvastatin and ", "from": "5807", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " doses were taken with food.\n\nTreatment group 2.\nIn period 1, subjects received "}, {"to": "6046", "prefix": " plus ", "from": "6037", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " (1,250 mg BID) for an additional 14 days (days 15 to 28). All simvastatin and n"}, {"to": "6135", "prefix": ". All simvastatin and ", "from": "6126", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " doses were taken with food.\n\nPharmacokinetic sample collection. (i) Atorvastati"}, {"to": "6480", "prefix": " ", "from": "6471", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "Nelfinavir", "suffix": " sample collections\nTrough samples (7 ml) were collected prior to initiation of "}, {"to": "6570", "prefix": " were collected prior to initiation of ", "from": "6561", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " on day 14 and prior to dosing on days 20 and 25. Serial blood samples (7 ml) we"}, {"to": "6763", "prefix": " ", "from": "6754", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "Nelfinavir", "suffix": " and AG1402.\nConcentrations of nelfinavir and its active metabolite AG1402, prev"}, {"to": "6804", "prefix": " Nelfinavir and AG1402.\nConcentrations of ", "from": "6795", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " and its active metabolite AG1402, previous named M8 (25), in plasma were measur"}, {"to": "7093", "prefix": " containing various concentrations of ", "from": "7084", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " and AG1402 were mixed with an internal standard [6,7-dimethyl-2,3-di(2-pydridyl"}, {"to": "7846", "prefix": "C with a flow rate of 1.5 ml and detection of ", "from": "7837", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " and AG1402 via UV detection at 220 nm. The typical elution times of nelfinavir,"}, {"to": "7925", "prefix": "nelfinavir and AG1402 via UV detection at 220 nm. The typical elution times of ", "from": "7916", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": ", AG1402, and the internal standard were 14.5, 6, and 11 min, respectively. This"}, {"to": "8092", "prefix": "ml for ", "from": "8083", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " and AG1402. The standard curves were linear with R2 values of "}, {"to": "8173", "prefix": "0.997. ", "from": "8164", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "Nelfinavir", "suffix": " and AG1402 were stable ("}, {"to": "8348", "prefix": " of the assay for ", "from": "8339", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " and AG1402 was "}, {"to": "8477", "prefix": " of the assay for ", "from": "8468", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " and AG1402 was "}, {"to": "10851", "prefix": "h postdose for atorvastatin and simvastatin and time zero to 12 h postdose for ", "from": "10842", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " and AG1402). The geometric mean and its associated 95% CI of the Cmax were calc"}, {"to": "10983", "prefix": "sociated 95% CI of the Cmax were calculated for atorvastatin, simvastatin, and ", "from": "10974", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": ". The ratio and its associated 90% CI of the geometric mean of the AUC"}, {"to": "11137", "prefix": " and Cmax of atorvastatin and simvastatin in the presence and absence of ", "from": "11128", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " were also calculated. Analysis of variance was used to compare logarithmically "}, {"to": "11320", "prefix": "rameter values for atorvastatin and simvastatin in the absence and presence of ", "from": "11311", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": ", with the exception of Tmax, which was analyzed by a nonparametric method. Phar"}, {"to": "11437", "prefix": ", which was analyzed by a nonparametric method. Pharmacokinetic parameters for ", "from": "11428", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " and AG1402 were compared to results from previous studies with healthy voluntee"}, {"to": "11544", "prefix": "ompared to results from previous studies with healthy volunteers who had taken ", "from": "11535", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " (1,250 mg BID) for at least 10 days. Mean baseline values and percent changes i"}, {"to": "12029", "prefix": "atorvastatin and ", "from": "12020", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": ") developed a rash, requested withdrawal from the study, and was not included in"}, {"to": "12979", "prefix": " period 1 and between days 20 to 25 in period 2. Mean trough concentrations of ", "from": "12970", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " on days 15, 20, 25, and 28 were 0 (0), 2.4 (1.9), 3.0 (2.3), and 3.4 (2.0) ng-e"}, {"to": "13111", "prefix": "ml, indicating that the steady state of ", "from": "13102", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " was reached between days 20 and 35.\n\nThe mean (SD) concentration-time profiles "}, {"to": "13248", "prefix": " concentration-time profiles of atorvastatin in the absence and presence of ", "from": "13239", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " are presented in Fig. "}, {"to": "13554", "prefix": ". After the addition of ", "from": "13545", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " at 1,250 mg BID to the atorvastatin regimen, the geometric mean steady-state AU"}, {"to": "13854", "prefix": " and 122% in the Cmax after the addition of ", "from": "13845", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": ".\n\nFIG. 1\nFIG. 1\nMean (SD) plasma concentration-time profiles of atorvastatin (A"}, {"to": "13980", "prefix": " in the absence and presence of ", "from": "13971", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " (NFV). eq., equivalents.\nTABLE 1\nTABLE 1\nPharmacokinetic parameters of atorvast"}, {"to": "14180", "prefix": " concentration-time profiles of simvastatin in the absence and presence of ", "from": "14171", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " are presented in Fig. "}, {"to": "14483", "prefix": ". After the addition of ", "from": "14474", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " at 1,250 mg BID to the simvastatin regimen, the geometric mean AUC"}, {"to": "14784", "prefix": " and 517% in the Cmax of simvastatin after the addition of ", "from": "14775", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": ".\n\nFIG. 2\nFIG. 2\nMean (SD) plasma concentration-time profiles of simvastatin (SI"}, {"to": "14908", "prefix": " in the absence and presence of ", "from": "14899", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " (NFV). eq., equivalents.\nThe geometric means of the AUC"}, {"to": "15017", "prefix": " and Cmax of ", "from": "15008", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " in the presence of atorvastatin were 44 (95% CI, 35 to 54) "}, {"to": "15188", "prefix": " and Cmax of ", "from": "15179", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " in the presence of simvastatin were 38 (range, 31 to 47) "}, {"to": "15340", "prefix": "ml, respectively. The median Tmax values of ", "from": "15331", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " in the presence of atorvastatin and simvastatin were 5.0 (range, 2.0 to 8.0) an"}, {"to": "15525", "prefix": " to the ", "from": "15516", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " AUC"}, {"to": "15765", "prefix": " to the ", "from": "15756", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " AUC"}, {"to": "15827", "prefix": ".\n\nSafety.\n", "from": "15818", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "Nelfinavir", "suffix": " in combination with atorvastatin or simvastatin was well tolerated in this stud"}, {"to": "16138", "prefix": "verse events were considered treatment-related adverse events, most related to ", "from": "16129", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " treatment. The most frequently reported adverse event was diarrhea (reported by"}, {"to": "18327", "prefix": "etween the medications. In this study, we investigated the interaction between ", "from": "18318", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " and two HMG-CoA reductase inhibitors, simvastatin and atorvastatin, because of "}, {"to": "18908", "prefix": "bitors.\n\nThe results of this study indicate that administration of 1,250 mg of ", "from": "18899", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " BID increases the steady-state simvastatin equivalent concentrations extensivel"}, {"to": "19227", "prefix": " inhibitors increased 505 and 517%, respectively, with the coadministration of ", "from": "19218", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": ". All of the subjects in the simvastatin arm showed an increase in the simvastat"}, {"to": "19355", "prefix": " in the presence of ", "from": "19346", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": ", with a range of 145 to 1,524% (Fig. "}, {"to": "19461", "prefix": ", suggesting a consistent inhibitory effect of ", "from": "19452", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " on simvastatin metabolism. Two subjects had a greater than 10-fold increase in "}, {"to": "19603", "prefix": "r than 10-fold increase in the simvastatin AUC, and they also had the greatest ", "from": "19594", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " AUCs (78 and 104 "}, {"to": "19752", "prefix": "e magnitude of the increase in simvastatin levels was related to the levels of ", "from": "19743", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " in plasma. Linear regression of the simvastatin AUC ratio (the ratio of the AUC"}, {"to": "19863", "prefix": "the ratio of the AUC of simvastatin plus ", "from": "19854", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " to that of simvastatin alone) versus the nelfinavir AUC in the individual subje"}, {"to": "19915", "prefix": " versus the ", "from": "19906", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " AUC in the individual subjects also demonstrated a high correlation between the"}, {"to": "20036", "prefix": "also demonstrated a high correlation between the simvastatin AUC ratio and the ", "from": "20027", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " AUC with an R2 value of 0.81. Other factors, such as the simvastatin AUC in the"}, {"to": "20138", "prefix": "R2 value of 0.81. Other factors, such as the simvastatin AUC in the absence of ", "from": "20129", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": ", gender, and race, were not related to the simvastatin AUC ratio. These results"}, {"to": "20248", "prefix": "ere not related to the simvastatin AUC ratio. These results suggested that the ", "from": "20239", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " level was a major determinant of the change in simvastatin levels. In contrast,"}, {"to": "20489", "prefix": "ibitors increased only 74 and 122%, respectively, with the coadministration of ", "from": "20480", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": ". Fourteen of the 15 subjects in the atorvastatin arm showed an increase in the "}, {"to": "20631", "prefix": " of atorvastatin equivalents in the presence of ", "from": "20622", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": ", with a range of "}, {"to": "20741", "prefix": ", suggesting a fairly consistent inhibitory effect of ", "from": "20732", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " on atorvastatin metabolism. Two subjects had a greater-than-threefold increase "}, {"to": "20869", "prefix": "ts had a greater-than-threefold increase in atorvastatin. However, the AUCs of ", "from": "20860", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " (42 and 60 "}, {"to": "21066", "prefix": "nitude of the increase in atorvastatin levels was not related to the levels of ", "from": "21057", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " in plasma. Factors such as the nelfinavir AUC, the atorvastatin AUC in the abse"}, {"to": "21108", "prefix": "els was not related to the levels of nelfinavir in plasma. Factors such as the ", "from": "21099", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " AUC, the atorvastatin AUC in the absence of nelfinavir, gender, and race were n"}, {"to": "21163", "prefix": "ma. Factors such as the nelfinavir AUC, the atorvastatin AUC in the absence of ", "from": "21154", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": ", gender, and race were not related to the atorvastatin AUC ratio. The differenc"}, {"to": "21284", "prefix": "ted to the atorvastatin AUC ratio. The difference in the inhibitory effects of ", "from": "21275", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " on simvastatin and atorvastatin was not unexpected. Simvastatin appears to be v"}, {"to": "21805", "prefix": " values in the absence and presence of ", "from": "21796", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": ". (Right) Comparative plot of simvastatin AUC"}, {"to": "21900", "prefix": " values in the absence and presence of ", "from": "21891", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": "\nThe interaction between nelfinavir and simvastatin or atorvastatin is likely du"}, {"to": "21935", "prefix": " values in the absence and presence of nelfinavir\nThe interaction between ", "from": "21926", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " and simvastatin or atorvastatin is likely due mainly to the inhibition of CYP3A"}, {"to": "22030", "prefix": "imvastatin or atorvastatin is likely due mainly to the inhibition of CYP3A4 by ", "from": "22021", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " since the in vitro and in vivo drug metabolism of these compounds is well estab"}, {"to": "22152", "prefix": "rug metabolism of these compounds is well established. Inhibition of CYP3A4 by ", "from": "22143", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " could occur at the gastrointestinal wall, which would have a major effect on th"}, {"to": "22516", "prefix": " studies have suggested that ", "from": "22507", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": ", atorvastatin, and simvastatin may also be substrates"}, {"to": "22659", "prefix": "inhibitors of the efflux pump P-glycoprotein. Inhibition of P-glycoprotein by ", "from": "22650", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " may increase the oral absorption of atorvastatin and simvastatin and contribute"}, {"to": "23297", "prefix": "ncentrations of atorvastatin and simvastatin caused by the coadministration of ", "from": "23288", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " may not reflect the change in drug concentrations in the liver. It was interest"}, {"to": "23502", "prefix": "owering effects of atorvastatin and simvastatin in the presence and absence of ", "from": "23493", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " (Table "}, {"to": "23668", "prefix": "f atorvastatin and simvastatin. These results may suggest different effects of ", "from": "23659", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " on the systemic and liver pharmacokinetics of atorvastatin and simvastatin.\n\nNo"}, {"to": "23994", "prefix": "to extrapolate to chronic coadministration of atorvastatin or simvastatin with ", "from": "23985", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " in HIV-positive patients. The greater-than-500% increase in the simvastatin con"}, {"to": "24114", "prefix": "greater-than-500% increase in the simvastatin concentration in the presence of ", "from": "24105", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " was quite extensive and may increase the risk of skeletal muscle damage. Theref"}, {"to": "24271", "prefix": "mage. Therefore, it is recommended that simvastatin not be coadministered with ", "from": "24262", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": ". Nelfinavir had a more moderate effect on atorvastatin concentrations. The reco"}, {"to": "24283", "prefix": "ore, it is recommended that simvastatin not be coadministered with nelfinavir. ", "from": "24274", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "Nelfinavir", "suffix": " had a more moderate effect on atorvastatin concentrations. The recommended dose"}, {"to": "24548", "prefix": "d titrated with caution to achieve the desired effect when coadministered with ", "from": "24539", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": ".\n\nIn previous studies, the AUC"}, {"to": "24603", "prefix": " and Cmax of ", "from": "24594", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " after administration of 1,250 mg BID to healthy volunteers ranged from 25 to 40"}, {"to": "24798", "prefix": " to the ", "from": "24789", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " AUC"}, {"to": "24872", "prefix": " ranged from 0.2 to 0.4. The pharmacokinetic parameters of ", "from": "24863", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " and AG1402 in this study were similar to those in a previous studies with healt"}, {"to": "25060", "prefix": "esting that atorvastatin and simvastatin did not alter the pharmacokinetics of ", "from": "25051", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " and its active metabolite. These results were not unexpected, as atorvastatin a"}, {"to": "25247", "prefix": " weak CYP3A4 inhibitors and their concentrations were much lower than those of ", "from": "25238", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " and AG1402.\n\nIn conclusion, a clinical dose of nelfinavir (1,250 mg BID) increa"}, {"to": "25305", "prefix": " lower than those of nelfinavir and AG1402.\n\nIn conclusion, a clinical dose of ", "from": "25296", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "nelfinavir", "suffix": " (1,250 mg BID) increased systemic exposure to simvastatin approximately 500% an"}, {"to": "25465", "prefix": "y 500% and is not recommended for long-term coadministration with simvastatin. ", "from": "25456", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC90851", "exact": "Nelfinavir", "suffix": " also increased systemic exposure to atorvastatin moderately and should be coadm"}, {"to": "5712", "prefix": "", "from": "5705", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019888", "setId": "PMC90851", "exact": "Viracept", "suffix": "; 1,250 mg twice a day [BID]) for an additional 14 days (days 15 to 28). All ato"}, {"to": "757", "prefix": "etween nelfinavir, a protease inhibitor, and two HMG-CoA reductase inhibitors, ", "from": "746", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " and simvastatin, in healthy volunteers. Thirty-two healthy subjects received ei"}, {"to": "1243", "prefix": " of ", "from": "1232", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " 74% and the maximum concentration (Cmax) of atorvastatin 122% and increased the"}, {"to": "1300", "prefix": " of ", "from": "1289", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " 122% and increased the AUC"}, {"to": "1403", "prefix": " of simvastatin 505% and the Cmax of simvastatin 517%. Neither ", "from": "1392", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " nor simvastatin appeared to alter the pharmacokinetics of nelfinavir. It is rec"}, {"to": "1584", "prefix": "hat coadministration of simvastatin with nelfinavir should be avoided, whereas ", "from": "1573", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " should be used with nelfinavir with caution.\n\nThe combination of a human immuno"}, {"to": "3355", "prefix": " of simvastatin and lovastatin approximately fivefold but increased the AUC of ", "from": "3344", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " only 60% (16, 17). The greatly elevated concentrations of simvastatin and lovas"}, {"to": "3881", "prefix": "plus ritonavir has been shown to increase the concentration of simvastatin and ", "from": "3870", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " (C. Fichtenbaum, J. Gerber, S. Rosenkranz et al., Abstr. 7th Conf. Retrovir. Op"}, {"to": "4364", "prefix": "ctase inhibitors. Two HMG-CoA reductase inhibitors were chosen for this study. ", "from": "4353", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "Atorvastatin", "suffix": " was studied because it is the most prescribed HMG-CoA reductase inhibitor, and "}, {"to": "4724", "prefix": "nter study to determine the pharmacokinetic interaction between nelfinavir and ", "from": "4713", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " or nelfinavir and simvastatin in healthy volunteers. Thirty-two subjects were e"}, {"to": "5801", "prefix": ". All ", "from": "5790", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " and nelfinavir doses were taken with food.\n\nTreatment group 2.\nIn period 1, sub"}, {"to": "6216", "prefix": " ", "from": "6205", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "Atorvastatin", "suffix": " and simvastatin sample collections\nTrough samples (7 ml) were collected prior t"}, {"to": "8559", "prefix": " ", "from": "8548", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "Atorvastatin", "suffix": " and simvastatin.\nPlasma samples were analyzed for atorvastatin equivalent conce"}, {"to": "8622", "prefix": " Atorvastatin and simvastatin.\nPlasma samples were analyzed for ", "from": "8611", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " equivalent concentrations (as the total of atorvastatin acid and its active met"}, {"to": "8678", "prefix": "as the total of ", "from": "8667", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " acid and its active metabolites) or simvastatin equivalent concentrations (as t"}, {"to": "8981", "prefix": ". ", "from": "8970", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "Atorvastatin", "suffix": " or simvastatin was isolated from 0.25 ml of human plasma by protein precipitati"}, {"to": "9123", "prefix": ". The ", "from": "9112", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " or simvastatin equivalent concentration was estimated by inhibition of the prod"}, {"to": "9386", "prefix": "r microsomes and cofactor. Since it was an enzyme inhibition assay, all of the ", "from": "9375", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " or simvastatin and its active metabolites in plasma capable of inhibiting HMG-C"}, {"to": "9518", "prefix": "s in plasma capable of inhibiting HMG-CoA reductase was quantified. Therefore, ", "from": "9507", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " or simvastatin concentrations were expressed as atorvastatin or simvastatin equ"}, {"to": "9579", "prefix": "ified. Therefore, atorvastatin or simvastatin concentrations were expressed as ", "from": "9568", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " or simvastatin equivalents. The standard curves were linear with R2 values of "}, {"to": "9686", "prefix": "0.997 for both ", "from": "9675", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " and simvastatin. This method was validated within concentration ranges of 0.18 "}, {"to": "9796", "prefix": "ml for ", "from": "9785", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " and 0.3 to 15.2 ng"}, {"to": "9921", "prefix": " of the assay for ", "from": "9910", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " and simvastatin were "}, {"to": "10067", "prefix": " of the assay for ", "from": "10056", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " and simvastatin were within 0.1 to 3.7% and "}, {"to": "10789", "prefix": "time zero to 24 h postdose for ", "from": "10778", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " and simvastatin and time zero to 12 h postdose for nelfinavir and AG1402). The "}, {"to": "10954", "prefix": ". The geometric mean and its associated 95% CI of the Cmax were calculated for ", "from": "10943", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": ", simvastatin, and nelfinavir. The ratio and its associated 90% CI of the geomet"}, {"to": "11079", "prefix": " and Cmax of ", "from": "11068", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " and simvastatin in the presence and absence of nelfinavir were also calculated."}, {"to": "11262", "prefix": " variance was used to compare logarithmically transformed parameter values for ", "from": "11251", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " and simvastatin in the absence and presence of nelfinavir, with the exception o"}, {"to": "12014", "prefix": "", "from": "12003", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " and nelfinavir) developed a rash, requested withdrawal from the study, and was "}, {"to": "12199", "prefix": " ages of the ", "from": "12188", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " and simvastatin groups were 31.5 (5.0) and 38.3 (9.7) years, respectively. The "}, {"to": "12321", "prefix": " body weights of the ", "from": "12310", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " and simvastatin groups were 74 (12) and 72 (9) kg, respectively.\n\nPharmacokinet"}, {"to": "12435", "prefix": " trough ", "from": "12424", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " equivalent concentrations on days 1, 5, 10, 14, 20, 25, and 28 were 0 (0.1), 1."}, {"to": "12850", "prefix": "ml. These results indicated that the steady state of ", "from": "12839", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " and simvastatin was reached on day 5 in period 1 and between days 20 to 25 in p"}, {"to": "13206", "prefix": " concentration-time profiles of ", "from": "13195", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " in the absence and presence of nelfinavir are presented in Fig. "}, {"to": "13318", "prefix": "Fig.1.1. Following the 14 days of ", "from": "13307", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " dosing at 10 mg QD, the geometric mean AUC"}, {"to": "13388", "prefix": " and Cmax for ", "from": "13377", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " equivalents (sum of atorvastatin acid and active metabolites) were 77 ng-eq"}, {"to": "13421", "prefix": "sum of ", "from": "13410", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " acid and active metabolites) were 77 ng-eq"}, {"to": "13590", "prefix": ". After the addition of nelfinavir at 1,250 mg BID to the ", "from": "13579", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " regimen, the geometric mean steady-state AUC"}, {"to": "13662", "prefix": " and Cmax for ", "from": "13651", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " equivalents were 134 ng-eq"}, {"to": "13931", "prefix": " plasma concentration-time profiles of ", "from": "13920", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " (ATOR) in the absence and presence of nelfinavir (NFV). eq., equivalents.\nTABLE"}, {"to": "14064", "prefix": ". eq., equivalents.\nTABLE 1\nTABLE 1\nPharmacokinetic parameters of ", "from": "14053", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " and simvastatina\nThe mean (SD) concentration-time profiles of simvastatin in th"}, {"to": "15049", "prefix": " and Cmax of nelfinavir in the presence of ", "from": "15038", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " were 44 (95% CI, 35 to 54) "}, {"to": "15372", "prefix": "ml, respectively. The median Tmax values of nelfinavir in the presence of ", "from": "15361", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " and simvastatin were 5.0 (range, 2.0 to 8.0) and 5.0 (range, 2.0 to 6.0) h, res"}, {"to": "15627", "prefix": " in the presence of ", "from": "15616", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " and simvastatin, respectively. There was no difference in the AUC"}, {"to": "15860", "prefix": ".\n\nSafety.\nNelfinavir in combination with ", "from": "15849", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " or simvastatin was well tolerated in this study. There were no serious adverse "}, {"to": "18394", "prefix": "ction between nelfinavir and two HMG-CoA reductase inhibitors, simvastatin and ", "from": "18383", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": ", because of the potential for drug interaction and the potential of the coadmin"}, {"to": "18533", "prefix": "and the potential of the coadministration of these drugs. Both simvastatin and ", "from": "18522", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " are extensively metabolized by humans, and a number of active and inactive meta"}, {"to": "18706", "prefix": "lites are produced. The active metabolites account for most of the activity of ", "from": "18695", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " and simvastatin. The enzyme inhibition assay used in this study measured the to"}, {"to": "19033", "prefix": "mvastatin equivalent concentrations extensively and increases the steady-state ", "from": "19022", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " equivalent concentrations moderately. The geometric mean AUC"}, {"to": "20377", "prefix": " and Cmax of ", "from": "20366", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": "-associated HMG-CoA inhibitors increased only 74 and 122%, respectively, with th"}, {"to": "20538", "prefix": "y, with the coadministration of nelfinavir. Fourteen of the 15 subjects in the ", "from": "20527", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " arm showed an increase in the AUC"}, {"to": "20589", "prefix": " of ", "from": "20578", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " equivalents in the presence of nelfinavir, with a range of "}, {"to": "20757", "prefix": ", suggesting a fairly consistent inhibitory effect of nelfinavir on ", "from": "20746", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " metabolism. Two subjects had a greater-than-threefold increase in atorvastatin."}, {"to": "20836", "prefix": "atorvastatin metabolism. Two subjects had a greater-than-threefold increase in ", "from": "20825", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": ". However, the AUCs of nelfinavir (42 and 60 "}, {"to": "21015", "prefix": "s were not particularly high, suggesting that the magnitude of the increase in ", "from": "21004", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " levels was not related to the levels of nelfinavir in plasma. Factors such as t"}, {"to": "21130", "prefix": "to the levels of nelfinavir in plasma. Factors such as the nelfinavir AUC, the ", "from": "21119", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " AUC in the absence of nelfinavir, gender, and race were not related to the ator"}, {"to": "21218", "prefix": "tin AUC in the absence of nelfinavir, gender, and race were not related to the ", "from": "21207", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " AUC ratio. The difference in the inhibitory effects of nelfinavir on simvastati"}, {"to": "21316", "prefix": "tio. The difference in the inhibitory effects of nelfinavir on simvastatin and ", "from": "21305", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " was not unexpected. Simvastatin appears to be very sensitive to CYP3A4 inhibito"}, {"to": "21576", "prefix": "tatin equivalents markedly, whereas itraconazole had only a moderate effect on ", "from": "21565", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " equivalents (16, 17). This difference may be explained by the different roles o"}, {"to": "21751", "prefix": " Comparative plot of ", "from": "21740", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " AUC"}, {"to": "21967", "prefix": "d presence of nelfinavir\nThe interaction between nelfinavir and simvastatin or ", "from": "21956", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " is likely due mainly to the inhibition of CYP3A4 by nelfinavir since the in vit"}, {"to": "22281", "prefix": "all, which would have a major effect on the bioavailability of simvastatin and ", "from": "22270", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": ", and"}, {"to": "22406", "prefix": " have an effect on the bioavailability and elimination rate of simvastatin and ", "from": "22395", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": ". In addition, a number of in vitro (4, 10, 23, 24) and in vivo (5, 10) studies "}, {"to": "22530", "prefix": " studies have suggested that nelfinavir, ", "from": "22519", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": ", and simvastatin may also be substrates"}, {"to": "22708", "prefix": "Inhibition of P-glycoprotein by nelfinavir may increase the oral absorption of ", "from": "22697", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " and simvastatin and contribute to the observed clinical interaction. However, i"}, {"to": "23236", "prefix": "y during the absorption period. The increase in the systemic concentrations of ", "from": "23225", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " and simvastatin caused by the coadministration of nelfinavir may not reflect th"}, {"to": "23444", "prefix": "e liver. It was interesting to observe similar cholesterol-lowering effects of ", "from": "23433", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " and simvastatin in the presence and absence of nelfinavir (Table "}, {"to": "23593", "prefix": " despite a significant increase in the systemic exposure of ", "from": "23582", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " and simvastatin. These results may suggest different effects of nelfinavir on t"}, {"to": "23727", "prefix": " different effects of nelfinavir on the systemic and liver pharmacokinetics of ", "from": "23716", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " and simvastatin.\n\nNo significant CPK elevation or rhabdomyolysis was observed i"}, {"to": "23963", "prefix": " while reassuring, are difficult to extrapolate to chronic coadministration of ", "from": "23952", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " or simvastatin with nelfinavir in HIV-positive patients. The greater-than-500% "}, {"to": "24326", "prefix": "ot be coadministered with nelfinavir. Nelfinavir had a more moderate effect on ", "from": "24315", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " concentrations. The recommended doses of atorvastatin are 10 to 80 mg"}, {"to": "24380", "prefix": " more moderate effect on atorvastatin concentrations. The recommended doses of ", "from": "24369", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " are 10 to 80 mg"}, {"to": "24438", "prefix": "day. Thus, the 10-mg dose of ", "from": "24427", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " should be started and titrated with caution to achieve the desired effect when "}, {"to": "24995", "prefix": "imilar to those in a previous studies with healthy volunteers, suggesting that ", "from": "24984", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " and simvastatin did not alter the pharmacokinetics of nelfinavir and its active"}, {"to": "25138", "prefix": "of nelfinavir and its active metabolite. These results were not unexpected, as ", "from": "25127", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " and simvastatin are weak CYP3A4 inhibitors and their concentrations were much l"}, {"to": "25514", "prefix": "dministration with simvastatin. Nelfinavir also increased systemic exposure to ", "from": "25503", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " moderately and should be coadministered with atorvastatin with caution.\n\nGo to:"}, {"to": "25572", "prefix": "systemic exposure to atorvastatin moderately and should be coadministered with ", "from": "25561", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "atorvastatin", "suffix": " with caution.\n\nGo to:\nACKNOWLEDGMENTS\nWe thank Gary Hutton, Statistical Associa"}, {"to": "25737", "prefix": "ssociates, Inc., for excellent statistical analysis of the data and the Pfizer ", "from": "25726", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC90851", "exact": "Atorvastatin", "suffix": " Team for valuable suggestions for the study."}, {"to": "862", "prefix": "imvastatin, in healthy volunteers. Thirty-two healthy subjects received either ", "from": "843", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "PMC90851", "exact": "atorvastatin calcium", "suffix": " (10 mg once a day) or simvastatin (20 mg once a day) for the first 14 days of t"}, {"to": "5539", "prefix": "treatments were as follows.\n\nTreatment group 1.\nIn period 1, subjects received ", "from": "5520", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "PMC90851", "exact": "atorvastatin calcium", "suffix": " (Lipitor; 10 mg once a day [QD]) in the morning for the first 14 days of the st"}, {"to": "5548", "prefix": "", "from": "5542", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "PMC90851", "exact": "Lipitor", "suffix": "; 10 mg once a day [QD]) in the morning for the first 14 days of the study. In p"}, {"to": "5675", "prefix": "the morning for the first 14 days of the study. In period 2, subjects received ", "from": "5656", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "PMC90851", "exact": "atorvastatin calcium", "suffix": " (10 mg QD) plus nelfinavir (Viracept; 1,250 mg twice a day [BID]) for an additi"}, {"to": "773", "prefix": ", a protease inhibitor, and two HMG-CoA reductase inhibitors, atorvastatin and ", "from": "763", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": ", in healthy volunteers. Thirty-two healthy subjects received either atorvastati"}, {"to": "896", "prefix": " or ", "from": "886", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " (20 mg once a day) for the first 14 days of the study. Nelfinavir (1,250 mg twi"}, {"to": "1343", "prefix": " of ", "from": "1333", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " 505% and the Cmax of simvastatin 517%. Neither atorvastatin nor simvastatin app"}, {"to": "1376", "prefix": " of simvastatin 505% and the Cmax of ", "from": "1366", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " 517%. Neither atorvastatin nor simvastatin appeared to alter the pharmacokineti"}, {"to": "1419", "prefix": "of simvastatin 505% and the Cmax of simvastatin 517%. Neither atorvastatin nor ", "from": "1409", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " appeared to alter the pharmacokinetics of nelfinavir. It is recommended that co"}, {"to": "1528", "prefix": "the pharmacokinetics of nelfinavir. It is recommended that coadministration of ", "from": "1518", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " with nelfinavir should be avoided, whereas atorvastatin should be used with nel"}, {"to": "3077", "prefix": " significantly increases the levels of HMG-CoA reductase inhibitors in plasma. ", "from": "3067", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "Simvastatin", "suffix": " and lovastatin appear to be especially sensitive to P450 3A4 inhibition. For ex"}, {"to": "3279", "prefix": " of ", "from": "3269", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " and lovastatin approximately fivefold but increased the AUC of atorvastatin onl"}, {"to": "3425", "prefix": ". The greatly elevated concentrations of ", "from": "3415", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " and lovastatin caused by itraconazole or other CYP3A4 inhibitors may increase t"}, {"to": "3864", "prefix": "n of saquinavir plus ritonavir has been shown to increase the concentration of ", "from": "3854", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " and atorvastatin (C. Fichtenbaum, J. Gerber, S. Rosenkranz et al., Abstr. 7th C"}, {"to": "4455", "prefix": "was studied because it is the most prescribed HMG-CoA reductase inhibitor, and ", "from": "4445", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " was studied because it is particularly susceptible to CYP3A4 inhibition.\n\nGo to"}, {"to": "4754", "prefix": "rmacokinetic interaction between nelfinavir and atorvastatin or nelfinavir and ", "from": "4744", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " in healthy volunteers. Thirty-two subjects were enrolled in the study. The stud"}, {"to": "5907", "prefix": "doses were taken with food.\n\nTreatment group 2.\nIn period 1, subjects received ", "from": "5897", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " (Zocor; 20 mg QD) in the morning for the first 14 days of the study. In period "}, {"to": "5914", "prefix": "", "from": "5910", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "Zocor", "suffix": "; 20 mg QD) in the morning for the first 14 days of the study. In period 2, subj"}, {"to": "6019", "prefix": "the morning for the first 14 days of the study. In period 2, subjects received ", "from": "6009", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " (20 mg QD) plus nelfinavir (1,250 mg BID) for an additional 14 days (days 15 to"}, {"to": "6120", "prefix": ". All ", "from": "6110", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " and nelfinavir doses were taken with food.\n\nPharmacokinetic sample collection. "}, {"to": "6232", "prefix": " Atorvastatin and ", "from": "6222", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " sample collections\nTrough samples (7 ml) were collected prior to dosing on days"}, {"to": "8575", "prefix": " Atorvastatin and ", "from": "8565", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": ".\nPlasma samples were analyzed for atorvastatin equivalent concentrations (as th"}, {"to": "8726", "prefix": " or ", "from": "8716", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " equivalent concentrations (as the total of simvastatin acid and its active meta"}, {"to": "8996", "prefix": ". Atorvastatin or ", "from": "8986", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " was isolated from 0.25 ml of human plasma by protein precipitation with acetoni"}, {"to": "9138", "prefix": ". The atorvastatin or ", "from": "9128", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " equivalent concentration was estimated by inhibition of the production of [14C]"}, {"to": "9401", "prefix": " cofactor. Since it was an enzyme inhibition assay, all of the atorvastatin or ", "from": "9391", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " and its active metabolites in plasma capable of inhibiting HMG-CoA reductase wa"}, {"to": "9533", "prefix": "ble of inhibiting HMG-CoA reductase was quantified. Therefore, atorvastatin or ", "from": "9523", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " concentrations were expressed as atorvastatin or simvastatin equivalents. The s"}, {"to": "9594", "prefix": ", atorvastatin or simvastatin concentrations were expressed as atorvastatin or ", "from": "9584", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " equivalents. The standard curves were linear with R2 values of "}, {"to": "9702", "prefix": "0.997 for both atorvastatin and ", "from": "9692", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": ". This method was validated within concentration ranges of 0.18 to 7.35 ng"}, {"to": "9834", "prefix": "ml for ", "from": "9824", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": ". The precision levels (percent coefficient of variation) of the assay for atorv"}, {"to": "9937", "prefix": " of the assay for atorvastatin and ", "from": "9927", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " were "}, {"to": "10083", "prefix": " of the assay for atorvastatin and ", "from": "10073", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " were within 0.1 to 3.7% and "}, {"to": "10805", "prefix": "time zero to 24 h postdose for atorvastatin and ", "from": "10795", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " and time zero to 12 h postdose for nelfinavir and AG1402). The geometric mean a"}, {"to": "10967", "prefix": "c mean and its associated 95% CI of the Cmax were calculated for atorvastatin, ", "from": "10957", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": ", and nelfinavir. The ratio and its associated 90% CI of the geometric mean of t"}, {"to": "11095", "prefix": " and Cmax of atorvastatin and ", "from": "11085", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " in the presence and absence of nelfinavir were also calculated. Analysis of var"}, {"to": "11278", "prefix": "d to compare logarithmically transformed parameter values for atorvastatin and ", "from": "11268", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " in the absence and presence of nelfinavir, with the exception of Tmax, which wa"}, {"to": "12215", "prefix": " ages of the atorvastatin and ", "from": "12205", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " groups were 31.5 (5.0) and 38.3 (9.7) years, respectively. The mean (SD) body w"}, {"to": "12337", "prefix": " body weights of the atorvastatin and ", "from": "12327", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " groups were 74 (12) and 72 (9) kg, respectively.\n\nPharmacokinetics.\nMean (SD) t"}, {"to": "12634", "prefix": " trough ", "from": "12624", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " equivalent concentrations on days 1, 5, 10, 14, 20, 25, and 28 were 0 (0), 0.4 "}, {"to": "12866", "prefix": "ml. These results indicated that the steady state of atorvastatin and ", "from": "12856", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " was reached on day 5 in period 1 and between days 20 to 25 in period 2. Mean tr"}, {"to": "14138", "prefix": " concentration-time profiles of ", "from": "14128", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " in the absence and presence of nelfinavir are presented in Fig. "}, {"to": "14249", "prefix": "Fig.2.2. Following the 14 days of ", "from": "14239", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " dosing at 20 mg QD, the geometric mean AUC"}, {"to": "14318", "prefix": " and Cmax for ", "from": "14308", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " equivalents (sum of simvastatin acid and active metabolites) were 42 ng-eq"}, {"to": "14518", "prefix": ". After the addition of nelfinavir at 1,250 mg BID to the ", "from": "14508", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " regimen, the geometric mean AUC"}, {"to": "14576", "prefix": " and Cmax for ", "from": "14566", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " equivalents were 255 ng-eq"}, {"to": "14751", "prefix": " and 517% in the Cmax of ", "from": "14741", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " after the addition of nelfinavir.\n\nFIG. 2\nFIG. 2\nMean (SD) plasma concentration"}, {"to": "14860", "prefix": " plasma concentration-time profiles of ", "from": "14850", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " (SIM) in the absence and presence of nelfinavir (NFV). eq., equivalents.\nThe ge"}, {"to": "15219", "prefix": " and Cmax of nelfinavir in the presence of ", "from": "15209", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " were 38 (range, 31 to 47) "}, {"to": "15388", "prefix": "vely. The median Tmax values of nelfinavir in the presence of atorvastatin and ", "from": "15378", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " were 5.0 (range, 2.0 to 8.0) and 5.0 (range, 2.0 to 6.0) h, respectively. The g"}, {"to": "15643", "prefix": " in the presence of atorvastatin and ", "from": "15633", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": ", respectively. There was no difference in the AUC"}, {"to": "15875", "prefix": ".\n\nSafety.\nNelfinavir in combination with atorvastatin or ", "from": "15865", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " was well tolerated in this study. There were no serious adverse events. Twenty-"}, {"to": "18377", "prefix": "gated the interaction between nelfinavir and two HMG-CoA reductase inhibitors, ", "from": "18367", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " and atorvastatin, because of the potential for drug interaction and the potenti"}, {"to": "18516", "prefix": "rug interaction and the potential of the coadministration of these drugs. Both ", "from": "18506", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " and atorvastatin are extensively metabolized by humans, and a number of active "}, {"to": "18722", "prefix": "d. The active metabolites account for most of the activity of atorvastatin and ", "from": "18712", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": ". The enzyme inhibition assay used in this study measured the total active HMG-C"}, {"to": "18951", "prefix": "e that administration of 1,250 mg of nelfinavir BID increases the steady-state ", "from": "18941", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " equivalent concentrations extensively and increases the steady-state atorvastat"}, {"to": "19119", "prefix": " and Cmax of ", "from": "19109", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": "-associated HMG-CoA inhibitors increased 505 and 517%, respectively, with the co"}, {"to": "19267", "prefix": "pectively, with the coadministration of nelfinavir. All of the subjects in the ", "from": "19257", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " arm showed an increase in the simvastatin equivalent AUC"}, {"to": "19309", "prefix": "lfinavir. All of the subjects in the simvastatin arm showed an increase in the ", "from": "19299", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " equivalent AUC"}, {"to": "19476", "prefix": ", suggesting a consistent inhibitory effect of nelfinavir on ", "from": "19466", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " metabolism. Two subjects had a greater than 10-fold increase in the simvastatin"}, {"to": "19556", "prefix": "imvastatin metabolism. Two subjects had a greater than 10-fold increase in the ", "from": "19546", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " AUC, and they also had the greatest nelfinavir AUCs (78 and 104 "}, {"to": "19705", "prefix": ", suggesting that the magnitude of the increase in ", "from": "19695", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " levels was related to the levels of nelfinavir in plasma. Linear regression of "}, {"to": "19800", "prefix": "ls was related to the levels of nelfinavir in plasma. Linear regression of the ", "from": "19790", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " AUC ratio (the ratio of the AUC of simvastatin plus nelfinavir to that of simva"}, {"to": "19847", "prefix": "the ratio of the AUC of ", "from": "19837", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " plus nelfinavir to that of simvastatin alone) versus the nelfinavir AUC in the "}, {"to": "19886", "prefix": "the ratio of the AUC of simvastatin plus nelfinavir to that of ", "from": "19876", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " alone) versus the nelfinavir AUC in the individual subjects also demonstrated a"}, {"to": "20007", "prefix": "UC in the individual subjects also demonstrated a high correlation between the ", "from": "19997", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " AUC ratio and the nelfinavir AUC with an R2 value of 0.81. Other factors, such "}, {"to": "20105", "prefix": "io and the nelfinavir AUC with an R2 value of 0.81. Other factors, such as the ", "from": "20095", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " AUC in the absence of nelfinavir, gender, and race, were not related to the sim"}, {"to": "20193", "prefix": "in AUC in the absence of nelfinavir, gender, and race, were not related to the ", "from": "20183", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " AUC ratio. These results suggested that the nelfinavir level was a major determ"}, {"to": "20307", "prefix": "s suggested that the nelfinavir level was a major determinant of the change in ", "from": "20297", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " levels. In contrast, the geometric mean AUC"}, {"to": "21299", "prefix": "rvastatin AUC ratio. The difference in the inhibitory effects of nelfinavir on ", "from": "21289", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " and atorvastatin was not unexpected. Simvastatin appears to be very sensitive t"}, {"to": "21348", "prefix": "tory effects of nelfinavir on simvastatin and atorvastatin was not unexpected. ", "from": "21338", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "Simvastatin", "suffix": " appears to be very sensitive to CYP3A4 inhibitors. Itraconazole, a classical CY"}, {"to": "21490", "prefix": "Itraconazole, a classical CYP3A4 inhibitor, also increased the AUC and Cmax of ", "from": "21480", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " equivalents markedly, whereas itraconazole had only a moderate effect on atorva"}, {"to": "21846", "prefix": " Comparative plot of ", "from": "21836", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " AUC"}, {"to": "21951", "prefix": " the absence and presence of nelfinavir\nThe interaction between nelfinavir and ", "from": "21941", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " or atorvastatin is likely due mainly to the inhibition of CYP3A4 by nelfinavir "}, {"to": "22264", "prefix": "strointestinal wall, which would have a major effect on the bioavailability of ", "from": "22254", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " and atorvastatin, and"}, {"to": "22389", "prefix": "ver, which would have an effect on the bioavailability and elimination rate of ", "from": "22379", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " and atorvastatin. In addition, a number of in vitro (4, 10, 23, 24) and in vivo"}, {"to": "22547", "prefix": " studies have suggested that nelfinavir, atorvastatin, and ", "from": "22537", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " may also be substrates"}, {"to": "22724", "prefix": "lycoprotein by nelfinavir may increase the oral absorption of atorvastatin and ", "from": "22714", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " and contribute to the observed clinical interaction. However, it is difficult t"}, {"to": "23252", "prefix": "rption period. The increase in the systemic concentrations of atorvastatin and ", "from": "23242", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " caused by the coadministration of nelfinavir may not reflect the change in drug"}, {"to": "23460", "prefix": "nteresting to observe similar cholesterol-lowering effects of atorvastatin and ", "from": "23450", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " in the presence and absence of nelfinavir (Table "}, {"to": "23609", "prefix": " despite a significant increase in the systemic exposure of atorvastatin and ", "from": "23599", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": ". These results may suggest different effects of nelfinavir on the systemic and "}, {"to": "23743", "prefix": "s of nelfinavir on the systemic and liver pharmacokinetics of atorvastatin and ", "from": "23733", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": ".\n\nNo significant CPK elevation or rhabdomyolysis was observed in this small, sh"}, {"to": "23978", "prefix": "g, are difficult to extrapolate to chronic coadministration of atorvastatin or ", "from": "23968", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " with nelfinavir in HIV-positive patients. The greater-than-500% increase in the"}, {"to": "24070", "prefix": "ith nelfinavir in HIV-positive patients. The greater-than-500% increase in the ", "from": "24060", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " concentration in the presence of nelfinavir was quite extensive and may increas"}, {"to": "24233", "prefix": "increase the risk of skeletal muscle damage. Therefore, it is recommended that ", "from": "24223", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " not be coadministered with nelfinavir. Nelfinavir had a more moderate effect on"}, {"to": "25011", "prefix": "n a previous studies with healthy volunteers, suggesting that atorvastatin and ", "from": "25001", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " did not alter the pharmacokinetics of nelfinavir and its active metabolite. The"}, {"to": "25154", "prefix": " its active metabolite. These results were not unexpected, as atorvastatin and ", "from": "25144", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " are weak CYP3A4 inhibitors and their concentrations were much lower than those "}, {"to": "25363", "prefix": " increased systemic exposure to ", "from": "25353", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": " approximately 500% and is not recommended for long-term coadministration with s"}, {"to": "25453", "prefix": " approximately 500% and is not recommended for long-term coadministration with ", "from": "25443", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC90851", "exact": "simvastatin", "suffix": ". Nelfinavir also increased systemic exposure to atorvastatin moderately and sho"}, {"to": "2340", "prefix": "r. 6th Eur. Conf. Clin. Aspect Treatment HIV Infect., 1997; package insert for ", "from": "2334", "name": "efavirenz", "fullId": "http://purl.bioontology.org/ontology/MESH/C098320", "setId": "PMC90851", "exact": "Sustiva", "suffix": " [efavirenz]), and lipodystrophy (13, 21) have been observed in HIV-positive pat"}, {"to": "2351", "prefix": "r. Conf. Clin. Aspect Treatment HIV Infect., 1997; package insert for Sustiva [", "from": "2343", "name": "efavirenz", "fullId": "http://purl.bioontology.org/ontology/MESH/C098320", "setId": "PMC90851", "exact": "efavirenz", "suffix": "]), and lipodystrophy (13, 21) have been observed in HIV-positive patients. The "}, {"to": "2953", "prefix": "substrates such as ", "from": "2942", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC90851", "exact": "itraconazole", "suffix": " (16, 17) and cyclosporine (1, 11) significantly increases the levels of HMG-CoA"}, {"to": "3176", "prefix": "astatin appear to be especially sensitive to P450 3A4 inhibition. For example, ", "from": "3165", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC90851", "exact": "itraconazole", "suffix": " increases the mean peak concentration and area under the concentration-time cur"}, {"to": "3463", "prefix": ". The greatly elevated concentrations of simvastatin and lovastatin caused by ", "from": "3452", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC90851", "exact": "itraconazole", "suffix": " or other CYP3A4 inhibitors may increase the risk of rhabdomyolysis (18, 20; R. "}, {"to": "21412", "prefix": "not unexpected. Simvastatin appears to be very sensitive to CYP3A4 inhibitors. ", "from": "21401", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC90851", "exact": "Itraconazole", "suffix": ", a classical CYP3A4 inhibitor, also increased the AUC and Cmax of simvastatin e"}, {"to": "21533", "prefix": ", also increased the AUC and Cmax of simvastatin equivalents markedly, whereas ", "from": "21522", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC90851", "exact": "itraconazole", "suffix": " had only a moderate effect on atorvastatin equivalents (16, 17). This differenc"}, {"to": "2979", "prefix": " and ", "from": "2968", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "PMC90851", "exact": "cyclosporine", "suffix": " (1, 11) significantly increases the levels of HMG-CoA reductase inhibitors in p"}, {"to": "3092", "prefix": "ncreases the levels of HMG-CoA reductase inhibitors in plasma. Simvastatin and ", "from": "3083", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC90851", "exact": "lovastatin", "suffix": " appear to be especially sensitive to P450 3A4 inhibition. For example, itracona"}, {"to": "3294", "prefix": " of simvastatin and ", "from": "3285", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC90851", "exact": "lovastatin", "suffix": " approximately fivefold but increased the AUC of atorvastatin only 60% (16, 17)."}, {"to": "3440", "prefix": ". The greatly elevated concentrations of simvastatin and ", "from": "3431", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC90851", "exact": "lovastatin", "suffix": " caused by itraconazole or other CYP3A4 inhibitors may increase the risk of rhab"}, {"to": "3789", "prefix": "YP3A4 and are inhibitors of CYP3A4. The dual protease inhibitor combination of ", "from": "3780", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83395", "setId": "PMC90851", "exact": "saquinavir", "suffix": " plus ritonavir has been shown to increase the concentration of simvastatin and "}, {"to": "3804", "prefix": "hibitors of CYP3A4. The dual protease inhibitor combination of saquinavir plus ", "from": "3796", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC90851", "exact": "ritonavir", "suffix": " has been shown to increase the concentration of simvastatin and atorvastatin (C"}, {"to": "4136", "prefix": " is an inhibitor of CYP3A4, although it is not as strong a CYP3A4 inhibitor as ", "from": "4128", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC90851", "exact": "ritonavir", "suffix": ". Nelfinavir is a widely prescribed protease inhibitor. It is therefore importan"}, {"to": "3957", "prefix": "C. Fichtenbaum, J. Gerber, S. Rosenkranz et al., Abstr. 7th Conf. ", "from": "3950", "name": "Zidovudine", "fullId": "http://purl.bioontology.org/ontology/MESH/D015215", "setId": "PMC90851", "exact": "Retrovir", "suffix": ". Opportunistic Infect., abstr LB 6, 2000). Nelfinavir, like the other protease "}, {"to": "7338", "prefix": "", "from": "7327", "name": "acetonitrile", "fullId": "http://purl.bioontology.org/ontology/MESH/C032159", "setId": "PMC90851", "exact": "acetonitrile", "suffix": " (9:1 ratio) mixture. The mixture was centrifuged for 5 min at 1,000 "}, {"to": "7637", "prefix": "25 mM sodium phosphate, monobasic pH 3.4, ", "from": "7626", "name": "acetonitrile", "fullId": "http://purl.bioontology.org/ontology/MESH/C032159", "setId": "PMC90851", "exact": "acetonitrile", "suffix": "-methanol; 60:32.5:7.5 by volume) and subjected to high-performance liquid chrom"}, {"to": "9081", "prefix": "statin was isolated from 0.25 ml of human plasma by protein precipitation with ", "from": "9070", "name": "acetonitrile", "fullId": "http://purl.bioontology.org/ontology/MESH/C032159", "setId": "PMC90851", "exact": "acetonitrile", "suffix": ""}, {"to": "7616", "prefix": "25 mM ", "from": "7590", "name": "Sodium Phosphate, Monobasic", "fullId": "http://purl.bioontology.org/ontology/RXNORM/235496", "setId": "PMC90851", "exact": "sodium phosphate, monobasic", "suffix": " pH 3.4, acetonitrile-methanol; 60:32.5:7.5 by volume) and subjected to high-per"}, {"to": "9089", "prefix": "", "from": "9083", "name": "Acetone", "fullId": "http://purl.bioontology.org/ontology/MESH/D000096", "setId": "PMC90851", "exact": "acetone", "suffix": " (95:5, vol"}, {"to": "10383", "prefix": ", triglycerides, glucose, ", "from": "10377", "name": "Insulin", "fullId": "http://purl.bioontology.org/ontology/MESH/D007328", "setId": "PMC90851", "exact": "insulin", "suffix": ", and C-peptide, were determined after an overnight fast on screening, before fi"}, {"to": "17127", "prefix": "ot be assessed with confidence. Other metabolic parameters, including glucose, ", "from": "17121", "name": "Insulin", "fullId": "http://purl.bioontology.org/ontology/MESH/D007328", "setId": "PMC90851", "exact": "insulin", "suffix": ", and C-peptide, were generally within the normal range and showed no consistent"}, {"to": "13331", "prefix": "Fig.1.1. Following the 14 days of atorvastatin dosing ", "from": "13327", "name": "Dihydrotachysterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D004097", "setId": "PMC90851", "exact": "at 10", "suffix": " mg QD, the geometric mean AUC"}, {"to": "16430", "prefix": " severe rash on day 23 and withdrew from the study. Subject 3 was treated with ", "from": "16423", "name": "Diphenhydramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D004155", "setId": "PMC90851", "exact": "Benadryl", "suffix": " and prednisone orally plus Kenalog intramuscularly. The rash resolved after 13 "}, {"to": "16445", "prefix": "on day 23 and withdrew from the study. Subject 3 was treated with Benadryl and ", "from": "16436", "name": "Prednisone", "fullId": "http://purl.bioontology.org/ontology/MESH/D011241", "setId": "PMC90851", "exact": "prednisone", "suffix": " orally plus Kenalog intramuscularly. The rash resolved after 13 days. Subject 1"}, {"to": "16465", "prefix": "from the study. Subject 3 was treated with Benadryl and prednisone orally plus ", "from": "16459", "name": "Triamcinolone Acetonide", "fullId": "http://purl.bioontology.org/ontology/MESH/D014222", "setId": "PMC90851", "exact": "Kenalog", "suffix": " intramuscularly. The rash resolved after 13 days. Subject 14 experienced a seve"}, {"to": "16597", "prefix": "ays. Subject 14 experienced a severe migraine headache, which was treated with ", "from": "16591", "name": "Tylenol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/202433", "setId": "PMC90851", "exact": "Tylenol", "suffix": " and resolved after 2 days. Seven subjects received medications other than the s"}, {"to": "360", "prefix": "ors, we aimed to evaluate the potential for a pharmacokinetic interaction with ", "from": "350", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": ".\n\nMETHODS\n\nA randomized, two-period, two-treatment, balanced, open-label, cross"}, {"to": "518", "prefix": "label, crossover study in 12 healthy subjects was performed. Subjects received ", "from": "508", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " 40 mg alone or anacetrapib 150 mg co-administered with simvastatin 40 mg, once "}, {"to": "585", "prefix": "ts received simvastatin 40 mg alone or anacetrapib 150 mg co-administered with ", "from": "575", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " 40 mg, once daily. Both treatments were administered following a low-fat breakf"}, {"to": "770", "prefix": ", separated by a wash-out period of at least 14 days. Safety and tolerability, ", "from": "760", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " and simvastatin acid concentrations, and lipoproteins, were assessed.\n\nRESULTS\n"}, {"to": "923", "prefix": "sessed.\n\nRESULTS\n\nBoth treatments were well tolerated. The pharmacokinetics of ", "from": "913", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " and simvastatin acid were similar with and without anacetrapib administration "}, {"to": "1101", "prefix": "] for simvastatin acid and ", "from": "1091", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " were 1.36 [1.17, 1.57] and 1.30 [1.14, 1.47], respectively"}, {"to": "1252", "prefix": ". Treatment with ", "from": "1242", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " alone led to a mean (95% CI) % reduction from baseline in low-density lipoprote"}, {"to": "1467", "prefix": " for anacetrapib co-administered with ", "from": "1457", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": ".\n\nCONCLUSIONS\n\nThere appears to be no clinically meaningful effect of anacetrap"}, {"to": "1598", "prefix": "inically meaningful effect of anacetrapib on the pharmacokinetic parameters of ", "from": "1588", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": ". When co-administered with simvastatin, anacetrapib appeared to exhibit increme"}, {"to": "1637", "prefix": "ib on the pharmacokinetic parameters of simvastatin. When co-administered with ", "from": "1627", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": ", anacetrapib appeared to exhibit incremental LDL-C-lowering efficacy, due to CE"}, {"to": "1780", "prefix": "owering efficacy, due to CETP inhibition. Co-administration of anacetrapib and ", "from": "1770", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " was well tolerated.\n\nKeywords: CETP inhibition, LDL-C, simvastatin\nWHAT IS ALRE"}, {"to": "1847", "prefix": "etrapib and simvastatin was well tolerated.\n\nKeywords: CETP inhibition, LDL-C, ", "from": "1837", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": "\nWHAT IS ALREADY KNOWN ABOUT THIS SUBJECT\n\nInhibition of cholesteryl ester trans"}, {"to": "2685", "prefix": "inically meaningful effect of anacetrapib on the pharmacokinetic parameters of ", "from": "2675", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": ".\nWhen co-administered with simvastatin, anacetrapib appeared to exhibit increme"}, {"to": "2724", "prefix": "ib on the pharmacokinetic parameters of simvastatin.\nWhen co-administered with ", "from": "2714", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": ", anacetrapib appeared to exhibit incremental LDL-C-and apolipoprotein (Apo) B-l"}, {"to": "4473", "prefix": " to investigate and quantify any potential pharmacokinetic interaction between ", "from": "4463", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " and anacetrapib, following multiple oral doses of each, when the drugs are co-a"}, {"to": "4797", "prefix": " the two treatments. Safety and tolerability of treatment with anacetrapib and ", "from": "4787", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " were also assessed.\n\nGo to:\nMethods\nStudy participants\n\nAll study participants "}, {"to": "5662", "prefix": " subjects. In Treatment A, subjects received a once daily oral dose of a 40-mg ", "from": "5652", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " tablet (ZOCOR"}, {"to": "5880", "prefix": "liquid-filled capsules, co-administered with a once-daily oral dose of a 40-mg ", "from": "5870", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " tablet for 14 days in the morning. All doses were administered following a stan"}, {"to": "6118", "prefix": "days in duration between treatment periods.\n\nPharmacokinetic blood samples for ", "from": "6108", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " and simvastatin acid were collected on day 14 of Treatments A and B and predose"}, {"to": "7542", "prefix": "z.\n\nSafety and tolerability\n\nThe safety and tolerability of anacetrapib and ", "from": "7532", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " were assessed throughout the study by physical examinations, vital signs, 12-le"}, {"to": "8232", "prefix": "cluded from analysis.\n\nThe pharmacokinetic parameters for simvastatin acid and ", "from": "8222", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": ", AUC0"}, {"to": "8665", "prefix": " of ", "from": "8655", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " and simvastatin acid following multiple oral doses of 40 mg simvastatin (vs. an"}, {"to": "8737", "prefix": " of simvastatin and simvastatin acid following multiple oral doses of 40 mg ", "from": "8727", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " (vs. anacetrapib alone) is contained within the interval (0.50, 2.00). Summary "}, {"to": "9006", "prefix": "Apo A1 and Apo B.\n\nGo to:\nResults\nAnacetrapib administered in combination with ", "from": "8996", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " was generally well tolerated. There were no serious clinical or laboratory adve"}, {"to": "9403", "prefix": "e clinical site for dosing and was lost to follow-up.\n\nThe pharmacokinetics of ", "from": "9393", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " and simvastatin acid were similar with and without anacetrapib administration ("}, {"to": "9595", "prefix": " for simvastatin acid and ", "from": "9585", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " were 1.36 (1.17, 1.57) and 1.30 (1.14, 1.47), respectively. Similarly, the Cmax"}, {"to": "9725", "prefix": " for simvastatin acid and ", "from": "9715", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " were 1.26 (1.03, 1.55) and 1.24 (1.01, 1.52), respectively. There were no meani"}, {"to": "9917", "prefix": "2 between the two treatments for either simvastatin acid or ", "from": "9907", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": ". While calculated, the half-life values should be interpreted with caution give"}, {"to": "10035", "prefix": "-life values should be interpreted with caution given reversible metabolism of ", "from": "10025", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " to simvastatin acid.\n\nTable 1\nTable 1\nSummary of simvastatin acid and simvastat"}, {"to": "10117", "prefix": "vastatin to simvastatin acid.\n\nTable 1\nTable 1\nSummary of simvastatin acid and ", "from": "10107", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " pharmacokinetic parameters\nFigure 1\nFigure 1\nPlasma concentration"}, {"to": "10238", "prefix": " and ", "from": "10228", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " (B). Treatment A (Simvastatin alone) ("}, {"to": "10268", "prefix": "", "from": "10258", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "Simvastatin", "suffix": " alone) ("}, {"to": "10307", "prefix": "", "from": "10297", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "Simvastatin", "suffix": " "}, {"to": "10468", "prefix": "DL-C, Apo B and A1 at baseline and on day 14 at 24 h post dose. Treatment with ", "from": "10458", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " alone led to a mean (95% CI) % reduction from baseline in LDL-C of "}, {"to": "10645", "prefix": " for anacetrapib co-administered with ", "from": "10635", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": ". The estimated difference (90% CI) (anacetrapib "}, {"to": "10707", "prefix": " ", "from": "10697", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " vs. simvastatin alone) in LDL-C mean % change from baseline was therefore "}, {"to": "10723", "prefix": " simvastatin vs. ", "from": "10713", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " alone) in LDL-C mean % change from baseline was therefore "}, {"to": "10870", "prefix": " ", "from": "10860", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " vs. simvastatin alone) in other lipoprotein parameters were as follows: HDL-C 8"}, {"to": "10886", "prefix": " simvastatin vs. ", "from": "10876", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " alone) in other lipoprotein parameters were as follows: HDL-C 85% (66, 105); Ap"}, {"to": "11182", "prefix": "iscussion\nThe study explored primarily the pharmacokinetic interaction between ", "from": "11172", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " and anacetrapib, as it relates to the effect of anacetrapib on simvastatin phar"}, {"to": "11257", "prefix": "een simvastatin and anacetrapib, as it relates to the effect of anacetrapib on ", "from": "11247", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " pharmacokinetics. Simvastatin is a lactone that is readily hydrolysed in vivo t"}, {"to": "11287", "prefix": "b, as it relates to the effect of anacetrapib on simvastatin pharmacokinetics. ", "from": "11277", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "Simvastatin", "suffix": " is a lactone that is readily hydrolysed in vivo to the corresponding "}, {"to": "11532", "prefix": "rated that CYP3A4 is the major enzyme system responsible for the metabolism of ", "from": "11522", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " [10]. Simvastatin is well absorbed (about 60"}, {"to": "11550", "prefix": "is the major enzyme system responsible for the metabolism of simvastatin [10]. ", "from": "11540", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "Simvastatin", "suffix": " is well absorbed (about 60"}, {"to": "11774", "prefix": "tem [10]. The bioavailability of active HMG-CoA reductase inhibitors following ", "from": "11764", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " tablets is "}, {"to": "11830", "prefix": "5% of the oral dose. Therefore, ", "from": "11820", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " was selected as the statin for this drug interaction study. Although the 80-mg "}, {"to": "11929", "prefix": "cted as the statin for this drug interaction study. Although the 80-mg dose of ", "from": "11919", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " is the highest currently approved dose, the recommended usual starting dose is "}, {"to": "12150", "prefix": "a cardiovascular event [10]. Therefore, the study investigated a 40-mg dose of ", "from": "12140", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " with and without anacetrapib. This simvastatin dose was chosen to increase the "}, {"to": "12197", "prefix": "dy investigated a 40-mg dose of simvastatin with and without anacetrapib. This ", "from": "12187", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " dose was chosen to increase the sensitivity of the potential for a pharmacokine"}, {"to": "12324", "prefix": "itivity of the potential for a pharmacokinetic interaction of anacetrapib with ", "from": "12314", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": ". The anacetrapib dose of 150 mg once daily with a low-fat breakfast evaluated i"}, {"to": "12699", "prefix": "acokinetics is less variable in this state than with a high-fat breakfast [3]. ", "from": "12689", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "Simvastatin", "suffix": "'s absorption is not affected by food, hence not impacted by the low-fat meal gi"}, {"to": "12858", "prefix": "fat meal given in this study [10]. A multiple-dose study design was used where ", "from": "12848", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " and anacetrapib were dosed orally to steady state and the effect of anacetrapib"}, {"to": "12974", "prefix": "d orally to steady state and the effect of anacetrapib on the plasma levels of ", "from": "12964", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " was studied. A duration of 14 days as multiple oral daily dosing was considered"}, {"to": "13287", "prefix": "e is no clinically meaningful effect of anacetrapib on the pharmacokinetics of ", "from": "13277", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " (simvastatin acid or simvastatin). This is not unexpected, given data in the li"}, {"to": "13320", "prefix": "simvastatin acid or ", "from": "13310", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": "). This is not unexpected, given data in the literature showing drug interaction"}, {"to": "13418", "prefix": "is not unexpected, given data in the literature showing drug interactions with ", "from": "13408", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " were metabolic in nature, as a result of inhibition or induction of the CYP3A e"}, {"to": "13618", "prefix": " of clinically meaningful interaction with a sensitive CYP3A substrate such as ", "from": "13608", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " is consistent with the finding that anacetrapib does not induce or inhibit CYP3"}, {"to": "13843", "prefix": "armacodynamic, particularly the lipid-altering biomarkers, interaction between ", "from": "13833", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " and anacetrapib. Anacetrapib is an investigational CETP inhibitor that has show"}, {"to": "15160", "prefix": "cholesterol or triglycerides, and hence was not measured in the present study. ", "from": "15150", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "Simvastatin", "suffix": " is a highly effective marketed drug for the reduction of LDL-C and triglyceride"}, {"to": "15399", "prefix": "enzyme that catalyses the rate-limiting step in cholesterol biosynthesis [10]. ", "from": "15389", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "Simvastatin", "suffix": ", at a dose of 80 mg per day, effectively reduced LDL-C by 47%, increased HDL-C "}, {"to": "15655", "prefix": " Dose Comparison Study [10]. In the Multicenter Combined Hyperlipidemia Study, ", "from": "15645", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": ", when administered either at 40 or 80 mg per day, elicited LDL-C decreases of 2"}, {"to": "15839", "prefix": "33% [10].\n\nIn this study, ", "from": "15829", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " alone reduced LDL-C by 36% and Apo B by 29%, whereas in combination with anacet"}, {"to": "18371", "prefix": "ein metabolism may explain this lack of an additive effect for anacetrapib and ", "from": "18361", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": ". Recently, it was reported that whereas subjects treated with torcetrapib alone"}, {"to": "19372", "prefix": "in the less than additive LDL-C-lowering effects observed with anacetrapib and ", "from": "19362", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " (current study) or with atorvastatin [7].\n\nAlthough anacetrapib appears to have"}, {"to": "19532", "prefix": "rs to have less than additive lipid-altering effects with atorvastatin [7] and ", "from": "19522", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " (present study), the lipid-altering effects were anacetrapib dose dependent bas"}, {"to": "19902", "prefix": "o be no clinically meaningful effect of anacetrapib on the pharmacokinetics of ", "from": "19892", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": ". When co-administered with simvastatin, anacetrapib appeared to exhibit increme"}, {"to": "19941", "prefix": " anacetrapib on the pharmacokinetics of simvastatin. When co-administered with ", "from": "19931", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": ", anacetrapib appeared to exhibit incremental LDL-C-and Apo B-lowering efficacy."}, {"to": "20070", "prefix": "mental LDL-C-and Apo B-lowering efficacy. Co-administration of anacetrapib and ", "from": "20060", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " was well tolerated.\n\nGo to:\nCompeting interests\nR.K., A.G., B.J., S.S.K., J.C. "}, {"to": "20547", "prefix": "f this study, the assistance of Rita Chiou and Jin Zhang in outsourcing of the ", "from": "20537", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC2686068", "exact": "simvastatin", "suffix": " assay, and the assistance of Josee Cote at the conclusion of the study.\n\nGo to:"}, {"to": "1346", "prefix": " % reduction from baseline in low-density lipoprotein-", "from": "1336", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC2686068", "exact": "cholesterol", "suffix": " (LDL-C) of "}, {"to": "2461", "prefix": "between a CETP inhibitor and a statin, and whether the low-density lipoprotein-", "from": "2451", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC2686068", "exact": "cholesterol", "suffix": " (LDL-C)-lowering effects are additive with the combination.\nWHAT THIS STUDY ADD"}, {"to": "6414", "prefix": "]. Serum samples were collected for the measurement of low-density lipoprotein-", "from": "6404", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC2686068", "exact": "cholesterol", "suffix": " (LDL-C), high-density lipoprotein-cholesterol (HDL-C), and the apolipoproteins "}, {"to": "6460", "prefix": ", high-density lipoprotein-", "from": "6450", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC2686068", "exact": "cholesterol", "suffix": " (HDL-C), and the apolipoproteins (Apo) B and A1 predose on day 1 (Treatments A "}, {"to": "15081", "prefix": "ts with dyslipidaemia [7]. Anacetrapib does not meaningfully alter serum total ", "from": "15071", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC2686068", "exact": "cholesterol", "suffix": " or triglycerides, and hence was not measured in the present study. Simvastatin "}, {"to": "15368", "prefix": "tion of HMG-CoA reductase, the enzyme that catalyses the rate-limiting step in ", "from": "15358", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC2686068", "exact": "cholesterol", "suffix": " biosynthesis [10]. Simvastatin, at a dose of 80 mg per day, effectively reduced"}, {"to": "2212", "prefix": "Clinical studies published to date with other investigational CETP inhibitors, ", "from": "2202", "name": "torcetrapib", "fullId": "http://purl.bioontology.org/ontology/MESH/C483909", "setId": "PMC2686068", "exact": "torcetrapib", "suffix": " (Pfizer) and dalcetrapib (Roche), have been evaluated in the presence of statin"}, {"to": "17195", "prefix": "nacetrapib. Similar, less than strict additive effects have been observed with ", "from": "17185", "name": "torcetrapib", "fullId": "http://purl.bioontology.org/ontology/MESH/C483909", "setId": "PMC2686068", "exact": "torcetrapib", "suffix": ", another CETP inhibitor alone and in combination with atorvastatin [15].\n\nThe e"}, {"to": "18445", "prefix": " and simvastatin. Recently, it was reported that whereas subjects treated with ", "from": "18435", "name": "torcetrapib", "fullId": "http://purl.bioontology.org/ontology/MESH/C483909", "setId": "PMC2686068", "exact": "torcetrapib", "suffix": " alone demonstrated an enhanced rate of LDL apoB100 catabolism, in subjects pret"}, {"to": "19039", "prefix": "ds with HDL. It is not known whether anacetrapib would behave differently from ", "from": "19029", "name": "torcetrapib", "fullId": "http://purl.bioontology.org/ontology/MESH/C483909", "setId": "PMC2686068", "exact": "torcetrapib", "suffix": " with regard to lipoprotein metabolism, and this is currently being investigated"}, {"to": "19178", "prefix": "is currently being investigated. These results appear to suggest, at least for ", "from": "19168", "name": "torcetrapib", "fullId": "http://purl.bioontology.org/ontology/MESH/C483909", "setId": "PMC2686068", "exact": "torcetrapib", "suffix": ", that there may be a pharmacologically shared mechanism of LDL-C lowering, whic"}, {"to": "3421", "prefix": "8].\n\nA ", "from": "3413", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC2686068", "exact": "midazolam", "suffix": " clinical study in healthy subjects for the assessment of effects of CYP3A4 with"}, {"to": "7722", "prefix": "serum sodium, potassium, chloride, bicarbonate, calcium, ", "from": "7713", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003404", "setId": "PMC2686068", "exact": "creatinine", "suffix": ", blood urea nitrogen, fasting serum glucose, bilirubin, aspartate aminotransfer"}, {"to": "7734", "prefix": "serum sodium, potassium, chloride, bicarbonate, calcium, creatinine, blood ", "from": "7731", "name": "Urea", "fullId": "http://purl.bioontology.org/ontology/MESH/D014508", "setId": "PMC2686068", "exact": "urea", "suffix": " nitrogen, fasting serum glucose, bilirubin, aspartate aminotransferase, alanine"}, {"to": "7814", "prefix": "d urea nitrogen, fasting serum glucose, bilirubin, aspartate aminotransferase, ", "from": "7808", "name": "Alanine", "fullId": "http://purl.bioontology.org/ontology/MESH/D000409", "setId": "PMC2686068", "exact": "alanine", "suffix": " aminotransferase, alkaline phosphatase, albumin; haemoglobin, haematocrit, plat"}, {"to": "14090", "prefix": "s and in patients with dyslipidaemia, both alone as well as in the presence of ", "from": "14079", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2686068", "exact": "atorvastatin", "suffix": " [4,5,7]. Thus, the findings of this 14-day study on the lipoprotein parameters "}, {"to": "14286", "prefix": "light of available data on anacetrapib, as monotherapy and in combination with ", "from": "14275", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2686068", "exact": "atorvastatin", "suffix": ". Anacetrapib has been associated with maximal pharmacodynamic lipid effects in "}, {"to": "14670", "prefix": ", the maximal reductions in LDL-C and Apo B were similar to those with ", "from": "14659", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2686068", "exact": "atorvastatin", "suffix": " 20 mg [7]. Moreover, incremental reductions in LDL-C and Apo B were observed wh"}, {"to": "14802", "prefix": "ons in LDL-C and Apo B were observed when anacetrapib was co-administered with ", "from": "14791", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2686068", "exact": "atorvastatin", "suffix": " 20 mg. The net result of treatment with anacetrapib and atorvastatin was approx"}, {"to": "14871", "prefix": "ered with atorvastatin 20 mg. The net result of treatment with anacetrapib and ", "from": "14860", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2686068", "exact": "atorvastatin", "suffix": " was approximately 70% lowering of LDL-C, approximately 50% lowering of Apo B, a"}, {"to": "16632", "prefix": " and ", "from": "16621", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2686068", "exact": "atorvastatin", "suffix": " 20 mg in the Phase 2b study, wherein atorvastatin 20 mg reduced LDL-C by approx"}, {"to": "16682", "prefix": " and atorvastatin 20 mg in the Phase 2b study, wherein ", "from": "16671", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2686068", "exact": "atorvastatin", "suffix": " 20 mg reduced LDL-C by approximately 42% and when atorvastatin 20 mg was given "}, {"to": "16745", "prefix": " study, wherein atorvastatin 20 mg reduced LDL-C by approximately 42% and when ", "from": "16734", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2686068", "exact": "atorvastatin", "suffix": " 20 mg was given with anacetrapib 150 mg, LDL-C was reduced by about 65% [7]. In"}, {"to": "17262", "prefix": "bserved with torcetrapib, another CETP inhibitor alone and in combination with ", "from": "17251", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2686068", "exact": "atorvastatin", "suffix": " [15].\n\nThe exact reason for a lack of an additive effect on the LDL-C-lowering "}, {"to": "18549", "prefix": "trated an enhanced rate of LDL apoB100 catabolism, in subjects pretreated with ", "from": "18538", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2686068", "exact": "atorvastatin", "suffix": ", in which LDL apoB100 catabolism was already enhanced as a result of atorvastat"}, {"to": "18631", "prefix": "rvastatin, in which LDL apoB100 catabolism was already enhanced as a result of ", "from": "18620", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2686068", "exact": "atorvastatin", "suffix": " treatment, there was a reduced LDL apoB100 production rate [18]. Because CETP t"}, {"to": "19409", "prefix": " or with ", "from": "19398", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2686068", "exact": "atorvastatin", "suffix": " [7].\n\nAlthough anacetrapib appears to have less than additive lipid-altering ef"}, {"to": "19512", "prefix": "ugh anacetrapib appears to have less than additive lipid-altering effects with ", "from": "19501", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC2686068", "exact": "atorvastatin", "suffix": " [7] and simvastatin (present study), the lipid-altering effects were anacetrapi"}, {"to": "17775", "prefix": "17], nonlinear and pharmacologically dependent effects have been observed with ", "from": "17767", "name": "gemcabene", "fullId": "http://purl.bioontology.org/ontology/MESH/C111024", "setId": "PMC2686068", "exact": "gemcabene", "suffix": " [16], a discontinued lipid-altering drug. It should be noted that both ezetemib"}, {"to": "18008", "prefix": "C-lowering effects compared with statins, whereas the exact mechanism by which ", "from": "18000", "name": "gemcabene", "fullId": "http://purl.bioontology.org/ontology/MESH/C111024", "setId": "PMC2686068", "exact": "gemcabene", "suffix": " lowers LDL-C and, more importantly, whether there is a common element in the me"}, {"to": "19", "prefix": "ABSTRACT\n", "from": "10", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "Telaprevir", "suffix": " is a hepatitis C virus protease inhibitor that is both a substrate and an inhib"}, {"to": "306", "prefix": "y patients with hepatitis C. This study was conducted to examine the effect of ", "from": "297", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " on atorvastatin and amlodipine pharmacokinetics (PK). This was an open-label, s"}, {"to": "566", "prefix": "rmulation of 5 mg amlodipine and 20 mg atorvastatin was administered on day 1. ", "from": "557", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "Telaprevir", "suffix": " was taken with food as a 750-mg dose every 8 h from day 11 until day 26, and a "}, {"to": "802", "prefix": "stered on day 17. Plasma samples were collected for determination of the PK of ", "from": "793", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": ", amlodipine, atorvastatin, ortho-hydroxy atorvastatin, and para-hydroxy atorvas"}, {"to": "924", "prefix": "-hydroxy atorvastatin, and para-hydroxy atorvastatin. When administration with ", "from": "915", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " was compared with administration without telaprevir, the least-square mean rati"}, {"to": "976", "prefix": ". When administration with telaprevir was compared with administration without ", "from": "967", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": ", the least-square mean ratios (90% confidence limits) for amlodipine were 1.27 "}, {"to": "1328", "prefix": ". ", "from": "1319", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "Telaprevir", "suffix": " significantly increased exposure to amlodipine and atorvastatin, consistent wit"}, {"to": "1445", "prefix": "osure to amlodipine and atorvastatin, consistent with the inhibitory effect of ", "from": "1436", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " on the CYP3A-mediated metabolism of these agents.\n\nGo to:\nINTRODUCTION\nTelaprev"}, {"to": "1527", "prefix": "aprevir on the CYP3A-mediated metabolism of these agents.\n\nGo to:\nINTRODUCTION\n", "from": "1518", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "Telaprevir", "suffix": " is an orally administered inhibitor of the nonstructural 3"}, {"to": "1741", "prefix": ", the addition of ", "from": "1732", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " as part of a combination regimen with pegylated interferon and ribavirin signif"}, {"to": "1904", "prefix": ". ", "from": "1895", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "Telaprevir", "suffix": " was recently approved in the United States of America for the treatment of geno"}, {"to": "3431", "prefix": ".\n\n", "from": "3422", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "Telaprevir", "suffix": " inhibits CYP3A-mediated metabolism at therapeutic concentrations and may inhibi"}, {"to": "3648", "prefix": "refore, this study was designed to evaluate the drug-drug interactions between ", "from": "3639", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " and amlodipine and atorvastatin in healthy volunteers.\n\nGo to:\nMATERIALS AND ME"}, {"to": "5371", "prefix": " design.\nThis was a phase 1, open-label, single-center, nonrandomized study of ", "from": "5362", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " in combination with Caduet tablets containing 5 mg of amlodipine and 20 mg of a"}, {"to": "5632", "prefix": " dose of amlodipine-atorvastatin alone on day 1, followed by a washout period, ", "from": "5623", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " at a dose of 750 mg every 8 h (q8h) on days 11 through 26, with a single dose o"}, {"to": "6143", "prefix": "1 to 2, 10 to 11, and 15 to 20.\n\nDrugs administered.\n", "from": "6134", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "Telaprevir", "suffix": " (375-mg tablets, Patheon, Mississauga, Ontario, Canada) was administered at 750"}, {"to": "6753", "prefix": "90% compliant with the ", "from": "6744", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " dosing regimen, and all volunteers received their scheduled doses of amlodipine"}, {"to": "7050", "prefix": "pine, atorvastatin, ortho-hydroxy atorvastatin, para-hydroxy atorvastatin, and ", "from": "7041", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " in plasma.\n\nPlasma amlodipine, atorvastatin, ortho-hydroxy atorvastatin, and pa"}, {"to": "7577", "prefix": "on day 17. Neither amlodipine nor atorvastatin is an inhibitor of CYP3A, while ", "from": "7568", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " is a potent inhibitor of CYP3A. Thus, an effect of amlodipine and atorvastatin "}, {"to": "7670", "prefix": "a potent inhibitor of CYP3A. Thus, an effect of amlodipine and atorvastatin on ", "from": "7661", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " pharmacokinetics (PK) was not anticipated. Therefore, telaprevir PK were evalua"}, {"to": "7735", "prefix": " was not anticipated. Therefore, ", "from": "7726", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " PK were evaluated only on day 17 and compared to those found historically. Plas"}, {"to": "7828", "prefix": "were evaluated only on day 17 and compared to those found historically. Plasma ", "from": "7819", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " concentrations were determined at steady state predose and at 0.25, 0.5, 0.75, "}, {"to": "7972", "prefix": " and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, and 8 h after the morning dose of ", "from": "7963", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " on day 17.\n\nAnalysis of all plasma samples was performed using validated liquid"}, {"to": "8386", "prefix": "o-hydroxy atorvastatin-phenyl-d5, para-hydroxy atorvastatin-phenyl-d5, and d11-", "from": "8377", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": ") were extracted from human plasma by liquid-liquid extraction. After evaporatio"}, {"to": "9059", "prefix": "ml for ", "from": "9050", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " (LLOQ, 2.00 ng"}, {"to": "10737", "prefix": "astatin following a single dose of amlodipine-atorvastatin coadministered with ", "from": "10728", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " were compared to those measured following a single dose of amlodipine-atorvasta"}, {"to": "10889", "prefix": "with or without ", "from": "10880", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": ") was considered a fixed effect and subject was a random effect. Geometric LS me"}, {"to": "11599", "prefix": "atorvastatin when administered alone and when administered in combination with ", "from": "11590", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": ". Clinical chemistry and hematology were assessed predose and on days 10, 15, an"}, {"to": "12447", "prefix": "pine, atorvastatin, ortho-hydroxy atorvastatin, para-hydroxy atorvastatin, and ", "from": "12438", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": ". Day 17 plasma samples from 2 volunteers were not available because they discon"}, {"to": "12633", "prefix": "after providing blood samples for day 1 amlodipine-atorvastatin PK.\n\nEffect of ", "from": "12624", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " on the PK of amlodipine.\nThe mean plasma amlodipine concentration-time profile "}, {"to": "13033", "prefix": "re increased 1.27-fold and 2.79-fold, respectively, by the coadministration of ", "from": "13024", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " (Table 1). The mean t1"}, {"to": "13319", "prefix": "tion-time profile of amlodipine following oral administration with and without ", "from": "13310", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": ". Error bars represent the standard error of the mean.\nTable 1.\nTable 1.\nEffects"}, {"to": "13413", "prefix": "or bars represent the standard error of the mean.\nTable 1.\nTable 1.\nEffects of ", "from": "13404", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " on the PK of amlodipine, atorvastatin, and its metabolite ortho-hydroxy atorvas"}, {"to": "13519", "prefix": "odipine, atorvastatin, and its metabolite ortho-hydroxy atorvastatin\nEffect of ", "from": "13510", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " on the PK of atorvastatin and metabolites.\nThe mean plasma atorvastatin concent"}, {"to": "13949", "prefix": "ly increased 10.6-fold and 7.88-fold, respectively, by the coadministration of ", "from": "13940", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " (Table 1). The mean apparent clearance (CL"}, {"to": "14122", "prefix": " h with ", "from": "14113", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " coadministration; the difference in t1"}, {"to": "14328", "prefix": "on-time profile of atorvastatin following oral administration with and without ", "from": "14319", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": ". Error bars represent the standard error of the mean.\nThe mean plasma concentra"}, {"to": "15450", "prefix": "e of ortho-hydroxy-atorvastatin following oral administration with and without ", "from": "15441", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": ". Error bars represent the standard error of the mean.\nMost of the concentration"}, {"to": "15778", "prefix": " 1. The Cmax of para-hydroxy atorvastatin in these 2 volunteers increased with ", "from": "15769", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " coadministration from 0.30 and 0.54 (mean of 0.42) ng"}, {"to": "15922", "prefix": ".\n\nSteady-state PK of ", "from": "15913", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " after coadministration with amlodipine and atorvastatin.\nSelected steady-state "}, {"to": "16059", "prefix": "vastatin.\nSelected steady-state pharmacokinetic parameters were calculated for ", "from": "16050", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " on day 17 after coadministration with a single dose of amlodipine-atorvastatin."}, {"to": "16172", "prefix": " Cmax of ", "from": "16163", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " was 3,167 (778) ng"}, {"to": "16237", "prefix": " AUC0-last of ", "from": "16228", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " was 20,471 (5,317) h "}, {"to": "16495", "prefix": " during the ", "from": "16486", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": "-alone period. This was considered possibly related to treatment, was mild in se"}, {"to": "16776", "prefix": "mild severity. The exception was moderate diarrhea in one volunteer during the ", "from": "16767", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": "-amlodipine-atorvastatin combination period.\n\nThirteen (62%) volunteers reported"}, {"to": "17379", "prefix": "ing the amlodipine-atorvastatin-alone period, in 2 volunteers [10%] during the ", "from": "17370", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": "-alone period, and in 1 volunteer [5%] during the telaprevir-amlodipine-atorvast"}, {"to": "17439", "prefix": "s [10%] during the telaprevir-alone period, and in 1 volunteer [5%] during the ", "from": "17430", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": "-amlodipine-atorvastatin combination period); dizziness (occurred in 2 volunteer"}, {"to": "17548", "prefix": "occurred in 2 volunteers [10%] during the ", "from": "17539", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": "-alone period, and in 3 volunteers [15%] during the telaprevir-amlodipine-atorva"}, {"to": "17610", "prefix": "[10%] during the telaprevir-alone period, and in 3 volunteers [15%] during the ", "from": "17601", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": "-amlodipine-atorvastatin combination period); diarrhea (occurred in 1 volunteer "}, {"to": "17784", "prefix": "occurred in 1 volunteer [5%] during the ", "from": "17775", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": "-alone period and in 2 volunteers [11%] during the telaprevir-amlodipine-atorvas"}, {"to": "17845", "prefix": "r [5%] during the telaprevir-alone period and in 2 volunteers [11%] during the ", "from": "17836", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": "-amlodipine-atorvastatin combination period). Rash has been previously reported "}, {"to": "17940", "prefix": ". Rash has been previously reported with ", "from": "17931", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " administration (3). A mild papular rash was reported in a single volunteer (4.8"}, {"to": "18112", "prefix": "on day 24 during the period of coadministration of amlodipine-atorvastatin and ", "from": "18103", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": "; the rash resolved without treatment or a change in study drug dosing.\n\nThere w"}, {"to": "18603", "prefix": "ents in any volunteers.\n\nGo to:\nDISCUSSION\nPotential drug-drug interactions of ", "from": "18594", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " with amlodipine and atorvastatin were investigated in healthy volunteers by com"}, {"to": "18763", "prefix": "rs by comparing the PK of these drugs with and without the coadministration of ", "from": "18754", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": ". A formulation containing a combination of amlodipine and atorvastatin (Caduet)"}, {"to": "19021", "prefix": "pine and atorvastatin was expected.\n\nA clinical drug-drug interaction study of ", "from": "19012", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " and midazolam showed that telaprevir increased the AUC of oral midazolam almost"}, {"to": "19058", "prefix": "A clinical drug-drug interaction study of telaprevir and midazolam showed that ", "from": "19049", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " increased the AUC of oral midazolam almost 9-fold (4), indicating that telaprev"}, {"to": "19140", "prefix": ", indicating that ", "from": "19131", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " is a potent inhibitor of CYP3A4. Amlodipine is a dihydropyridine calcium antago"}, {"to": "19834", "prefix": "astatin, administered as Caduet, were anticipated with the coadministration of ", "from": "19825", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": ".\n\nResults from the present study indicate that telaprevir significantly inhibit"}, {"to": "19892", "prefix": " coadministration of telaprevir.\n\nResults from the present study indicate that ", "from": "19883", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " significantly inhibited the metabolism of both amlodipine and atorvastatin. The"}, {"to": "20328", "prefix": ". When amlodipine was coadministered with ", "from": "20319", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": ", its AUC0-"}, {"to": "20668", "prefix": "2 associated with the clearance decrease signifies the inhibitory effect of ", "from": "20659", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " on the metabolism of amlodipine. An effect of a similar magnitude on amlodipine"}, {"to": "20975", "prefix": ".\n\nThe effect of ", "from": "20966", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " on atorvastatin disposition was more pronounced. Atorvastatin is given in the a"}, {"to": "21444", "prefix": ".\n\nUpon the coadministration of ", "from": "21435", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " with a single dose of amlodipine-atorvastatin, the atorvastatin AUC0-"}, {"to": "21642", "prefix": "tin Cmax increased 10.6-fold. These results suggest that the primary effect of ", "from": "21633", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " on atorvastatin is to increase its bioavailability (F) by decreasing its first-"}, {"to": "21870", "prefix": "on by inhibiting P-glycoprotein-mediated efflux back to the gut. The effect of ", "from": "21861", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " on the hepatic metabolism of atorvastatin does not appear to be significant in "}, {"to": "22273", "prefix": ".\n\nWith coadministration of ", "from": "22264", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": ", the mean (SD) apparent clearance decreased from 685 (272) liters"}, {"to": "22576", "prefix": " h with the coadministration of ", "from": "22567", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": ", although this difference was not statistically significant. Inhibition of ator"}, {"to": "23580", "prefix": ". However, at this time, the effect of ", "from": "23571", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " on OATP1B1 is unknown.\n\nThe mean AUC0-"}, {"to": "23699", "prefix": " for ortho-hydroxy atorvastatin decreased by approximately 70% after ", "from": "23690", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " coadministration; however, most concentrations of para-hydroxy atorvastatin wer"}, {"to": "24001", "prefix": " the coadministration of ", "from": "23992", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": ", the concentrations of this metabolite increased about 6-fold. On day 17, but n"}, {"to": "24471", "prefix": "ce of greater systemic exposure of atorvastatin during the coadministration of ", "from": "24462", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": ", it is plausible that more para-hydroxy atorvastatin is formed via CYP2C8 and i"}, {"to": "24613", "prefix": " is formed via CYP2C8 and its concentration in plasma is increased.\n\nThe PK of ", "from": "24604", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " were evaluated after coadministration at steady state with a single dose of aml"}, {"to": "24849", "prefix": ". This suggests that adequate ", "from": "24840", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " exposure was achieved in this study and a clinically significant effect of amlo"}, {"to": "24965", "prefix": "his study and a clinically significant effect of amlodipine or atorvastatin on ", "from": "24956", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " is unlikely.\n\nThe coadministration of multiple doses of telaprevir with one dos"}, {"to": "25032", "prefix": "vastatin on telaprevir is unlikely.\n\nThe coadministration of multiple doses of ", "from": "25023", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " with one dose of amlodipine and atorvastatin administered in 2 periods was well"}, {"to": "25481", "prefix": " which have been reported in other clinical trials after the administration of ", "from": "25472", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " alone (8, 17, 23). The low frequency and"}, {"to": "25744", "prefix": " drugs used in this study.\n\nIn summary, the results of this study suggest that ", "from": "25735", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " significantly increased exposure to amlodipine and atorvastatin (Cmax and AUC0-"}, {"to": "25873", "prefix": ". Atorvastatin coadministration with ", "from": "25864", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": " is contraindicated. When amlodipine is coadministered with telaprevir, caution "}, {"to": "25943", "prefix": "ion with telaprevir is contraindicated. When amlodipine is coadministered with ", "from": "25934", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "PMC3187007", "exact": "telaprevir", "suffix": ", caution should be used and an amlodipine dose reduction should be considered. "}, {"to": "26083", "prefix": "ion should be considered. Clinical monitoring is recommended. Please check the ", "from": "26077", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/MESH/C486464", "setId": "PMC3187007", "exact": "INCIVEK", "suffix": " package insert for full information and"}, {"to": "124", "prefix": "C virus protease inhibitor that is both a substrate and an inhibitor of CYP3A. ", "from": "115", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "Amlodipine", "suffix": " and atorvastatin are both substrates of CYP3A and are among the drugs most freq"}, {"to": "337", "prefix": "is study was conducted to examine the effect of telaprevir on atorvastatin and ", "from": "328", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " pharmacokinetics (PK). This was an open-label, single sequence, nonrandomized s"}, {"to": "505", "prefix": "study involving 21 healthy male and female volunteers. A coformulation of 5 mg ", "from": "496", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " and 20 mg atorvastatin was administered on day 1. Telaprevir was taken with foo"}, {"to": "675", "prefix": " as a 750-mg dose every 8 h from day 11 until day 26, and a single dose of the ", "from": "666", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": "-atorvastatin combination was readministered on day 17. Plasma samples were coll"}, {"to": "814", "prefix": "y 17. Plasma samples were collected for determination of the PK of telaprevir, ", "from": "805", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": ", atorvastatin, ortho-hydroxy atorvastatin, and para-hydroxy atorvastatin. When "}, {"to": "1045", "prefix": " for ", "from": "1036", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " were 1.27 (1.21, 1.33) for the maximum drug concentration in serum (Cmax) and 2"}, {"to": "1375", "prefix": ". Telaprevir significantly increased exposure to ", "from": "1366", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " and atorvastatin, consistent with the inhibitory effect of telaprevir on the CY"}, {"to": "2060", "prefix": ".\n\n", "from": "2051", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "Amlodipine", "suffix": " is a dihydropyridine calcium channel antagonist used to treat high blood pressu"}, {"to": "2501", "prefix": ". Both ", "from": "2492", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " and atorvastatin are metabolized primarily by CYP3A (1). CYP3A-mediated metabol"}, {"to": "3103", "prefix": ". ", "from": "3094", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "Amlodipine", "suffix": " is extensively metabolized, primarily involving oxidation to the pyridine deriv"}, {"to": "3413", "prefix": "f the metabolites have any significant calcium antagonist activity relative to ", "from": "3404", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " (20).\n\nTelaprevir inhibits CYP3A-mediated metabolism at therapeutic concentrati"}, {"to": "3663", "prefix": "udy was designed to evaluate the drug-drug interactions between telaprevir and ", "from": "3654", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " and atorvastatin in healthy volunteers.\n\nGo to:\nMATERIALS AND METHODS\nVolunteer"}, {"to": "5436", "prefix": "ized study of telaprevir in combination with Caduet tablets containing 5 mg of ", "from": "5427", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " and 20 mg of atorvastatin (amlodipine-atorvastatin). Volunteers received the fo"}, {"to": "5474", "prefix": "", "from": "5465", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": "-atorvastatin). Volunteers received the following treatment: a single dose of am"}, {"to": "5562", "prefix": ". Volunteers received the following treatment: a single dose of ", "from": "5553", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": "-atorvastatin alone on day 1, followed by a washout period, telaprevir at a dose"}, {"to": "5724", "prefix": " on days 11 through 26, with a single dose of ", "from": "5715", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": "-atorvastatin on day 17. Outpatient visits occurred at the screening visit (betw"}, {"to": "6311", "prefix": ".\n\n", "from": "6302", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "Amlodipine", "suffix": "-atorvastatin (25-mg fixed dose combination tablets containing 5 mg amlodipine a"}, {"to": "6389", "prefix": "25-mg fixed dose combination tablets containing 5 mg ", "from": "6380", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " and 20 mg atorvastatin; Pfizer Incorporated, New York, NY) was administered ora"}, {"to": "6833", "prefix": "elaprevir dosing regimen, and all volunteers received their scheduled doses of ", "from": "6824", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": "-atorvastatin (administered at the clinic).\n\nBioanalysis.\nPharmacokinetic evalua"}, {"to": "6965", "prefix": "\n\nBioanalysis.\nPharmacokinetic evaluations were based on the concentrations of ", "from": "6956", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": ", atorvastatin, ortho-hydroxy atorvastatin, para-hydroxy atorvastatin, and telap"}, {"to": "7080", "prefix": "oxy atorvastatin, para-hydroxy atorvastatin, and telaprevir in plasma.\n\nPlasma ", "from": "7071", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": ", atorvastatin, ortho-hydroxy atorvastatin, and para-hydroxy atorvastatin concen"}, {"to": "7313", "prefix": " 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 240 h after a single dose of ", "from": "7304", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": "-atorvastatin on day 1 and predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8"}, {"to": "7474", "prefix": " 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 240 h after another single dose of ", "from": "7465", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": "-atorvastatin on day 17. Neither amlodipine nor atorvastatin is an inhibitor of "}, {"to": "7517", "prefix": " 240 h after another single dose of amlodipine-atorvastatin on day 17. Neither ", "from": "7508", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " nor atorvastatin is an inhibitor of CYP3A, while telaprevir is a potent inhibit"}, {"to": "7639", "prefix": " of CYP3A, while telaprevir is a potent inhibitor of CYP3A. Thus, an effect of ", "from": "7630", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " and atorvastatin on telaprevir pharmacokinetics (PK) was not anticipated. There"}, {"to": "8247", "prefix": "", "from": "8238", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": "-d4 maleic acid, atorvastatin-d5 sodium salt, ortho-hydroxy atorvastatin-phenyl-"}, {"to": "8770", "prefix": "ml for ", "from": "8761", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " (lower limit of quantitation [LLOQ], 0.0500 ng"}, {"to": "10638", "prefix": " of ", "from": "10629", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " and atorvastatin following a single dose of amlodipine-atorvastatin coadministe"}, {"to": "10693", "prefix": " of amlodipine and atorvastatin following a single dose of ", "from": "10684", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": "-atorvastatin coadministered with telaprevir were compared to those measured fol"}, {"to": "10807", "prefix": "red with telaprevir were compared to those measured following a single dose of ", "from": "10798", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": "-atorvastatin alone. In the analysis, treatment effect (with or without telaprev"}, {"to": "11509", "prefix": " were assessed predose and at 8, 10, and 24 h postdose for ", "from": "11500", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": "-atorvastatin when administered alone and when administered in combination with "}, {"to": "12362", "prefix": "t 19 volunteers were available following all dosing occasions and analyzed for ", "from": "12353", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": ", atorvastatin, ortho-hydroxy atorvastatin, para-hydroxy atorvastatin, and telap"}, {"to": "12594", "prefix": "le because they discontinued the study after providing blood samples for day 1 ", "from": "12585", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": "-atorvastatin PK.\n\nEffect of telaprevir on the PK of amlodipine.\nThe mean plasma"}, {"to": "12657", "prefix": "mples for day 1 amlodipine-atorvastatin PK.\n\nEffect of telaprevir on the PK of ", "from": "12648", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": ".\nThe mean plasma amlodipine concentration-time profile is shown in Fig. 1, and "}, {"to": "12685", "prefix": "torvastatin PK.\n\nEffect of telaprevir on the PK of amlodipine.\nThe mean plasma ", "from": "12676", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " concentration-time profile is shown in Fig. 1, and the pharmacokinetic paramete"}, {"to": "12825", "prefix": " the pharmacokinetic parameter estimates from the noncompartmental analysis of ", "from": "12816", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " concentration data are shown in Table 1. Based on the ratio of the LS means, th"}, {"to": "12941", "prefix": " of ", "from": "12932", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " were increased 1.27-fold and 2.79-fold, respectively, by the coadministration o"}, {"to": "13072", "prefix": "2 of ", "from": "13063", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " increased from 41.3 h to 95.1 h, and the mean apparent clearance (CL"}, {"to": "13261", "prefix": "h.\n\nFig. 1.\nFig. 1.\nMean plasma concentration-time profile of ", "from": "13252", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " following oral administration with and without telaprevir. Error bars represent"}, {"to": "13437", "prefix": "andard error of the mean.\nTable 1.\nTable 1.\nEffects of telaprevir on the PK of ", "from": "13428", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": ", atorvastatin, and its metabolite ortho-hydroxy atorvastatin\nEffect of telaprev"}, {"to": "14477", "prefix": "ean plasma concentration-time profiles of ortho-hydroxy atorvastatin following ", "from": "14468", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": "-atorvastatin administration on day 1 and day 17 are shown in Fig. 3. Because a "}, {"to": "15961", "prefix": ".\n\nSteady-state PK of telaprevir after coadministration with ", "from": "15952", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " and atorvastatin.\nSelected steady-state pharmacokinetic parameters were calcula"}, {"to": "16125", "prefix": "lculated for telaprevir on day 17 after coadministration with a single dose of ", "from": "16116", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": "-atorvastatin. The mean (SD) Cmax of telaprevir was 3,167 (778) ng"}, {"to": "16787", "prefix": "ty. The exception was moderate diarrhea in one volunteer during the telaprevir-", "from": "16778", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": "-atorvastatin combination period.\n\nThirteen (62%) volunteers reported an adverse"}, {"to": "17308", "prefix": "occurred in 5 volunteers [24%] during the ", "from": "17299", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": "-atorvastatin-alone period, in 2 volunteers [10%] during the telaprevir-alone pe"}, {"to": "17450", "prefix": "ing the telaprevir-alone period, and in 1 volunteer [5%] during the telaprevir-", "from": "17441", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": "-atorvastatin combination period); dizziness (occurred in 2 volunteers [10%] dur"}, {"to": "17621", "prefix": "g the telaprevir-alone period, and in 3 volunteers [15%] during the telaprevir-", "from": "17612", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": "-atorvastatin combination period); diarrhea (occurred in 1 volunteer [5%] during"}, {"to": "17856", "prefix": "ng the telaprevir-alone period and in 2 volunteers [11%] during the telaprevir-", "from": "17847", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": "-atorvastatin combination period). Rash has been previously reported with telapr"}, {"to": "18084", "prefix": " on day 24 during the period of coadministration of ", "from": "18075", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": "-atorvastatin and telaprevir; the rash resolved without treatment or a change in"}, {"to": "18619", "prefix": "nteers.\n\nGo to:\nDISCUSSION\nPotential drug-drug interactions of telaprevir with ", "from": "18610", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " and atorvastatin were investigated in healthy volunteers by comparing the PK of"}, {"to": "18817", "prefix": " the coadministration of telaprevir. A formulation containing a combination of ", "from": "18808", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " and atorvastatin (Caduet) was used in this study for dosing convenience. No sig"}, {"to": "18936", "prefix": " used in this study for dosing convenience. No significant interaction between ", "from": "18927", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " and atorvastatin was expected.\n\nA clinical drug-drug interaction study of telap"}, {"to": "19184", "prefix": ", indicating that telaprevir is a potent inhibitor of CYP3A4. ", "from": "19175", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "Amlodipine", "suffix": " is a dihydropyridine calcium antagonist drug and has been reported as a substra"}, {"to": "19735", "prefix": ". Thus, clinically significant changes in the PK of ", "from": "19726", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " and atorvastatin, administered as Caduet, were anticipated with the coadministr"}, {"to": "19950", "prefix": " study indicate that telaprevir significantly inhibited the metabolism of both ", "from": "19941", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " and atorvastatin. The bioavailability of amlodipine has been reported to be "}, {"to": "20002", "prefix": "ted the metabolism of both amlodipine and atorvastatin. The bioavailability of ", "from": "19993", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " has been reported to be "}, {"to": "20293", "prefix": ". When ", "from": "20284", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " was coadministered with telaprevir, its AUC0-"}, {"to": "20700", "prefix": "ce decrease signifies the inhibitory effect of telaprevir on the metabolism of ", "from": "20691", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": ". An effect of a similar magnitude on amlodipine has been observed in other stud"}, {"to": "20748", "prefix": "elaprevir on the metabolism of amlodipine. An effect of a similar magnitude on ", "from": "20739", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " has been observed in other studies with antiviral agents that are CYP3A inhibit"}, {"to": "20920", "prefix": ". For example, combined dosing of indinavir and ritonavir increased the median ", "from": "20911", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " AUC0-24 by 90% (n "}, {"to": "21477", "prefix": ".\n\nUpon the coadministration of telaprevir with a single dose of ", "from": "21468", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": "-atorvastatin, the atorvastatin AUC0-"}, {"to": "24700", "prefix": "ir were evaluated after coadministration at steady state with a single dose of ", "from": "24691", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": "-atorvastatin. The Cmax and AUClast were similar to the steady-state estimates o"}, {"to": "24935", "prefix": "vir exposure was achieved in this study and a clinically significant effect of ", "from": "24926", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " or atorvastatin on telaprevir is unlikely.\n\nThe coadministration of multiple do"}, {"to": "25060", "prefix": "likely.\n\nThe coadministration of multiple doses of telaprevir with one dose of ", "from": "25051", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " and atorvastatin administered in 2 periods was well tolerated. There were no se"}, {"to": "25584", "prefix": "or lack of adverse events commonly associated with ", "from": "25575", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " and atorvastatin may be attributed to the single-dose regimen of these drugs us"}, {"to": "25791", "prefix": "ults of this study suggest that telaprevir significantly increased exposure to ", "from": "25782", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " and atorvastatin (Cmax and AUC0-"}, {"to": "25909", "prefix": ". Atorvastatin coadministration with telaprevir is contraindicated. When ", "from": "25900", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " is coadministered with telaprevir, caution should be used and an amlodipine dos"}, {"to": "25985", "prefix": "en amlodipine is coadministered with telaprevir, caution should be used and an ", "from": "25976", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017311", "setId": "PMC3187007", "exact": "amlodipine", "suffix": " dose reduction should be considered. Clinical monitoring is recommended. Please"}, {"to": "141", "prefix": "e inhibitor that is both a substrate and an inhibitor of CYP3A. Amlodipine and ", "from": "130", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " are both substrates of CYP3A and are among the drugs most frequently used by pa"}, {"to": "322", "prefix": "h hepatitis C. This study was conducted to examine the effect of telaprevir on ", "from": "311", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " and amlodipine pharmacokinetics (PK). This was an open-label, single sequence, "}, {"to": "528", "prefix": "althy male and female volunteers. A coformulation of 5 mg amlodipine and 20 mg ", "from": "517", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " was administered on day 1. Telaprevir was taken with food as a 750-mg dose ever"}, {"to": "688", "prefix": "g dose every 8 h from day 11 until day 26, and a single dose of the amlodipine-", "from": "677", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " combination was readministered on day 17. Plasma samples were collected for det"}, {"to": "828", "prefix": " samples were collected for determination of the PK of telaprevir, amlodipine, ", "from": "817", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": ", ortho-hydroxy atorvastatin, and para-hydroxy atorvastatin. When administration"}, {"to": "856", "prefix": "determination of the PK of telaprevir, amlodipine, atorvastatin, ortho-hydroxy ", "from": "845", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": ", and para-hydroxy atorvastatin. When administration with telaprevir was compare"}, {"to": "887", "prefix": "previr, amlodipine, atorvastatin, ortho-hydroxy atorvastatin, and para-hydroxy ", "from": "876", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": ". When administration with telaprevir was compared with administration without t"}, {"to": "1237", "prefix": "; for ", "from": "1226", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": ", they were 10.6 (8.74, 12.9) for the Cmax and 7.88 (6.84, 9.07) for the AUC0-"}, {"to": "1392", "prefix": ". Telaprevir significantly increased exposure to amlodipine and ", "from": "1381", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": ", consistent with the inhibitory effect of telaprevir on the CYP3A-mediated meta"}, {"to": "2194", "prefix": "onist used to treat high blood pressure and angina or coronary artery disease. ", "from": "2183", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "Atorvastatin", "suffix": " is a hydroxymethyl glutaryl coenzyme A (HMG-CoA) reductase inhibitor used to lo"}, {"to": "2518", "prefix": ". Both amlodipine and ", "from": "2507", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " are metabolized primarily by CYP3A (1). CYP3A-mediated metabolism converts ator"}, {"to": "2606", "prefix": ". CYP3A-mediated metabolism converts ", "from": "2595", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " into two major active metabolites, ortho-hydroxy atorvastatin and para-hydroxy "}, {"to": "2668", "prefix": "abolism converts atorvastatin into two major active metabolites, ortho-hydroxy ", "from": "2657", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " and para-hydroxy atorvastatin, and three inactive lactone metabolites correspon"}, {"to": "2698", "prefix": "into two major active metabolites, ortho-hydroxy atorvastatin and para-hydroxy ", "from": "2687", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": ", and three inactive lactone metabolites corresponding to each acid form (12). B"}, {"to": "2946", "prefix": "70% of the total HMG-CoA reductase inhibitory activity of ", "from": "2935", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " (6). Excreted primarily in the bile, atorvastatin is also a substrate for P-gly"}, {"to": "2996", "prefix": ". Excreted primarily in the bile, ", "from": "2985", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " is also a substrate for P-glycoprotein and organic anion transporter protein (O"}, {"to": "3680", "prefix": "d to evaluate the drug-drug interactions between telaprevir and amlodipine and ", "from": "3669", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " in healthy volunteers.\n\nGo to:\nMATERIALS AND METHODS\nVolunteers.\nTwenty-one hea"}, {"to": "5462", "prefix": " in combination with Caduet tablets containing 5 mg of amlodipine and 20 mg of ", "from": "5451", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " (amlodipine-atorvastatin). Volunteers received the following treatment: a singl"}, {"to": "5487", "prefix": "amlodipine-", "from": "5476", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": "). Volunteers received the following treatment: a single dose of amlodipine-ator"}, {"to": "5575", "prefix": ". Volunteers received the following treatment: a single dose of amlodipine-", "from": "5564", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " alone on day 1, followed by a washout period, telaprevir at a dose of 750 mg ev"}, {"to": "5737", "prefix": " on days 11 through 26, with a single dose of amlodipine-", "from": "5726", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " on day 17. Outpatient visits occurred at the screening visit (between 3 and 28 "}, {"to": "6324", "prefix": ".\n\nAmlodipine-", "from": "6313", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " (25-mg fixed dose combination tablets containing 5 mg amlodipine and 20 mg ator"}, {"to": "6412", "prefix": "25-mg fixed dose combination tablets containing 5 mg amlodipine and 20 mg ", "from": "6401", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": "; Pfizer Incorporated, New York, NY) was administered orally as a single dose in"}, {"to": "6846", "prefix": "osing regimen, and all volunteers received their scheduled doses of amlodipine-", "from": "6835", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " (administered at the clinic).\n\nBioanalysis.\nPharmacokinetic evaluations were ba"}, {"to": "6979", "prefix": "s.\nPharmacokinetic evaluations were based on the concentrations of amlodipine, ", "from": "6968", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": ", ortho-hydroxy atorvastatin, para-hydroxy atorvastatin, and telaprevir in plasm"}, {"to": "7007", "prefix": "ns were based on the concentrations of amlodipine, atorvastatin, ortho-hydroxy ", "from": "6996", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": ", para-hydroxy atorvastatin, and telaprevir in plasma.\n\nPlasma amlodipine, atorv"}, {"to": "7034", "prefix": "trations of amlodipine, atorvastatin, ortho-hydroxy atorvastatin, para-hydroxy ", "from": "7023", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": ", and telaprevir in plasma.\n\nPlasma amlodipine, atorvastatin, ortho-hydroxy ator"}, {"to": "7094", "prefix": "atin, para-hydroxy atorvastatin, and telaprevir in plasma.\n\nPlasma amlodipine, ", "from": "7083", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": ", ortho-hydroxy atorvastatin, and para-hydroxy atorvastatin concentrations were "}, {"to": "7122", "prefix": "tin, and telaprevir in plasma.\n\nPlasma amlodipine, atorvastatin, ortho-hydroxy ", "from": "7111", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": ", and para-hydroxy atorvastatin concentrations were determined predose and at 0."}, {"to": "7153", "prefix": "\nPlasma amlodipine, atorvastatin, ortho-hydroxy atorvastatin, and para-hydroxy ", "from": "7142", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " concentrations were determined predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4,"}, {"to": "7326", "prefix": ", 8, 10, 12, 24, 48, 72, 120, 168, and 240 h after a single dose of amlodipine-", "from": "7315", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " on day 1 and predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24,"}, {"to": "7487", "prefix": "0, 12, 24, 48, 72, 120, 168, and 240 h after another single dose of amlodipine-", "from": "7476", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " on day 17. Neither amlodipine nor atorvastatin is an inhibitor of CYP3A, while "}, {"to": "7534", "prefix": "other single dose of amlodipine-atorvastatin on day 17. Neither amlodipine nor ", "from": "7523", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " is an inhibitor of CYP3A, while telaprevir is a potent inhibitor of CYP3A. Thus"}, {"to": "7656", "prefix": "e telaprevir is a potent inhibitor of CYP3A. Thus, an effect of amlodipine and ", "from": "7645", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " on telaprevir pharmacokinetics (PK) was not anticipated. Therefore, telaprevir "}, {"to": "8276", "prefix": "amlodipine-d4 maleic acid, ", "from": "8265", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": "-d5 sodium salt, ortho-hydroxy atorvastatin-phenyl-d5, para-hydroxy atorvastatin"}, {"to": "8319", "prefix": "amlodipine-d4 maleic acid, atorvastatin-d5 sodium salt, ortho-hydroxy ", "from": "8308", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": "-phenyl-d5, para-hydroxy atorvastatin-phenyl-d5, and d11-telaprevir) were extrac"}, {"to": "8356", "prefix": "torvastatin-d5 sodium salt, ortho-hydroxy atorvastatin-phenyl-d5, para-hydroxy ", "from": "8345", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": "-phenyl-d5, and d11-telaprevir) were extracted from human plasma by liquid-liqui"}, {"to": "8858", "prefix": "ml for ", "from": "8847", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " (LLOQ, 0.250 ng"}, {"to": "8928", "prefix": "ml for para-hydroxy ", "from": "8917", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " (LLOQ, 0.250 ng"}, {"to": "8999", "prefix": "ml for ortho-hydroxy ", "from": "8988", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " (LLOQ, 0.250 ng"}, {"to": "10655", "prefix": " of amlodipine and ", "from": "10644", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " following a single dose of amlodipine-atorvastatin coadministered with telaprev"}, {"to": "10706", "prefix": " of amlodipine and atorvastatin following a single dose of amlodipine-", "from": "10695", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " coadministered with telaprevir were compared to those measured following a sing"}, {"to": "10820", "prefix": "laprevir were compared to those measured following a single dose of amlodipine-", "from": "10809", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " alone. In the analysis, treatment effect (with or without telaprevir) was consi"}, {"to": "11522", "prefix": " were assessed predose and at 8, 10, and 24 h postdose for amlodipine-", "from": "11511", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " when administered alone and when administered in combination with telaprevir. C"}, {"to": "12376", "prefix": "ers were available following all dosing occasions and analyzed for amlodipine, ", "from": "12365", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": ", ortho-hydroxy atorvastatin, para-hydroxy atorvastatin, and telaprevir. Day 17 "}, {"to": "12404", "prefix": " all dosing occasions and analyzed for amlodipine, atorvastatin, ortho-hydroxy ", "from": "12393", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": ", para-hydroxy atorvastatin, and telaprevir. Day 17 plasma samples from 2 volunt"}, {"to": "12431", "prefix": "nalyzed for amlodipine, atorvastatin, ortho-hydroxy atorvastatin, para-hydroxy ", "from": "12420", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": ", and telaprevir. Day 17 plasma samples from 2 volunteers were not available bec"}, {"to": "12607", "prefix": "they discontinued the study after providing blood samples for day 1 amlodipine-", "from": "12596", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " PK.\n\nEffect of telaprevir on the PK of amlodipine.\nThe mean plasma amlodipine c"}, {"to": "13451", "prefix": " of the mean.\nTable 1.\nTable 1.\nEffects of telaprevir on the PK of amlodipine, ", "from": "13440", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": ", and its metabolite ortho-hydroxy atorvastatin\nEffect of telaprevir on the PK o"}, {"to": "13498", "prefix": "previr on the PK of amlodipine, atorvastatin, and its metabolite ortho-hydroxy ", "from": "13487", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": "\nEffect of telaprevir on the PK of atorvastatin and metabolites.\nThe mean plasma"}, {"to": "13545", "prefix": "nd its metabolite ortho-hydroxy atorvastatin\nEffect of telaprevir on the PK of ", "from": "13534", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " and metabolites.\nThe mean plasma atorvastatin concentration-time profile obtain"}, {"to": "13591", "prefix": "ffect of telaprevir on the PK of atorvastatin and metabolites.\nThe mean plasma ", "from": "13580", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " concentration-time profile obtained is shown in Fig. 2, and the pharmacokinetic"}, {"to": "13742", "prefix": " the pharmacokinetic parameter estimates from the noncompartmental analysis of ", "from": "13731", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " concentration data are shown in Table 1. Based on the ratio of the LS means, th"}, {"to": "14270", "prefix": "ically significant.\n\nFig. 2.\nFig. 2.\nMean plasma concentration-time profile of ", "from": "14259", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " following oral administration with and without telaprevir. Error bars represent"}, {"to": "14456", "prefix": "rror of the mean.\nThe mean plasma concentration-time profiles of ortho-hydroxy ", "from": "14445", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " following amlodipine-atorvastatin administration on day 1 and day 17 are shown "}, {"to": "14490", "prefix": "concentration-time profiles of ortho-hydroxy atorvastatin following amlodipine-", "from": "14479", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " administration on day 1 and day 17 are shown in Fig. 3. Because a substantial n"}, {"to": "14748", "prefix": ", the concentration-versus-time profile of ortho-hydroxy ", "from": "14737", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " is limited to 24 h postdose. As shown in Table 1, the variability of Cmax and A"}, {"to": "15392", "prefix": "lyte.\n\nFig. 3.\nFig. 3.\nMean plasma concentration-time profile of ortho-hydroxy-", "from": "15381", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " following oral administration with and without telaprevir. Error bars represent"}, {"to": "15560", "prefix": "ent the standard error of the mean.\nMost of the concentrations of para-hydroxy ", "from": "15549", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " were below the LLOQ, especially on day 1. Only 2 volunteers showed detectable c"}, {"to": "15682", "prefix": "y on day 1. Only 2 volunteers showed detectable concentrations of para-hydroxy ", "from": "15671", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " on day 1. The Cmax of para-hydroxy atorvastatin in these 2 volunteers increased"}, {"to": "15730", "prefix": "concentrations of para-hydroxy atorvastatin on day 1. The Cmax of para-hydroxy ", "from": "15719", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " in these 2 volunteers increased with telaprevir coadministration from 0.30 and "}, {"to": "15978", "prefix": ".\n\nSteady-state PK of telaprevir after coadministration with amlodipine and ", "from": "15967", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": ".\nSelected steady-state pharmacokinetic parameters were calculated for telaprevi"}, {"to": "16138", "prefix": "r telaprevir on day 17 after coadministration with a single dose of amlodipine-", "from": "16127", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": ". The mean (SD) Cmax of telaprevir was 3,167 (778) ng"}, {"to": "16800", "prefix": "eption was moderate diarrhea in one volunteer during the telaprevir-amlodipine-", "from": "16789", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " combination period.\n\nThirteen (62%) volunteers reported an adverse event, and 1"}, {"to": "17321", "prefix": "occurred in 5 volunteers [24%] during the amlodipine-", "from": "17310", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": "-alone period, in 2 volunteers [10%] during the telaprevir-alone period, and in "}, {"to": "17463", "prefix": "aprevir-alone period, and in 1 volunteer [5%] during the telaprevir-amlodipine-", "from": "17452", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " combination period); dizziness (occurred in 2 volunteers [10%] during the telap"}, {"to": "17634", "prefix": "revir-alone period, and in 3 volunteers [15%] during the telaprevir-amlodipine-", "from": "17623", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " combination period); diarrhea (occurred in 1 volunteer [5%] during each of the "}, {"to": "17869", "prefix": "previr-alone period and in 2 volunteers [11%] during the telaprevir-amlodipine-", "from": "17858", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " combination period). Rash has been previously reported with telaprevir administ"}, {"to": "18097", "prefix": " on day 24 during the period of coadministration of amlodipine-", "from": "18086", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " and telaprevir; the rash resolved without treatment or a change in study drug d"}, {"to": "18636", "prefix": "\nDISCUSSION\nPotential drug-drug interactions of telaprevir with amlodipine and ", "from": "18625", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " were investigated in healthy volunteers by comparing the PK of these drugs with"}, {"to": "18834", "prefix": "ration of telaprevir. A formulation containing a combination of amlodipine and ", "from": "18823", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " (Caduet) was used in this study for dosing convenience. No significant interact"}, {"to": "18953", "prefix": "tudy for dosing convenience. No significant interaction between amlodipine and ", "from": "18942", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " was expected.\n\nA clinical drug-drug interaction study of telaprevir and midazol"}, {"to": "19384", "prefix": ". ", "from": "19373", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "Atorvastatin", "suffix": ", one of the most commonly prescribed HMG-CoA reductase inhibitors, is also a su"}, {"to": "19752", "prefix": ". Thus, clinically significant changes in the PK of amlodipine and ", "from": "19741", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": ", administered as Caduet, were anticipated with the coadministration of telaprev"}, {"to": "19967", "prefix": " that telaprevir significantly inhibited the metabolism of both amlodipine and ", "from": "19956", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": ". The bioavailability of amlodipine has been reported to be "}, {"to": "20991", "prefix": ".\n\nThe effect of telaprevir on ", "from": "20980", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " disposition was more pronounced. Atorvastatin is given in the acid form, and it"}, {"to": "21037", "prefix": ".\n\nThe effect of telaprevir on atorvastatin disposition was more pronounced. ", "from": "21026", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "Atorvastatin", "suffix": " is given in the acid form, and its Cmax is achieved quickly ("}, {"to": "21137", "prefix": ". ", "from": "21126", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "Atorvastatin", "suffix": " acid undergoes extensive first-pass metabolism in the gut and the liver, and th"}, {"to": "21490", "prefix": ".\n\nUpon the coadministration of telaprevir with a single dose of amlodipine-", "from": "21479", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": ", the atorvastatin AUC0-"}, {"to": "21508", "prefix": "dministration of telaprevir with a single dose of amlodipine-atorvastatin, the ", "from": "21497", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " AUC0-"}, {"to": "21556", "prefix": " increased 7.88-fold and the ", "from": "21545", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " Cmax increased 10.6-fold. These results suggest that the primary effect of tela"}, {"to": "21658", "prefix": "ased 10.6-fold. These results suggest that the primary effect of telaprevir on ", "from": "21647", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " is to increase its bioavailability (F) by decreasing its first-pass metabolism "}, {"to": "21912", "prefix": " efflux back to the gut. The effect of telaprevir on the hepatic metabolism of ", "from": "21901", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " does not appear to be significant in its overall disposition. An effect of a si"}, {"to": "22023", "prefix": "be significant in its overall disposition. An effect of a similar magnitude on ", "from": "22012", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " has been observed in studies using some other CYP3A inhibitors. For example, th"}, {"to": "22133", "prefix": "in studies using some other CYP3A inhibitors. For example, the AUC and Cmax of ", "from": "22122", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " were increased about 9-fold when it was coadministered with tipranavir-ritonavi"}, {"to": "22664", "prefix": "vir, although this difference was not statistically significant. Inhibition of ", "from": "22653", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " metabolism would be expected to increase the atorvastatin t1"}, {"to": "22722", "prefix": "icant. Inhibition of atorvastatin metabolism would be expected to increase the ", "from": "22711", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " t1"}, {"to": "22846", "prefix": " be caused by the inhibition of transporters involved in the hepatic uptake of ", "from": "22835", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": ", such as organic anion-transporting polypeptide 1B1 (OATP1B1), which could redu"}, {"to": "22971", "prefix": ", which could reduce the volume of distribution of ", "from": "22960", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " to an extent similar to or greater than the observed decrease in systemic clear"}, {"to": "23398", "prefix": "statins that are substrates of OATP1B1, such as cerivastatin, fluvastatin, and ", "from": "23387", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": ", showed unaltered t1"}, {"to": "23651", "prefix": " for ortho-hydroxy ", "from": "23640", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " decreased by approximately 70% after telaprevir coadministration; however, most"}, {"to": "23775", "prefix": "fter telaprevir coadministration; however, most concentrations of para-hydroxy ", "from": "23764", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " were below the LLOQ, making noncompartmental analysis for this metabolite not f"}, {"to": "23917", "prefix": "sis for this metabolite not feasible. In the 2 volunteers in whom para-hydroxy ", "from": "23906", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " was measurable before (day 1) and after (day 17) the coadministration of telapr"}, {"to": "24174", "prefix": " day 1, several other volunteers had measurable concentrations of para-hydroxy ", "from": "24163", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": ". While these results were not anticipated, it has been reported that para-hydro"}, {"to": "24269", "prefix": "ile these results were not anticipated, it has been reported that para-hydroxy ", "from": "24258", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": ", but not ortho-hydroxy atorvastatin, is also formed by CYP2C8 in addition to CY"}, {"to": "24305", "prefix": "ed, it has been reported that para-hydroxy atorvastatin, but not ortho-hydroxy ", "from": "24294", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": ", is also formed by CYP2C8 in addition to CYP3A (7). Therefore, in the presence "}, {"to": "24429", "prefix": ". Therefore, in the presence of greater systemic exposure of ", "from": "24418", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " during the coadministration of telaprevir, it is plausible that more para-hydro"}, {"to": "24524", "prefix": "ing the coadministration of telaprevir, it is plausible that more para-hydroxy ", "from": "24513", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " is formed via CYP2C8 and its concentration in plasma is increased.\n\nThe PK of t"}, {"to": "24713", "prefix": "luated after coadministration at steady state with a single dose of amlodipine-", "from": "24702", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": ". The Cmax and AUClast were similar to the steady-state estimates obtained in ot"}, {"to": "24951", "prefix": "as achieved in this study and a clinically significant effect of amlodipine or ", "from": "24940", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " on telaprevir is unlikely.\n\nThe coadministration of multiple doses of telaprevi"}, {"to": "25077", "prefix": "administration of multiple doses of telaprevir with one dose of amlodipine and ", "from": "25066", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " administered in 2 periods was well tolerated. There were no serious, life-threa"}, {"to": "25601", "prefix": "or lack of adverse events commonly associated with amlodipine and ", "from": "25590", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " may be attributed to the single-dose regimen of these drugs used in this study."}, {"to": "25808", "prefix": "udy suggest that telaprevir significantly increased exposure to amlodipine and ", "from": "25797", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "atorvastatin", "suffix": " (Cmax and AUC0-"}, {"to": "25840", "prefix": ". ", "from": "25829", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3187007", "exact": "Atorvastatin", "suffix": " coadministration with telaprevir is contraindicated. When amlodipine is coadmin"}, {"to": "1800", "prefix": ", the addition of telaprevir as part of a combination regimen with pegylated ", "from": "1791", "name": "Interferons", "fullId": "http://purl.bioontology.org/ontology/MESH/D007372", "setId": "PMC3187007", "exact": "interferon", "suffix": " and ribavirin significantly increased the rates of sustained virologic response"}, {"to": "1814", "prefix": "n of telaprevir as part of a combination regimen with pegylated interferon and ", "from": "1806", "name": "Ribavirin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012254", "setId": "PMC3187007", "exact": "ribavirin", "suffix": " significantly increased the rates of sustained virologic response (8, 17, 23). "}, {"to": "2294", "prefix": " reductase inhibitor used to lower high ", "from": "2284", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3187007", "exact": "cholesterol", "suffix": " levels and reduce the risk of heart attack and stroke. These two drugs are freq"}, {"to": "2471", "prefix": "", "from": "2466", "name": "Caduet", "fullId": "http://purl.bioontology.org/ontology/RXNORM/404914", "setId": "PMC3187007", "exact": "Caduet", "suffix": "; Pfizer) (1). Both amlodipine and atorvastatin are metabolized primarily by CYP"}, {"to": "5398", "prefix": "en-label, single-center, nonrandomized study of telaprevir in combination with ", "from": "5393", "name": "Caduet", "fullId": "http://purl.bioontology.org/ontology/RXNORM/404914", "setId": "PMC3187007", "exact": "Caduet", "suffix": " tablets containing 5 mg of amlodipine and 20 mg of atorvastatin (amlodipine-ato"}, {"to": "18842", "prefix": "", "from": "18837", "name": "Caduet", "fullId": "http://purl.bioontology.org/ontology/RXNORM/404914", "setId": "PMC3187007", "exact": "Caduet", "suffix": ") was used in this study for dosing convenience. No significant interaction betw"}, {"to": "19776", "prefix": " significant changes in the PK of amlodipine and atorvastatin, administered as ", "from": "19771", "name": "Caduet", "fullId": "http://purl.bioontology.org/ontology/RXNORM/404914", "setId": "PMC3187007", "exact": "Caduet", "suffix": ", were anticipated with the coadministration of telaprevir.\n\nResults from the pr"}, {"to": "4660", "prefix": "an 2 days before the first administration of the study drug. Occasional use of ", "from": "4648", "name": "Acetaminophen", "fullId": "http://purl.bioontology.org/ontology/RXNORM/161", "setId": "PMC3187007", "exact": "acetaminophen", "suffix": " or ibuprofen was allowed during the study for the treatment of pain. Volunteers"}, {"to": "4673", "prefix": "the first administration of the study drug. Occasional use of acetaminophen or ", "from": "4665", "name": "Ibuprofen", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5640", "setId": "PMC3187007", "exact": "ibuprofen", "suffix": " was allowed during the study for the treatment of pain. Volunteers could not co"}, {"to": "19035", "prefix": "statin was expected.\n\nA clinical drug-drug interaction study of telaprevir and ", "from": "19027", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3187007", "exact": "midazolam", "suffix": " showed that telaprevir increased the AUC of oral midazolam almost 9-fold (4), i"}, {"to": "19094", "prefix": "y of telaprevir and midazolam showed that telaprevir increased the AUC of oral ", "from": "19086", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC3187007", "exact": "midazolam", "suffix": " almost 9-fold (4), indicating that telaprevir is a potent inhibitor of CYP3A4. "}, {"to": "20874", "prefix": "th antiviral agents that are CYP3A inhibitors. For example, combined dosing of ", "from": "20866", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "PMC3187007", "exact": "indinavir", "suffix": " and ritonavir increased the median amlodipine AUC0-24 by 90% (n "}, {"to": "20888", "prefix": "gents that are CYP3A inhibitors. For example, combined dosing of indinavir and ", "from": "20880", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC3187007", "exact": "ritonavir", "suffix": " increased the median amlodipine AUC0-24 by 90% (n "}, {"to": "22214", "prefix": "astatin were increased about 9-fold when it was coadministered with tipranavir-", "from": "22206", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC3187007", "exact": "ritonavir", "suffix": " at steady state (16).\n\nWith coadministration of telaprevir, the mean (SD) appar"}, {"to": "22204", "prefix": "ax of atorvastatin were increased about 9-fold when it was coadministered with ", "from": "22195", "name": "tipranavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C107201", "setId": "PMC3187007", "exact": "tipranavir", "suffix": "-ritonavir at steady state (16).\n\nWith coadministration of telaprevir, the mean "}, {"to": "23126", "prefix": "n systemic clearance. Such a mechanism has been hypothesized for the effect of ", "from": "23115", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "PMC3187007", "exact": "cyclosporine", "suffix": " (an inhibitor of OATP1B1) on rosuvastatin, a statin which is also a substrate o"}, {"to": "23294", "prefix": "2 was decreased by half upon the coadministration of ", "from": "23283", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "PMC3187007", "exact": "cyclosporine", "suffix": " (19). Other statins that are substrates of OATP1B1, such as cerivastatin, fluva"}, {"to": "23526", "prefix": "alfold AUC and Cmax increases resulted when the drugs were coadministered with ", "from": "23515", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "PMC3187007", "exact": "cyclosporine", "suffix": " (18). However, at this time, the effect of telaprevir on OATP1B1 is unknown.\n\nT"}, {"to": "23168", "prefix": " on ", "from": "23157", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3187007", "exact": "rosuvastatin", "suffix": ", a statin which is also a substrate of OATP1B1 and whose t1"}, {"to": "23367", "prefix": ". Other statins that are substrates of OATP1B1, such as ", "from": "23356", "name": "cerivastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C086276", "setId": "PMC3187007", "exact": "cerivastatin", "suffix": ", fluvastatin, and atorvastatin, showed unaltered t1"}, {"to": "23380", "prefix": ". Other statins that are substrates of OATP1B1, such as cerivastatin, ", "from": "23370", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC3187007", "exact": "fluvastatin", "suffix": ", and atorvastatin, showed unaltered t1"}]